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Abstract
Transmissible spongiform encephalopathies (TSEs) are a group of fatal
neurodegenerative diseases. They can be readily transmitted within a host species but
are rarely transmitted between different species. This "species barrier''' effect is
characterised by reduced susceptibility of exposed novel hosts and an increase in the
length and variability of the incubation period. The mechanisms that underlie this
barrier are yet to be fully understood; hence it is currently not possible to accurately
predict the host range of a novel TSE disease. During TSE pathogenesis the host
protein, PrP, misfolds and accumulates within the central nervous system. This
Sc C
misfolded form is denoted PrP to discriminate it from the normal cellular form PrP .
The prion hypothesis proposes that PrPSc is the TSE infectious agent and propagates
its aberrant conformation by inducing PrPc to misfold. PrP is variably glycosylated at
two sites in vivo, such that di-, mono- and un-glycosylated glycotypes are observed;
all of these PrP glycotypes can form PrPSc. However the role of each glycotype in
cross species transmission is unclear. In vitro conversion experiments have suggested
that PrPc's N-glycans specifically retard the cross species PrPSc seeded conversion of
PrPc. Thus glycosylation of PrPc may inhibit cross-species TSE transmission.
• C 'Previous studies have not examined the role of glycosylation of PrP in the cross-
species transmission of TSE disease. In this study glycosylation deficient transgenic
mice [NPU] were challenged with three non-murine TSE agents. A barrier to cross-
species transmission was observed in normally glycosylated control mice, although a
proportion of animals did develop signs of TSE disease after challenge with hamster
scrapie (263K) and variant CJD (vCJD). Transgenic mice that lack both N-glycan
attachment sites were resistant to cross-species TSE challenge (263K, vCJD and
sporadic CJD). Moreover, absence of N-glycans at the first site only, resulted in a
significant decrease in disease incidence after challenge with 263K. These data
suggest that glycosylation of the first site mediates the transmission of TSE between
species. However, this effect is not unique to cross-species transmission as previous
reports have demonstrated that the within-species transmission of TSE is also delayed
by the absence of the first N-glycan attachment site. Transgenic mice which lack
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glycosylation at the second site were shown to have a higher disease incidence than
controls after cross-species challenge with 263K or sporadic CJD. Therefore,
glycosylation of the second site inhibits the cross-species transmission of these
strains. This effect is specific to cross-species transmission as previous murine TSE
transmissions to these mice have not demonstrated an acceleration of disease. Thus
the site of glycosylation determines the role of the N-glycan in cross-species
transmission. Moreover, here it is shown that mice which lack the second N-glycan
attachment site exhibit a reduced disease incidence after challenge with vCJD
compared to control mice. Therefore, TSE strain determines the role of N-glycans in
disease transmission.
To further interpret these transmission studies, the localisation of PrPc in the
glycosylation deficient transgenics was investigated using confocal microscopy. No
significant difference in the cellular localisation of PrPc was detected in mice which
lack the first or second N-glycosylation sites. Therefore, the effect of N-glycan
attachment at these sites on TSE transmission occurs independently of PrP 's cellular
location. Lower levels of anti-PrP signal were detected in the neuropil of mice that
lack both N-glycan attachment sites than in control animals, suggesting a possible
mechanism for the enhanced resistance of these transgenic mice to TSE challenge.
Normally glycosylated PrP can be induced to adopt a misfolded conformation in
vitro, by exposure to infected brain homogenate, mimicking the in vivo formation of
PrPSc. Using an in vitro conversion assay, the ability of PrP derived from the
glycosylation deficient transgenic to misfold was studied. PrP that lacks the first N-
glycan attachment site did not misfold, suggesting a potential cause of the enhanced
resistance of the transgenic mice that lack this site to TSE transmission. PrP that
lacks the second N-glycan attachment site adopted a misfolded form in vitro, with
efficiency equal to that of normally glycosylated PrP. Therefore the higher disease
incidence observed in the transgenic mice, which lack the second PrP glycosylation
site, did not occur because PrP in these animals is more readily misfolded. This
suggests that other aspects of PrP biology, such as PrPSc toxicity or clearance, are
influenced by glycosylation of PrP's second site and that these can alter TSE disease.
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Table 1.1 History of TSE Research (References in body of text)
1732 Scrapie first identified in sheep
1883 Report of scrapie-like disease in a cow
1937 Transmission of scrapie to other sheep
1939 Report of scrapie in a goat
1940 Transmission of scrapie via pasture
1942 Experimental transmission of scrapie from sheep to goat
1947 TME identified
1957 Kuru first studied
1959 Kuru identified as a TSE
1961 Experimental transmission of scrapie to mice
1961 Multiple strains of scrapie identified in goats
1965 TSE species barrier proposed
1965 TME outbreak linked to a downer cow
1966 Transmission of Kuru to Chimpanzees
1967 Scrapie resistant to UV/ theory for non-nucleic acid replication
1967 CWD emergence
1968 Host genetic factor (Sine) controls murine scrapie incubation period
1977 CWD identified as TSE
1980 Infectivity associated with a protease resistant component
1981 Familial TSE infectious
1982 Prion hypothesis
1985 PrP identified as host factor putative prion
1986 First case of BSE identified in the United Kingdom
1989 PrP mutation linked to familial TSE
1989 Transmissibility of TSE linked to PrP amino acid homology
1990 Over-expressing tgPrP develop TSE signs
1991 PrP* not PrPSc the infectious agent
1992 PrP non-essential gene
1993 PrP knockout TSE resistant
1993 Efficient PrP conversion in vivo requires additional cellular factors
1993 Conformational difference between PrPc and PrPSc
1994 TSE strains differ in PrPSc conformations
1994 Cell free conversion of PrPc to PrPSc
1996 vCJD identified
1997 BSE causes vCJD
1997 BSE primary pass in the absence of detectable PrPSc
2002 Species barrier correlates with conformational change in PrPSc
2003 synthetic prions shown to be infectious
2005 in vitro generated PrPRes shown to be infectious
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1.1 Overview of TSE disease
Transmissible Spongiform Encephalopathies (TSEs) are a diverse group of relatively
rare diseases which include: scrapie in sheep and goats; transmissible mink
encephalopathy (TME); chronic wasting disease (CWD) in North American deer and
elk; and bovine spongiform encephalopathy (BSE) which has been reported to have
naturally infected cattle, exotic ungulates, cats (Feline Spongiform Encephalopathy
FSE), non-human primates, and to date 195 human patients world wide (variant CJD
- vCJD) (Table 1.2 and 1.3). A number of other human TSEs have also been
identified. These include: Creutzfeldt-Jakob disease (CJD) that has been shown to
have idiopathic, familial and iatrogenic aetiologies; Fatal Familial Insomnia (FFI) that
also has been observed in a sporadic form; Gerstmann-Staussler-Scheinker disease
(GSS), and Kuru which was an epidemic disease in the Eastern Highlands of New
Guinea during the first half of the last century (Table 1.3).
These fatal neurodegenerative diseases are characterised by long incubation periods
and present with symptoms such as ataxia, trembling, dementia, hallucinations,
depression, visual abnormalities and insomnia in human patients. A number of types
of TSE have been observed that have differing combinations of clinical symptoms
and rate of disease progression, although all share a common underlying pathology of
spongiform vacuolation of the brain. Neuronal loss, astrocytic proliferation and
activation are also commonly observed in these conditions.
Disease is frequently but not always associated with the accumulation of a protease
resistant form of the host glycoprotein PrP, denoted PrPSc, within the central nervous
system and in some cases peripheral lymphoid tissue (Bolton et al., 1982; Bruce et al.,
1989; DeArmond et al., 1993; Hill et al., 1997b; van Keulen et al., 1996). The
normal form of this host protein (PrPc) is required for the development of TSE
disease as mice that lack it are refractory to infection (Bueler et al., 1993; Manson et
al., 1994b). Currently there is no effective treatment, prophylaxis or accurate pre-
mortem test for TSEs. Therefore a greater understanding of this group of diseases
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Table 1.2 TSEs of animal species
TSE Natural host Species Route of
Transmission
First Identified
Scrapie domestic sheep (Ovis aries), moufflon
(Ovis musimon), goats (Capra hirus)
Unknown 1732 (Chelle, 1942)
Atypical
scrapie
domestic sheep {Ovis aries), Unknown (Benestad et al.,
2003)
TME mink {Mustela vison) Putatively oral (Hartsough and
Burger, 1965)
BSE cattle (Bos primigenius familiaris
taurus), greater kudu (Tragelaphus
strepsiceros), eland (Taurotragus oryx),
3 oryx spp. (Oryx spp.), nyala
(Tragelaphus angasi), bison (Bison
bison), goats (Capra hirus); rhesus




(Bons et ah, 1999;
Bons et ah, 1996;
Eloit et ah, 2005;
Kirkwood and
Cunningham, 1994;
Wells et ah, 1987)
FSE domestic cat (Felis catus), cheetah
(Acinonyx jubatus), puma (Felis
concolor), ocelot (Felis pardalis), tiger









cattle (Bos primigenius familiaris
taurus)
Unknown (Biacabe et ah,
2004; Casalone et
ah, 2004)
CWD white tailed deer (Odocoileus
virginianus), mule deer (Odocoileus
hemionus), elk (Cervus elaphus nelosini)
Unknown (Williams and
Young, 1980)
Table 1.3 TSEs of humans








Unknown (spontaneous) Creutzfeldt 1920
Jakob 1921





dura mater, cornea grafts and
hGH,
(Duffy et ah, 1974)
FFI Ataxia, insomnia Familial mutation in PRNP





Ataxia, insomnia Unknown sporadic (Mastrianni et ah,
1999)













Oral (consumption of BSE
contaminated beef), intravenous
(IV by blood transfusion)
(Will et ah, 1996)
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and the role of PrP in them is important for the development of both diagnostics and
treatments.
1.1.1 TSE, spontaneous, familial and acquired
TSE disease unusually occurs in spontaneous, familial and acquired forms. Many of
the spontaneous cases of disease have been demonstrated to be transmissible to new
hosts, suggesting that the de novo synthesis of an infectious agent has occurred
(Brown et ah, 1994). However, spontaneous or sporadic forms of disease may occur
because of an unidentified infectious agent, the source of which may be obscured by
the disease's long incubation time (Diringer, 1995). Equally, spontaneous disease
may theorectically result from a somatic mutation in PRNP (Prusiner, 1991), although
no such events have ever been identified. However, familial clusters of TSE disease
are clearly associated with mutations in the PrP gene (PRNP) (Figure 1.1). These
changes may increase the probability of PrP adopting the disease associated
misfolded conformation. However, others have suggested that these mutations may
enhance susceptibility to external TSE agents, rather than result in pure spontaneous
disease (Manson et ah, 1999). Moreover, clear evidence demonstrates that
susceptibility to acquired TSE disease is influenced by polymorphisms in PrP in a
number of host species (Figure 1.1); this is consistent with the known requirement for
PrP in TSE disease. TSE disease has only been observed in mammals, although all
chordates are proposed to carry Prnp/PRNP, and homologs of PrP have been
identified at the level of protein in fish, turtles and chickens (Rivera-Milla et ah,
2003; Wopfner et ah, 1999).
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1.1.2 Natural/iatrogenic TSE transmissions
Natural transmissions of TSE agents have been observed principally via oral routes
(Kuru, BSE and vCJD) (Mathews et al., 1968; Ward et al., 2006; Wilesmith et al.,
1988) and by undefined contact with infected individuals or a contaminated
environment, which may also be orally mediated (scrapie and CWD) (Greig, 1940;
Miller and Williams, 2004). Iatrogenic transmission by direct contact with infected
CNS material which can be mediated by: cadaver pituitary derived human growth
hormone treatment (Koch et ah, 1985); dura mater (Hoshi et ah, 2000); cornea
transplantation (Duffy et ah, 1974) and intracerebral EEG electrode recordings
(Bernoulli et ah, 1977). Recently, transmission of TSE by blood transfusion has been
reported (Llewelyn et ah, 2004; Peden et ah, 2004). Generally, natural TSE
transmissions exhibit long incubation periods which complicate epidemiological
study. However the majority of acquired TSE diseases have been reported to have an
epidemic nature and a number of recorded outbreaks have been self-limiting owing to
their poor transmissibility and fatal nature (e.g. TME). However, scrapie in sheep
and goats has become established as an endemic disease in a large number of
countries, although it too has an epidemic nature at the level of individual flocks
(Gubbins et ah, 2006). Furthermore, CWD has yet to be successfully controlled and
poses a risk of becoming an endemic disease in North America, although current
evidence does not suggest it has been transmitted to humans (Belay et ah, 2004).
A number of cases of natural TSE disease occurring in different host species from the
same geographical location have been recorded including scrapie in sheep and goats
(Mackay and Smith, 1961; Toumazos, 1991) and CWD in Mule, White-tailed deer
and Elk (Spraker et ah, 1997). This suggests that the TSE agent may have been
transmitted between these species. Additionally, BSE has been naturally transmitted
to fifteen other species including humans (Eloit et ah, 2005; Kirkwood and
Cunningham, 1994; Will et ah, 1996; Wyatt et ah, 1991). However cross-species
transmissions of TSEs are generally limited. Susceptibility to disease is often
observed to be reduced after transmission to a new host species and the incubation
period after transmission is often greatly prolonged (Pattison, 1965). This "species
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barrier" to disease transmission is attenuated on secondary and subsequent passage
within the same species, such that a reduction both in length and the variability of
incubation period is observed (Pattison, 1965). For conventional infectious agents the
species barrier would be interpreted as the requirement for the pathogen to adapt to
the new host species via a selection driven accumulation of mutations within the
pathogens genome.
1.1.3 Experimental TSE transmission
Experimental transmissions of TSEs to sheep, goats, non-human primates and, most
commonly rodents, (hamsters (Mesocricetus auratus), mice (Mus musculus) and bank
voles (Clethrionomys glareolus)) have been demonstrated by a variety of routes
including: intracerebral (Chandler, 1961); intraperitoneal (Kimberlin and Walker,
1988); intravenous (Hunter et ah, 2002); subcutaneous (Kimberlin and Walker,
1978b); skin scarification (Mohan et ah, 2004), intraocular (Fraser, 1996) and
oral/intragastric (Beekes et ah, 1998). TSE infectivity has been observed in the CNS
(Chandler, 1961), lymphoid tissues (Kimberlin and Walker 1988), kidneys, liver,
lung, eye (Brown et ah, 1994), sites of inflammation (Heikenwalder et ah, 2005) and
blood from both clinical and pre-clinical or sub-symptomatic individuals (Hunter et
ah, 2002). However, the tissue distribution of infectivity varies between types of TSE
disease. Transmission is generally most efficient via direct injection into the brain,
such that a high disease incidence and short incubation period are observed, although
significant transmission has been reported by other routes.
A number of mammalian species appear to have enhanced resistance to experimental
cross-species TSE challenge, including pigs (Sus domesticus), rabbits (Oryctolagus
cuniculus) and guinea pigs (Cavia porcellus) (Barlow and Rennie, 1976; Gibbs and
Gajdusek, 1973; Wells et ah, 2003). Equally other species, such as bank voles, have
shown unusual susceptibility to a range of TSE sources (Nonno et ah, 2006).
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1.1.4 Peripheral pathogenesis
The principal route of natural TSE infection appears to be via peripheral routes. The
greatest weight of evidence suggests that the most infection occurs via oral ingestion
of TSE-contaminated material. However, other routes may also be important,
especially direct introduction of infectivity into the blood via transfusion (1.1.2). It is
clear that the peripheral phase of TSE pathogenesis is important to the successful
transmission of some TSE agents and eventual fatal invasion of the CNS. However,
the target organs and form of the peripheral phase differ between TSE strains.
Additionally, the peripheral phase is bypassed when a high dose of TSE infected
material is administered in the periphery. Importantly, this stage of TSE disease is
not associated with pathological changes or a TSE specific immune response
(Mabbott and MacPherson, 2006).
Whether defined cells types are required for specific routes of invasion or whether
passive carriage of TSE infectivity via the blood or lymphatic system occurs has yet
to be experimentally resolved. Experimental systems have suggested that a number
of cell types may be important for the peripheral movement of infectivity, in
particular M-cells in the gut and migratory dendritic cells (Heppner et al., 2001;
Huang et ah, 2002). However the precise in vivo importance of these cell types in
TSE disease remains to be defined. Clear experimental evidence suggests that after
peripheral TSE challenge with some strains the agent accumulates in lymphoid
follicles in the spleen and other organs prior to CNS invasion (Fraser and Dickinson,
1970; Mabbott and MacPherson, 2006). This accumulation requires the presence of
PrP -expressing follicular dendritic cells (FDCs) (Brown et ah, 1999; Montrasio et
ah, 2000); these cells are localised in the B cell zone of mature lymphoid follicles,
their principal function appears to be to retain antigen for presentation to B cells
(Kapasi et ah, 1993). TSE accumulation on FDCs appears to be facilitated by
complement receptor CR2 and complement components (Klein et ah, 2001; Mabbott
et ah, 2001), although the mechanism of replication is not clear. This FDC
accumulation phase is proposed to be important for neuronal invasion, and nearness
of the FDCs to peripheral nerves has been linked to incubation time and hence, by
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inference, speed of neuronal invasion (Prinz et al., 2003). Work by McBride and
colleagues has demonstrated that CNS invasion can occur via both the sympathetic
and vagus nerve (Beekes et al., 1998; McBride et al., 2001). Direct invasion from
blood across the blood-brain barrier is also feasible as PrPSc can readily cross the
barrier (Banks et al., 2004). However, observed patterns of TSE pathology in the
brain are not consistent with direct spread from the blood (Armstrong et al., 2003).
Recent work by Aguzzi and colleagues demonstrated that accumulation of TSE
infectivity can also occur in ectoptic lymphoid tissue induced to form via a number of
experimental inflammatory models and in the mammary glands of some scrapie
infected sheep (Heikenwalder et al., 2005; Ligios et al., 2005; Seeger et al., 2005).
Although this does not appear to alter the incubation period in the affected host, it
does provide insight into potential transmission routes between hosts, especially as
regards inflammation in excretory or secretory organs of TSE infected hosts.
1.2 Pathological hallmarks of TSE disease
1.2.1 Misfolded PrP/PrPSc
TSE disease-associated PrP (PrPSc) has the same primary amino acid sequence as the
normal cellular form of PrP (PrPc). However, its secondary structure is enriched in B-
sheets/B-helix compared to the a-helical form of PrPc (Oesch et al., 1985; Pan et al.,
1993; Riek et al., 1996) (1.4). These differences in conformation have also been
demonstrated using more detailed structural studies which have suggested that PrPSc
may be in the form of trimers, in which amino acids 89-175 form a |3 helical structure
(Govaerts et al., 2004; Wille et al., 2002). This change in conformation is inferred to
lead to the unusual biochemical properties that define PrPSe including its partial
protease resistance, resistance to GPI anchor cleavage by PIPLC treatment, detergent
and chaotrophes insolubility and tendency to form aggregates and fibrils (Caughey et
al., 1990; Oesch et al., 1985; Safar et al., 1998).
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The pattern and type of PrPSc deposition varies both with host and source of the TSE
agent (Brown et al., 2003; Bruce et ah, 1989). In addition the biochemical properties
of PrPSc also differ between TSE sources. These properties include the extent of
resistance to proteinase K, both in terms of time to complete digestion and size of the
C-terminal resistant core, relative solubility in destabilising agents and structural
signatures (Bessen and Marsh, 1992a; Bessen and Marsh, 1994; Collinge et al., 1996;
Kascsak et al., 1985; Parchi et al., 1996). Additionally, clinical TSE disease in both
experimental models and natural cases can occur in the apparent absence of
detectable PrPSc as assayed by standard proteinase K resistance criteria (Dorandeu et
al., 1998; Lasmezas et al., 1997; Manson et al., 1999). In other models PrPSc
deposition is closely associated with TSE pathological hallmarks such as vacuolation
(DeArmond et al., 1993). However, clear dissociation of PrPSc and vacuolation has
also been reported in other systems, suggesting that PrPSc may not directly cause
neurodegeneration (Foster et al., 2001; Nitrini et al., 1997). Additionally, significant
deposition of PrPSc in peripheral lymphoid tissue occurs in the apparent absence of a
pathological effect (Hill et al., 1997b; Sigurdson et al., 2002; van Keulen et al., 1996).
1.2.2 Spongiosis of the CNS
Vacuolar pathology or spongiosis of the CNS is the defining characteristic of TSE
disease (Brownlee, 1940; Hadlow, 1959). However, in some cases of familial disease
associated with mutations in PRNP, particularly GSS (P102L), significant spongiform
change does not occur (Brown et al., 1994). The vacuoles are principally observed in
the dendrites and axons of both grey and white matter and occasionally within the cell
bodies. TSE vacuoles range from 5- 15 pm, although in areas that are densely
affected vacuoles may coalesce to form larger holes up to 40 pm (Baker et al., 1990).
Vacuolation is occasionally observed in healthy animals (Zlotnik and Rennie, 1958).
However, the frequency of vacuoles is much lower than that observed in TSE affected
animals. The degree and extent of vacuolation observed varies between TSE sources
and host species (Fraser and Dickinson, 1968). In some cases vacuolation is highly
restricted to small regions of the brain or cannot be detected at clinical endpoint
(Foster et al., 1996). Additionally, vacuolation is not unique to TSE disease, as
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similar pathology has been reported for murine retroviral infections and in some cases
of Alzheimer's disease (Dimcheff et al., 2003; Hansen et ah, 1989; Kim et ah, 2004).
However, the distribution of the spongiform changes differs from that normally
observed in TSE.
The underlying molecular mechanisms driving the formation of vacuoles are
unknown, as is their relationship to neurodegeneration. Some authors have suggested
they are derived from lysosomes as a consequence of accumulation of misfolded PrP
(Laszlo et ah, 1992). This over-filling of the lysosome is proposed to compromise the
lysosomal membrane leading to the spilling of the compartment's cytotoxic contents
into the cytoplasm (Laszlo et ah, 1992). Others postulate that vacuoles originate from
the ER because of ultrastructural similarities and hence may be a consequence of
elevated autophagy of cellular contents (Baker et ah, 1990). Alternatively,
DeArmond and colleagues have proposed that vacuolation may be the result of'focal
plasma abnormalities of electrolyte and water homeostasis" resulting in membrane
damage and vacuole formation (DeArmond et ah, 1997).
Early authors demonstrated that vacuolation increased linearly during the TSE
incubation period (Fraser and Dickinson, 1968), suggesting their generation reflects
an ongoing disease process. Work by Mallucci and colleagues suggested that
vacuolar change in the early stages of TSE disease was reversible, and is dependent
upon the expression of neuronal PrP (Mallucci et ah, 2003). Interestingly, null
mutations in an E3 ubiquitin ligase (mahogunin) and a transmembrane protein
involved in pigment regulation (attractin) lead to targeted age-dependent vacuolation
in the CNS that reassembles TSE spongiosis (Gunn et ah, 2001; He et ah, 2003).
Whether the pathology observed in these mutant mice is related to that observed in
TSE disease has yet to be experimentally demonstrated, although PrPSc is not detected
in zitter rats in which the attractin gene is mutated (Gomi et ah, 1994).
Vacuolation is often targeted to specific areas of the brain. The pattern and type
(vacuolar size and proximity) of vacuolation is reproduced on subpassage of the TSE
to hosts with the same genetic background (Fraser and Dickinson, 1967; Fraser and
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Dickinson, 1968). This may reflect targeting of the agent to specific cell types within
the CNS. Thus, by examining the region and density of vacuolation it is possible to
recognise different strains of TSE disease. This idea was formalised by Fraser and
Dickinson who defined nine grey matter and 3 white matter areas in inbred murine
hosts which can be easily delineated by anatomical features in which the extent of
TSE could be scored on a semi-quantitative scale (Fraser and Dickinson, 1968). This
allows the systematic and reproducible comparison of an agent/host specific lesion
profile between experimental challenges. However, different TSE sources/strains
may share the same pattern of vacuolar pathology despite having different clinical
presentations, duration of the disease or incubation periods.
1.2.3 Neuronal death and dysfunction
Neuronal death has been observed in TSE disease in both experimental and natural
infections (Fairbairn et al., 1994; Giese et al., 1995; Gray et al., 1999; Jamieson et al.,
2001; Lucassen et al., 1995). Synaptic loss and dendritic abnormalities are often
observed to precede neuronal death in TSE disease, often by long periods
(Belichenko et al., 2000; Jamieson et al., 2001). The brain regions in which neuronal
loss occurs differs between TSE strains (Cunningham et al., 2005; Fraser, 2002),
however a number of subsets of neurons appear to be particularly vulnerable to TSE-
induced death including granular neurons of the cerebellum in sporadic CJD and a
group of parvalbumin positive GABAergic inhibitory neurons (Budka, 2003). Most
evidence suggests that TSE neuronal loss occurs via apoptosis (Budka, 2003;
Fairbairn et al., 1994; Giese et al., 1995; Gray et al., 1999; Jamieson et al., 2001;
Lucassen et al., 1995), although death by autophagy has also been proposed as
potentially important (Liberski et al., 2004). Although a number of PrP murine
transgenic models exhibit dramatic apoptotic phenotypes (Chiesa et al., 2000;
Hachiya et al., 2005), the relevance of these models to natural TSE disease is unclear.
Apoptosis is mediated by a cascade of cysteine proteases/ caspases through which
intracellular or extracellular death signals are transduced to effector caspases which
result in the ordered demise of the cell, characterised by endonuclease DNA cleavage.
No inflammatory response is linked to this ordered cell death.
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The death signal which elicits neuronal apoptosis during TSE has not been
categorically determined. PrPSc is an obvious candidate; some authors have report a
correlation of PrPSc and cell death in vivo (1.4.3). Work using transgenic mice, in
which neuronal PrP expression was eliminated after the onset of TSE pathology by
Cre-lox gene-excision or in which expression was limited to astrocytes, has suggested
that neuronal death requires the expression of neuronal PrPc (Brandner et ah, 1996;
Mallucci et ah, 2003), although another study did not replicate this finding (Jeffrey et
ah, 2004). The work of Brandner et al, Mallucci et al, has led to the suggestion that
the death signal may be generated by the interaction of PrPc with PrPSc. Furthermore,
antibody crosslinking of PrP causes cell death in support of PrPc's role in the
transduction of death signals (Solforosi et ah, 2004). Others have suggested that
apoptotic signals may be elicited by ER in response to PrP misfolding in this
compartment (Eletz et ah, 2003). However, there is limited evidence for
accumulation of PrPSc in this compartment in vivo apart from in some very rare
inherited forms of TSE. Thus the probability of this mechanism being relevant to the
majority of transmitted TSE disease appears remote.
1.2.4 Astrogliosis and activation of microglia
Activation (upregulation of specific proteins including glial fibrillary acidic protein)
and proliferation of astrocytes are commonly observed during TSE disease. Although
astrogliosis is also a common feature of many other brain diseases including viral
infections such as HIV, the regulatory pathway by which astrocytes are activated has
been suggested to differ in TSE disease (Titeux et al., 2002). Importantly, once
activated and recruited, astrocytes will remain in the damaged region, even after
resolution of the acute phase of the astrocyte response, where they may permanently
alter the local environment. The normal function of astrocytes within the brain
includes the maintenance of a homeostatic extracellular environment, particularly the
concentration of glutamate, and the coupling of blood flow and supply of metabolic
substances to neurones (Sofroniew, 2005). In contrast the role of activated astrocytes
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is less clearly defined, and the context of activated astrocytes greatly influences their
precise function in vivo.
More recently, the activation of microglial, and an atypical inflammatory response
characterised by the upregulation of a subset of microglial-associated cytokines, has
been shown to occur during CNS TSE pathogenesis (Cunningham et al., 2002; Felton
et al., 2005; Williams et al., 1997b; Williams et al., 1994; Williams et al., 1995). TSE
incubation periods are slightly prolonged in mice that lack some of these factors,
supporting a specific role of microglia in TSE disease (Felton et al., 2005; Schultz et
al., 2004). Additionally, activation of microglia has been shown to precede neuronal
cell loss in a mouse scrapie model, suggesting that their activation may mediate TSE
neurodegeneration (Williams et al., 1997a). Activated microglia have also been
shown to correlate with the type of PrPSc deposited in vivo (Puoti et al., 2005).
Furthermore, PrPSc has been reported within microglial in mouse-passaged scrapie
suggesting that these cells may have a PrPSc-clearance function (Bruce et al., 1989).
1.3 TSE strains and strain typing
The great diversity of clinical signs and pathology observed in natural cases of TSE in
genetically identical hosts illustrates the existence of multiple strains of the agent
(1.1). The idea of TSE strains was first proposed by Pattison and Millison after they
isolated two distinct clinical phenotypes (scratching and drowsy) of scrapie in goats
(Pattison and Millson, 1961), the clinical symptoms of which could be reproduced
upon transmission to new hosts. Later work developed the definition of scrapie strain
by transmission to two inbred strains of mice (VM and C57/B6) and their F1 cross
(Bruce, 2003). These wild type mice have differing susceptibilities to TSEs
principally because of polymorphisms at amino acid 108 and 189 in PrP (Moore et
al., 1998). Repeat repassage of the original TSE isolate in mice is usually required
prior to strain definition because of the species barrier effect, as stabilisation of the
incubation period is required prior to strain classification. By comparison of this
reproducible incubation period and the associated pattern of vacuolar targeting (lesion
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profile) in the mice it is possible to categorise the nature of the original TSE agent
(Fraser and Dickinson, 1967; Fraser and Dickinson, 1968). By this method, the TSE
agent causing both BSE and vCJD was demonstrated to be caused by an identical
strain, formally proving that BSE could cross the species barrier to humans (Bruce et
ah, 1997). Over twenty different TSE strains have been isolated by this method from
a range of TSE sources (Bruce and Dickinson, 1987). In addition to differing in
lesion profile and incubation period, the pattern and type of PrPSc-deposition also
differs between strains (Brown et ah, 2003).
Multiple strains have been isolated from single TSE sources suggesting the
concurrence of multiple strains in natural hosts, or that strain isolation results in a
change of the TSE agent (Kimberlin and Walker, 1978a). A few strains have been
repeatedly isolated, whereas others have only been observed on a single occasion
(Bruce and Dickinson, 1987). This suggests that either the frequencies of strains vary
within hosts or natural population or that some strains are more able to establish
infection in murine hosts. Most TSE strains are stable when passaged within an
inbred host population, whereas transmission to a new host population often results in
a change in strain characteristics (Bruce and Dickinson, 1987). However, strain
characteristics have been observed to alter even after multiple stable passages within
an inbred population (Bruce and Dickinson, 1987). Some TSE strains exhibit
dominance or an interference effect in co-infections of hosts or in cell culture systems
(Dickinson et al., 1975; Dickinson et al., 1972; Nishida et al., 2005). In some cases
infection with a dominant but slow strain with a long incubation prevented the
establishment of infection with a more virulent TSE strain, effectively prolonging the
lifespan of the challenged host. These data suggest that TSE strains may compete for
some limited in vivo resource.
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1.4 The nature of the TSE agent
1.4.1 The prion hypothesis
The characteristic long incubation periods of TSE disease led to early suggestions that
the causative agent was a slow virus (Gibbs et ah, 1965). However, unlike
conventional viruses, infectivity of the TSE agent is not greatly diminished by
treatment with radiation or nucleases (Alper et al., 1967; Alper et ah, 1966; Hunter
and Millson, 1967; Latarjet et ah, 1970; Millson et ah, 1976; Prusiner et ah, 1980).
However, TSE infectivity was shown to be sensitive to phenol, proteases and urea
(Hunter et ah, 1969; Hunter and Millson, 1967). This led to the suggestion that the
agent does not have a nucleic acid component but may be a self-replicating protein
(Griffith, 1967). This idea was refined by Prusiner (1982) who hypothesised that the
TSE agent is a form of infectious protein or prion (proteinaceous infectious particle),
based upon its unusual biochemical properties. Subsequent work identified a host
protein PrP (prion related protein) as the prime prion candidate and demonstrated that
it was expressed at similar levels in the brains of both TSE diseased and healthy
individuals (Bolton et ah, 1982; Oesch et ah, 1985). It had been previously known
that an inherited host gene influenced the scrapie incubation in mice (Sine)
(Dickinson et ah, 1968). Two alleles were postulated, s7 (short scrapie incubation
time) and p7 (prolonged scrapie incubation time), based upon the segregation of ME7
incubation periods in the F1 cross of the RIII and VM inbred mouse strains. Further
work demonstrated that the incubation period of other TSE strains also differed
between these two lines of mice (Bruce et ah, 1991). It was later shown using gene-
targeted replacement of the PrP gene Pmp, that Prnp was synonymous with the
murine scrapie susceptibly factor Sine (Moore et ah, 1998). The s7 phenotype was
demonstrated to be caused by the Prnp" (108L and 189T) allele and the p7 phenotype
by Prnpb (108F and 189V) allele.
It was proposed that the host protein PrP could exist in both a normal cellular state
(PrPc) and a prion or scrapie-associated state (PrPSc) and that PrPSc was autocatalytic
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(Prusiner, 1991). The prion hypothesis thus suggests that PrPSc is infectious by
causing PrPc to adopt its pathogenic state, that PrPSc can spontaneously form de novo
and that changes in the primary sequence of PrP predispose this to occur. This model
then neatly explains the observed infectious, apparently spontaneous and familial
cases of TSE disease as the only factor required for the diseased state is expression
and subsequent misfolding of a host protein. In vitro conversion assays using purified
radio-labelled normal PrPc substrate and a vast excess of PrPSc have demonstrated
that PrPSc can induce PrPc to adopt its aberrant biochemical characteristics and hence
presumably its conformation, providing evidence of the autocatalytic nature of PrPSc
(Kocisko et ah, 1994).
PrP is essential for TSE disease, as mice in which Prnp had been ablated (PrP0/0 or
PrP null) are completely resistant to TSE disease (Bueler et al., 1993; Manson et ah,
1994b). Additionally, overexpression of PrP in mice has been linked to spontaneous
spongiform neurodegeneration and shortening of TSE incubation periods (Westaway
et ah, 1994). The identification of mutations in the human PrP gene, PRNP, in
familial clusters of TSE disease, provided further evidence of a link between PrP and
the TSE disease (Figure 1.1) (Doh-Ura et ah, 1989; Goldfarb et ah, 1991; Hsiao et ah,
1989; Mouillet-Richard et ah, 1999; Owen et ah, 1989). Additionally,
polymorphisms in the Prnp/PRNP have been linked to TSE disease incidence in
natural populations, and to susceptibility to, and incubation periods after,
experimental TSE challenge (Barron et ah, 2005; Bishop et ah, 2006; Goldmann et
ah, 1994; Moore et ah, 1998; Palmer et ah, 1991).
However, these conventional genetic data do not prove that PrP is sufficient for TSE
disease development, only that it is necessary. Overexpression of human PRNP,
carrying a GSS linked mutation, in transgenic mice led to the development of
transmissible spontaneous TSE disease, providing evidence that PrP was sufficient
for development of disease (Hsiao et ah, 1994; Hsiao et ah, 1990). However, the
failure to replicate this result in a comparable model with a low expression level or in
an alterative murine transgenic system questioned the validity of the original
conclusions (Barron et ah, 2001; Manson et ah, 1999; Nazor et ah, 2005).
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Figure 1.2 Model of misfolding of PrP (based on Baskakov et al 2002 and
Bocharova et al 2006)
a-PrP monomer
O
Thioflavin binding Thioflavin binding
PK sensitive p« resistant
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Recently, two novel methods of generating TSE infectivity ex vivo have provided
strong evidence in support of the prion hypothesis. TSE infectivity was reported to
be generated de novo by inducing recombinant PrP to misfold in vitro (Legname et
al., 2004; Legname et al., 2005). However, this form of artificial prion was only
infectious to transgenic mice which overexpress a truncated form of PrP. Moreover,
the titre of infectivity generated in this experiment was very low compared to the
amount of misfolded PrP used to challenge the animals. Ex vivo replication of TSE
infectivity has also been demonstrated in an independent system (Castilla et al.,
2004). In this case PrPc was induced to misfold using Protein Misfolding Cyclic
Amplification (PMCA), the reaction was seeded with clinical endpoint TSE infected
hamster brain and repeat rounds of incubation at 37 °C and sonication were used to
mediate amplification of proteinase K resistant PrP (Chapter 7). Many rounds of
serial PMCA were undertaken to significantly dilute the original TSE material. A
significant increase in infectivity was detected in the PMCA generated PrPRcs.
However, similarly to the synthetic prion work the level of infectivity was found to be
less than that predicted by the amount of PrPRes formed (Castilla et ah, 2005).
The discrepancy between the amount of misfolded PrP and TSE infectious titre
presented in these works suggests that the classical definition of the prion as
proteinase K resistant PrP may be flawed. Many previous pieces of evidence also
support this conclusion; both TSE infectivity in the absence of PrPSc and PrPSc in the
absence of infectivity have been previously reported in a range of experimental and
natural systems (Lasmezas et ah, 1997; Manson et ah, 1999; Prusiner et ah, 1990). A
discussion paper presented by Weissmann in 1990 suggested that the prion may
correspond to a subset of misfolded PrP, which he named PrP* (Weissmann, 1991).
The conformation and biophysical properties of PrP* remain to be determined.
However, recent work has suggested that TSE infectivity correlates with PrP
aggregate size and that mid-sized (14-28 PrP molecules) oligomers are more
infectious than those that are very small or larger aggregates of PrPSc, raising the
possibility that size in addition to conformation defines the prion (Silveira et ah,
2005).
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An early model of PrP replication suggested that that PrPSc acts as a template to
overcome the energy barrier of conversion of PrPc to PrPSc and that PrPSc is unique to
TSE disease (Prusiner, 1991). An alternate theory suggested that PrPc and PrPSc are
in reversible thermodynamic equilibrium and that introduced PrPSc seeds stabilize and
sequester endogenous PrPSc favouring its further production (Jarrett and Lansbury,
1993). This model hence suggests that PrPSc is not unique to TSE disease. Recent
experimental evidence has suggested that the PrP misfolding pathway may consist of
multiple steps, which include the formation of a B-rich structure, followed by
extensive structural rearrangement that may involve domain swapping between PrP
molecules (Figure 1.2) (Baskakov and Bocharova, 2005; Baskakov et al., 2002;
Bocharova et al., 2006). These in vitro experiments support the autocatalytic nature
of PrPSc and further suggest that the misfolded form's ability to induce PrPc to
misfold may be important to prion propagation (Baskakov and Bocharova, 2005).
Further experimentation is required to determine which of these forms of misfolded
PrP most closely resemble the in vivo TSE agent.
Data from in vitro conversion assays suggest that the conversion of PrPc to PrPSc may
be facilitated by additional factors in vivo (Deleault et al., 2005; Deleault et al., 2003;
Saborio et al., 1999). In particular a number of polyanionic molecules, including
RNA, have been suggested as potent promoters of conversion in some systems
(Deleault et al., 2005; Deleault et al., 2003). PrPSc is often tightly associated with a
poly-glucose scaffold in vivo which is distinct from the glycans that are conjugated to
the protein via asparagine 180 and 196 (Dumpitak et al., 2005). This scaffold may be
important in the formation or stabilisation of the misfolded form in vivo. Other
groups have suggested that the conversion factor is a brain and muscle specific
protein which fractionates with lipid rafts (Soto, 2006). Although there is clear
evidence that these factors can promote conversion in vitro, in vivo evidence of their
efficacy has yet to be presented. However given the crowded nature of the cellular
environment it would seem probable that additional factors influence the in vivo
generation and stabilisation of PrPSc.
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Propagation of the aberrant conformation of PrPSc in vivo requires that its rate of
formation exceeds its rate of clearance. Despite the proteinase resistance of PrPSc, it
is relatively efficiently degraded. Estimates of its half life range from 15-36 hours
(Borchelt et al., 1990; Peretz et ah, 2001; Safar et ah, 2005). Indeed, in a transgenic
murine model in which PrPc expression and hence de novo PrPSc formation can be
reversibly regulated, clearance of a significant load of PrPSc from the CNS has been
reported (Safar et ah, 2005). Numerous pharmacological studies have suggested that
degradation of PrPSc principally occurs in lysosomes and acid endosomes (Doh-Ura et
ah, 2000; Gilch et ah, 2001; Supattapone et ah, 1999; Supattapone et ah, 2001),
although both the precise mechanism and the effect of TSE strain on this process have
yet to be elucidated.
The mechanism of cell to cell spread of PrPSc within the CNS has yet to be
determined and may occur by diffusion. Recent work has suggested that cell to cell
spread may be mediated by exosomes that are derived from the fusion of multi¬
vesicular bodies with the plasma membrane (Fevrier et ah, 2004). This hypothesis is
c
supported by data that suggest that PrP conversion occurs most efficiently when PrP
and PrPSc are inserted in contiguous membranes (Baron et ah, 2002). Work by
Pinheiro and colleagues has suggested that the lipid composition of membranes
greatly influences the preferred conformation of PrP (Pinheiro, 2006). Thus
localisation within in the cell membrane may contribute to PrPSc propagation.
Opponents of the prion hypothesis have long cited the great number of TSE strains as
a major flaw in the hypothesis (Bruce and Dickinson, 1987; Farquhar et ah, 1998).
This is mainly owing to the molecular biology dogma that polypeptide sequence
defines protein conformation, based upon the seminal work of Anfinsen (Anfmsen,
1973), and hence the diversity of TSE strains can not be encoded by a single protein
sequence. However, many protein sequences can adopt more than one conformation,
often as part of their normal function.
Experimental evidence suggests that multiple conformations of PrPSc do exist and that
these may correlate with different TSE strains. The first evidence for this was
21
presented by Bessen and Marsh, who isolated two clinically distinct strains of TSE in
hamsters that also reproducibly differed in the biophysical properties of PrPSc (Bessen
and Marsh, 1992a; Bessen and Marsh, 1994). Most notably the size of the PK-
resistant core significantly differed between the two strains (Bessen and Marsh,
1992a). N-terminal amino acid sequencing after PK digestion has demonstrated that
these size differences are the result of an alteration in the extent of proteinase
sensitivity of the N-terminus. This difference in N-terminal cleavage is proposed to
occur because of conformational differences in PrPSc that results in variation in the
PK accessibility (Bessen and Marsh, 1994). Similar differences in the size of the PK
resistant core or PrPSc types have also been reported for different isolates of bovine
and human TSE diseases (Biacabe et al., 2004; Casalone et al., 2004; Collinge et al.,
1996; Parchi et al., 1996), and inconsistently for sheep scrapie (Hill et al., 1998; Hope
et al., 1999; Sweeney et al., 2000). Difference in the conformation of PrPSc from TSE
strains has also been demonstrated by an independent method based upon variation in
the sensitivity of PrP from different strains to undergo denaturation in guanidine
hydrochloride, as detected by the availability of an internal epitope which is shielded
in PrP (Safar et al., 1998). Propagation of PrPSc conformation ex vivo has been
demonstrated, providing evidence of the feasibility of TSE strain being maintained in
vivo by PrPSc conformation (Bessen et al., 1995; Soto et al., 2005). However,
significant co-occurrence of multiple PrPSc types in the same host has been
demonstrated in sporadic CJD patients (Head et al., 2004; Puoti et al., 1999). This
suggests that either PrPSc type, and hence potentially conformation, does not
categorically define TSE strain or that multiple strains of TSE coexist in the same
host.
In addition to variation in the size of the PK resistant core, differences in the
glycoform (ratio of glycotypes) of PrPSc have also been shown to correlate with TSE
strain (Collinge et al., 1996; Parchi et al., 1996). For example, BSE in cattle, vCJD
from human patients and both isolates passaged in mice display a very distinctive,
predominantly di-glycosylated glycoform (Collinge et al., 1996; Hill et al., 1997a).
This reproducibility of PrPSc glycoform in numerous hosts infected with the same
TSE source led to the suggestion that glycoform itself may encode TSE strain
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characteristics (Collinge et al., 1996). However this observation has a number of
alternative explanations, as glycoform may equally be a consequence of strain rather
than its cause. The glycoform of PrPc varies between regions of the brain
(Somerville, 1999) and PrPSc glycoform may occur as a result of the regional
targeting of PrPSc formation observed in TSE disease (Bruce et al., 1989). Similarly,
subcellular differences in the localisation of PrP glycotype may influence resultant
PrPSc glycoform. Additionally, a PrPSc glycotype will represent an equilibrium state
determined not only by rate of formation but also rate of clearance. It is also
important to emphasise that glycoform analysis of PrPSc is generally made after
proteinase K (PK) digestion and thus assumes that the different glycotypes of PrPSt
have equal resistance to PK. Alternatively, TSE infection may alter the glycosylation
of all proteins including PrPc (1.8). Glycoforms may result from variation in the
propensity of each glycotype to adopt the misfolded conformation of a TSE strain;
thus the resultant glycoform will be determined by the relative abundance of each
glycotype at the site of conversion and the probability of each converting, as
suggested by in vitro conversion assays (Vorberg and Priola, 2002).
Although significant evidence supports the prion hypothesis a number of major
questions regarding it remain to be addressed. For example how does PrPSc
conformation result in the manifestation of TSE strain characteristics? Additionally,
what confers the transmissibility of PrPSc as compared to other similarly misfolded
proteins that are not infectious (AB, Huntingtin)? Moreover, what aspects of PrPSc
dictate TSE host range?
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1.4.2 The Virino hypothesis
An alternative to the prion hypothesis has been proposed by some TSE workers
(Bruce and Dickinson, 1987; Farquhar et al., 1998). This virino hypothesis proposes
that TSE strain characteristics are conferred by an "agent specific replicable
information molecule" (nucleic acid) tightly associated with a form of PrP, and that
PrP is a disease rate limiting host factor (Farquhar et al., 1998). The observed
resistance of the TSE agent to UV non-penetrating radiation may be attributable to
shielding of this hypothesized nucleic acid by PrP, as is observed in the viroid
subgroup of plant viruses (Diener, 1972). This unusual property is explained by
energy transfer between the nucleic acid and protein which elevates the dose of UV
tolerated (Millson et al., 1976). Similarly, X-ray radiation inactivation studies can be
interpreted to show that the TSE agent may contain between 2-4 kilobases of nucleic
acid, if results are calibrated against known viruses that displayed enhanced resistance
to radiation (Chesebro, 1999). Furthermore, radiation tolerance may be further
enhanced if the agent can self repair as is observed for human immunodeficiency
virus (Chesebro, 1999). Thus the inactivation evidence which originally suggested
that the TSE agent may be devoid of nucleic acid, does not disprove that the agent
may be viral in nature. However, there is a lack of any experimental evidence for the
existence of a TSE specific nucleic acid despite numerous attempts to identify it.
1.4.3 The neurotoxic form of PrP
The form of PrP which causes neural degeneration may differ from that which
transmits TSE disease to new hosts (Hill and Collinge, 2003). The neurotoxicity of a
number of forms of PrP has been demonstrated in cell culture, including peptides that
correspond to amino acid 106-126 of human PrP, N-terminal truncated PrPSc, fibrillar
or P-oligimeric recombinant PrP (Forloni et al., 1993; Hetz et al., 2003; Novitskaya et
al., 2006). Alternative localisations of PrP, including in the cytoplasm (cytPrP) or
across the Golgi membrane (PrPCtm) may be neurotoxic in vivo (Hegde et al., 1998;
Hegde et al., 1999; Ma et al., 2002; Stewart and Harris, 2005). However the
relevance of these forms of PrP to natural TSE disease is unclear, although an up
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regulation of PrPCtm has been suggested in some human familial TSE cases (Hegde et
al., 1998). The subcellular localisation of a particular PrP conformation is likely to
affect its behaviour and may also modify conformation itself. Indeed, the
conformation of huntingtin protein, the causative agent of Huntington's disease, has
been previously reported to be affected by its cellular localisation (Rousseau et al.,
2004).
1.4.4 Non PrP prions
Many other proteins adopt disease-associated misfolded conformations in vivo,
indeed some have suggested that all proteins have an innate tendency to misfold
(Stefani and Dobson, 2003). However, only a limited number of proteins have been
observed to exhibit autocatalytic prion-like properties in vivo. In particular, a number
of yeast proteins exhibit prion-like properties. These prions are able to propagate their
misfolded conformation to daughter cells and mating partners (Ross et al., 2005).
Although the prion state in yeast has a clear phenotype, it is not associated with
reduced host fitness in an experimental setting and appears to be highly conserved
(Lindquist, 1997). Thus although yeast prions may reflect the proposed propagation
of PrPSc they do not share its pathogenic role. The yeast prions have diverse
functions including catabolic regulation (Ure2 associated with the [URE3] prion trait)
and suppression of nonsense mutations (Sup35 associated with the [RS7+] prion trait)
(Stansfield et al., 1995; Wickner, 1994). These proteins encode a domain that adopts
a specific conformation associated with the prion like state. This region of the protein
is separate from the protein's functional domains. In contrast, the PrP putative
functional domain is also that which adopts the prion state (Lindquist, 1997). Despite
these differences, studies of yeast prions may be informative as to the propagation of
the PrPSc state.
Propagation of the [77S7+] prion state in budding yeast is influenced by the expression
level of chaperones (Chernoff et al., 1995), implicating the regulation of protein
folding as a key determinate of prions. Work in yeast has demonstrated that the
conformation variation in prions correlates with phenotypic differences, lending
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support to the hypothesis that misfolded PrP could encode TSE strain diversity
(Tanaka et ah, 2004). King and colleagues have presented data demonstrating that in
vitro generated misfolded Sup35p can infect yeast cells and cause them to change
phenotype in support of the prion hypothesis (King and Diaz-Avalos, 2004).
Additionally, Chien and colleagues have demonstrated a species barrier to yeast prion
propagation and that propagation of the prion state between species is associated with
a change in prion structure (Chien et ah, 2003; Chien and Weissman, 2001),
supporting the similar finding for PrPSc (Peretz et ah, 2002).
1.5 The cell biology and function of PrPc
Prnp is a single copy gene located on the short arm of human chromosome twenty.
Proximal to the Prnp is the related gene Prnd (Doppel) and the putative tumour
suppressor RASSF2 (Deloukas et ah, 2001). The open reading frame is located within
a single exon such that no splice variants of the gene occur. Consistent with its role
in neurodegenerative disease, PrP is predominately expressed in neurons from early
in development, although it is observed at lower levels in many other tissues
(Manson et ah, 1992b) (1.5.2). Some studies have reported that the expression of PrP
displays a circadian rhythm, with a peak of expression occurring 2 hours after onset
of the active dark period in rats (Cagampang et ah, 1999). The normal biological
function of PrPc has yet to be elucidated, as PrP0/0 mice have only subtle phenotypes
which differ between lines of transgenic mice; these include alterations in circadian
rhythms, sleep regulation, synaptic transmission and impaired long-term-potentiation
(LTP) (Bueler et ah, 1992; Manson et ah, 1994a; Tobler et ah, 1996). A number of
biological roles for PrPc have been suggested including: a role in copper homeostasis
(Brown et ah, 1997), resistance to oxidative stress (Brown et ah, 1998), cell survival
and neurite outgrowth (Chen et ah, 2003; Kuwahara et ah, 1999), apoptosis (Brandner
et ah, 1996; Solforosi et ah, 2004) and signal transduction (Mouillet-Richard et ah,
2000).
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PrPc contains two structural domains: an N-terminal region of around 100 amino
acids which is highly flexible during nuclear magnetic (NMR) spectroscopy and a C-
terminal region which forms a globular structure amenable to NMR (Donne et ah,
1997; Riek et ah, 1997). The structure of recombinant PrPc from different species,
including those with low amino acid identity, is remarkably similar (Calzolai et al.,
2005; Donne et al., 1997; Lysek et al., 2005; Riek et al., 1997). Replication of this
structure using native glycosylated bovine protein has also been shown, validating use
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of recombinant protein to investigate PrP structure (Hornemann et al., 2004). PrP
from all species contains three a-helices (144-154, 175-193 and 200-219 in human
PrP) the length of the third is species specific (Calzolai et al., 2000). Additionally,
the extent of the structural rigidity of the loop between helix one and two, and the
length of a short parallel B-sheet (160-163 in hamster) also varies between species
(Calzolai et al., 2000; Gossert et al., 2005).
1.5.1 Post-translational processing of PrPc
PrP contains two N-glycan attachment sequences (N-X-T) at amino acids 180 and
196 in mice (Figure 1.1) (Locht et al., 1986). These sites are variably glycosylated in
vivo such that un-, mono- and di-glycosylated glycotypes are observed (Rudd et al.,
1999; Stimson et al., 1999). Although there are a number of potential O-
glycosylation sites in PrP, none is utilised in vivo (Rudd et al., 2001). The relative
ratio of the N-glycotypes varies between areas of the brain and species, however the
species variation observed may be caused by differences in antibody binding
(Betemps and Baron, 2001; Somerville, 1999; Zanusso et al., 1998). Both N-
glycosylation sites are conserved in Prnp/PRNP from all species, suggesting the N-
glycans play an important role in the protein's function (Rivera-Milla et al., 2003; van
Rheede et al., 2003; Wopfner et al., 1999). The biological significance of each of the
glycotypes of PrP (un-, mono- and di-glycosylated) is unknown. However, protein
attached glycans have been shown to have a wide range of biological functions in
other proteins, most notably conformational stabilisation and control of cellular
trafficking. Additionally, glycosylation of host proteins has been implicated in
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resistance to infectious disease, principally by a prevention of protein-protein
interactions (Marin et al., 2003; Wentworth and Holmes, 2001).
PrP is targeted to the endoplasmic reticulum (ER) by its hydrophobic N-terminal
signal sequence (amino acids 1-23), which is subsequently cleaved (Turk et al.,
1988). Recent work has suggested that PrP's signal sequence is complex and less
efficient compared to that of other proteins, suggesting that in vivo a proportion of
PrP may not be translocated into the ER but remain un-glycosylated and
cytoplasmatic (Rane et al., 2004). Indeed cytoplasmic but nucleus-excluded PrP
(cytPrP) has been observed in a subset of cells in murine brains (Barmada et al.,
2004; Mironov et al., 2003). These cytPrP cells are interneuronal in character, have a
normal distribution of another GPI-anchored protein, Thy-1, and do not display any
signs of apoptosis (Mironov et al., 2003). Thus PrP appears to have a cell type
specific localisation pattern in vivo.
Within the oxidising environment of the ER, a disulphide bond between cysteine
residues 179 and 214 (hamster sequence) is formed (Turk et al., 1988). Also within
this compartment a glycosyl-phosphatidylinositol (GPI) anchor is attached to serine
231 of PrP with the concurrent cleavage of the carboxy terminus (amino acids 232-
254), leading to membrane anchorage of the protein (Stahl et al., 1990; Stahl et al.,
1987). Although GPI anchorage is the predominant method of PrP membrane
attachment in vivo, other mechanisms also occur. A small proportion of PrP exhibits
transmembrane topology, in which amino acids 111-134 are inserted across the
membrane, such that only the N-terminus of PrP reaches the ER lumen (PrPNtm) and
hence is not glycosylated (Hegde et al., 1998). Additionally, transmembrane PrP is
also observed in the reverse orientation, with its C-terminal within the ER lumen and
a cytoplasmic N-terminal that retains the ER signal sequence (PrPCtm) (Hegde et al.,
1998). The normal function of these forms of PrP is unknown, although PrPCtm has
been suggested to have a role in the pathogenesis of some inherited forms of TSE
(Hegde et al., 1998), although its production is not elevated by the majority of TSE
associated PrP mutations (Stewart and Harris, 2001).
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Early work suggested that membrane anchorage is essential for the glycosylation of
PrP (Walmsley et ah, 2001). However further studies revealed that these results were
an artefact and attributable to a requirement for the site of N-glycan attachment to
access the oligosaccharyltransferase prior to detachment of the ribosome (Walmsley
and Hooper, 2003). This enzyme transfers the core high mannose N-glycan (GIC3-
Man9-GlcNAc2) from its dolichol carrier to the amide nitrogen of asparagines (Taylor
and Drickamer, 2003). The final glycotype of PrP is thus determined at this early
stage in the ER. In vitro translation has suggested that PrP may be preferentially
glycosylated at the first site, suggesting that PrP may be predominately mono-
glycosylated at the first attachment site (Walmsley and Hooper, 2003), consistent
with the in vivo observation of preferential glycosylation of the first site (Stahl et al.,
1993). However, antibody binding experiments have suggested that both mono-
glycosylated forms of PrPc occur in sheep and mice (Moudjou et al., 2004). Rapid
folding of PrP may prevent access of asparagines to the active site of
oligosaccharyltransferase and hence lead to the un- or mono-glycosylated forms
(Ermonval et al., 2003). Inhibition of the formation of the Cys179-Cys214disulphide
bond that is likely to slow the rate of folding has been linked to an increase in PrP
glycosylation (Capellari et al., 1999). Equally, N-glycan attachment at the first site
has been shown to facilitate formation of the disulphide bond, demonstrating the
close link between glycosylation and protein folding (Bosques and Imperiali, 2003).
The attached glycans are then trimmed in the ER, first glucose molecules are removed
by ER glucosidase I and II and then the terminal mannose by ER a 1,2 mannosidase
(Taylor and Drickamer 2003). Following this, correctly folded proteins are
transported to the Golgi apparatus for further glycan modification. Within the Golgi,
further mannose residues are removed in the cis compartment such that mature PrPc
contains no oligomannose species, in contrast to many glycoproteins found in the
brain (Rudd et al., 1999). Further sugars are then added to the core N-glycan moiety,
resulting in a great diversity of mature glycotypes of PrP , over 50 of which have
been identified by 2-D electrophoresis (Pan et al., 2002). These N-glycans are
heavily sialylated and contain bisecting GlcNAc, a typical pattern for brain sugars
(Rudd et al., 1999; Stimson et al., 1999). The profile of the glycans attached to the
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two sites is broadly similar, however the second site carries more highly processed
acidic structures which result in a different range in molecular weight at this site
(2000-3020 kDa) as compared to the first (1600-2340 kDa) (Stimson et ah, 1999).
1.5.2 Localisation of PrPc
In the central nervous system wild type PrPc is principally observed within the
neuropil (dendrite-axon-synapse complex) (Barmada et al., 2004; Fournier et ah,
2000; Haeberle et ah, 2000; Mironov et ah, 2003; Moya et ah, 2000; Sales et ah,
1998). Early reports that suggested PrP was principally localised within only a subset
of cell bodies can be attributed to the destruction of plasma membrane associated
PrPc during tissue embedding and dehydration (Bendheim et ah, 1992; DeArmond et
ah, 1987; Ford et ah, 2002a; Manson et ah, 1992b; Piccardo et ah, 1990). The
amount of PrP detected varies between regions of the brain, high levels have been
consistently reported in the cortex and hippocampus (Barmada et ah, 2004; Mironov
et ah, 2003; Sales et ah, 1998), although species and antibody differences in the
pattern (Liu et ah, 2001; Moya et ah, 2000; Sales et ah, 1998) and regional
differences in glycoform (Liu et ah, 2001; Somerville, 1999) have also been
reported.
A number of groups have reported a preferential localisation to the synapse in vivo
(Fournier et ah, 2000; Haeberle et ah, 2000; Moya et ah, 2000; Sales et ah, 1998).
However, other studies have not reproduced this result (Laine et ah, 2001; Mironov et
ah, 2003). Others have reported preferential localisation of PrP to cellular processes
associated with intraparenchymal blood vessels (Verghese-Nikolakaki et ah, 1999).
Specific PrP localisation to Purkinje cells has also been reported (DeArmond et ah,
1987; Ford et ah, 2002a; Manson et ah, 1992a; Piccardo et ah, 1990), although a
number of other groups have not observed this (Bendheim et ah, 1992; Mironov et ah,
2003; Sales et ah, 1998). Additionally, some groups have reported PrP localisation
to glial cells (Laine et ah, 2001), although this has not been consistently observed
(Mironov et ah, 2003). In addition to CNS, PrPc is also observed in peripheral nerves
and has also been reported in the FDCs in the spleen and other organs, in circulating
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leuckocytes, in muscle (particularly cardiac) and in lung, although the levels observed
in peripheral tissues are much lower than in the CNS (Bendheim et al., 1992; Ford et
al., 2002b; Manson et al., 1992a; McBride et al., 1992).
PrPc plasma membrane staining is patchy, consistent with biochemical studies which
have demonstrated that PrP is localised in lipid rafts (Madore et al., 1999; Vey et al.,
1996). These domains are enriched for cholesterol, sphinolipids and other GPI
anchored proteins and are classically defined by their resistance to extraction in cold
non-ionic detergent (Brown and Rose, 1992). Lipid rafts are proposed to act as signal
centres that transduce extracellular information into the cells interior (Helms and
Zurzolo, 2004). Specific localisation of PrPc may occur as early as in the Golgi
apparatus, as has been reported for other GPI anchored proteins (Simons and van
Meer, 1988). Work has shown that PrPc is localised to a subtype of rafts (Madore et
al., 1999; Sunyach et al., 2003). These rafts differ from those in which the common
neuronal raft protein Thy-1 is found. Moreover, a proportion of PrP is found outside
of lipid rafts, this may be related to the mechanism of PrP internalisation. Work in
cell cultures has suggested that glycosylation of PrP is not required for its normal
localisation to rafts, however, the N-terminal of the protein does appear to be required
(Walmsley and Hooper, 2003).
In cell culture models, in which PrP is normally glycosylated, all glycotypes of PrP
have been shown to reach the plasma membrane, however un-glycosylated PrPc is
transported more slowly to the cell surface (Caughey et al., 1989; Petersen et al.,
1996). Experimental results from conventional PrP glycosylation deficient transgenic
mice, in which the transgene copy number and site of integration in the genome are
not controlled (1.8), have suggested that removal of the first N-glycan attachment site
(T183A) leads to a dramatic alteration in the cellular localisation of PrP , either when
expressed alone or in the double mutant (T183A, T199A) (DeArmond et al., 1997).
In this model PrP was observed to accumulate in the nerve cell bodies and only a
little was observed within the neuropil. Subtle changes in cellular localisation were
also observed in the transgenic mice in which the second N-glycan attachment site
was disrupted (T199A) (DeArmond et al., 1997). However, two different amino acid
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changes (hamster N181Q and mouse T182N), which also disrupt glycosylation of the
first site, do not alter the cellular localisation of PrPc (Capellari et ah, 2000b;
Neuendorf et ah, 2004) (appendix table 1). Therefore the observed change in the
localisation of PrPc in DeArmond and colleagues' model is attributable to the
mutation they used to disrupt glycosylation rather than an effect of absence of a N-
glycan at the first site, however, the rate of export of PrPc was not explored in these
experiments and may be altered. In normal central nervous tissues, intracellular PrP
is also observed. However it only makes up a small fraction of the total PrP and has
only been detected by sensitive experimental techniques. In the CNS of uninfected
wild type mice, PrPc is observed principally in the Golgi and endosome
compartments and to a lesser extent the ER (Laine et ah, 2001; Mironov et ah, 2003).
PrP is rapidly internalised from the plasma membrane in cultured cells (Shyng et ah,
1993; Shyng et ah, 1995). Internalised PrPc colocalises with endosomal markers and
rate of internalisation can be elevated by application of copper (Cu2+) or zinc (Zn2+)
ions (Pauly and Harris, 1998), although other groups have reported that extensive
internalisation is observed in the absence of Cu2+ (Sunyach et ah, 2003). Endocytosis
requires the presence of PrP's N-terminus (Nunziante et ah, 2003; Shyng et ah, 1995),
which may also control the protein's exit from lipid rafts (Taylor et ah, 2005). The
mechanism by which PrPc is internalised is controversial. Some groups have
suggested that PrP is endocytosed via clathrin-coated pits because of observed
colocalisation and biochemical isolation of PrPc with pits and the prevention of
endocytosis of PrPc by specific inhibition of clathrin-mediated endocytosis (Laine et
ah, 2001; Madore et ah, 1999; Shyng et ah, 1994; Shyng et ah, 1993; Sunyach et ah,
2003; Taylor et ah, 2005). However, clathrin internalisation of PrPc requires an
unidentified transmembrane cofactors to act as intermediary between extracellular
PrP and the intracellular clathrin pit machinery (Taylor et ah, 2005). Colocalisation
p
of PrP and caveolae, flask shaped invagination of the plasma membrane, and
cholesterol dependence of internalisation have been reported in non-neuronal cell
cultures (Peters et ah, 2003). This leads to the suggestion that PrPc is also
internalised by a caveola dependent mechanism in neuronal cells. The intracellular
destination of PrPc appears to differ between that internalised by caveloae which is
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primarily targeted to the lysosome and that by clathrin to recycling endosomes (Peters
et al., 2003; Sunyach et al., 2003). Thus, perhaps both internalisation mechanisms
occur in vivo, although neuronal cells have been reported to lack caveolin and
caveolae (Shyng et al., 1994).
1.5.3 Degradation of PrPc
During the folding process within the ER errors can occur such that a protein adopts
an aberrant or misfolded conformation. These misfolded proteins are potentially
toxic and hence must be removed. This process, the ER associated degradation
(ERAD) pathway, is ubiquitous in eukaryotes (Goldberg, 2003). Misfolded proteins
are retained within the ER by chaperonins to prevent export to the Golgi by bulk
transport. Misfolded proteins that have been resident in the ER for an extended period
are recognised by their completely processed glycans (Sitia and Braakman, 2003;
Wang and Hebert, 2003). These misfolded proteins are targeted to the
retrotranslocation machinery for export into the cytoplasm where they are
deglycosylated and ubiquitinated. Ubiquitination targets the protein to the
proteasome for complete digestion. If large amounts of unfolded protein are detected
in the ER, the unfolded protein response (UPR) is elicited; this leads to the down
regulation of protein translation and the up regulation of a number of ER chaperonins
and protein degradative machinery (Mori, 2000). Continued accumulation of
misfolded proteins leads to the triggering of the ER stress response that leads to
apoptosis of the affected cell, via expression of the proapoptotic gene CHOP
(Oyadomari and Mori, 2004).
It has been suggested that about 10% of PrPc is subject to ERAD and that subsequent
cytosolic accumulation of PrP is neurotoxic when the proteasome is compromised,
such as in an aging brain (Grenier et al., 2006; Jin et al., 2000; Ma and Lindquist,
2001; Ma et al., 2002; Yedidia et al., 2001). These results have been questioned in
two papers which found no evidence that PrP is a substrate for retrotranslocation
(Drisaldi et al., 2003; Fioriti et al., 2005). Others have reported that cytoplasmic
accumulation of PrP mediated by proteasome inhibition is not neurotoxic (Kristiansen
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et al., 2005; Roucou et al., 2003). N-glycans may have a direct effect on binding to
mediators of UPR and ERAD, in addition to their proposed role in stabilising folding
of the protein.
Cell culture studies have suggested that the half-life of PrPc is between 3 and 6 hours
(Borchelt et al., 1990; Caughey et al., 1989). Work using a murine transgenic model
in which PrPc production can be halted has suggested the longer half-life of 18 hours
in vivo (Safar et al., 2005). This may in part be attributable to differences in the half-
life of Prnp mRNA between cultured cells and in vivo (Safar et al., 2005). Blockage
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of lysosmal function by raising the pH of the compartment demonstrates that PrP is
normally degraded in the lysosome (Vetrugno et al., 2005). Interestingly it is possible
to selectively upregulate the lysosomal degradation of PrPSc without altering the
steady state level of PrPc, although half-life of PrPc was not investigated in this work
p .
(Ertmer et al., 2004). Cell culture studies have suggested that the half life of PrP is
significantly reduced in the absence of its N-glycans (Taraboulos et al., 1990a), the in
vivo relevance and the mechanism this effect is mediated by is currently unclear.
1.5.4 Truncation and secretion of PrPc in the CNS
A proportion of PrP is cleaved immediately N-terminal to the putative transmembrane
domain during endocytosis of the protein in a cell culture system (Shyng et al., 1994;
Shyng et al., 1995). This cleavage results in the production of a stable 17 kDa CI
terminal fragment that appears to be recycled to the plasma membrane and the N1
fragment. The cleavage has been suggested to be mediated by a serine protease
within an acidic compartment (Shyng et al., 1995). The metalloproteases ADAM 10
and ADAM 17 have also been suggested to mediate production of the N1 fragment
(Vincent et al., 2001). A similar truncated form of PrPc (CI) is also observed in
normal human brain and human neuroblastoma cell lines (Chen et al., 1995). A
larger truncated (21 kDa) form of PrP (C2), that is cleaved prior to amino acid 90, has
also been reported although this form is rarely observed under normal conditions
(Chen et al., 1995). However, this cleavage event is promoted by oxidative stress and
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a similar sized fragment is produced by the action of calpains (Watt et al., 2005;
Yadavalli et al., 2004).
The N-glycans attached to the CI and C2 truncated forms differ from those of full-
length PrP, as indicated by a lectin binding assay, suggesting that the truncation of
PrP may be affected by the protein's glycosylation state (Pan et al., 2002). The
authors of this paper also proposed that the majority of lower weight PrPc observed in
vivo is truncated di-glycosylated PrPc, rather than mono- and un-glycosylated forms
of the protein.
PrPc has been detected within the CSF (Tagliavini et al., 1992), consistent with the
observed release of PrP into cell culture medium via a cleavage proximal to the GPI
anchor (Borchelt et al., 1993). Work in cell culture has suggested that the shedding of
PrPc may occur both via the action of endogenous phospholipases and zinc
metalloproteases (Parkin et al., 2004). Additionally, PrPc is released from the cell in
exosomes that form when multivesicular bodies fuse with the plasma membrane
(Fevrier et al., 2004). These soluble forms of PrP may not play an important role in
TSE pathogenesis as has been suggested by studies in transgenic mice that express
PrP which lacks its GPI anchor (Chesebro et al., 2005). TSE challenge in these mice
results in the formation of extracellular PrPSc plaques without the development of
TSE disease.
1.5.5 The interaction of PrP( with other molecules
PrP has been proposed to interact with a large number of other molecules. It
immunoprecipitates with the ER resident proteins calnexin, calreticulin and protein
disulphide isomerise with which it presumably forms a strong interaction as part of its
normal folding (Capellari et al., 1999). An additional number of putative PrP
interactors have been identified by yeast two hybrid screens, immunoprecipitation in
mammalian cells or by an alkaline phosphatase reporter assay, including: the
unidentified protein pint-1, Bcl-2, Heat shock protein 60 (Hsp60), synapsin lb, Grb2,
amyloid precursor protein-like protein 1 (Aplpl) and the laminin receptor precursor
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(LRP) (Rieger et al., 1997; Spielhaupter and Schatzl, 2001; Yehiely et al., 1997).
r t .
However, PrP is normally associated with membranes, therefore interactions
between non-membrane attached PrPc and other molecules may not be representative
of in vivo (Schmitt-Ulms et al., 2001). However, further work supports the in vivo
interaction of PrP with LRP, as LRP mediates the internalisation of recombinant PrPc
and it is necessary for accumulation of PrPSc in scrapie infected cells (Gauczynski et
al., 2001; Leucht et al., 2003). Other studies using an in situ cross-linking technique
have suggested that PrP binds a subset of neural cell adhesion molecule (N-CAMs)
(Schmitt-Ulms et al., 2001). These interactions has been suggested to be important
for the putative role of PrPc in neurite outgrowth (Santuccione et al., 2005).
N-glycans attached to PrP are large and negatively charged and may alter the
interactions of PrP with other molecules. Importantly, the N-glycans will also
influence each other. Moudjou and colleagues have proposed that when both
glycosylation sites are occupied the N-glycans will repel each other, revealing an area
of PrP that would otherwise be shielded (Moudjou et al., 2004). Equally the N-
glycans on two different PrP molecules may prevent the molecules interacting. Thus
the different glycotypes may exhibit very different behaviour in the cell, solely
because of potential shielding by the attached N-glycans. Equally, N-glycans may
mediate interactions between PrP and other molecules, of particular interest in this
regard are the Lewisx epitope carried on the N-glycans attached to Asn180 and Lewisx
and sialyl-Lewisx epitopes on the Asn196 attached N-glycans (Stimson et al., 1999).
These epitopes are highly regulated during development of the central nervous system
and may have a role in specific ligand recognition (Roberts et al., 1991). Although
previous work has demonstrated that glycosylation of PrPc is not required for its
interaction with NCAM (Schmitt-Ulms et al., 2001), glycosylation's importance to
other key binding partners, such as the laminin receptor, have yet to be explored.
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1.6 The TSE species barrier
The TSE species barrier has been experimentally analysed in a wide range of model
systems, including in vitro PrP conversion assays, TSE infected cell cultures and by
experimental transmission to many animal species. In vivo there is a clear barrier to
replication of the TSE agent both in the CNS and lymphoid tissue of the novel host
species (Muramoto et ah, 1993). Recent parallels between the factors controlling
within and between species spread have led a number of TSE researchers to adopt the
term "transmission barrier" to describe both the species barrier and factors limiting
the spread within-species (Hill and Collinge, 2003). Although some mechanisms
may be common to within and between species TSE transmission, the extent of the
barrier to transmission is generally far greater between than within-species. Thus
consideration of the factors that affect specifically cross-species TSE transmission is
important.
1.6.1 Observations of the TSE species barrier
The first reported case of a species other than sheep being infected with a TSE
disease occurred in 1883 when a cow exhibiting a scrapie like disease was reported
by Sarradett (Sarradett, 1883). However, as no pathological examination was
undertaken in this case it may not reflect an actual case of TSE. Subsequently,
putative natural transmission of scrapie to a goat was reported (Chelle, 1942).
Experimental transmission of scrapie to goats and rodents formally proved that TSEs
could infect novel host species (Chandler, 1961; Cuille and Chelle, 1939). Cross-
species TSE transmission was observed to be linked with an increase in length and
variation of the incubation period, reduction in disease incidence in challenged hosts
and an alteration in pathology. On subsequent passage within the new host the
incubation period was observed to fall during the second and third passage until a
stable or ''fixed" incubation time was achieved within the new host species. This
phenomenon, the "species barrier", was defined by Pattison in 1964 at a Slow Latent
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and Temperate Viral Infection Meeting at the National Institute of Health (NIH)
(Pattison, 1965).
Extensive efforts to transmit Kuru and other human diseases of the CNS, including a
number of TSEs, to animal species were undertaken during the 1960s and 1970s by
Gajdusek and colleagues at the NIH (Brown et al., 1994). Successful transmission of
Kuru to a number of primate species was demonstrated, but there appeared to be a
strong species barrier between human TSE and rodent hosts (Gajdusek et al., 1966;
Gibbs and Gajdusek, 1973). Furthermore, a number of human TSE isolates appear
relatively untransmissible to other species, providing evidence that the species barrier
may be influenced by TSE strain (Brown et al., 1994).
Epidemiological study of three outbreaks of TME that occurred in 1947, 1961-2 and
1963 suggested that this disease of mink resulted from a cross-species TSE
transmission via an oral route (Hartsough and Burger, 1965). The most likely TSE
source in these and later TME outbreaks was the feeding of "downer" cattle
(Hartsough and Burger, 1965; Marsh et al., 1991). The disease incidence approached
100% of adults but no kits exhibited disease on the index farm in the 1947 outbreak;
this observation and the occurrence of disease in animals that had been exported to
another farms without subsequent spread suggested that mink to mink spread was not
responsible for the high disease incidence (Hartsough and Burger, 1965). These data
suggests that the species barrier between the TSE source animal (putatively cattle)
and mink was small or nonexistent in this natural outbreak. This hypothesis was later
provided with experimental support as TME is readily transmissble to cattle (Marsh et
al., 1991). Additionally, the resultant bovine TSE is also readily transmissible to mink
via the oral route. Moreover both cross-species transmissions were not associated
with a significant increase in incubation period at primary passage. Thus TME
demonstrates the unpredictable nature of the TSE species barrier.
The BSE epidemic provided categorical evidence that the TSE species barrier is
neither absolute nor predictable. The BSE agent transmitted to over fifteen non-cattle
animal host species prior to its detection and elimination from the British bovine herd.
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The genetic relatedness of the hosts (to date) is somewhat unusual and includes
species in distantly related genus from the family Felidae (puma, domestic cats,
tigers, cheetahs and lions) but not the similarly exposed Canidae (Kirkwood and
Cunningham, 1994; Sigurdson and Miller, 2003). TSE disease linked to BSE
exposure was also observed in a number of non-human primates in French zoos
(Bons et al., 1999; Bons et al., 1996), in addition to an apparently random subset of
Bovinea species. Despite the observed wide dissemination, BSE does display a
classic species barrier on transmission to many new hosts species and some host
species including pigs are relatively resistant to BSE infection (Wells et al., 2003).
The high numbers of infected cows entering the food chain (estimated to be 1-3
million) (Anderson et al., 1996) may have contributed to the wide dissemination of
BSE to other species. Additionally, a number of host species exhibited unusually
high susceptibility to BSE such as Greater kudu (Tragelaphus strepsiceros)
(Kirkwood and Cunningham, 1994), although secondary within-species spread may
have contributed to the extremely high disease incidence observed in this species
(Cunningham et al., 2004). However, the great number of transmissions observed
suggested that cross-species transmissibility of BSE may differ from other TSE
diseases such as scrapie.
In 1995 the first cases of a new form of human TSE were reported in the UK
(Bateman et al., 1995; Britton et al., 1995). Patients were unusually young and had a
different clinical and pathological presentation compared to known human TSEs. In
1996 this disease was classified as a new variant of CJD (Will et al., 1996). Clinical
illness differed starkly from sporadic CJD, early signs were often psychiatric in
nature and early development of ataxia was common. The neuropathology of the
variant CJD patients also varied from that of sporadic cases, in particular the
extensive deposition of PrP "florid" plaques (surrounded by vacuolation) in the
cerebrum and cerebellum (Ironside et al., 2000). The emergence of this novel
disease within the UK population led to obvious suspicions about its origin.
Similarities in the PrPSc glycoform from vCJD patients and BSE strengthened the
hypothesis that vCJD was the result of transmission of BSE to man (Hill et al.,
1997a), and in vivo strain typing by Bruce and colleagues demonstrated that vCJD
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and BSE were caused by the same TSE strain (Bruce et al., 1997). Thus the human
barrier to cross-species TSE transmission had failed and the question now became
why?
1.6.2 Subclinical infections
Transmission of TSE diseases to novel host species often results in subclinical TSE
infections, in which, despite an absence of outward signs of disease within the hosts
natural lifespan, significant replication of the agent has occurred (Hill et ah, 2000;
Kimberlin and Walker, 1978a; Race et al., 2001; Zlotnik, 1965). Transmissions of
TSE from these subclinical individuals has resulted in the development of clinical
disease both in hosts of the original species and more importantly hosts of the new
species (Hill et al., 2000; Race et al., 2001), thus demonstrating that adaptation to the
new host species occurred during the subclinical TSE infection. Thus, the species
barrier can be breeched in a two part process: first, by subclinical and therefore
undetectable infection in the novel host, and then by onward transmission to further
individuals of the novel species, causing significant disease. This phenomenon has
obvious public health implications and is informative as to the mechanism of the
species barrier. Perhaps there is something unique about the agent in these
subclinical cases such that its toxicity is reduced or merely that the replication rate is
slowed to such an extent that it does not reach a disease-causing load within the
host's natural lifespan.
1.6.3 Species barrier mechanism
The prolongation of incubation period at first passage in a new species leads to the
hypothesis of a special zero-phase or period of non-replication in the new host species
(Kimberlin and Walker, 1979). They suggested that the zero-phase may occur
because of an alteration in TSE replication efficiency in new hosts or the requirement
for a different transmission route. Furthermore, successful transmission of TSE
disease across a range of species barriers results in a modification of the infectious
agent (Bartz et al., 1998; Kimberlin and Walker, 1978a; Kimberlin et al., 1989;
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Pattison, 1965). In some cases the agent loses the ability to infect the original host
and in others acquires transmissibility to additional species. Additionally, alteration
of strain characteristics such as the targeting of vacuolation have also been reported to
result from transmission through an intermediate host species (Kimberlin et al.,
1989). This suggests that the TSE agent was irreversibly altered when it established
an infection in a new host. Equally, in other cases the species barrier effect has been
observed in the absence of any detectable change in TSE strain, for example BSE
maintained its identity after passage in a number of non-bovine hosts (Bruce et al.,
1997). Thus, although passage across the species barrier does not automatically result
in an alteration of the agent, transmission to a new host species greatly elevates the
chances of TSE agent change. This disparity in the effects of cross-species
transmission on the nature of the TSE agent suggests that multiple mechanisms may
contribute to the species barrier. The observed resistance to cross-species TSE
transmission may be thought of as species barriers rather than a single mechanism.
Additionally, there appears to be a uniquely stochastic nature to cross-species
transmission of TSE disease as indicated by the variation in incubation period
observed at primary passage in a new host species, which is not observed for within-
species transmission (Scott et al., 1989).
1.6.3.1 Involvement of the immune system
Preimmunisation of mice with hamster brain prior to peripheral challenge with
hamster scrapie both increased the incubation period and decreased disease incidence,
suggesting that a peripheral immune response may contribute to the species barrier
(Kimberlin et al., 1975). However, the invasive method of TSE challenge used in this
experiment (intraperitoneal injection) may not reflect natural transmission events.
Thus the suggested immune effect may be artefactual. Limited evidence has been
reported that the Human Leukocyte Antigen type DQ7 is more abundantly observed
in vCJD patients than would be expected by chance (Jackson et al., 2001), suggesting
that this immune molecule may influence the cross-species transmission of BSE.
However other groups have not replicated this observation (Laplanche et al., 2003;
Pepys et al., 2003).
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1.6.3.2 PrP amino-acid sequence
Work using transgenic mice expressing hamster or hamster/murine chimeric PrP
suggested that the TSE species barrier was attributable to the degree of PrP sequence
homology between the TSE donor species and the new host (Prusiner et al., 1990;
Scott et al., 1989; Scott et al., 1993). Indeed, in transgenic mice overexpressing
hamster PrP, the usual strong barrier to hamster scrapie transmission was completely
absent (Prusiner et al., 1990; Scott et al., 1989). Furthermore, the TSE disease
phenotype in these transgenic mice was similar to that observed in hamster (Scott et
al., 1989). Similar effects have been reported in PrP in vitro conversion assays in
which efficiency of conversion was linked to PrPSc and PrPc sequence homology
(Bossers et al., 1997; Horiuchi et al., 2000; Kocisko et al., 1995; Raymond et al.,
2000; Raymond et al., 1997). This would suggest that the observed effect of host
PrPc sequence on the species barrier is directly related to its ability to form PrPSc.
However, in the chimeric mouse/hamster transgenic system the TSE disease
phenotype was influenced by the TSE source species, showing that disease outcome
is not purely dictated by PrPc sequence (Prusiner et al., 1990). Additionally, the
species barrier effect in this system is influenced by the strain of TSE (Scott et al.,
1993). Furthermore, different strains of TSE, in which donor PrPSc have identical
amino acid sequence, can have radically different transmission characteristics to new
host species, e.g. variant compared to sporadic CJD (Bruce et al., 1997).
Further transgenic animal studies revealed that increasing the amino acid sequence
homology between host and donor can enhance or have no effect on the species
barrier (Collinge et al., 1995; Telling et al., 1995). Conversely, single amino acid
changes at key residues can have dramatic effects on the species barrier, in some
cases without increasing amino acid homology with the TSE source (Barron et al.,
2001; Bishop et al., 2006; Manson et al., 1999; Telling et al., 1995). For example, the
human methionine/valine polymorphism at amino acid position 129 is a key
determinate of susceptibility to BSE. Approximately thirty percent of the UK human
population are 129 MM homozygotes, yet all clinical vCJD cases reported to date are
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of this genotype (Will, 2003). However, work in transgenic mice expressing either
MM, MV or VV human PrP suggests that people who have MV or VV genotypes
may be also be susceptible to vCJD infection but may have longer incubation periods
than MM individuals (Asante et ah, 2006; Bishop et ah, 2006). The pattern and type
of PrPSc which accumulated after cross-species transmission also differed between
mice expressing the methionine and valine forms of PrP (Bishop et ah, 2006),
consistent with the observed accumulation of PrPSc in peripheral tissues of an MV
individual suspected to have subclinical vCJD (Peden et ah, 2004). This suggests that
the differences in incubation period and/or susceptibility observed in these animals
may be related to the formation of PrPSc. Importantly, the same single amino acid
change can render a host more susceptible to cross-species infection with some TSE
sources and enhance resistance to others, demonstrating that the change does not
simply just destabilise PrP (Barron et ah, 2001; Manson et ah, 1999).
1.6.3.3 Species specific conversion factors
One group proposed that the TSE species barrier may be contributed to by a
requirement for species specific factors to promote the conversion of PrP to PrPSc
(Telling et ah, 1994; Telling et ah, 1995). This work was based on data which
demonstrated that endogenous murine PrP specificity inhibited the transmission of
human TSE agents to transgenic mice expressing human PrP. This led to the
hypothesis of a murine specific factor "Protein X" that is essential for the PrP
conversion process and TSE transmission. This factor is proposed to have higher
affinity for murine PrP than the transgenic HuPrP and hence to preferentially interact
with it. However, the ability of chimeric murine/human PrP (murine amino acids 1 -
95 and 168-231) to support the transmission of human TSE agents is not greatly
affected by the expression of endogenous murine PrP (Telling et ah, 1995). The
authors thus proposed that "Protein X" specifically interacts with the murine
component of PrP and suggest that the protein's binding site is in PrP C-terminal, via
an epitope that includes murine amino acids 167, 171, 214 and 218 which are on the
opposite face of PrP to its attached N-glycan (Kaneko et ah, 1997; Telling et ah,
1995). An alternative explanation of this result is that a direct interaction between
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endogenous murine PrP and transgenic hamster PrP caused the prolongation of the
incubation period. The authors argued against this hypothesis on the basis of the
presence of an excess of the hamster PrP in their murine transgenic model. However
small amounts of heterologous PrP could disrupt the formation of PrPSc.
Despite this there is growing evidence from other systems of the importance of
factors both in the CNS and the periphery, other than PrP, which influence the TSE
disease process. Cross-species transmission of BSE to mice suggests that four
identified loci influence the TSE disease incubation period in mice (Manolakou et al.,
2001). The authors of this paper suggested a number of immune system genes as
likely candidates at these loci. However, the loci identified in this work were large
and contain many genes thus it is currently unclear which molecules other than PrP
influence cross-species TSE transmission. Additionally, only half of the incubation
period heritability was accounted for in this study suggesting that additional loci of
small effect may also be important.
1.6.3.4 Conformational compatibility
A kinetic model of the TSE species barrier proposed by Kellershohn and Laurent
suggested that a PrPSc conformational adaptation step may underlie the species barrier
(Kellershohn and Laurent, 1998). In particular the authors proposed the production of
an intermediary conformation of PrP during cross-species TSE infection prior to the
production of host specific PrPSc that differed from that of the donor. This was based
on experimental work that demonstrated PrPSc could not be detected at primary and
secondary passage of BSE in mice (Lasmezas et al., 1997), and was consistent with
observations in vitro of a change in PrPRes size during cross-species conversions
(Kocisko et al., 1995). Complementary to this idea is recent experimental work by
Peretz and colleagues who elegantly demonstrated that the TSE species barrier effect
is correlated with an alteration in the conformation of PrPSc (Peretz et al., 2002). In
this work, transmission of a TSE across a species barrier required the emergence of a
novel PrPSc conformation. The authors propose that delay in incubation period,
associated with the species barrier, occurs because of this conformational-
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transition/adaptation stage; akin to the zero-phase proposed by Kimberlin in 1979
(Kimberlin and Walker, 1979). This hypothesis has been further supported by work
in a yeast prion model that showed a correlation between the ability to transmit the
prion state to novel yeast species and protein conformation (Chien et al., 2003; Chien
and Weissman, 2001). Additionally, in vitro conversion of the N-terminus of PrP
demonstrated that cross-species seeding compatibility is determined by conformation
not primary sequence (Jones and Surewicz, 2005).
This model would suggest that factors that affect the conformational adaptability of
host PrP will also influence the TSE species barrier, and provides a mechanistic
understanding for the observed strain dependence of the species barrier. Thus
destabilising amino acid mutations, removal of post-translational stabilisers such as
the di-sulphide bond or PrP's N-glycans will render the host more susceptible to
cross-species TSE challenge. However, the species barrier effect has also been
observed in the absence of a change in the nature of the agent (Bruce et al., 2002) and
thus by inference the conformation of PrPSc. Thus conformational compatibility may
be part of the species barrier but other mechanisms may also be important.
1.7 PrP's N-glycans and TSE transmission
1.7.1 Alteration of glycosylation after TSE transmission
The glycosylation of proteins may be altered by TSE infection, as given the dramatic
neuropathology observed in TSE disease an impact on cellular processing would be
anticipated. Indeed, glycosylation of the insulin receptor,, but not the insulin-like
growth factor, is changed in chronically scrapie infected N2a cells compared to those
that are uninfected (Nielsen et al., 2004). However the uninfected and infected cell
lines used in this study may represent two clonally distinct populations and thus the
difference in glycosylation observed may not be directly related to TSE disease
status. Other work has suggested that the amount of dolichol and dolichyl phosphate,
key components of the glycosylation machinery, may be altered in TSE infected
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individuals (Guan et al., 1996). However this has not been linked to an in vivo
change in glycosylation. Rudd and colleagues suggested that the differences in
glycosylation observed between hamster PrPc and 263K PrPSc could be most readily
explained by a change in the activity of a single glycosylation enzyme, however this
hypothesis was not further explored (Rudd et al., 1999).
1.7.2 Role of PrP's N-glycans in TSE disease
Molecular modelling of the importance of N-glycans to the conformation of PrP has
suggested they may have a stabilising effect on the protein's structure, via a reduction
in water molecule motility (Zuegg and Gready, 2000). However, NMR comparisons
of the un-glycosylated and glycosylated PrP show only minimal conformational
differences, suggesting that glycosylation of PrP may have a functional rather than a
conformational role (Bosques and Imperiali, 2003; Hornemann et al., 2004). In
addition, glycosylation of the first site has been linked to the promotion of formation
of the disulphide bond and a reduced tendency to form fibrils, suggesting that
glycosylation may be important to conformational change rather than conformation
per se (Bosques and Imperiali, 2003).
Glycosylation of PrP may influence and be influenced by mutations in the protein, as
suggested by molecular modelling (Wong et al., 2000). Indeed, in addition to the
changes in PrP glycosylation associated with the rare TSE disease linked T183A
mutation, which ablates the second N-glycan attachment site (Grasbon-Frodl et al.,
2004; Nitrini et al., 1997), changes at other amino acid positions also correlate with
specific PrPSc glycoforms (Capellari et al., 2000a; Chasseigneaux et al., 2006; Hill et
al., 2006; Monari et al., 1994). Little un-glycosylated PrPSc is observed in familial
TSE patients that carry D178N and E200K mutations that lie close to the first N-
glycan attachment site. Cell culture studies have suggested that the absence of un-
glycosylated PrP in patients carrying these mutations may be attributed to their
instability and consequent failure of traffic to the cell surface (Capellari et al., 2000a;
Petersen et al., 1996). In addition abnormal glycosylation of the second site was
shown to be associated with the E200K mutation (Capellari et al., 2000a). A
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mutation at codon 180 (VI801) has been reported to be associated with the absence of
di-glycosylated PrPSc in a CJD patient (Chasseigneaux et al., 2006). Interestingly this
mutation does not prevent the glycosylation of PrPc in cell culture, suggesting that
this mutation prevents the accumulation of di-glycosylated PrPSc (Chasseigneaux et
al., 2006). A similar, atypical form of sporadic CJD has been recently reported in
which no di-glycosylated PrPSc is observed (Zanusso, 2006). However, no mutations
in PRNP were detected in this patient. Thus the glycosylation state of PrPSc may be
influenced by factors other than the primary sequence of PrP.
Spontaneous induction of PrPRes formation in cell culture expressing PrP lacking the
N-glycan attachment sites and by blockage of N-glycosylation by tunicamycin has
been reported (Lehmann and Harris, 1997). However, this may be an artefact of cell
stress linked to over expression of PrP or owign to the pathogenic mutations used to
disrupt the glycosylation of PrP (Capellari et al., 2000b). Similarly, prevention of
complex glycosylation by inhibition of heat shock protein 90 (Hsp90) or a-
mannosidase treatment increased the formation of PrPRes in scrapie infected cell
culture (Winklhofer et al., 2003). Additionally, an independent study reported more
rapid generation of PrPRcs in scrapie-infected cell culture when glycosylation was
inhibited with tunicamycin or point mutation (Taraboulos et al., 1990a). However, in
these experiments overall production of PrPRes was decreased. Moreover, if
glycosylation of PrP generically prevented the proteins misfolding, un-glycosylated
PrPSc would be predicted to be the predominant form observed in vivo. However,
many different PrPSc glycoforms are observed in vivo, including the heavily di-
glycosylated signature of BSE and vCJD (Collinge et al., 1996; Parchi et al., 1996;
Somerville et al., 1997) (1.4). This indicates that the in vivo role of PrP's N-glycans
in TSE disease is not to simply prevent the formation of PrPSc.
Conventional murine transgenics expressing hamster PrP in which the first N-glycan
site had been ablated either alone (T183A) or in conjunction with the second site
(T183A, T199A) [UCSF] were resistant to challenge with hamster passaged scrapie
(DeArmond et al., 1997). Comparable murine transgenics, carrying ablative
mutations in the second glycosylation site only, were resistant to strain 139H but
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susceptible to strain Sc237, albeit with greatly extended incubation periods compared
to controls (DeArmond et al., 1997) (appendix i). Differences in the pattern of PrPSc
deposition were also reported including an absence of deposition in the thalamus, a
reduction of deposition in the habenula and hypothalamus in the second site N-glycan
deficient transgenic mice, compared to controls. However, these transmissions
studies were compounded by the observed overexpression of PrP (2-4 X), the
potential aberrant expression of the transgene caused by the random site of integration
of the transgene, and the use of hamster PrP in a murine host. Furthermore, altered
localisation of PrPc was observed in these experimental models; the first site deficient
model exhibited white matter PrPc expression, and the second and both sites deficient
model lacked cell surface PrPc. Similar results have also been reported in a cell
culture model expressing comparable mutations (Rogers et al., 1990). Additionally,
cell culture studies have shown that the T183A mutation used to disrupt the first
glycosylation site has pathogenic effects independent of the disruption of N-glycan
attachment (Capellari et al., 2000b; Neuendorf et al., 2004). This is consistent with
its association with two independent incidences of familial spongiform
encephalopathy with this mutation (Grasbon-Frodl et al., 2004; Nitrini et al., 1997).
Thus it is not possible to fully interpret the importance of PrP glycosylation state to
TSE transmission in this study because of the large number of confounding effects.
Independently generated conventional transgenic mice expressing 3F4-tagged murine
PrP lacking the second glycosylation site (T198A) [Riems] were also susceptible to
infection with a range of murine TSE strains/isolates (Neuendorf et al., 2004)
(appendix ii). These transgenic mice exhibited greatly extended incubation times
compared to normally glycosylated controls. However, in contrast to the work of
DeArmond and colleagues, disruption of the first N-glycan attachment site (T182N
two independent lines) [Riems] did not lead to complete resistance to TSE challenge.
These lines were susceptible to infection with murine TSE strains ME7, Chandler
(139A) and murine passaged BSE. The differences between the UCSF and Riems
glycosylation deficient transgenic mice may be attributed to the different point
mutation used to disrupt the glycosylation sites. In particular, that used in the Riems
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transgenic models was reported to allow transportation of PrP to the plasma
membrane in cell culture (Neuendorf et al., 2004).
However, the incubation times for the two independent Riems lines in which the first
attachment site was disrupted were significantly different (Neuendorf et al., 2004).
For example, in one line the incubation period for Chandler equalled that of the
normally glycosylated control, whereas a significant extension was observed in an
independent line carrying the same transgene. Thus, the specific role of the first N-
glycan site in transmission can not be clearly determined from these data. This
discrepancy between independent lines expressing the same transgene, highlights the
potential for artefacts caused by copy number and site of transgene integration in
conventional transgenic mice.
Work using gene-targeted PrP glycosylation deficient transgenic mice lacking the
first glycosylation site (N180T) [NPU] suggests that glycosylation of this site
facilitates within-species TSE transmission (Tuzi et al., in preparation) (appendix
table ii). Moreover, the requirement for glycosylation of the first site is highly TSE
strain dependent. Comparable gene-targeted transgenic mice lacking the second
glycosylation site (N196T) [NPU] are also susceptible to a number of murine TSE
strains (Tuzi et al, in preparation). Similarly, absence of glycosylation at this site
results in an elongation of the incubation period for some strains of TSE only, as
previously observed in conventional transgenic mice (DeArmond et al., 1997;
Neuendorf et al., 2004). However, in contrast to the absence of disease in UCB un-
glycosylated PrP transgenic mice after TSE challenge, gene-targeted un-glycosylated
PrP transgenic mice (N180T, N196T) [NPU] are susceptible to TSE disease, albeit
only when challenged with one strain (Tuzi et al., in preparation; appendix table ii).
1.7.3 The role of glycosylation of PrP in TSE strain determination
The glycoform of PrPSc often correlates with TSE strain (Collinge et al., 1996; Parchi
et al., 1996), leading to the hypothesis that glycoform itself encodes TSE strain
characteristics, such as the targeting of neuropathology and the length of the
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incubation period (Collinge et al., 1996). Transmission of TSE to conventional
glycosylation deficient transgenic mice has been reported to alter the pattern of PrPSc
deposition in vivo (DeArmond et al., 1997) suggesting that the strain of TSE may also
have been altered. However the authors of this work did not further examine this
possibility. Recent work by Tuzi and colleagues has further investigated the
importance of glycosylation of host PrP to strain determination; they suggest that, for
some TSE strains, glycosylation at the second site contributes to the maintenance of
TSE strain characteristics in vivo (Tuzi et al., in preparation; appendix table ii).
1.7.4 The role of glycosvlation of PrPc in cross-species TSE transmission
Cell-free conversion studies, in which PrPc is converted to PrPRes by seeding with
PrPSc, have shown that un-glycosylated PrPc appears to be two-to three-fold more
efficiently converted to the protease resistant form, compared to that normally
glycosylated, when the seeding PrPSc originates from a different host species (Priola
and Lawson, 2001). This suggests that glycosylation of PrP may influence the TSE
species barrier. However, this effect has not been replicated in other studies
(Raymond et al., 1997) nor investigated in vivo. Glycosylation of PrP could feasibly
influence the species barrier by a number of mechanisms including by affecting the
accumulation or nature of PrPSc formed in vivo or alternatively by influencing other
aspects of TSE pathogenesis. PrP's N-glycans may modify the flexibility of the
protein and hence change the range of misfolded conformations that it can adopt, as
previously suggested by DeArmond and colleagues (DeArmond et al., 1997). This
may be of specific importance to the cross-species transmission of the TSE agent
which has been proposed to involve an alteration in the conformation of PrPSc
(1.6.3.4).
Glycosylation of other host proteins has been implicated in cross-species resistance to
infection and pathogenic effects (Chu and Whittaker, 2004; Falk et al., 1995;
Gambaryan et al., 2003; Griffitts et al., 2003; Kunz et al., 2005; Marin ct al., 2003;
Wentworth and Holmes, 2001). In some cases this effect is mediated by specific
differences in the combination of glycans attached to proteins of different species
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with which the host pathogen is adapted to interact (Gagneux et ah, 2003; Gambaryan
et ah, 2003). Alternatively, the effect of glycosylation is to shield the target host
protein and hence prevent the pathogen gaining access to them (Chu and Whittaker,
2004; Falk et ah, 1995; Griffitts et ah, 2003; Kunz et ah, 2005). Similar mechanisms
may contribute to the potential role of glycosylation of PrP in the cross-species
transmission of the TSE agent.
1.8 PrP transgenic mice
Despite recent advances in TSE susceptible cell cultures (Klohn et ah, 2003), not all
TSE strains can be successfully transmitted in vitro; additionally it is not possible to
study TSE pathogenesis outside a host. It is thus necessary to use animal models to
address questions of all TSE pathogenic processes or strain. PrP transgenic mice
have been used to address these issues for over fifteen years. All model systems carry
experimental limitations and choice of model has been shown to greatly impact on the
experimental interpretation and conclusions
The earliest PrP transgenic animal models were generated by conventional methods,
whereby the Prnp transgene is introduced into the murine genome at random by
microinjection of DNA into fertilised oocytes. The transgene may integrate into the
genome at multiple sites. The expression of the transgene in these conventional
model systems is therefore regulated differently than the endogenous gene. These
mice also exhibited high transgene copy number and over-expressed PrP (Hsiao et ah,
1990; Scott et ah, 1989). Work by Westaway and colleagues demonstrated that this
led to neurodegeneration even if PrP bore no mutations (Westaway et al., 1994).
Additionally, in early conventional murine transgenics the Prnp /PRNP transgene was
expressed alongside endogenous murine Prnp; and interaction of murine and
transgenic PrP altered TSE disease outcome in some models (Telling et ah, 1995).
The production of PrP knock-out transgenic mice circumvented this problem
permitting the production of transgenic animal models using a murine PrP null
background (Bueler et ah, 1992; Manson et ah, 1994a; Moore, 1997; Sakaguchi et ah,
1996). However two of the four knock-out lines generated exhibited an ataxic
phenotype, leading to suggestions that loss of PrP function may cause TSE disease
(Moore, 1997; Sakaguchi et ah, 1996). However the pattern of neurodegeneration in
these murine transgenics was unlike that observed in TSE disease. Further
characterisation of these mice demonstrated that the gene disruption strategy
employed resulted in the ectopic neuronal expression of a nearby gene, Doppel, the
expression of which was normally restricted to the testis and heart (Moore et al.,
1999). Despite a high degree of homology to PrP, Doppel appears to have little
relevance to TSE disease (Tuzi et al., 2002), highlighting the importance of
understanding the model system used.
Importantly the site of transgene integration is not controlled during the generation of
conventional transgenic models. Gene expression is greatly affected by its genomic
context thus aberrant spatial and temporal expression of the transgene may occur.
Equally, use of non-Prnp promoters and absence of specific regulatory regions may
occur at some distance to Prnp and could also affect expression pattern. This may
lead to spurious effects such as the observed absence of tgPrP expression in Purkinje
cells, when the transgene is driven by the endogenous promoters contained in the 6 kb
of Prnp upstream sequence (Fischer et al., 1996). Such effects may impact on TSE
pathogenesis as is clearly demonstrated by the great variation of TSE incubation
periods observed in independent conventional PrP transgenics mice which express the
same transgene at apparently comparable levels in vivo (Neuendorf et al., 2004).
Thus comparisons between the effects of changes in Prnp are difficult to make,
especially if subtle.
PrP gene-targeted transgenic mice in which murine Prnp is directly replaced by the
Prnp transgene circumvent the problems of mis- and over-expression observed in
conventional transgenic animal models; this can be achieved using a two step strategy
(Moore et al., 1995). Genomic Prnp in murine embryonic stem (ES) cells is first
replaced with a hypoxanthine phosphorbosyl transferase (HPRT) minigene by
homologous recombination. At this first step HPRT positive cell are selected, using
specific growth media. Thus in all the selected cells, wildtype Prnp exon three has
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been replaced by the HPRT minigene. In the second step the HPRT minigene is then
itself replaced with the Prnp transgene by the use of selective growth media.
An alternative strategy uses a LoxP neomycin/thymidine kinase-selectable cassette
(Neo/TK) into which the Prnp transgene is ligated (Cancellotti et al., 2005) (Figure
1.3 B). This cassette is used to replace genomic Prnp by homologous recombination
in ES cells, which can then be selected using gancylovir. The Neo/TK selection
marker is flanked by LoxP, so that it can be removed via the action of Cre
recombinase, leaving a single LoxP site downstream of the Prnp open reading frame.
Both selection strategies result in transgenic Prnp ES cells in which the transgene has
directly replaced the genomic Prnp and thus is subject to control by all the
appropriate regulatory elements, be they local or distal. These ES cells derived from
the inbred 129/Ola strain are then injected into a 3.5 day old C57/B6 blastocyst. If
the transgenic cells colonise the blastocyst, a chimeric mouse will result from a
successful pregnancy (Manson et al., 1999). Germ line transmission of the 129/Ola
transgenic cells then results in the production of the gene targeted line which can be
directly compared to other gene targeted Prnp lines, avoiding the need for the
generation of multiple lines.
This method was used to generate three directly comparable lines of PrP
glycosylation deficient transgenic mice used in this thesis (Figure 1.3 C). In these
mice the first (Gl), second (G2) or both (G3) glycosylation sites have been disrupted
by N180T, N196T or N180T and N196T respectively (NPU). All lines are
maintained on the 129/Ola inbred genetic background, so they only differ from
129/Ola wild type mice at the outlined amino acid changes and the single 3' LoxP
site. To control for the effect of this site a control transgenic mouse line (CL) was
also used; these transgenic mice carry the wild type Prnp open reading frame and
hence produce PrP that is normally glycosylated, however they also carry the single 3'
LoxP site. These CL transgenic mice are equivalent to non-transgenic 129/Ola mice
save for this non-translated LoxP site.
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Figure 1.3 Schematic representation of the production of the PrP glycosyla¬
te deficient transgenic mice by double-step Prnp gene targeting
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In vitro experimental evidence suggests that glycosylation of PrP may specifically
inhibit the cross-species transmission of TSE and hence contribute to the TSE species
barrier (1.7). The aim of this thesis is to investigate this hypothesis in vivo.
Specific Aims
• 1) To validate three lines of gene-targeted PrP glycosylation deficient
transgenic mice [NPU] (1.8) as suitable models in which to investigate the effect of
glycosylation of PrP on the transmission of TSE between species. This will consist of
a) establishing that the alteration in the PrP amino acid sequence in
these transgenic mice prevents N-glycan attachment to the protein.
b) establishing whether the alterations in PrP in these transgenic mice
changes the steady-state level of the protein in the brain.
• c
c) determining, using confocal microscopy, if the localisation of PrP
in the brains of the glycosylation deficient transgenic mice is altered.
d) to establish whether the glycosylation deficient transgenic mice
develop TSE specific vacuolation, clinical disease or spontaneous
formation of PrPSc, in the absence of TSE challenge.
• 2) To test the hypothesis that glycosylation of PrPc inhibits the cross species
transmission of TSE disease, by transmission of one hamster and two human TSE
strains to the PrP glycosylation deficient transgenic and normally glycosylated control
mice.
• 3) To determine if the change in disease incidence and time to disease onset
observed in the glycosylation deficient transgenic mice after cross-species TSE
challenge, is linked to an alteration in TSE strain characteristics including, the pattern
of vacuolar pathology and PrPSc deposition.
■ 4) To test the hypothesis that the glycosylation of PrP alters its ability to
adopt a misfolded form.
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2.0 Materials and Methods
All Chemicals are from BDH unless otherwise stated. All experiments were carried
out at room temperature unless otherwise stated.
2.1 Murine genomic DNA extraction
2.1.1 Taking of tail snips
Tail snips were taken from live animals under 3 % fluothane (delivered in oxygen)
anaesthesia and from culled animals post-mortem. For each live animal the tip of
the tail -0.5 cm long was removed using a flamed scalpel which cauterised the
wound. Culled animals also had a larger piece of tail (-3 cm) removed in addition
to the small snip; all tail snips were stored at -20 °C for DNA extraction.
2.1.2 Uninfected mice (Qiagen DNeasy Tissue Kit) (All tails from uninfected
mice prior to 17th November 2004 and all tails from prnp'/' (PrP null) mice)
DNA was extracted from tail snips (0.5 cm) using DNeasy Tissue Kit (all reagents
Qiagen, Sussex, UK), as per manufacturer's protocol. Briefly, tissue was lysed in
Buffer ATL plus proteinase K (2 mg/ml) for 6-18 hours, with shaking at 55 °C.
Double volume of Buffer AL-ethanol (1:1) was added to lysed tissue. The resultant
solution was transferred to a DNeasy spin column, the membrane of which
selectively binds DNA, and centrifuged at 8000 rpm for 1 minute. Bound DNA
was washed two times with Buffer AW1 and AW2, before eluting with 200 pi of
Buffer AE. DNA was stored at 4 °C.
2.1.3 Uninfected mice (Jackson Laboratory Direct PCR after lysis method) (All
tails from uninfected mice after 17th November 2004 except those to be genotyped
for the pmp null allele)
DNA was extracted from tail snip fragments (2 mm) by proteinase K (10 mg/ml)
digestion for 14-18 hours at 55 °C in polymerase chain reaction (PCR) buffer with
non-ionic detergent (50 mM potassium chloride, 10 mM tris-HCl [pH 8.3], 2.5 mM
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magnesium chloride, 0.1 mg/ml gelatine, 0.45 % Nonidet P40, 0.45 % Tween 20).
Proteinase K was inactivated by heating to 95 °C for 15 minutes. PCR was carried
out directly on the resultant solution without further purification, which was stored
at 4 °C.
2.1.4 TSE inoculated mice (phenol/chloroform extraction)
Tail snips (0.5 cm) were lysed by shaking over night at 37 °C or for 2-3 hours at 64
°C, in tail lysis solution [15 mM sodium acetate, 1% SDS, 1 mM tris (pH 8), 1 mM
EDTA] and PK (200 pg/ml, Qiagen, Sussex, UK). The resultant lysate was
thoroughly mixed with phenol (Qbiogene)/chloroform [1 part AquaPhenol (pH 8): 1
part chloroform] before separation of the aqueous phase by centrifugation at 13,000
rpm for 5 minutes at room temperature. DNA was isolated from the aqueous phase
by incubation for 10 minutes with sodium acetate (final concentration 50 mM) and
an equal volume of isopropanol, followed by separation of the precipitated DNA by
centrifugation at 13,000 rpm for 2 minutes. Prior to resuspension in buffer AE
(DNeasy Tissue Kit, Qiagen, Sussex, UK) DNA pellet was washed in 70% ethanol
(v/v in dH20). DNA was then stored at 4 °C.
2.1.5 Quantification of DNA
The concentration of murine genomic DNA solution isolated by phenol/chloroform
extraction was assayed by determining optical density at 260 nm (DNA absorption)
using a Beckman spectrophotometer and the Beer-Lambert equation [1] to
standardise concentration for PCR. If required, DNA stock solution was then
diluted in autoclaved ultrapure water prior to PCR analysis. To check for
contamination of DNA stock the ratio of 260 nm to 280 nm (protein and single
stranded nucleic acid absorption) was also calculated. If a ratio of lower than 1.8
was observed a new DNA sample was extracted prior to PCR.
Optical Density = ebc [ 1 ]
Where e = extinction coefficient (~20 g/cm/L), b = spectrophotometer path length
(1 cm), c = concentration of DNA
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2.2 Genotyping for Prnp transgenes by PCR
2.2.1 Detection of the Gl, G2, G3 mutant and wild type prnp alleles
Presence of the Gl mutant allele was determined by mismatch PCR, using a primer
specific for the Gl-mutation (Gl-mutant) and standard reaction mix (IX
magnesium chloride free PCR buffer [200 mM Tris-HCl (pH 8.4), 500 mM KC1;
Invitrogen Life Technologies, Paisley, UK]; 1.5 mM Magnesium chloride
[Invitrogen Life Technologies, Paisley, UK]; 200 pM deoxynucleotide 5'-phosphate
(dNTP) mix [equal parts deoxyadenosine, deoxyguanosine, deoxythymidine and
deoxycytidine; Promega, Southampton, UK]; 30 units/ml Taq DNA polymerase
[Invitrogen Life Technologies, Paisley, UK]; 1 pi of a three primer mix [9910 (48.8
pmol/pl), Gl-mutant (48.8 pmol/pl), 9912 (2.4 pmol/pl)] (Table 2.1) to which 1-2
pi of DNA solution was added, dependent on DNA stock concentration. The final
volume of 50 pi was achieved by addition of the appropriate volume of distilled
water that had also been autoclaved.
Cycle conditions were 94 °C for 3 minutes, followed by 30 cycles, of 50 seconds at
94 °C, 30 seconds at 60 °C and 1 minute at 72 °C. This was followed by a final 10
minutes at 72 °C (Biometra Triblock). The reaction was then stored at 4 °C, prior
to size separation of DNA product by gel electrophoresis (1% Agarose). In the
presence of the Gl-mutant allele a 268 base pair fragment is amplified (Gl-mutant
and 5'), in addition to the control 585 base pair fragment (5' and 3') which is
produced in the presence of both wild type and Gl-mutant Prnp.
Similarly, presence of the Gl- wild type, G2- mutant and G2- wild type allele was
determined using the same PCR reaction conditions and mix, save the primer
combination. For detection of the Gl wild type allele 5' (48.8 pmol/pl), Gl-wild
type (48.8 pmol/pl) and 3' (2.4 pmol/pl) primers were used (Table 2.1). In the
presence of the wild type allele a 268 base pair product was amplified in addition to
the control 585 base pair fragment (5' and 3'). For detection of the G2 mutant allele
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5' (48.8 pmol/pl), G2-mutant (48.8 pmol/pl) and 3' (2.4 pmol/pl) primers were
used. In the presence of DNA containing the G2 mutant Pmp allele a 320 base pair
fragment in addition to the control 585 base pair fragment (5' and 3') was observed.
For detection of the G2 wild type allele 5' (48.8 pmol/pl), G2-wild type (48.8
pmol/pl) and 3' (2.4 pmol/pl) primers were used (Table 2.1). In the presence of
DNA containing the G2 wild type allele a 320 base pair fragment in addition to the
control 585 base pair fragment (5' and 3') was observed. G3 mice were genotyped
for presence of the G1-mutant, G2-mutant, Gl-wild type and G2-wild type alleles.
2.2.2 Detection of the 3' lox-P site of the Prnp allele present in all the Cre-loxP
generated transgenic mice used including the control line (CL)
Presence of the 3' lox-P site was determined by PCR using a standard reaction mix
(IX magnesium chloride free PCR buffer [200 mM Tris-HCl (pH 8.4), 500 mM
KC1; Invitrogen Life Technologies, Paisley, UK]; 1.5 mM magnesium chloride
[Invitrogen Life Technologies, Paisley, UK]; 80 pM deoxynucleotide 5'-phosphate
(dNTP) mix [equal parts deoxyadenosine, deoxyguanosine, deoxythymidine and
deoxycytidine; Promega]; 20 units/ml Taq DNA polymerase [Invitrogen Life
Technologies, Paisley, UK]; 1 pi of a two primer mix [CreA (100 pmol/pl) and
CreB (100 pmol/pl) (Table 2.1)] to which 1-2 pi of DNA solution was added,
dependent on DNA stock concentration. The final volume of 50 pi was achieved by
addition of the appropriate volume of distilled water that had also been autoclaved.
Cycle conditions were 94 °C for 3 minutes, followed by 30 cycles of 45 seconds at
94 °C, 45 seconds at 60 °C and 45 seconds at 72 °C. This was followed by a final
10 minutes at 72 °C (Biometra Triblock). The reaction was then stored at 4 °C,
prior to size separation of DNA product by gel electrophoresis (2 % Agarose). In
the presence of the 3' lox-P site a 342 base pair fragment is amplified, in the
absence of the site a 322 base pair fragment is observed.
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2.2.3 Screening of the NPU Prnp'A mice
The NPU Prnp'A mice have a neomycin resistance gene (neo), inserted into exon 3
of Prnp. To detect this insert, primers specific to a region in the neo cassette were
used. A standard PCR reaction mix was used (IX magnesium chloride free PCR
buffer [200 mM Tris-HCl (pH 8.4), 500 mM KC1; Invitrogen Life Technologies,
Paisley, UK]; 1.5 mM magnesium chloride [Invitrogen Life Technologies, Paisley,
UK]; 200 pM deoxynucleotide 5'-phosphate (dNTP) mix [equal parts
deoxyadenosine, deoxyguanosine, deoxythymidine and deoxycytidine; Promega];
12 units/ml Taq DNA polymerase [Invitrogen Life Technologies, Paisley, UK]) in
addition to 1 pi of a two primer mix (Null A (100 pmol/pl) and Null B (100
pmol/pl) Table 2.1) and 1-2 pi of DNA solution.
Cycle conditions were 94 °C for 3 minutes, followed by 30 cycles of 50 s at 94 °C,
50 seconds at 57 °C and 50 seconds at 72 °C. This was followed by a final 10
minutes at 72 °C (Biometra Triblock). The reaction was then stored at 4 °C, prior
to size separation of DNA product by gel electrophoresis (1% Agarose gels). In the
presence of the NPU Prnp'1' template a 1200 base pair fragment is amplified.
2.1 Table of primers used for PCR (All supplied by MWG Biotech)











2.2.4 Gel electrophoresis of PCR products
Glycerol loading buffer (5 pi; 30 % glycerol, 0.25 % bromophenol blue, 0.25 %
xylene cyanol FF) was added to the total PCR reaction. This was then run on a 1 or
2 % agarose (Roche Diagnostics, Basel, Switzerland) gel [IX TBE (89 mM Tris, 89
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mM Orthoboric acid, 2 mM EDTA (pH 8 with NaOH)]; 1 mM ethidium bromide,
Sigma-Aldrich Company Ltd, Dorset, UK], dependent upon PCR reaction product
size, at 100 V for approximately 2 hours in IX TBE. A 1 Kb ladder (12216 - 75
base pair fragments; Invitrogen Life Technologies, Paisley, UK) was used as a
standard. DNA bands were visualised under UV and photographed (The Imager;
Appligene).
2.3 Preparation of total protein from murine brain
2.3.1 Tissue sources used for biochemical analysis of PrP
Uninfected wild type 129/Ola, PrP null (Prnp~A), CL (control line), G1
(homozygous for N180T), G2 (homozygous for N196T) and G3 (homozygous for
N180T and N196T) all on a 129/Ola genetic background, sourced from breeding
stock maintained at NPU, Edinburgh.
PrPSc positive control; ME7 mouse (129/Ola) passaged scrapie; experiment (NPU
experiment number 522D-2P/animal number 26) kind gift of Dr. Rona Barron NPU,
Edinburgh.
Experimentally infected animals, that were challenged with hamster scrapie 263K
(experiment 568C-1A), variant CJD (experiment 567G-1A), sporadic CJD MM
type 2A (experiment 567H-1A).
2.3.2 Preparation of post-nuclear brain tissue homogenate for biochemical
analysis
After sacrifice, brain was removed (in some cases saggitally divided in half), flash
frozen in liquid nitrogen and then stored at -70 °C until required. Half or whole
brains were weighed and mechanically homogenised from frozen in nine volumes
of ice cold NP40 lysis buffer [1% Nonidet 40, 0.5% sodium deoxycholate, 150 mM
sodium chloride, 50 mM Tris (pH 7.5 with HC1)] with the addition of
phenylmethylsulfonyl fluoride (PMSF) [final concentration 1 mM; Sigma-Aldrich
Company Ltd, Dorset, UK] to prevent protein degradation by endogenous
proteases. PMSF was not added if the homogenate was intended for Proteinase K
treatment. The homogenate was centrifuged at 8000 rpm for 10 minutes to remove
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unhomogenised debris. The resultant protein containing supernatant was aliquoted
and flash frozen in liquid nitrogen for storage at -70 °C.
2.3.3 Preparation of brain tissue homogenate in physiological saline (inoculum)
for biochemical analysis
An equal volume of 2 X NP40 lysis Buffer (2% Nonidet 40, 1% sodium
deoxycholate, 150 mM sodium chloride, 100 mM Tris (pH 7.5 with HC1)) was
added to 10 % brain homogenates in physiological saline and mixed by vortexing
prior to biochemical analysis.
2.3.4 Serial dilution of brain homogenate
Homogenate was diluted in an equal volume of NP-40 lysis buffer and mixed by
vortexing.
2.3.5 PNGase F treatment of brain homogenate
Total brain protein (10 % brain homogenate; NP-40 lysis buffer, 10 mM PMSF)
was diluted 2-fold in NP-40 lysis buffer prior to denaturation in 1 X Glycoprotein
Denaturing Buffer [0.5 % sodium dodecyl sulphate (SDS), 1 % P-mercaptoethanol;
New England Biolabs, Ipswich, MA, USA] at 100 °C for 10 minutes prior to
incubation with Peptide: N-Glycosidase F (PNGase F) (30,000 units/ml; New
England Biolabs, Ipswich, MA, USA) in 1 % Nonidet 40 (New England Biolabs,
Ipswich, MA, USA) and 1 X G7 Reaction Buffer [50 mM NaPC>4 (pH 7.5); New
England Biolabs, Ipswich, MA, USA] at 37 °C for 2-4 hours with shaking. The
reaction was stopped by freezing at -20 °C or by SDS denaturation.
2.3.6 Proteinase K digestion of brain homogenate
Brain homogenate (5 % or 10 % in NP-40 lysis buffer) was incubated with
Proteinase K (PK) (20, 10, 5 or 1 pg/ml, lOOmM Tris-HCl, ImM Ca CI2, pH 7;
Roche Diagnostics, Basel, Switzerland) (PK) at 37 °C for one hour. Reaction was
stopped by the addition of the PMSF (final concentration 10 mM) and by freezing
at -20 °C or by SDS denaturation.
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2.3.7 Sodium phosphotungstic acid (NaPTA) concentration of PrPSc
Total brain protein (10 % or 5 % brain homogenate in NP-40 lysis buffer) was
mixed with an equal volume of 4 % sarkosyl /phosphate buffered saline (Oxoid,
Basingstoke, UK) (PBS) by shaking at 37 °C for 5 minutes. The homogenate was
then incubated with PK (20 pg/ml, lOOmM tris-HCl, ImM Ca CI2, pH 7 Roche
Diagnostics, Basel, Switzerland) for 1 hour at 37 °C with shaking. The reaction
was stopped by the addition of PMSF (final concentration 10 mM). NaPTA stock
solution was added (4 % NaPTA; 10 mM magnesium chloride; pH 7.4) (final
concentration 0.3 % NaPTA). The reaction was briefly vortexed and incubated at
37 °C for 20 minutes with shaking. The precipitated PrPSc was then collected by
centrifugation at 13,000 rpm for 20 minutes at room temperature. The resultant
supernatant was removed and retained at - 70 °C and the pellet washed with 0.1%
sarkosyl/PBS. The pellet was then re-isolated by centrifugation at 13,000 rpm for
20 minutes, the wash solution discarded and the pellet stored at - 70 °C or directly
resuspended in 1 X Novex Tris-Glycine SDS Sample Buffer (Invitrogen Life
Technologies, Paisley, UK) and 1 X NuPage Sample Reducing Agent (Invitrogen
Life Technologies, Paisley, UK) by denaturation at 95 °C.
2.4 Characterisation of glycosylation deficient transgenic mice and analysis of
cross species transmission studies by western blotting
2.4.1 Protein denaturation and separation by Sodium Dodecyl Sulphate
Polyacrylamide gel electrophoresis (SDS-PAGE)
Total brain protein was denatured in 1 X Novex Tris-Glycine SDS Sample Buffer
(Invitrogen Life Technologies, Paisley, UK) and 1 X NuPage Sample Reducing
Agent (Invitrogen Life Technologies, Paisley, UK) for 30 minutes at 95 °C.
Proteins were size/charge separated by gel electrophoresis at 125V using Novex
Pre-cast Tris-Glycine gel (12 or 14 % acrylamide, tris-glycine; Invitrogen Life
Technologies, Paisley, UK) which were run for between 1 hour 40 minutes and 2
hours 15 minutes in 1 X Running Buffer [24 mM tris, 0.19 M glycine, 0.1 % SDS].
SeeBlue Pre-Stained standard (Invitrogen Life Technologies, Paisley, UK) was used
to estimate the molecular weight of the separated proteins (250 kDa myosin, 98 kDa
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bovine serum albumin, 64 kDa glutamic dehydrogenase, 50 kDa alcohol
dehydrogenase, 36 kDa carbonic anhydrase, 30 kDa myoglobin, 16 kDa lysozyme,
6 kDa aprotinin, 4 kDa insulin, B chain).
2.4.2 Western blotting semi-dry transfer of separated protein to a membrane
Proteins in the acrylamide gel were transferred to polyvinylidene fluoride (PVDF)
membrane (Hybond-P, Amersham Biosciences, Buckinghamshire, UK) at a current
of 125 A/gel (25 V) using a semi-dry transfer blotter (BioRad Laboratories, Hemel
Hempstead, UK) in 1 X Transfer Solution (48 mM tris, 39 mM glycine, 0.375 %
SDS, 20 % methanol); a maximum of 2 gels per blotter were simultaneously
transferred.
2.4.3 Identification of membrane bound PrP and Tubulin by immunodetection
The amount of protein bound to the PVDF membrane was checked by staining with
Ponceau S solution (0.1 % Ponceau S, 5 % acetic acid; Sigma-Aldrich Company
Ltd, Dorset, UK) for 5 minutes in order to confirm that transfer was successful.
After destaining with TBS/Tween [50 mM tris, 150 mM sodium chloride, (pH to
7.5 with HC1), 1 % Tween 20] (TBST) the membrane was blocked with 1 X
Western Blocking reagent (10 X, supplied by Roche Diagnostics, Basel
Switzerland) diluted in TBS [50 mM Tris, 1.5 M sodium chloride, (pH to 7.5 with
HC1)] for 1 hour at room temperature. To allow use of the anti-tubulin control the
PVDF membrane was cut between 50 and 36 kDa markers (for non-proteinase K
treated samples) and the two parts processed separately. The upper portion (~45-
250 kDa) was incubated with anti-tubulin rat antibody ab6160 (1/4000; Abeam,
Cambridge) which was used as a control for protein loading, in 0.5 X Western
Blocking Reagent (10 X, supplied by Roche Diagnostics, Basel, Switzerland),
diluted in TBS, rocking overnight at room temperature. The lower portion of the
membrane (~45-4 kDa) was incubated with the anti-PrP mouse monoclonal
antibodies 7A12, 8H4 (1/20,000; kind gift of M.S. Sy, Cleveland) or 6H4 (1/20,000,
Prionics, Schlieren Switzerland) in 0.5 X Western Blocking Reagent (10X supplied
by Roche Diagnostics, Basel, Switzerland) TBS, rocking overnight at room
temperature (Table 2.2). The membrane was washed with TBS/Tween to remove
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excess primary antibody and blocked for 20 minutes with 0.5 X Western Blocking
Reagent (supplied by Roche Diagnostics, Basel, Switzerland)/TBS. Membranes
treated with anti-tubulin were then incubated with peroxidase-conjugated
AffmiPure rabbit anti-rat antibody (1/10,000; Jackson ImmunoResearch, West
Grove, PA, USA) in 0.5 X Western Blocking Reagent (10X supplied by Roche
Diagnostics, Basel, Switzerland) TBS, for 30 minutes, rocking at room temperature.
Membranes treated with anti-PrP antibodies were then incubated with peroxidase-
conjugated AffiniPure rabbit anti-mouse antibody (1/10,000; Jackson
ImmunoResearch West Grove, PA, USA) in 0.5 X Western Blocking Reagent
(10X, supplied by Roche Diagnostics, Basel) TBS, for 30 minutes, rocking at room
temperature. Membranes were washed 4 times for 15 minutes in TBST to remove
excess secondary antibody. Bound secondary antibody was detected on film
(Lumi-Film; Roche Diagnostics, Basel, Switzerland) by light emission from the BM
Chemiluminescece Blotting Substrate POD (Roche Diagnostics, Basel,
Switzerland). Typically 30 second, 3 minute and 10 minute exposures were taken.
Film was developed manually using developer and fixative (AGFA, Mortsel,
Belgium).
2.2 Table of antibodies used in western blotting
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2.5 Analysis of the amount of PrP in murine brain homogenate by Dissociation
Enhanced Lanthanide Fluoroimmunoassay (DELFIA® )
2.5.1 Preparation of brain homogenate for DELFIA
PrPc was extracted from total protein brain homogenate (100 mg/ml ; NP-40 lysis
buffer; 1 mM PMSF) by mechanical homogenisation in 1M guandine
hydrocholoride (Gnd HC1) solution (25 mM tris; 1M Gnd HC1, Sigma-Aldrich
Company Ltd, Dorset, UK; 0.5 % Triton X-100, Sigma-Aldrich Company Ltd,
Dorset, UK). This was then diluted in DELFIA Assay Buffer (supplied by Perkin
Elmer Life Sciences), leading to final concentration equivalent to 10 mg/ml of
original tissue. Proteins insoluble in 1 M Gnd HC1 (PrPSc) were separated from
those that were soluble (PrPc) by centrifugation 13000 rpm for 10 minutes. The
resultant pellet was resuspended in 6 M Gnd HC1 prior to dilution in DELFIA
Assay Buffer to a concentration equivalent to 10 mg/ml original tissue.
2.5.2 Preparation of recombinant PrP standard for DELFIA
Murine recombinant PrP (kind gift from Dr. Ian Sylvester, IAH Compton) was
serially diluted 2-fold in DEFLIA Assay Buffer (25 - 0.781 ng/ml) for use as a
standard.
2.5.3 DELFIA time-resolved fluorescence immunoassay
The method is an adaptation of that of Barnard and colleagues (Barnard et ah,
2000). Capture antibody (1/200; FH11 and AG4; TSE Resource Centre, IAH
Compton) was bound to 96 well plates by overnight incubation, at 4 °C. Plates
were then blocked with 2 % bovine serum albumin (BSA) (Roche Diagnostics,
Basel, Switzerland) in sterile 1 X PBS (Oxoid, Basingstoke, UK) with 3 M NaN3
for 1 hour with shaking at room temperature. The blocking solution was discarded
and the plate was then incubated with samples and standards, shaking at room
temperature for one hour. Samples and standards were then discarded and the plate
was then incubated with europhium (Eu3+) labelled detector antibody (7A12 or
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8H4, 1/3000, kindly labelled by Mr. Declan King, NPU, Edinburgh), with shaking
at room temperature for one hour. The plate was then incubated with DELFIA
Enhancement Solution, to facilitate the formation of Eu-(2-NTA)3(TOPO)2-3. After
shaking for 5 minutes at room temperature Eu emission was read (615 nm), using a
time-resolved technique. Between each step, plate was washed in 1 X DELFIA
Wash Concentrate (supplied by; PerkinElmer Life Sciences) using the DELFIA
automatic plate washer (Wallac). The programme WorkOut was used to analyse
absorbance from standard and samples and to produce the standard curve (based on
a linear model of emission).
2.6 Localisation of PrPc in murine brain by confocal microscopy
This work was carried out at Institute of Animal Health Bioimaging Facility, at
Pirbright, UK, under the guidance of Dr. Paul Monaghan.
2.6.1 Fixation and sectioning of brain tissue
Post-mortem tissues were fixed, by immersion, in a range of fixatives (4 %
paraformaldehyde/PBS or 4 % paraformaldehyde/0.25 % gluteraldehyde/PBS or 4
% paraformaldehyde/0.025 % gluteraldehyde/PBS or periodate-lysine-
paraformaldehyde (PLP) for 3-5 hours. Fixed tissues were then stored at 4 °C in
sterile PBS (Sigma-Aldrich Company Ltd, Dorset, UK) for transport before the
cutting of 70 pm coronal sections using a vibrating microtome (Leica Microsytems,
Milton Keynes, UK).
2.6.2 Immunofluorescence on free-floating thick brain sections
Tissue sections were permeabilised for 1 hour at room temperature with 0.1 %
Triton-XlOO in phosophate buffered saline (PBS) (0.01 M phosphate buffer, 0.0027
M potassium chloride and 0.137 M sodium chloride, pH 7.4; Sigma-Aldrich
Company Ltd, Dorset, UK). The sections were then blocked at room temperature
overnight in a humid chamber in 0.5 % bovine serum albumin (BSA) (Sigma-
Aldrich Company Ltd, Dorset, UK), IX PBS. To eliminate non-specific cross-
reactivity of the anti-PrP mouse monoclonal antibody sections were then blocked
for a further hour with mouse on mouse (MOM) Ig blocking reagent (Vector
68
Laboratories, California, UK). To remove this reagent sections were washed for 10
minutes in PBS/ protein concentrate (Vector Laboratories, California, UK), before
incubated with primary antibody in protein concentrate/PBS at either room
temperature or 37 °C for 90 minutes. Sections were then washed in 1 X PBS 10
times, each for 2 minutes; before incubating with the appropriate Alexa conjugated
goat secondary antibody (1/200; Molecular Probes, Cambridge, UK) in 0.5%
protein concentrate/lX PBS for 90 minutes at room temperature or 37 °C.
Unbound secondary antibody was removed by washing with IX PBS for 2 minutes,
10 times. Sections were then stained for DNA using 4',6-diamidino-2-phenylindole
(DAPI) (1 pg/ml; Molecular Probes, Cambridge, UK) dissolved in ultra pure water
(Sigma-Aldrich Company Ltd, Dorset, UK, Dorset, UK) for 30 minutes. Sections
were then washed 5 times in ultra pure water, each for 1 minute, before mounting in
Vectashield (Vector Laboratories, Burlingame, CA, USA) and sealing with nail
varnish.
2.6.3 Immunofluorescence on free-floating thick brain sections to colocalise
PrP and intracellular markers
Colocalisation experiments were carried out using the same basic method as 2.6.2
with some modifications. For ERp60/8H4 the primary antibodies were mixed in 1 X
PBS/protein concentrate so that the tissue was incubated with them simultaneously.
Similarly the secondary antibodies Alexa488 conjugated goat anti-mouse antibodies
and Alexa568 conjugated goat anti-rabbit antibodies were simultaneously incubated.
Controls for cross reactivity were used and none was detected. For PDI/8H4 cross
reactivity was detected; to eliminate it a sequential staining method was used. For
the two-step staining technique, sections were first incubated with 8H4, washed in 1
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X PBS then incubated with Alexa conjugated goat anti-mouse using a method
identical to that for single 8H4 labelling. Sections were then washed 10 times in IX
PBS before being blocked for one hour in MOM Ig blocking reagent. Block was
removed by washing for 10 minutes in 1 X PBS/protein concentrate before
incubation of the section with anti-PDI in PBS/ protein concentrate. The sections
were then washed and incubated with Alexa568 conjugated goat anti-mouse (PDI) as
above. The sections were washed, stained with DAPI and mounted for analysis.
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Cross reactivity between 23C and Alexa488 conjugated goat anti-mouse was also
488
detected. To eliminate this either the sequential staining technique (8H4, Alexa
C/TO
conjugated goat anti-mouse; 23C, Alexa conjugated goat anti-rat) or an isotype
specific secondary (Alexa488 conjugated goat anti-mouse IgGl) was used.
2.3 Table of antibodies used in immunofluorescence
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2.6.4 Confocal imaging
Sections were imaged with a Leica TCS SP2 laser scanning confocal microscope
using argon 405, 488 and 568 lasers to excite the Alexa-flourophores. Sequential
imaging of each channel was undertaken ifbleed through of DAPI emission into the
488 channel was observed. All images were analysed using Leica confocal
software and prepared for presentation at 300 dpi, RGB in Adobe Photoshop.
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2.7 Cross species transmission of TSEs
All experiments were approved by the Neuropathogenesis Unit's Local Ethical
Review Committee. All inoculations were kindly performed by Mrs Val Thomson,
in accordance with Health and Safety recommendations in Category 2 (263K) or 3
(variant and sporadic CJD) facilities under sterile conditions.
2.7.1 Tissue sources used in cross species transmissions
Hamster passaged scrapie strain 263K: NPU experiment 263K-5L (clinical end
point female Syrian hamster whole brain).
Variant CJD, 129MM (NHBY0/0003 10% homogenate in 0.25M sucrose; National
Institute for Biological Standards and Controls; corresponding to CJD surveillance
unit sample number RU 98/148).
Sporadic CJD 129MM type (CJD surveillance unit, tissue sample number RU
98/73).
2.4 Summary table of TSE transmissions to the glycosylation deficient
transgenics
Source Concentration Genotypes Injected Protocol
263K (263K-5L1/3) 10% Gl, G2, G3,CL 568C-1A
vCJD (RU 98/148) 1 % *G2, G3, CL 567G-1A
Sporadic CJD (RU 98/73) 1 % *G2, G3, CL 567H-1A
*Breeding problems with the G1 transgenic line from November 2002 such that
insufficient experimental G1 mice were available for protocols 567G-1A and 567H-
1A until March 2006, when these mice were inoculated.
2.7.2 Preparation of TSE infected inoculum
Brain tissue (263K and sporadic CJD MM) was weighed and mechanically
homogenised using a pestle with nine volumes of sterile physiological saline
solution (Martindale Pharmaceuticals, UK) to prepare a 10 % unspun homogenate.
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The NIBSC variant CJD sample was supplied as a 10% homogenate. Previous
inoculations at NPU of 10 % NIBSC vCJD homogenate had led to unacceptable
toxicity to mice (NPU protocol; toxicity testing at 10" ; experiment number 553A-
1A). Thus both this and the comparative sporadic CJD isolate were diluted a
further 10 fold with sterile physiological saline solution (Martindale
Pharmaceuticals, UK) for inoculations. After preliminary homogenisation and
dilution all the inoculum was passed through a 26 gauge needle to ensure it could be
injected safely. Excess inoculum was frozen at -70 °C.
2.7.3 Intra-cerebral inoculation of mice
Mice were anaesthetised with 3 % fluothane gas (delivered in oxygen) before
injection of 20 pi of the inoculum in the right hemisphere of the brain using a 26
gauge needle. A needle sheath, exposing 2 mm of the needle, was used so that
inoculum was consistently injected into the mid-temporal cortex. Animals were
then monitored and any not recovering as normal from the procedure were culled
(Home Office Schedule 1) and excluded from experimental analysis.
2.7.4 TSE clinical assessment
After inoculation animals were numerically coded to blind for genotype, such that
all clinical assessments were carried out with no reference to transgenic genotype.
Animals were monitored daily, and formally assessed for clinical TSE disease
weekly, as previously defined by Dickinson, from 100 days after inoculation, by
experienced animal technicians (Miss Emma Murdoch and Miss Sally Shillinglaw)
(Dickinson et al., 1968). Clinical signs were reviewed by Mrs Val Thomson, Mrs
Irene McConnell (senior animal facility stafl) as required and frequently monitored
by F. Wiseman. Animals were scored as TSE "unaffected", "possibly affected" or
"definitely affected" using standard criteria (pronounced spinal hunching, ataxia or
paralysis and "freezing" behaviour or hyperactivity). "Unaffected animals"
exhibited no signs of clinical TSE disease. Animals that displayed signs of disease
but also exhibited an aging phenotype (kyphosis, reduced activity, weight loss and
loss of condition) were classified as "possibly affected" which can be misdiagnosed
as a TSE clinical state. Animals with standard clinical signs but no aging phenotype
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were classified as "definitely affected" In some cases clinically affected animals
also displayed weight loss and urinary incontinence. Disease endpoint was defined
as occurring 1) after two consecutive "definitely affected" score were observed on
the formal scoring day, 2) after the third "definitely affected" score (on the weekly
formal scoring day) within a four week period 3) if the animal was culled on
welfare grounds linked to a "definitely affected" score or 4) if the animal was found
dead after receiving a "definitely affected" score in the previous week. Other
causes of death are defined as inter-current deaths (either found dead or culled on
welfare grounds) and are allocated a clinical negative score.
Table 2.5 Clinical scoring criteria
TSE Clinical Status Clinical Criteria
Unaffected no signs of neurological disease
Probably Affected pronounced spinal hunching, ataxia or paralysis and
"freezing" behaviour or hyperactivity (TSE signs)
AND
kyphosis (curvature of upper spine), weight loss, loss
of condition, reduced activity (ageing phenotype)
Definitely Affected pronounced spinal hunching, ataxia or paralysis and
"freezing" behaviour or hyperactivity (TSE signs)
All animals were culled in accordance with the Animals (Scientific Procedures) Act
1986 (Home Office Schedule 1-cervical dislocation). After cull, brains of both
inter-current deaths and TSE disease endpoint animals were removed under aseptic
conditions and divided asymmetrically saggitally. The brain was then assigned a
unique number such that all subsequent experiments could be carried out blind to
transgenic genotype and TSE strain. However, for reasons of health and safety all
brain material is also labelled with a letter code (B for biohazard category 2 and C
for biohazard category 3). The larger half of the brain was then fixed in 10 %
formal saline for 48 hours. Biohazard category 3 material was then treated with
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formic acid, for 90 minutes, to reduce TSE infective titre further as a biosafety
measure. The tissue was then incubated for a further 2 hours in 10 % formal saline
before being cut into five defined areas for embedding (Figure 2.1). The smaller
half of the brain was flash frozen in liquid nitrogen for storage at -70 °C. Two
pieces of tail were also removed post-mortem from which DNA was extracted by
the phenol/chloroform method to confirm the animals genotype.
2.7.5 Embedding and sectioning of murine brain for lesion profiling and
immuno-histo-chemistry
After fixation and trimming brain tissue was taken through an industrial methylated
spirits (IMS) (70-99 %) and xylene gradient before embedding in paraffin wax
using an automated Leica Tissue Processor (TP1050). Excess wax was removed
from embedded tissue using a Histogical Microtome. The cutting surface was then
rehydrated and softened, after trimming, up placing trimmed side down on wet ice
for 2-3 hours. Sections (6 pm thick) were then cut. To assist mounting sections
were briefly floated in a waterbath (40 °C), to flatten and soften the wax before
attaching them to Superfrost or Superfrost+ (for PrPd detection) ground slides
(VWR International). Mounted sections were allowed to dry overnight at 37 °C.
Category 3 material was kindly trimmed and sectioned by trained and experienced
histological staff (Mrs Sandra Coupar and Mrs Gillian MacGregor) in accordance
with NPU Health and Safety Policy.
2.7.6 Lesion profiling of TSE vacuolar pathology in murine brain
Sections of paraffin wax embedded brain tissue (6 pm thick) were stained with
haematoxylin and eosin using a Leica XL automatic staining machine. Briefly,
mounted sections were taken down a xylene and IMS (99-95%) gradient, washed
and stained with haematoxylin (3 minutes) followed by 2 minutes in Scott's Tap
Water Substitute (sodium hydrogen carbonate 42 mM; magnesium sulphate 160
mM in tap water). After washing sections were counter stained with eosin, washed,
and taken up an IMS (70-99 %) and xylene gradient before mounting in Pertex.
Vacuolation density in nine grey matter regions were scored on a scale of 0-5 and
three white matter regions on a scale of 1-3 by trained and experience histology
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staff (Miss Wingee Liu and Mrs Aileen Boyle) blinded to animal genotype or TSE
agent and reviewed by F. Wiseman (Figure 2.1, 2.2) (Fraser and Dickinson, 1967;
Fraser and Dickinson, 1968).
2.7.6.1 TSE vacuolation scoring scale
Grey matter 0; indicating an absence of vacuolation,
Grey matter 1; limited vacuolation may be caused by ageing,
Grey matter 2 /white matter 1; definite but uneven vacuolation,
Grey matter 3 /white matter 2; even vacuolation of entire brain area,
Grey matter 4 /white matter 3; heavier vacuolation defined but some merging of
small vacuoles to form larger holes,
Grey matter 5; severe vacuolation many vacuoles merged.
2.7.6.2 TSE vacuolation scoring areas
Nine grey matter areas (Greyl dorsal medulla; Grey2 cerebellar cortex; Grey3
superior colliculus; Grey4 hypothalamus; Grey5 thalamus: Grey6 hippocampus;
Grey7 septum; Grey8 retrosplenial and adjacent motor cortex; Grey9 cingulate and
adjacent motor cortex) and 3 white matter areas (White 1 inferior and middle
cerebellar peduncles; White2 decussation of the superior cerebellar peduncles;
White3 cerebral peduncles) were scored.
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Figure 2.1 TSE vacuolation scoring areas in the brain
A) Forebrain, B) Caudal Midbrain, C) Rostral Midbrain, D)
Flindbrain. TSE vacuolation scoring areas 1) dorsal medulla;
2) cerebellar cortex; 3) superior colliculus; 4) hypothalamus;
5) thalamus: 6) hippocampus; 7) septum; 8) retrosplenial and
adjacent motor cortex; 9) cingulate and adjacent motor cortex;
W1) inferior and middle cerebellar peduncles; W2) decussation
of the superior cerebellar peduncles; W3) cerebral peduncles.
76
TSE vacuolation in (he hypothalamus score 0 (A), 1 (B), 2 (Q, 3 (D), 4 (E),
Figure 2.2 Examples of TSE vacuolation scores 0-5 (hypothalamus,
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2.8 Immuno-histo-chemistry of brain tissue experimental infected with TSE
2.8.1 CSA signal amplification method for the detection of PrP
All reagents were from DakoCytomation Inc, California, USA, Catalyzed Signal
Amplification (CSA) System. All reactions were carried at room temperature
unless otherwise stated.
Slide mounted paraffin embedded sections were de-paraffinized in xylene and
rehydrated in an 99-70 % ethanol gradient, before blocking for endogenous
peroxidases in 1 % hydrogen peroxide (Sigma-Aldrich Company Ltd, Dorset, UK)/
methanol (BDH) for 30 minutes. PrP antigen was retrieved from the highly fixed
sections by wet autoclaving at 121 °C for 15 minutes and treatment with 98 %
formic acid for 5 minutes. Sections were then washed in TBS/Tween (tris pH 7.6;
sodium chloride 150 mM; 1% Tween 20) prior to blocking for 20 minutes with
normal rabbit serum (Jackson ImmunoResearch, West Grove, PA, USA; 1/1000)
diluted in TBS/ Tween; Avidin-D (Vector Laboratories, Burlingame, CA USA) for
15 minutes and biotin (Vector Laboratories, Burlingame, CA, USA) for 15 minutes
to remove endogenous rabbit antigens, biotin and streptavidin respectively. Slides
were then incubated with anti-PrP primary antibody for 1-2 hours (6H4 1/20,000 or
8H4 1/5000). Unbound primary antibody was removed by washing in TBS/ Tween.
The CSA kit uses a multiple step approach to amplify the signal from each bound
primary antibody molecule fifty fold. Sections were incubated with biotinylated
rabbit anti-mouse antibody for 15 minutes, washed, then incubated with
streptavidin-biotin conjugated to horseradish peroxidase for 15 minutes. After
further washing the sections were then incubated with amplification reagent
(biotinyl tyramide and hydrogen peroxide in PBS) and washed again before the
final incubation with peroxidase conjugated streptavidin for 15 minutes. Sections
were incubated with hydrogen peroxide activated 3,3'-diaminobenzidine (DAB)
(Sigma-Aldrich Company Ltd, Dorset, UK) which converts to a brown precipitate
upon contact with the peroxidase conjugated streptavidin. Sections were counter
stained with haematoxylin before dehydrating in an 70- 99% ethanol gradient and
100 % xylene before mounting in pertex (CellPath, Hemel Hempstead, UK).
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2.8.2 Avidin-Biotinylated peroxidase complex (ABC) immuo-histo-chemistry
for the detection of astrocytes
Slide mounted paraffin embedded sections were de-paraffmized in xylene and
rehydrated in an 99-70 % ethanol gradient, before blocking for endogenous
peroxidases in 1 % hydrogen peroxide (Sigma-Aldrich Company Ltd, Dorset, UK)/
methanol (BDH) for 10 minutes. Sections were then blocked with normal goat
serum (1/20) diluted in 1 X PBS/ 2% BSA (Sigma-Aldrich Company Ltd, Dorset,
UK) for 15 minutes. Then sections were incubated with rabbit anti-cow glial
fibrillary acid protein (1/500; DakoCytomation Inc, California, USA) diluted in 1 X
PBS/ 2% BSA for 1 hour. Unbound primary antibody was removed by washing in
1 X PBS/ BSA before incubation with biotinylated goat anti-rabbit antibody
(Jackson) diluted in 1 X PBS/ 2% BSA for 1 hour. Excess secondary antibody was
removed by washing before incubation for 30 minutes with an Avidin-Biotinylated
conjugated peroxidase complex (Vectastain Elite ABC Kit, Vector Laboratories,
California, USA). Peroxidase was detected by incubation with hydrogen peroxide
activated 3,3'-diaminobenzidine (DAB) (Sigma-Aldrich Company Ltd, Dorset,
UK), sections were then counter stained with haematoxylin before dehydrating in
an 70- 99% ethanol gradient and xylene for mounting in pertex (CellPath, Hemel
Hempstead, UK).
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2.9 Thioflavin treatment of paraffin embedded sections for the detection of
amyloid
Slide mounted paraffin embedded sections were de-paraffmized in xylene and
rehydrated in an 99-70 % ethanol gradient before staining in Haematoxylin for 5
minutes prior to incubation with Thioflavin-S (lOmg/ml) for 5 minutes, then 70 %
ethanol for 5 minutes before rinsing in water and mounting in Fluoresecent
Mounting Medium (DakoCytomation Inc, California, USA). Fluorescence was
analysed using a Nikon eclipse (E400) microscope illuminated with a mercury bulb.
2.10 Diagnostic western blotting of human TSE samples
The standard diagnostic protocol (National CJD Surveillance Unit (NCJDSU)) for
western blotting of suspect human TSE cases was used to examine the Parchi type
(mobility in SDS-PAGE of the un-glycosylated band) and glycoform of the inocula
used in the cross species transmission experiments. All work was carried out in the
category 3 laboratory at the, NCJDSU using methods adapted from Collinge et al
1996 under the supervision of Dr. Mark Head. Dissection of standard reference
samples was kindly carried out by Dr. Mark Head.
2.10.1 Preparation (dilution, proteinase K treatment and denaturation) of
human TSE samples and reference standards
Diagnostic reference standards were prepared from frozen tissue dissected from the
frontal cortex. Briefly, tissues was mechanically homogenised using a pestle in
nine volumes of sterile saline solution (0.9 % w/v) (Martindale Pharmaceuticals,
UK) to prepare a 10% homogenate. This was then diluted a further 10 fold in
sterile physiological saline solution (Martindale Pharmaceuticals, UK) to form a 1%
homogenate comparable to the inocula prepared at NPU. Protein from standards
and inocula was then extracted by the addition of saline free Extraction Buffer (0.5
% NP-40, 0.5 % sodium deoxycholate, TBS [pH7.4]; all Sigma-Aldrich Company
Ltd, Dorset, UK) and centrifugation at 2000 rpm for 5 minutes at 4 °C. The
supernatant was then removed from the pellet and treated with PK at 37 °C for 1
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hour (50 pg/ml; Merck). Reaction was stopped by the addition of Pefabloc (ImM;
Roche Diagnostics, Basel, Switzerland) and freezing at - 20 °C. In some cases
samples were concentrated prior to SDS-PAGE separation by centrifugation at
14,000 rpm for 1 hour at 4 °C. The supernatant was discarded and the pellet
resuspended in 1 X Extraction Buffer (0.5 % NP-40, 0.5 % sodium deoxycholate,
TBS [pH7.4]; all Sigma-Aldrich Company Ltd, Dorset, UK)
2.10.2 Sodium Dodecyl Sulphate Polyacrylamide gel electrophoresis (SDS-
PAGE)
Samples were denatured by heating at 102 °C for 10 minutes with NuPAGE LDS 4
X Sample Buffer (final concentration glycerol 10 %, tris 157 mM, lithium dodecyl
sulphate 2 %, EDTA 0.51 mM, SERVA Blue G250 0.22 mM, Phenol Red 0.175
mM [pH 8.5]; Invitrogen, Paisley, UK). Proteins were then separated on the basis
of weight and charge by gel electrophoresis at 200 V for 50 minutes using NuPAGE
Novex 10 % Bis-Tris Gels (1.0 mm Invitrogen Life Technologies, Paisley, UK) in
NuPAGE 1 X MES SDS running buffer (MES 50 mM [pH 7.2], tris 50mM, SDS
0.1 %, EDTA 1 mM; Invitrogen Life Technologies, Paisley, UK). Extraction buffer
and NuPAGE LDS 4 X Sample Buffer blanks were used as negative controls. A
mixture of SeeBlue (Invitrogen Life Technologies, Paisley, UK) and Magic-marker
(Invitrogen Life Technologies, Paisley, UK) were used as molecular weight
markers.
2.10.3 Transfer of separated proteins to a membrane
Proteins separated by SDS gel electrophoresis were transferred to PDVF membrane
(Hybond-P, Amersham Biosciences, Piscataway, NJ, USA) at 30 V for 1 hour,
using the NuPAGE transfer system, in 1 X NuPAGE Transfer Buffer (Invitrogen
Life Technologies, Paisley, UK; final concentration, bicine 25 mM, bis-tris (free
base) 25 mM, EDTA 1.0 mM, chlorobutanol 0.05 mM) and 20 % methanol.
2.10.4 Detection of PrP protein bound to a membrane
Membrane was washed 2X3 minutes in TBST before blocking in 5 % milk
(Safeway non-fat dried milk powder)/ TBST (Sigma-Aldrich Company Ltd, Dorset,
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UK) overnight, shaking at 4 °C. After blocking the membrane was washed with
TBST prior to incubation with the primary anti-PrP antibodies 3F4 (1/20,000;
Dako) or 6H4 (1/20,000; Prionics, Schlieren, Switzerland) in TBST for 1 hour.
Membrane was then washed to remove excess primary antibody before incubation
with HRP-conjugated secondary antibody (goat anti-mouse IgG (Fab-specific)
peroxidase conjugate 1/40,000; Sigma-Aldrich Company Ltd, Dorset, UK) in
TBST. Membrane was washed with TBST to remove excess secondary antibody
prior to incubation with chemiluminescent substrate for 5 minutes (ECL plus,
Amersham Biosciences, Piscataway, NJ, USA) followed by exposure to X-ray film
(Hyperfilm ECL; Amersham Biosciences, Piscataway, NJ, USA). Films were
developed using an automatic film processor (Hyperprocessor™; Amersham
Biosciences, Piscataway, NJ)). Digital images of the chemiluminescence were also
recorded when the signal was adequate using a Storm860 digital imager (Molecular
Dynamics, Sunnyvale, CA).
2,10.5 Strain typing, densitometry and glycoform analysis
After X-ray films had been developed they were scanned using a GS-700
Densitometer (BioRad). Densitometry was performed using the Quantity One
(4.4.1) programme. Band density was confirmed to be within the linear range by
reference to previous standards kindly provided by Dr. Mark Head, and was
recorded for glycoform analysis. Band width was determined manually by intensity
minima. Samples were compared to standard reference samples for both glycoform
analysis and typing of the size of the un-glycosylated band (Parchi et al 1996)
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2.11 Protein misfolding cyclic amplification (PMCA)
PMCA was undertaken in the laboratory of Dr. Claudio Soto, under the supervision
of Dr. Joaquin Castilla, University of Texas Medical Branch (UTMB), Galveston,
Texas, USA. Infectious materials were transported on dry ice in accordance with
IATA Dangerous Goods requirements from NPU to UTMB. This was kindly
arranged by Dr. Rona Barron and Mr. Declan King. All chemicals supplied by
Fisher Scientific, unless otherwise stated.
2.11.1 TSE infected samples used in PMCA
263K (Syrian Hamster NPU protocol 263K-5Z animal number 33; B34853 and
animal number 3; B34855)
ME7 (129/Ola mouse NPU protocol 5666G-1A; animal number 52, CI 1147 and
animal number 53, CI 1172) kind gift of Dr. Nadia Tuzi, NPU, Edinburgh.
79A (129/Ola mouse NPU protocol 567C-1A animal number 40, C10760 and
animal number 50, C10759) kind gift of Dr. Nadia Tuzi, NPU, Edinburgh.
2.11.2 Normal brain homogenate preparation for PMCA
Whole brains were taken post mortem, rinsed in PBS and immediately snap frozen
in liquid nitrogen for transport on dry ice to UTMB. The brains were weighed
separately and homogenized in glass homogenisers with a plastic pestle on ice in
nine volumes of conversion buffer (1 X Dulbecco's phosphate buffered saline
(136.9 mM sodium chloride, 8.1 mM sodium phosphate, 1.5 mM potassium
phosphate, 1.5 mM potassium chloride (supplied by Sigma-Aldrich Company Ltd,
St. Louis, MO, USA; D-PBS), 150 mM sodium chloride, 1% Triton X-100 [Sigma-
Aldrich Company Ltd, St. Louis, MO, USA, T8787] with 1 X Complete Protease
Inhibitor Cocktail containing 1 mM EDTA [Roche Diagnostics, Basel,
Switzerland]). Cell debris was removed by brief centrifugation at 2000 rpm for 45
seconds (Harrier 18/10 SANYO). The resultant supernatant was either directly
frozen at - 80 °C in 450 pi aliquots or mixed with additional EDTA [Promega,
Madison, WI, V4231, (final concentration 5 mM)] prior to aliquoting and freezing.
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Normal hamster brain homogenate was a kind gift of Dr. Paula Prieto Saa, UTMB,
Galveston.
2.11.3 TSE infected brain homogenate preparation for PMCA
Partial brains were weighed and homogenized in nine volumes of 1 X D-PBS (with
IX Complete Protease Inhibitor Cocktail that contains 1 mM EDTA (Roche
Diagnostics, Basel, Switzerland 1836 145) (PBS/PI). Un-spun homogenate was
then aliquoted for storage at -80 °C. Prior to PMCA, aliquots of 263K were heated
at 55 °C for 10 minutes, with shaking, to denature any PrPc rendering it incompetent
as substrate for PMCA. It was necessary to purify the mouse ME7 and 79A
infected brain homogenates further. They were mixed with an equal volume of
20% sarkosyl and centrifuged at 100,000g for 1 hour. The resultant pellet was
washed in PBS/PI and centrifuged for 30 minutes at 100,000g in polycarbonate
tubes before resuspension in PBS by manual sonication (40 X 1 second pulses at
10% power output) using a Sonoplus HD 2070 sonicator with a titanium microtip
MS73 (Bandelin Electronic, Berlin, Germany).
2.11.4 Automatic protein misfolding cyclic amplification
Optimisation experiments were performed to determine the conditions under which
PrPSc (263K, ME7, 79A) seeded the in vitro conversion of PrPc to the protease
resistance form (PrPRes) would occur. The ratio of TSE infected brain homogenate
to the normal brain homogenate, the concentration of EDTA and the number of
cycles were examined to determine optimum conditions for in vitro generation of
PrpRes control samples of the normal brain homogenate/ TSE infected brain
homogenate mix were either directly frozen or incubated at 37 °C for the same
period of time as PMCA was performed. An equal volume of mix (80 pi) was used
for PMCA and 37 °C control samples as amplification may be volume dependent
(personal communication, J. Castilla). PMCA was performed in a bath sonicator
using a microplate horn (Misonix 3000), such that the ultrasound is applied to the
samples indirectly. Thin wall PCR tubes (GeNunc, Nalge Nunc International, 0.2
ml tubes) were used to permit adequate penetration of ultrasound into the PMCA
samples. Each cycle consists of a 30 minute incubation at 37 °C followed by 40
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second pulse at power output 6. Samples were frozen at - 80 °C prior to analysis
by gel electrophoresis and western blotting.
2.11.6 Proteinase K treatment and sample denaturation for western blotting
Samples subjected to PMCA and controls which had either been frozen or
incubated at 37 °C without sonication were treated with 50 pg/ml Proteinase K
(Roche Diagnostics, Basel, Switzerland) for one hour at 37 °C. The reaction was
stopped with NuPAGE LDS Sample Buffer (Invitrogen, Carlsbad, CA, USA)
followed by immediate denaturation by heating to 100 °C for 10 minutes or freezing
at - 20 °C for denaturation later. Control samples not treated with PK were
similarly denatured in NuPAGE LDS Sample Buffer prior to electrophoresis.
2.11.7 Sodium Dodecyl Sulphate Polyacrylamide gel electrophoresis (SDS-
PAGE)
LDS denatured total proteins were separated by size and charge in NuPAGE 12 4%
Bis-Tris Gels (15 minutes at 70 V; 50-70 minutes at 150 V) using 1 X NuPAGE
MES Running Buffer (Invitrogen, Carlsbad, CA, USA) using the Invitrogen
cassette system. SDS-PAGE prestained low-range molecular weight markers
(phosphoylase B 103 kDa, bovine serum albumin 81 kDa, ovalbumin 48 kDa,
carbonic anhydrase 36 kDa, soybean trypsin inhibitor 27 kDa and lysozyme 19
kDa; BioRad, Hercules CA, USA) was used.
2.11.8 Western blotting and detection of membrane bound proteins
Total proteins were transferred to Hybond-ECL nitrocellulose membrane
(Amersham Biosciences, Piscataway, NJ, USA) in 1 X Tris-glycine transfer Buffer
(20 % Methanol; 25 mM tris; 200 mM glycine) at 0.8 Amps, for 1 hour, using a
BioRad immersion blotter cooled by ice. Membranes were blocked in 5 % non-fat
milk (Carnation) PBS/0.05 % Tween 20 (PBST) for 1 hour, rocking at room
temperature, prior to incubation with anti-PrP mouse monoclonal antibodies 3F4
(1/5000) for the detection of hamster PrP, and 6H4 (1/5000 Prionics, Schlieren,
Switzerland) or 6D11 (1/5000 Signet, Dedham, MA, USA) for the detection of
murine PrP, in 2 % milk PBST, rocking either for 1 hour at room temperature or
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overnight at 4 °C. Membranes were washed in PBST (once for 10 minutes and
three times for 5 minutes), prior to incubation with ECL sheep horseradish
peroxidase linked anti-mouse antibody (Amersham Bioscience, Piscataway, NJ,
USA) for 1 hour rocking at room temperature. Excess secondary antibody was
removed by washing in PBST (once for 10 minutes and three times for 5 minutes).
Bound HRP-conjugated secondary antibody was detected using ECL plus Western
Blotting Detection System (Amersham Bioscience, Piscataway, NJ, USA) and the
EpiChemi3 Darkroom (UVP Biolmaging Systems; California, USA) linked to
LabWorks program via a Hamamatsu Camera, with exposures of 30 seconds and 15
minutes.
2.11.9 Stripping of bound antibody from nitrocellulose membranes
To permit re-probing of western blots with a second antibody, the blots were
stripped with Western Stripping solution (100 mM B-Mercaptothanol; 2 % SDS;
62.5 mM Tris pH 6.7) by shaking at 50 °C for 30-45 minutes. Prior to reprobing,
blots were washed in distilled water and PBST, and blocked in 5 % milk/PBST for
1 hour at room temperature.
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3.0 Characterisation of PrP in uninfected PrP glvcosylation deficient
transgenic mice
3.1 Aim to characterise the biochemistry of PrPc, the spontaneous formation of PrPSc
and development of spontaneous TSE clinical disease in the glycosylation deficient
transgenic mice.
3.2 Introduction and experimental techniques
In order to interpret the importance of the glycosylation status of PrP to cross-
species TSE transmission, it is necessary to understand the influence of
glycosylation of PrP on the protein's normal biochemistry. The N-linked
glycosylation of proteins is known to influence multiple aspects of their
biochemistry. These include the protein's half-life, folding efficiency and
identification of misfolded forms in the ER, functionality (catalytic ability) and
interactions with other molecules (Mitra et al., 2006). The relative importance of
glycosylation to these parameters varies between individual proteins and it is not
possible to predict the biochemical effects ofN-linked glycan attachment. Therefore
altering the glycosylation of PrP may change the ability of the protein to fold or
misfold, its steady state or lead to the spontaneous formation of PrPSc (Rudd et al.,
2001).
These potential changes may have a major impact on the key role of PrP in TSE
disease, perhaps via an influence on the conversion of PrPc to PrPSc. Equally, PrP's
glycosylation state may change the tendency of the protein to form dimers or be
truncated, which may also impact on disease phenotype or incidence. Thus it is
necessary to determine which of these factors are influenced by the change in N-
linked glycosylation of PrP in vivo in the transgenic model system employed here
[NPU]. To validate the model, the disruption of glycosylation by the amino acid
changes in PrP will be investigated. Additionally, it is important to ascertain if the
models used here develop spontaneous TSE disease. This will provide a baseline
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against which experimental TSEs transmission can be compared. Thus both the
spontaneous development of TSE neurological signs as defined by Dickinson and
Fraser (1968) and subclinical TSE specific vacuolar pathology were investigated by
standard methods over the normal lifespan of the PrP glycosylation deficient
transgenic mice.
The alteration of glycosylation state in the PrP glycosylation deficient murine
transgenics may reduce the stability or turnover of PrPc such that its steady state is
altered, as has been demonstrated for other proteins (Chen et al., 2006; Li et al.,
2004). Previous work has demonstrated that the level of Prnp mRNA in the PrP
glycosylation deficient transgenic mice [NPU] is comparable to that in normally
glycosylated wild type mice (Cancellotti et al., 2005; Wiseman, 2003). Consistent
with previous models generated using PrP gene-targeting (Moore et al., 1998), this
indicates that the point mutations introduced into the Prnp transgene in these
transgenics do not alter the amount of Prnp mRNA in the CNS. Further
c
experimentation is required to assess if these changes alter the amount of PrP
produced in the CNS of these transgenic murine models. The level of PrPc greatly
affects the disease incubation period for many TSE strains (Manson et al., 1994b;
Prusiner et al., 1990), thus these data are important to correctly interpret TSE
transmission studies in the glycosylation deficient transgenic mice.
Preliminary studies to determine PrP level in the unchallenged glycosylation
deficient transgenic mice using western blot analysis produced ambiguous results
because of the semi-quantitative nature of the assay (data not shown). This approach
was abandoned in favour of a quantitative analysis using Dissociation Enhanced
Lanthanide Fluoroimmunoassay (DELFIA) adapted from the method of Barnard and
colleagues (Barnard et al., 2000). This technique uses pairs of PrP specific
antibodies. An N-terminal specific antibody (FH11 or AG4) captures PrP and
anchors it to an ELISA plate such that is concentrated. A second detector antibody
(8H4 or 7A12) labelled with the lanthanide, europium, which can be
spectometrically detected is then used to detect bound PrP. The amount of PrP in
each sample can then be determined by comparison with a known recombinant PrP
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standard. As this system uses monoclonal antibodies, comparison of multiple pairs
is required as PrP may exist in more than one conformation or in truncated forms in
vivo. Thus a specific epitope may only be available for binding in a fraction of the
total PrP molecules. Importantly, the binding of PrP to antibodies may be influenced
by its glycosylation state.
Expression of mutant or truncated forms of PrP in vivo has led to the development of
spontaneous neurological dysfunction in a number of models (Castilla et al., 2005;
Chiesa et al., 1998; Hsiao et al., 1990; Ma et al., 2002; Muramoto et al., 1997;
Shmerling et al., 1998). However only in limited cases has TSE spongiosis been
observed (Castilla et al., 2005; Hsiao et al., 1990). These neurodegenerative
phenotypes can confound TSE transmission studies, as it is difficult to determine
whether neurological signs are the result of expression of the transgene, TSE
transmission or a combination of both. Neurological phenotypes have only been
previously observed when the PrP transgene is over expressed (Nazor et al., 2005).
Thus in the gene-targeted transgenic mice used here the development of spontaneous
TSE disease is unlikely. Despite this, it is important to experimentally demonstrate
this so that any observed cases of TSE disease, after cross-species TSE challenge,
can be attributed to the experimental TSE exposure (Chapters 5 and 6). This is
particularly pertinent to cross-species transmission studies for which long incubation
periods are anticipated as spontaneous disease is particularly apparent in older mice.
Additionally, these data are informative regarding the mechanism of non-acquired
TSE disease which includes both familial and sporadic forms, some of which are
associated with PrPSc that is abnormally glycosylated (Capellari et al., 2000a;
Grasbon-Frodl et al., 2004; Monari et al., 1994; Nitrini et al., 1997; Zanusso, 2006).
Spontaneous formation of PrPSc or partial PrPSc-like properties may occur in the
absence of overt clinical signs in the glycosylation deficient transgenic mice. This
would also confound cross-species TSE transmission studies, as PrPSc formation will
be used as a marker of disease susceptibility (Chapters 5 and 6). Spontaneous
formation of misfolded PrP, including that which is PK sensitive, has been reported
in a number of experimental systems in which primary amino acid sequence of PrP
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has been altered (Castilla et al., 2005; Chiesa et al., 1998; Hsiao et al., 1994; Hsiao et
al., 1990; Lehmann and Harris, 1996a; Lehmann and Harris, 1996b; Lehmann and
Harris, 1997; Ma and Lindquist, 2002; Ma et al., 2002; Nazor et al., 2005; Singh et
al., 1997). However, spontaneous formation of misfolded PrP in vivo has only been
demonstrated when PrP is highly expressed (Chiesa et al., 1998; Hsiao et al., 1990;
Manson et al., 1999; Nazor et al., 2005). In some experiments, changes in the
biochemistry of PrP, such as enhanced PK resistance, have been observed even in
young animals (Chiesa et al., 1998).
Previous studies have suggested that glycosylation of PrP contributes to the stability
of the protein's conformation and its resistance to misfolding (Lehmann and Harris,
1997; Rudd et al., 2001). Cell culture studies have suggested that, in the absence of
its N-glycans, PrP spontaneously exhibits some biochemical properties of PrPSc,
including enhanced insolubility and resistance to protease digestion (Lehmann and
Harris, 1997). This led these authors to conclude that this partially misfolded PrP
may resemble an intermediate pre-PrPSc like state. Furthermore, the authors suggest
this effect may be mediated by reduced solubility, or an enhancement of the ability
of the un-glycosylated form to adopt a partially misfolded conformation. Thus the
in vivo effect of the absence of PrP's N-glycans on the biochemical properties of PrP
was investigated in the PrP glycosylation deficient transgenic mice.
To investigate the folding status of PrP, a standard PK digestion and a solubility
assay were employed. PrPSc is resistant to digestion with relatively high
concentrations of PK, compared to PrPc (Buschmann et al., 1998). A range of PK
concentrations was thus investigated to determine if PrPc from the glycosylation
transgenic mice had enhanced resistance to digestion. Previous studies have
demonstrated that not all misfolded forms of PrP are PK resistant (Nazor et al.,
2005). To determine if such forms of PK sensitive PrPSc spontaneously formed in
glycosylation deficient murine transgenics, a solubility assay was additionally used.
Misfolded PrP is insoluble at low guanidine hydrochloride (Gnd HC1) concentrations
(1 M), at which PrP is predominately soluble, but soluble at higher concentrations
of the chaotroph (6 M) (Barnard et al., 2000; Safar et al., 1998). Thus total brain
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proteins were separated on the basis of their solubility in Gnd HC1 and the amount of
PrP in each fraction determined quantitatively.
3.3 Optimisation of experimental techniques
3.3.1 PNGase deglvcosylation of PrPc
Optimum conditions for the enzymatic deglycosylation of normally glycosylated
PrPc, in total brain homogenate were experimentally determined using commercially
available PNGase enzyme derived from Chryseobacterium [Flavobacteriwn]
menigosepticum. De-glycosylation of PrPc was incomplete using conditions
recommended by the enzyme manufacture (New England Biolabs) (data not shown).
Increasing the incubation time resulted in the formation of truncated forms of PrP,
irrespective of the presence of PNGase, perhaps because of the action of endogenous
proteinases (data not shown). Increasing the ratio of PNGase to total brain protein
for short incubation periods was found to facilitate complete deglycosylation of
normally glycosylated PrPc without the formation of truncated forms. This
experimental method was thus used to investigate the glycosylation state of PrP in
the PrP glycosylation deficient transgenics.
3.3.2 Western blot tubulin loading control
A rat anti-a tubulin monoclonal antibody was used to confirm that equal amounts of
total protein were loaded in each lane of western blots, as has been previously used
by other workers (Allen et al., 2005). The optimum anti-tubulin antibody
concentration was experimentally determined to be 1/4000 (appendix iii).
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3.4 Experimental results
3.4.1 Threoine for asparagine substitution at position 180 and 196 prevent the
attachment of N-glycans to PrP
To confirm that the N180T and N196T substitutions in the PrP glycosylation
deficient transgenics altered the glycosylation of PrP in vivo, the sensitivity of PrP
to enzymatic deglycosylation was investigated. A three hour treatment of total brain
protein with PNGase (30,000 Units/ml) resulted in the complete deglycosylation of
wild type PrP such that predominant -35-37 kDa forms, and the minor -31-34 kDa
forms, were observed to disappear with a concurrent increase in the amount of the
previously minor -30 kDa form (Figure 3.1 A, n = 4 8H4 and 7A12). This observed
change in molecular weight is consistent with the well documented variable
glycosylation of PrPc in vivo, and supports the proposal that the 35-37, 31-34 and 30
kDa forms correspond to di-, mono- and un-glycosylated forms of PrPc respectively.
Minimal truncated forms of PrP were detected by this method in samples in which
PrP was normally glycosylated, supporting the hypothesis that the 31-34 kDa forms
are mono-glycosylated PrP and not truncated forms as has been previously suggested
(Chen et al., 1995). The molecular weight of p-tubulin was unchanged by the
PNGase treatment consistent with its un-glycosylated state.
Similar treatment of total brain protein with PNGase from G1 and G2 glycosylation
deficient transgenic mice resulted in the disappearance of -31-34 KDa PrPc and an
increase in -30 KDa PrPc (Figure 3.1 A). This change in molecular weight after
enzymatic deglycosylation is consistent with a single site of N-glycan attachment
being utilised in these transgenic lines. The molecular weight of PrPc from the
brains of G3 PrP glycosylation deficient transgenic mice was unchanged by
enzymatic deglycosylation, consistent with PrPc not being glycosylated in this
transgenic model (Figure 3.1 A).
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Figure 3.1 Western blots of total brain proteins from glycosylation deficient
transgenic and control mice
A
G1 G1 G2 G2 G3 G3 129/Ola129/Ola Null









3.1 (A) Western blot of PNGase deglycosylated total brain protein (3 hours 37
°C 30,000 Units/ml) from uninfected PrP glycosylation deficient transgenic
and normally glycosylated control (129/Ola) mice demonstrates that the
N180T (G1 and G3) and the N196T (G2 and G3) substitution disrupt the first
and second PrP glycosylation site of PrP respectively. PrP detected using
anti-PrP mouse monoclonal 8H4, antibody specificity demonstrated by the
use of PrP null mice total brain homogenate control (Null). Upper band
indicated by arrow anti-p-tubulin loading control (rat monoclonal). (B) Western
blot demonstrating the difference in the electrophoretic mobility of
mono-glycosylated PrP from G1 and G2 transgenic murine brain. Total brain
protein from uninfected PrP glycosylation transgenic (single samples assayed
in duplicate) and two independent normally glycosylated 129/Ola control
(129/(a) and 129/(b)) mice run under denaturing conditions. PrP detected
using anti-PrP monoclonal 6H4.
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3.4.2 The molecular weight of mono-glycosylated PrPc differs between G1
(T180N) and G2 (T196N) transgenic mice
Visual inspection of western blots suggests that the electrophorectic mobility of
mono-glycosylated PrPc differs between G1 and G2 transgenic mice (Figure 3.1 B).
This was examined further using densitometry (Figure 3.2). Normally glycosylated
wild type PrP exhibits three peaks of PrP densitometry that correspond to the di- ,
mono- and un-glycosylated forms of the protein. Both G1 and G2 PrP glycosylation
deficient transgenic mice exhibit two major peaks, however the predominate heavier
peak (mono-glycosylated) from G1 transgenic mice reproducibly ran slower than
that of either G2 transgenic mice or normally glycosylated controls (Figure 3.2 6H4
n = 3). This supports the hypothesis that the combination of sugars attached to G1
and G2 PrPc differ and suggests that those attached to G2 PrP more closely resemble
the predominate wild type mono-glycosylated form. However further experimental
investigation is required to confirm this as the prevention of glycosylation at one site
may alter the combination of sugars attached to the other.
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Figure 3.2 Densitometry profile of western blot of PrP from PrP glycosylation
deficient transgenic and normally glycosylated control (129/Ola) mice
Relative Distance
PrP detected using anti-PrP monoclonal 6H4 and corresponds to the that
represented in western blot 3.1 B. Intensity of anti-PrP signal displayed
on y-axis, relative distance from top of gel on the x-axis. Predominate
129/Ola (129/Ola (a) in figure 3.1 B) PrP control peak observed at ap¬
proximately 25 units on x-axis, minor peaks observed at 37 units and 47
units; G1 PrP major peak observed at 34 units and minor peak at 50
units; G2 PrP major peak at 37 units and minor peak at 46 units; G3 PrP
major peak at 47 units, as indicated by arrows. This data supports the
hypothesis that the electrophorectic mobility of mono-glycosylated PrPc
differs between G1 and G2 transgenic mice and that from G2 animals
most closely reassembles mono-glycosylated PrPc from normally glyco-
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3.4.3 Comparison of the amount of PrP( in the glycosylation deficient
transgenic and normally glycosylated control mice
To investigate if alteration of the glycosylation state of PrP in the Gl, G2, and G3
transgenic mice changed the overall amount of the protein in vivo, the amount of
PrPc in the brains of transgenic mice and normally glycosylated controls was
compared by Dissociation Enhanced Lanthanide Fluoroimmunoassay (DELFIA).
For this assay PrPc was solubilised in a weak solution of guanidine hydrocholoride
(Gnd HC1; 1M) in which PrPSc is insoluble. The amount of PrPc in the sample is then
determined using an un-glycosylated recombinant PrP standard. The apparent
amount of normally glycosylated PrP detected varied by a factor of 10 between
antibody pairs, in particular the capture antibody AG4 was associated with higher
anti-PrP signals (Figure 3.3, compare A and B to C). Thus the ratio of detectable
recombinant and native PrP displays antibody dependence. This may either reflect
enhanced detection of the normally glycosylated form or reduced detection of
recombinant PrP. A higher signal was detected in the assay buffer negative control
than in the PrP null brain homogenate negative control when the capture antibody
FH11 was used (Figure 3.3 A and B). This suggests that molecules in the murine
brain homogenate act to block non-specific interactions between FH11 and both 8H4
and 7A12 capture antibodies. A similar effect is not observed when AG4 is used as
the capture.
For antibody pair FH11-7A12, no significant difference in the amount of PrPc was
observed between the PrP glycosylation deficient murine transgenics and normally
glycosylated controls (Figure 3.3 A, n = 2-4, assayed three times in duplicate,
ANOVA p = 0.177). In contrast, significantly more PrPc was detected in Gl and G3
transgenic mice than in wild type controls using the FH11-8H4 antibody pair (Figure
3.3 B, n = 2-4, assayed twice in duplicate, ANOVA p = 0.004). However, a
difference in the amount of PrPc was also observed between the two normally
glycosylated controls (wild type and control line) which was not observed using the
other antibody pairs.
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Figure 3.3 Amount of soluble and insoluble PrP detected by DELFIA
A (FH11-7A12)















































G1 G2 G3 129/Ola CL Null ME7 Assay
Buffer
PrP detected by DELFIA using an anti-PrP capture (A & B) FH11 or (C) AG4 and a euro-
phium labelled detector antibody (A &C) 7A12 or (B) 8H4, in brain homogenates from unin¬
fected G1 (N180T), G2 (N196T) and G3 (N180T, N196T) PrP glycosylation deficient trans¬
genic, normally glycosylated control (129/Ola, and transgenic control line (CL) that ex¬
presses normally glycosylated PrP but carry a LoxP site downstream of exon 3), PrP null
(Null) and murine scrapie infected 129/Ola mice (ME7). Recombinant PrPa used as the
standard, to determine relative amount of soluble (1 M Gnd HCI) and insoluble (1 M Gnd
HCI insoluble 6 M soluble) PrP. Mean amount of PrP detected for 3 (A) or 2 (B and C)
DELFIA experiments using n independent samples (G1 n = 2, G2 n = 4, G3, 129/Ola and
CL n = 3, Blank, ME7 and PrP Null n = 1) each sample assayed in duplicate during each
experiment. Error bars indicate the standard deviation between individual animals and the
assay buffer between different experiments. Significantly more soluble PrP was detected
using FH11-8H4 in G1 and G3 brain homogenates than in the 129/Ola control (B, ANOVA p
= 0.0004) and significantly less soluble PrP was detected using AG4-7A12 in G1, G2 and
G3 brain homogenates than in the 129/Ola control (C, ANOVA p < 0.001). 97
This result questions the validity of the differences between the wild type control and
glycosylation deficient transgenic mice observed using this antibody pair. The anti-
PrP signal was particularly low when using FH11-8H4, this may have contributed to
the apparent inaccuracy of this combination of antibodies. A significant but small
reduction in the amount of Gl, G2 and G3 PrPc detected as compared to the
normally glycosylated controls was observed using the AG4-7A12 antibody pair
(Figure 3.3 C, n = 2-4 assayed twice in duplicate, ANOVA p < 0.001). Interestingly,
the AG4-7A12 antibody pair did not detect any (1M guanidine hydrochloride
insoluble 6 M soluble PrP) PrPSc in the ME7 clinical endpoint positive control,
suggesting it cannot bind misfolded forms of PrP. Thus the reduced level of protein
observed in the glycosylation deficient transgenic mice using AG4-7A12 may be the
result of only a subset of total PrP being captured by AG4.
The same group of age and sex matched mice were assayed using each antibody pair,
thus the observed differences between pairs are not attributable to intra-animal
variation and are likely to result from differential antibody recognition of the
glycotypes in each transgenic line. Thus these data do not suggest that there are
underlying differences in the amount of PrPc between the murine PrP glycosylation
deficient transgenics and normally glycosylated controls, but that variation in
antibody recognition between PrP glycotypes occurs. In particular, there is no
evidence of a reproducible reduction in the amount of PrPc detected in any of the
PrP murine glycosylation deficient transgenics, suggesting that in vivo an absence of
N-glycans does not compromise the overall amount of PrPc in the CNS.
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3.4.4 Absence of PrP's N-glycans does not lead to the spontaneous formation of
PrPSc like properties in vivo.
Previous cell culture studies have suggested that un-glycosylated or partially
glycosylated PrP spontaneously adopts PrPSc-like properties (Lehmann and Harris,
1997). These biochemical changes included enhanced insolubility and resistance to
PK. To investigate if this occurred in vivo in the PrP murine glycosylation deficient
transgenics, a number of biochemical features of PrP where examined. Misfolded
PrP, as assayed by low concentration Gnd HC1 insolubility (1M insoluble), was not
observed in any of the uninfected murine PrP glycosylation deficient transgenics,
suggesting that PrPSc had not spontaneously formed in these mice (Figure 3.3 A and
B).
Additionally, no PK resistant PrP was observed in uninfected murine PrP
glycosylation deficient transgenics as assayed by standard PK digested (20 gg/ml 37
°C for 1 hour) and measured by western blot using two anti-PrP monoclonal
antibodies (8H4 n = 3, 7A12 n = 3). In contrast, PK resistant PrP can be clearly
detected in TSE infected mice (murine scrapie strain ME7) at clinical endpoint by
this method (Figure 3.4 A). Moreover, even using low concentrations of PK (10
pg/ml 37 °C for one hour), resistant PrP was not detected in the murine PrP
glycosylation deficient transgenics (Figure 3.4 B, 8H4 n = 2, 7A12 n = 3). The use
of lower concentrations of PK (5 or 1 pg/ml 37 °C for one hour) resulted in the
incomplete digestion of normally glycosylated and glycosylation deficient PrP,
consistent with previous reports (Figure 3.4 C, 7A12 n = 2, 8H4 n = 3) (Buschmann
et ah, 1998). No significant differences in the amount of PrP remaining were
apparent between transgenic mice and normally glycosylated controls by this
method. No PK resistant PrP (20 pg/ml 37 °C for 1 hour) was detected in G3
transgenic mice that were in excess of 800 days old (Figure 3.5 A, 8H4 n = 3).
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Figure Legend 3.4 PK resistance of PrP from the glycosylation deficient
transgenic and normally glycosylated control mice as analysed by
western blot. Total brain proteins from murine scrapie strain ME7 infected
clinical endpoint and uninfected glycosylation deficient transgenic (G1
N180T; G2 N196T; G3 N180T and N196T), normally glycosylated control
(129/Ola and control line (CL) mice that express murine wild type PrP but
carry a single transgenic LoxP site downstream of exon three) and PrP null
mice (Null) were treated for 1 hour at 37 °C with (A) 20 pg/ml (B) 10 pg/ml
or (C) 1 pg/ml PK; the reaction was stopped with PMSF and samples were
denatured and western blotted. Di-, mono- and un-glycosylated PrP was
detected with anti-PrP mouse monoclonal 8H4 (indicated by small arrows)
and the control for protein loading B-tubulin of approximately 50 kDa was
detected with a rat monoclonal anti-B-tubulin (indicated by large arrow).
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Figure 3.4 PK resistance of PrP from PrP glycosylation deficient transgenic
and normally glycosylated control mice as analysed by western blot
A (20 pg/ml PK)
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Figure 3.5 The PK resistance of PrP in aged G3 transgenic and control (CL) mice
ME7
PK +
G3 G3 G3 G3 G3 G3 CL CL CL CL CL CL Null




To investigate the PK resistance of PrP in aged G3 transgenic mice, total brain
proteins from aged G3 transgenic and normally glycosylated (CL) control mice
were treated for 1 hour at 37 °C with 20 pg/ml PK as indicated, denatured and
western blotted, no PK resistant PrP was detected by this method in either the
aged G3 or CL mice, despite clear detection of di-, mono- and un-glycosylated
PrPc in corresponding samples which were not treated with PK (indicated by
small black arrows) and p-tubulin which was used as a control for the amount of
total brain proteins loaded in each lane (large black arrow). A normally
glycosylated control mouse, infected with ME7, which was at TSE clinical
endpoint, was used as a control for PrP PK resistance, di-, mono- and
un-glycosylated PrPSc (indicated with blue arrows).
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3.4.5 The effect of glycosylation on PrPc truncation
An increased incidence and quantity of PrP truncated forms were observed in the
glycosylation deficient transgenic mice compared to normally glycosylated control
mice (Figure 3.1 B, 3.4 and 3.5 A). The size difference observed between the
truncated forms in the transgenic mice is likely to reflect the different predominant
glycotypes of PrP in these mice. However, these truncated forms were not always
observed in the murine PrP glycosylation deficient transgenics (Figure 3.1 A) and
appeared more frequently in samples that had experienced longer storage at -80 °C.
This variability suggests that the truncated products may be a result on the action of
endogenous proteases in the total brain homogenate samples as has previously been
reported (Jimenez-Huete et al., 1998). Furthermore, it appears that partially or
completely un-glycosylated PrP is more sensitive to their action. Further
experimentation is required to investigate this hypothesis and to asses whether if the
processing of PrP is influenced by its N-glycosylation state in vivo.
3.4.6 Absence of PrP's N-glycans does not lead to the development of
spontaneous clinical signs or TSE vacuolar pathology
Groups of twelve male and twelve female PrP glycosylation deficient transgenic
mice, and normally glycosylated controls, were aged and assessed for the
spontaneous development of TSE clinical signs over the natural life span of the
animals using standard techniques (Dickinson et al., 1968). A number of animals of
all genotypes survived in excess of 700 days (G1 = 5, G2 = 6, G3 = 5) and none
exhibited clinical TSE disease. The brains from all aged animals were removed post¬
mortem and sagitally divided in two asymmetrically. The larger right halves were
fixed for assessment of TSE vacuolar pathology by standard methods (Fraser and
Dickinson, 1967; Fraser and Dickinson, 1968). No TSE specific vacuolation was
detected in any genotype of the glycosylation deficient transgenic mice over the
course of the aging experiment (n = 24 data not shown).
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3.4.7 Results summary
These data demonstrate that the absence of PrP's N-glycans does not lead to
spontaneous formation PrPSc-like properties in vivo or to a reduction in the steady
state of PrPc.
- The N180T and N196T substitutions prevent the in vivo glycosylation of PrP's first
and second glycosylation site respectively and support the hypothesis that the
combination of sugars attached at each site differ.
- Absence of PrP's N-glycans does not lead to the spontaneous formation of PrPSc-
like properties but may elevate truncation of the protein.
- Absence of PrP's N-glycans does not lead to the spontaneous development of TSE
clinical signs or TSE specific vacuolar pathology.
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3.5 Discussion
3.5.1 Discussion of experimental techniques
Significance of the antibody dependent detection of PrPSc
Detection of PrP by DELFIA demonstrated significant antibody dependence in the
detection of soluble and insoluble forms of PrP, and of different PrP glycotypes. This
suggests that the antibodies used in these experiments may recognise subsets of PrP,
consistent with their monoclonal nature. In particular, AG4 does not appear to
recognise PrP that is insoluble in low concentrations of Gnd HC1. This suggests that
in this form of PrP, that may be equivalent to PrPSc, the AG4 epitope is hidden. Thus
this epitope is conformational and is irreversibly disrupted by the higher
concentration of Gnd HC1 used to solubilise the low concentration insoluble fraction;
alternatively, the epitope may be shielded in the PrPSc-like form.
The apparent amount of PrP detected using AG4 appeared to be ten-fold higher than
when FH11 was used to probe identical samples. Thus the ratio of wild type PrP
relative to recombinant PrP differs between these antibodies. The structure of
recombinant PrP has been reported to reflect that of mammalian PrP (Homemann
et al., 2004), suggesting that the observed difference in antibody recognition is not
caused by differences in the conformation of the two forms. This differential
recognition may be attributable to the absence of N-glycans or the GPI anchor from
recombinantly produced PrP. However, as a similar difference in the ratio of FH11
to AG4 signal is also apparent for samples from G3 transgenic mice, in which PrP is
un-glycosylated, it seems unlikely that the difference is caused by the un-
glycosylated state of recombinant PrP. Alternatively, the binding of native PrP to
the capture antibody may be modified by other molecules in the total brain
homogenate used in this assay; experimental data measuring the binding of
recombinant PrP in the presence of PrP null brain homogenate are required to
investigate this possibility.
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The observed antibody dependence of the amount of PrP detected in the
glycosylation deficient transgenic mice may be caused by differences in the
interaction of PrP in these samples with other cellular factors. Further
experimentation is required to address this possibility. Equally the antibodies used
in these studies may differentially recognise Gl, G2, G3 and wild type PrP or the
predominant glycotypes in these samples. In particular, the epitope of 8H4 is located
between amino acid 175 and 185 (Zanusso et al., 1998). Therefore the N180T
substitution in the Gl and G3 transgenic mice may alter the interaction of these
transgenic forms of PrP with this antibody. Indeed, the amount of PrP (1M Gnd
HC1 soluble) detected using 8H4 is increased in both the Gl and G3 transgenic mice
relative to normally glycosylated controls. Previous reports have suggested that 8H4
recognises un-glycosylated recombinant PrP as well as the glycosylated form,
although PrP in this study did not carry the N180T substitution (Zanusso et al.,
1998). Similarly, the reduced level of PrPc detected in the murine PrP glycosylation
deficient transgenics, as compared to controls when an AG4 capture antibody is
used, may reflect a partial glycosylation requirement for this antibody's epitope.
Alternatively, this result may be attributable to the apparent inability of AG4 to
recognise all conformations of PrP.
3.5.2 Discussion of experimental results
3.5.2.1 Differences in the molecular weight of Gl and G2 mono-glycosylatcd
PrPc
Previous studies have demonstrated that the molecular weight of the sugars attached
at the first and second site differs (Moudjou et al., 2004; Stimson et al., 1999).
Electro-spray mass spectrometry analysis has suggested this is owing to a different
subset of sugars being attached at the two sites, in particular the preferential addition
of sialyl Lewis-x residues at the second site (Stimson et al., 1999). The difference in
molecular weight of mono-glycosylated PrPc in the Gl and G2 transgenic mice is
consistent with the observed molecular weight of the first and second site mono-
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glycosylated form in normally glycosylated PrPc (Stimson et al., 1999). This
suggests that the glycans attached to PrPc in G1 and G2 transgenic mice are
representative of the wild type mono-glycosylated forms. However, further
experimentation is required to determine the precise glycan composition attached at
the two sites in the PrP transgenic mice and during normal CNS glycosylation of
PrP. Previous work has demonstrated that more than forty different combinations of
glycans are attached to PrP in vivo (Pan et al., 2002), although some of this diversity
may represent cell type specific forms, although multiple glycan combinations are
likely to occur in the same cells. Additionally, the relative abundance of the two
mono-glycosylated forms for normally glycosylated PrP is unknown. N-Glycan
addition is governed by the local primary sequence surrounding the glycan
attachment site and by the folding dynamics and global conformation of the protein,
in addition to cell type specific variation in the N-glycan pool (Petrescu et al., 2004).
These differences in glycan composition will impact on the interaction of the entire
N-glycan with other molecules, including the protein to which it is attached. Hence
c
they may have a major impact on the function of PrP .
3.5.2.2 Glycosylation of PrP does not affect the steady state levels of the protein
in vivo
Glycosylation is known to increase the half life of a number of proteins (Chen et al.,
2006; Li et al., 2004). This may occur via a number of mechanisms including
enhanced resistance to proteolytic attack or reduced endocytosis and lysomal
targeting. Glycosylation is also known to specifically contribute to the stability of
mutant protein forms (Buck et al., 2004). This is thought to occur by N-glycan
mediated interactions with ER chaperones preventing the ERAD export of proteins
that are slow to fold or are misfolded. In particular, a number of pathological
mutant forms of PrP are stabilised by the attachment of N-glycans in cell culture
systems (Capellari et al., 2000a; Lehmann and Harris, 1996a; Petersen et al., 1996;
Singh et al., 1997).
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However, here we show, by direct comparison with normally glycosylated PrP, that
the steady state level of PrPc is unchanged by the absence of the first, second or both
glycosylation sites in vivo. Thus either the half-life of wild-type PrP is independent
of its glycosylation state or a compensatory up-regulation of PrP translation occurs
in these transgenic mice. Previous work has shown that the Prnp mRNA levels in
these transgenic mice are comparable to the level in wild type mice of the same
genetic background, negating the second scenario (Cancellotti et ah, 2005; Wiseman,
2003). Therefore glycosylation of PrP does not appear to be necessary to prevent
ERAD or post-ER degradation of wild type PrP. Therefore, any influence of the
absence of the first, second or both glycosylation sites on PrPc function or role in
TSE disease pathogenesis in these models will not be mediated by differences in the
amount of PrPc.
3.5.2.3 Absence of PrP's N-glycans does not lead to spontaneous formation of
PrPSc in vivo.
Cell culture studies have suggested that, in the absence of its N-glycans, PrP adopts a
PrPSc-like form, displaying enhanced PK resistance and insolubility (Lehmann and
Harris, 1997). A number of transgenic PrP murine models have also demonstrated
that PrP can spontaneous misfold in vivo in the absence of exposure to the TSE
agent; however, in all these models spontaneous PrPSc formation was only observed
when PrP was highly overexpressed (Castilla et al., 2005; Chiesa et al., 1998; Hsiao
et al., 1990; Ma et al., 2002; Muramoto et al., 1997; Nazor et al., 2005; Shmerling et
al., 1998). No spontaneous misfolded PrP was detected in the glycosylation
deficient transgenic mice including by a PK independent method of insolubility in a
low concentration of Gnd HC1. Furthermore, no spontaneous PK resistance was
observed even in aged G3 transgenic mice, in which maximal accumulation of
misfolded forms might be anticipated to occur owing to the age related decline of
protein folding and clearance mechanisms (Erickson et al., 2006). Thus when
expressed at endogenous levels, glycosylation of PrP is not required to prevent the
spontaneous misfolding of the protein in vivo within the normal lifespan of the
mouse. These data suggest that the primary role of PrP's highly conserved N-
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glycans is not to stabilise the protein. However, this does not negate the possibility
that the glycans prevent conformational change under perturbed conditions, as may
occur when a host is exposed to the TSE agent. Additionally, glycosylation of PrP
may help stabilise the soluble PrP conformation in the presence of pathogenic
mutations in the primary amino acid sequence as has been previously suggested
(Capellari et al., 2000a; Petersen et al., 1996). Consistent with these conclusions is
the observation that the glycosylation deficient transgenic mice do not spontaneously
develop TSE clinical signs. Thus these models can validly be used to investigate the
importance of PrP's N-glycans to the TSE species barrier.
Recent work has suggested that PrP's N-glycans retard the formation of dimeric PrP
in cell culture, as indicated by slower electrophorectic mobility of a fraction of total
PrP (Biswas et al., 2006). During the characterisation studies of PrPc in the
glycosylation deficient transgenic mice, no form of dimeric PrP were observed. In
the original cell culture study, glycosylation of PrPc was disrupted by removal of the
C-terminus of the protein including the GPI anchor. The observed enhanced
dimerisation in this model therefore may be attributable to the absence of the anchor
rather than a direct effect of glycosylation status. Indeed, previous work has
suggested that dimerisation of PrP may be promoted by glycosylation of the protein
(Meyer et al., 2000). Further specific experimental investigations are required to
investigate the effect of glycosylation state on the occurrence of PrP dimers in vivo
in the murine glycosylation deficient transgenics, such as the use of cross-linkers or
size exclusion chromatography.
In conclusion, the biochemistry of PrP in the murine glycosylation deficient
transgenics resembles that of wild type mice, save for the alteration of the protein's
glycosylation state. Thus these murine transgenic models are a valid system in
which to investigate the role of PrP's N-glycans in the cross-species transmission of
the TSE agent.
109
4.0 Glycosylation of PrPc and the localisation of the protein
in vivo
4.1 Aim To determine if the cellular location of PrP is altered in vivo by absence of
the protein's N-glycans.
4.2 Introduction and experimental technique
p ...
The cellular localisation of PrP is thought to be key in determining the protein's
misfolding during TSE disease, in addition to its importance to the protein's native
function (Caughey et al., 1991; Rudd et al., 2001). Experiments in which the
p (
subcellular location of PrP has been altered have demonstrated changes in TSE
disease susceptibility or the ability to form PrPSc (Caughey et al., 1991; DeArmond et
al., 1998; Taraboulos et al., 1992b; Verghese-Nikolakaki et al., 1999; Vetrugno et al.,
2005). However, the in vivo location of the PrPc to PrPSc conversion event is
currently unknown, although a number of potential site have been suggested
including lysosomes, endosomes and the plasma membrane (Caughey et al., 1991;
Taraboulos et al., 1992b; Taraboulos et al., 1995). Furthermore, the preferred site of
conversion within the cell may differ between TSE strains. Additionally,
experimental studies using transgenic models have suggested that aberrant
localisation of PrP to the cytoplasm is neurotoxic, although this finding has been
contested by a number of other published works (Drisaldi et al., 2003; Fioriti et al.,
2005; Ma et al., 2002; Roucou et al., 2003).
Previous work has shown that normally glycosylated PrP is principally located on
the plasma membrane within lipid rafts in vivo (Barmada et al., 2004; Haeberle et al.,
2000; Laine et al., 2001; Mironov et al., 2003; Sales et al., 1998; Vey et al., 1996).
Limited amounts of intracellular PrP are also apparent in the majority of cells and a
minor subpopulation of cells have high levels of PrP throughout the cytoplasm
(Barmada et al., 2004; Mironov et al., 2003). Glycosylation of PrPc has been
suggested to influence the cellular localisation of the protein (Capellari et al., 2000b;
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DeArmond et al., 1997; Korth et al., 2000; Lehmann and Harris, 1997; Neuendorf et
al., 2004; Rodolfo et al., 1999; Rogers et al., 1990; Russelakis-Carneiro et al., 2002)
(Chapter 1). The localisation of PrPc may be altered in the murine PrP glycosylation
deficient transgenics [NPU]; this could affect the ability of the protein to participate
in TSE disease.
Subcellular localisation of PrP in uninfected murine glycosylation deficient
transgenics (NPU) was investigated in sections of adult brain. Immunofluorescence
and confocal microscope analysis was used; as immunohistochemistry would not
have provided the degree of resolution required to assess the subcellular localisation.
Paraffin embedding and dehydration of brain materials have been suggested to disrupt
the plasma membrane and reduce detectable PrPc (Laine et al., 2001; Mironov et al.,
2003). Indeed, standard embedding and dehydration techniques completely eliminate
detectable PrP in uninfected murine brains, even when signal amplification kits are
employed (Chapter 5). To avoid elimination of detectable PrP, whole uninfected
brains were lightly fixed and rapidly processed. Sections were not mounted and
immunofluorescence was carried out using a free-floating method (Monaghan et al.,
2001). GPI proteins like PrP are prone to antibody mediated rearrangement in
conventionally fixed tissues (Mayor et al., 1994). Although previous studies have
suggested this is not the case for PrPc, a range of fixation conditions were
investigated (Laine et al., 2001; Mironov et al., 2003). A number of antibodies were
screened to identify those which could successfully and specifically detect
endogenous expression of PrPc in vivo. Colocalisation studies using a marker of the
ER (Endoplasmic Reticulum) or Golgi were then undertaken to determine if in the
p #
absence of its N-glycans, PrP accumulated in these compartments.
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4.3 Optimisation and validation of experimental technique
4.3.1 Anti-PrP antibody screen
Seven anti-PrP monoclonal and polyclonal antibodies were screened for the effective
and specific detection of PrPc by immunofluorescence in whole brain sections from
129/Ola wild type and PrP null mice. No specific signal was detected for the
polyclonals 1B3, 1A8 or mouse monoclonals 7A12, FH11 or AG4 (data not shown).
A strong and specific signal was observed for 8H4 in accordance with previous
reports (Laine et al., 2001; Liu et ah, 2001; Mironov et ah, 2003) (Figure 4.1 A).
Optimum 8H4 antibody concentration was experimentally determined to be 1/1000
for staining of PrP alone and 1/500 for colocalisation experiments (data not shown).
The IgGl isotype of 8H4 was experimentally confirmed for use in colocalisation
experiments (Liu et ah, 2001) (Figure 4.2 C and D). A weaker specific anti-PrP
signal was observed for AH6 (Figure 4.1 B). The staining pattern of Ah6 observed in
129/Ola mice was similar to that observed for 8H4. However the signal was too weak
for complete confocal analysis.
4.3.2 Use of the Mouse on Mouse blocking kit
During preliminary experiments, non-specific binding of the anti-mouse Alexa
conjugated secondary antibody to blood vessels was observed (Figure 4.1 C and D).
This may be mediated by interaction of the antibody with murine immunoglobulins
carried in the blood. The effectiveness of the Mouse on Mouse (MOM) blocking kit
(Vector Laboratories) to reduce this non-specific background was investigated. This
kit is designed to specifically block the interaction of anti-murine secondary
antibodies with mouse immunoglobulins. The observed non-specific interaction of
the anti-mouse secondary antibody with the brain sections was reduced by the MOM
blocking kit. However use of the blocking kit also reduced the detection of PrP by
8H4, but, because of the great reduction in non-specific staining the kit was used in
all experiments (Figure 4.2 A and B).
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Figure 4.1 Immunofluorescent localisation of PrP in sections of the
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Localisation of PrP in the hippocampus was examined in (A & B) 129/Ola
70 pm sections using equivalent (C & D) PrP null sections as controls for
specificity of antibody binding. Two anti-PrP mouse monoclonal antibodies
were investigated (A & C) 8H4 1/1000 and (B & D) AH6 1/1000 both were
detected using 1/200 anti-mouse Alexa568. Scale bar 500 pm.
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Figure 4.2 Comparison of anti-PrP (8H4) staining in 129/Ola brain sections
using different methods.
Comparison of 8H4 staining in the dentate gyrus and portion of the thalamus
(1/1000 8H4, 1/200 anti-mouse Alexa488) with (B) and without (A) use of the
MOM blocking kit. Note the absence of blood vessel staining within the
thalamus in B. Binding of lgG1 specific Alexa488 antibody (C) to 8H4 is less
efficient that that of 1/200 anti-mouse A!exa488 (C). Area shown is the
pyramidal cell layer and adjacent neuropil similar results observed for other
brain regions. Scale bar (A & B) 500 pm, (C & D) 50 pm.
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4.3.3 Comparison of tissue fixation conditions
The cellular localisation of GPI anchored proteins, like PrP, may be altered by the
fixation conditions used (Mayor et ah, 1994). To investigate the importance of
fixation to PrP immunofluorescence whole brains were fixed by post-mortem
immersion: in 4 % paraformaldehyde; 0.025 % glutaraldehyde 4 %
paraformaldehyde; 0.25 % glutaraldehyde 4 % paraformaldehyde; or periodate-
lysine-paraformaldehyde (PLP). No alteration in the subcellular localisation of
normally glycosylated PrP was observed under the different fixation conditions
investigated, consistent with previous reports (Laine et ah, 2001; Liu et ah, 2001;
Mironov et ah, 2003). In contrast to previous reports, PLP did not enhance PrP
antigenicity, perhaps because of the different antibody used here (DeArmond et ah,
1987).
However a dramatic decrease in detectable PrP at the surface of the brain was
observed when the fixative contained glutaraldehyde (Figure 4.3 B). The area of
PrPc signal decrease was greater for the higher concentration of glutaraldehyde and
for longer fixation intervals, indicating that this effect may be caused by the degree of
penetration of glutaraldehyde. This surface decrease in signal was not observed for
detection of tubulin in glutaraldehyde fixed tissue (Figure 4.3 C). Thus the use of low
concentrations of glutaraldehyde fixation appeared to selectively eliminate the 8H4
epitope. Previous reports have observed a reduction in the detection of murine PrP
p
by using 8H4 and hamster PrP by 3F4 after glutaraldehyde fixation (Laine et ah,
2001; Moya et ah, 2000). Indeed one group has generated specific antibodies against
glutaraldehyde fixed PrP to circumvent this problem (Ford et ah, 2002a). However,
the use of glutaraldehyde during fixation generated a hard edge to the tissue which
facilitated the cutting of sections and prevented the break-up of sections during the
experiment. All tissue was fixed in 0.025 % glutaraldehyde and 4 %
paraformaldehyde to facilitate experimental manipulation and fixation time was
reduced to 3 hours 30 minutes to minimise surface loss of PrPc signal owing to use of
glutaraldehyde. PrPc localisation data were not collected from areas in which 8H4
signal was reduced because of fixation.
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Figure 4.3The effect of glutaraldehyde fixation on 8H4 epitope availability
Use of glutaraldehyde during fixation of brain tissue selectively destroys the
8H4 PrP epitope (A) but not that of tubulin (C). The 8H4 epitope is maintained
if tissue is fixed by paraformaldehyde alone (B). A & B) 1/1000 anti-PrP 8H4,
1/200 anti-mouse Alexa488 C) 1/1000 anti-tubulin, 1/200 anti-mouse
Alexa568. A & B) 129/Ola; C) PrP null. Tissue fixed in A & C) 4%
paraformaldehyde, 0.25 % gluteraldehyde; B) 4% paraformaldehyde. Scale
bar 500 pm.
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4.3.4 Antibody screen markers of the ER and Golgi
Two ER lumen marker antibodies, anti-PDI, a mouse, monoclonal antibody, and anti-
ERp60, a rabbit polyclonal antibody (kind gift of T. Wileman, IAH-Pirbright), were
investigated to determine if they were compatible with 8H4 for immunofluorescence.
Clear anti-PrP and anti-ERp60 staining were observed on wild type brain sections
(Figure 4.4 A). Additionally, no cross reactivity between 8H4 and the anti-rabbit
secondary antibody, nor anti-ERp60 and the anti-mouse secondary antibody was
detected (Figure 4.4 B and C). Thus anti-ERp60 was an 8H4 compatible ER marker.
As both 8H4 and anti-PDI are mouse monoclonal antibodies a two part staining
strategy was employed. Sections were first incubated with anti-PDI antibody, then
the first anti-mouse secondary antibody. These sections were then blocked with
MOM kit, incubated with 8H4 and finally the second anti-mouse secondary antibody.
Alternatively, 8H4 was used first and anti-PDI second. Despite the two-step staining
technique, cross reactivity between these two mouse monoclonal antibodies was
apparent (data not shown). Thus anti-PDI was unsuitable to determine if PrP was
localised in the ER in vivo and only anti-ERp60 was used for further study.
Three Golgi marker antibodies were investigated. The signals for rabbit polyclonal
anti-B-cop (kind gift of T. Wileman, IAH-Pirbright) and GM130 antibodies on murine
brain sections were too weak and non-specific for confocal analysis and thus were not
used for the PrP colocalisation study (data not shown). A low level of cross
reactivity occurred between the 23C anti-B-cop, which is a rat monoclonal antibody,
and the anti-mouse secondary antibody used (data not shown). Thus it was necessary
to use an anti-mouse IgGl subclass specific secondary antibody for 8H4 detection for
these experiments, which eliminated cross reactivity (Figure 4.4), or to carry out a
two-step staining strategy (data not shown). The IgGl specific secondary antibody
was less efficient in its detection of 8H4 compared to the general anti-mouse
secondary antibody (Figure 4.3). Despite this lower sensitivity, apparently
intracellular PrP could still be detected in the 23C colocalisation experiment. Thus

















The anti-ERp60 rabbit polyclonal antibody can bind to murine brain and is recognised
by an anti-rabbit Alexa568 conjugated secondary antibody (red channel A & C). The
anti-rabbit Alexa568 conjugated secondary antibody does not interact with 8H4 (red
channel B) and the anti-mouse Alexa488 conjugated secondary antibody does not
interact with anti-ERp60 (green channel C). Therefore anti-ERp60 and 8H4 are
suitable for colocalisation studies. The antibody 23C which recognises beta-cop on
the outer leaflet of the Golgi apparatus can bind to murine brain and is recognised by
anti-rat Alexa568 conjugated secondary antibody (red channel D and E). Anti-mouse
lgG1 Alexa488 conjugated secondary antibody does not interact with 23C (green
channel E). Therefore 23C and 8H4 are suitable for colocalisation studies. Scale bar
50 pm 118
Figure 4.4 Antibody screen for markers of the ER and Golgi
4.4 Experimental results
4.4.1 The role of glycosylation of PrP in the protein's in vivo localisation
Previous work has suggested that subcellular localisation of PrP may be altered by
the protein's glycosylation state (Capellari et ah, 2000b; DeArmond et al., 1997;
Korth et al., 2000; Lehmann and Harris, 1997; Neuendorf et al., 2004; Rodolfo et al.,
1999; Rogers et al., 1990; Russelakis-Carneiro et al., 2002). The localisation of PrPc
in whole coronal brain sections was compared between PrP glycosylation deficient
transgenic [NPU] and 129/Ola control mice, to determine if the protein's localisation
was influenced by its glycosylation state in vivo. The animals from which the brain
tissue was taken were age and sex matched, and were between 6-32 weeks old. PrP
null brain sections, incubated with 8H4, were used in all experiments to determine the
level of specific anti-PrP signal. Analysis was principally focussed on the
c
hippocampus, as previous work has demonstrated this is an area of high PrP
expression (Bendheim et al., 1992; DeArmond et al., 1987; Liu et al., 2001; Manson
et al., 1992a; Mironov et al., 2003; Moya et al., 2000; Sales et al., 1998; Taraboulos et
al., 1992a). Also, by using the clear anatomical features of the hippocampus,
equivalent areas from transgenic and control mice could be matched. The intracellular
localisation of PrPc was analysed in the clearly defined hippocampal cell layers
(pyramidal and granular). Additionally, previous studies examining the importance
of glycosylation state to PrP 's localisation have focussed on this region (DeArmond
et al., 1997). Three sections were examined from each brain to control for potential
regional differences in PrP localisation.
In 129/Ola controls, in which PrP is normally glycosylated, anti-PrP specific staining
was observed throughout the neuropil (axon-synapse-dendrite complex) of the
hippocampus, cerebral cortex and thalamus (Figure 4.5). Some anti-PrP signal was
observed in the corpus collosum but the signal was weaker than the surrounding
c
neuropil. The staining pattern was consistent with surface localisation of PrP on
axons.
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Figure 4.5 Comparison of anti-PrP (8H4) staining intensity between the
PrP glycosylation deficient transgenics and controls in the neuropil.
The amount of PrP detectable using 8H4 (1/1000) and anti-mouse A!exa488
(1/200) differs between the hippocampi of normally glycosylated 129/Ola mice (A)
and some PrP N-glycan deficient G2 (E) and all G3 (F) transgenic mice. The
amount and localisation of PrP detected in the hippocampi of G1 transgenic mice
(D) is similar to that observed in control mice (A). All images were taken using the
same microscope settings. Specificity of anti-mouse Alexa488 secondary
antibody is demonstrated by the absence of signal in a 129/Ola section incubated
with anti-mouse Alexa488 (1/200) only (B) and the PrP null section (C) incubated
with 8H4 (1/1000) and anti-mouse Alexa488 (1/200). Scale bar 250 pm.
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Variation in the intensity of PrP staining was observed in the neuropil of the
hippocampus. Higher levels of signal were detected in the neuropil adjacent to the
granular cell layer of the dentate gyrus. In some cases slightly higher anti-PrP signal
was detected in the stratum oriens and stratum radium than the stratum molecular.
However this was not consistently observed in contrast to the clear results reported
for hamster PrP (Mironov et al., 2003; Moya et al., 2000). No consistent difference
in the staining intensity or pattern was observed between the anterior and posterior
sections, although section to section differences in staining intensity were apparent
(data not shown). This is likely to reflect variations in experimental technique rather
than differences in PrP expression level.
Low levels of specific anti-PrP signal were detected within both the pyramidal and
granular cell layers in 129/Ola brain sections. In the cell layers staining was
principally observed in a pattern consistent with the expect localisation of PrP at the
plasma membrane. At high magnification this staining was observed to be clustered
in patches, in a pattern consistent with lipid raft localisation on the plasma membrane
(Figure 4.6 A). Furthermore, low levels of intracellular signal were observed. The
anti-PrP signal was excluded from the nucleus and formed discrete clusters in the cell,
consistent with localisation within a subcellular compartment (Figure 4.6 A). The
staining pattern observed is similar to previous work investigating the localisation of
PrPc in vivo (Barmada et al., 2004; Mironov et al., 2003; Moya et al., 2000; Sales et
al., 1998). Thus this method is valid to analyse the effect of PrPc's glycosylation
state on its localisation in vivo.
A clear and consistent reduction of PrP signal in the neuropil was detected in
c
transgenic mice expressing un-glycosylated PrP (G3) as compared to normally
p
glycosylated PrP controls (Figure 4.5) (n = 3, assayed in triplicate). The ratio of
intracellular to plasma membrane associated signal in the cell layer appeared to be
elevated in the G3 transgenic mice and a pattern of staining consistent with plasma
membrane localisation was not detected (Figure 4.6). This alteration in staining
suggests that in the G3 transgenic mice little PrP is found at the plasma membrane.
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Figure 4.6 Comparison of anti-PrP staining pattern in the molecular layer
of the dentate gyrus and adjacent neuropil.
A 129/Ola
. V •'
mmW&r*5K 1 % * ' ■
. V
C G2
PrP in murine brain was detected using
8H4 (1/1000) and anti-mouse Alexa488
(1/200) in 129/Ola control mice in which
PrP is normally glycosylated (A), G1
(B), G2 (C) and G3 (D) transgenic mice
int the molecular layer of the dentate
gyrus. Microscope setting were
individually optimised for each image,
the lowest threshold was used for G3
(D), these settings were used to image
an PrP null (8H4 (1/1000) (E) to
demonstrate specificity. Scale bar
(A-D) 25 pm (E) 50 pm.
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However specific anti-PrP signal above background was observed in the neuropil of
G3 transgenic mice (Figure 4.5). This suggests that some PrP may be localised to
the plasma membrane in the G3 transgenic mice, however further biochemical studies
are required to investigate this.
Some variation was observed in the intensity of PrPc detected in the neuropil on
sections from G1 transgenic mice (n = 4). This is likely to reflect section to section
variation rather than any underlying biological difference, as both higher and lower
intensities than the wild type controls were observed. G2 sections generally
displayed lower 8H4 neuropil staining intensity but the effect was not as dramatic that
seen on G3 sections, and in some instances the intensity of anti-PrP staining in the
neuropil was equivalent to that observed in 129/Ola controls (n = 4).
4.4.2 The role of glycosylation of PrPc in the protein's cellular localisation
To determine if the pattern of intracellular localisation was changed in the G3
transgenic mice, colocalisation studies were undertaken. The absence of its N-glycans
may lead to the retention of PrPc in the ER/Golgi. This may occur via a direct effect
on recognition of PrPc for export out of the compartment, as a N-glycan may act as
"tag for transport" (Rudd et al., 2001). Alternatively, the attached N-glycans may
facilitate the folding of PrP within the ER and thus in their absence the protein may
accumulate in this compartment because of its less efficient folding (Rudd et al.,
2001). Therefore the colocalisation of anti-PrP signal with markers of both the ER
and Gogli apparatus was studied.
4.4.2.1 Colocalisation of PrPc and ER marker ERp60
Localisation of PrPc within the ER has only been reported in one previous study
(Laine et al., 2001). Colocalisation of PrP (8H4) with a marker of the ER lumen
ERp60 (rabbit polyclonal, a kind gift of T. Wileman, Insitute for Animal Health
(Pirbright)) was undertaken (Figure 4.7). The pattern of ERp60 staining differed
between the pyramidal and molecular cell layers (Figures 4.8 and 4.9).
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Figure 4.7 Absence of colocalisation of PrP (8H4) and a marker of the ER
(anti-ERp60) in the pyramidal cell layer
E PrP null If 8H4 & anti-rabbit
PrP (8H4 (1/500) anti-mouse Alexa488 (1/200) green) does not colocalise with a
marker of the ER (anti-ERp60 (1/400), anti-rabbit Alexa568 (1/200) red) in normally
glycosylated 129/Ola (A) nor PrP N-glycan deficient G1 (B), G2 (C) or G3 (D)
transgenics in the pyramidal cell layer of the hippocampus. Microscope setting were
individually optimised for each image, the lowest threshold was used for G3 (D); these
settings were used to image an PrP nul (8H4 (1/500) and anti-mouse Alexa488
(1/200)) stained section (E). No cross reaction of 8H4 with the anti-rabbit secondary
(8H4 (1/500), anti-rabbit Alexa568 (1/200)) was detected (F). Scale bar 50 pm
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Figure 4.8 Close up of anti-PrP staining (8H4) and a marker of the ER
(anti-ERp60) in the pyramidal cell layer of the hippocampus.
E PrP null
#*
F ERp60 & anti-mouse G 8H4 & anti-rabbit
No colocalisation of an ER marker (anti-ERp60 (1/400), anti-rabbit Alexa568
(1/200) red) and PrP (8H4 (1/500) anti-mouse Alexa488 (1/200) green) (see
arrows) is detected in normally glycosylated 129/Ola (A) nor PrP N-glycan
deficient G1 (B), G2 (C) or G3 (D) transgenic mice in the pyramidal cell layer
of the hippocampus. Microscope setting were individually optimised for each
image, the lowest threshold was used for G3 (D); these settings were used to
image an PrP null (8H4 (1/1000) and anti-mouse Alexa488 (1/200)) stained
section (E). No cross reaction of anti-ERp60 and anti-mouse secondary
(anti-ERp60 (1/1000), anti-mouse Alexa488 (1/200)) (F) nor 8H4 with the
anti-rabbit secondary (8H4 (1/500), anti-rabbit Alexa568 (1/200)) (G) was
detected. Scale bar 25 pm.
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Figure 4.9 Close up of anti-PrP (8H4) staining and a marker of the ER
(anti-ERp60) in the molecular cell layer of the dentate gyrus
B G1
* V m \ 9 «► * r
/ * i • # * ^
No colocalisation of an ER marker ERp60 (anti-ERp60 (1/400), anti-rabbit
Alexa568 (1/200) red) and intracellular PrP (8H4 (1/500) anti-mouse Alexa488
(1/200) green) is detected in normally glycosylated 129/Ola (A) nor PrP
N-glycan deficient G1 (B), G2 (C) or G3 (D) transgenic mice in the molecular
cell layer of the dentate gyrus. Scale bar 25 pm.
129/Ola
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In the molecular layer of the dentate gyrus ERp60 was localised almost exclusively
surrounding the nucleus, in the classic ER pattern. In the pyramidal cell layer, in
addition to perinuclear staining, extensive staining was observed in the cytoplasm of
the cell body, in a pattern consistent with layered ER cisternae. No difference in
pattern or intensity of ERp60 was observed between the controls and PrP
glycosylation deficient transgenic mice. The pattern of 8H4 staining in these ERp60
colocalisation experiments was similar to that observed for single staining
experiments, including the reduced neuropil intensity and higher intracellular to
plasma membrane associated ratio observed in G3 sections. A higher threshold
intensity was required to successfully image G3 sections compared to that needed for
imagining the other transgenic mice and 129/Ola controls. In all cases the
microscope settings used to image the G3 sections were also used to image all the
negative controls.
No colocalisation or significant association of ERp60 and 8H4 was observed in the
wild type or any of the PrP glycosylation deficient transgenic lines, in the cells of the
hippocampus, overlying cortex or thalamus (Figures 4.8, 4.9 and data not shown) (n =
3). Indeed significant amounts of non-ER associated PrP could be observed in all
c
sections, suggesting that the un- and mono-glycosylated PrP in the NPE1 murine PrP
glycosylation transgenics is not retained the ER.
p #
4.5.2.2 Colocalisation of PrP and Golgi/associated vesicles marker fi-cop
p
Colocalisation of PrP and a marker of the outer membrane of the Golgi and
associated vesicles, B-cop (rat monoclonal, 23C), was undertaken. 23C staining
displayed a Golgi-like pattern of punctuate intracellular dots which were
predominately located on one side of the nucleus in any one cell (Figure 4.10 and
4.11). These dots were observed to form rings in some cells which would appear to
delineate the Golgi compartment (Figure 4.11). No difference in 23C staining pattern
or intensity was observed between the control and transgenic brain sections.
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Figure 4.10 Colocalisation of PrP (8H4) and a marker of the Golgi (23C) in the
pyramidal cell layer.
PrP (8H4 (1/500) anti-mouselgG1
Alexa488 (1/200) green) does not
directly colocalise with marker of the
Golgi (anti-23C (1/50) anti-rat Alexa568
(1/200) red) in normally glycosylated
129/Ola (A) nor PrP N-glycan deficient
G1 (B), G2 (C) or G3 (D) transgenic
mice in the pyramidal cell layer of the
hippocampus. Microscope setting were
individually optimised for each image,
the lowest threshold was used for G3
(D); these settings were used to image
an PrP null murine brain (8H4 (1/500)
anti-mouselgG1 Alexa488 (1/200))
stained section (E). Scale bar 50 pm
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Figure 4.11 Close up of anti-PrP staining (8H4) and a marker of the Golgi
(23C) in the pyramidal cell layer of the hippocampus
PrP null
(8H4 anti-mouse, 23C anti-rat)
PrP (8H4 (1/500) anti-mouselgG1
Alexa488 (1/200) green) does not
directly colocalise but may associate with
a marker of the Golgi (anti-23C (1/50)
anti-rat Alexa568 (1/200) red) in normally
glycosylated 129/Ola (A) nor PrP
N-glycan deficient G1 (B), G2 (C) or G3
(D) transgenic mice in the pyramidal cell
layer of the hippocampus. Microscope
setting were individually optimised for
each image, the lowest threshold was
used for G3 (D) ; these settings were
used to image an PrP null murine brain
(8H4 (1/1000), anti-23C (1/50), and
anti-mouse Alexa488 (1/200), anti-rat
Alexa568 (1/200)) stained section (E) to demonstrate specificity of 8H4 and the
absence of cross reactivity of 23C with anti-lgG1 mouse Alexa488. Scale bar 25 pm
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Intracellular anti-PrP and anti-P-cop staining were associated, however no direct
colocalisation was observed (Figure 4.11). The P-cop labelling appeared to surround
a significant proportion of PrP in both wild type control and the glycosylation
deficient transgenic mice (Figure 4.11). This pattern is consistent with a proportion
of PrPc being localised in the Golgi lumen surrounded by the P-cop staining outer
membrane, although further experimentation is required to confirm this conclusion.
No difference in either the frequency or the intensity of Golgi-associated PrP was
observed between brain sections from PrP glycosylation deficient transgenic and
129/Ola control mice, suggesting that the alteration of localisation of PrP observed is
not linked to an accumulation or reduction of the protein within the Golgi (Figure
4.11) (n = 2, assayed in duplicate).
4.4.2.3 Cytoplasmatic PrPc
In the majority of cells there was no evidence that PrPc was located in the cytoplasm.
In the majority of cells anti-PrPc staining was observed to have a discrete clustered
distribution consistent with localisation within subcellular compartments, consistent
with localisation of PrP in endosomes, lysosomes or associated endocytic vesicles,
as previously reported (Laine et ah, 2001; Mironov et ah, 2003). However,
occasional cells in which anti-PrP staining was strongly detected in the entire cell
body (excluding the nucleus) were observed (Figure 4.12). These cells were observed
in the neuropil adjacent to, but not in, the granular cell layer of the dentate gyrus and
occurred very infrequently. This observation is similar to the cytPrP cells identified
by Mironov and colleagues, and those reported by Barmada et al from their work with




Figure 4.12 Cytoplasmic PrP
A
High level of PrP (8H4 (1/500) anti-mouse Alexa488 (1/200)) staining
throughout the cell body of a single cell, in the stratum molecular of the
hippocampus in a 129/Ola mouse (A& B) were observed. Scale Bar 100
pm (A) 50 pm (B).
131
4.4.3 Results summary
These data suggest that the glycosylation state of PrPc may influence the proteins
localisation in vivo.
That the absence of a N-glycan at the first attachment site does not
r>
significantly alter the cellular localisation of PrP .
That the absence of a N-glycan at the second attachment site may reduce
cthe amount of PrP localised in the neuropil.
p
That the complete absence of PrP 's N-glycans greatly reduces the amount
of PrP detected in the neuropil.
That the pattern of intracellular localisation of PrPc does not appear to be
altered by the partial or complete lack of the protein's N-glycans.




Early work suggested that normally glycosylated PrP was principally localised
within the cell bodies and that PrP was only detected in a subset of CNS cells
(Bendheim et ah, 1992; DeArmond et al., 1987; Ford et al., 2002a; Manson et al.,
P'
1992a; Piccardo et al., 1990). This contrasts with the ubiquitous localisation of PrP
within the neuropil observed here and by others (Barmada et al., 2004; Fournier et al.,
2000; Jdaeberle et al., 2000; Mironov et al., 2003; Moya et al., 2000; Sales et al.,
p-<
1998). Early experimental investigations into the localisation of PrP used
embedding and alcohol dehydration techniques to prepare CNS material for
immunohistochemical analysis. This method will disrupt the cells' plasma
membrane where PrP is predominately localised and is thought to lead to the loss of
the antigen (Eaine et al., 2001; Mironov et al., 2003). The free-floating immuno¬
detection method used here, and by others, eliminates the problem allowing plasma
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membrane PrP to be localised (Laine et al., 2001; Mironov et al., 2003; Moya et al.,
2000; Sales et al., 1998). The cell body PrP reported in papers in which embedding
tissue preparation was used may represent the instances of cytPrP, as described here
and by Mirnovo and Barmada (Barmada et al., 2004; Mironov et al., 2003).
Anti-PrP staining intensity observed in the molecular layer of the dentate gyrus was
only slightly lower and inconsistently observed than that in the stratum oriens and
stratum radium, in contrast to previous reports from hamsters and baboons (Mironov
et al., 2003; Moya et al., 2000). This difference may be caused by species differences
in PrPc levels between the regions of the hippocampus, as no difference in staining
intensity between the hippocampal regions has been reported for reported for humans,
macaques and murine GFP-tagged PrP (Barmada et al., 2004; Moya et al., 2000;
Sales et al., 1998). Alternatively these differences may be a result of the antibody
used, as the variation in hippocampal staining intensity observed in hamsters has
shown antibody dependence (Moya et al., 2000).
It was not possible to accurately quantify the amount of plasma membrane associated
PrPc in the glycosylation deficient transgenic and the 129/Ola control mice because
of the confocal method used. Further experiments using other techniques are required
to address this issue fully. This could be explored using primary neuronal cell
cultures from the glycosylation deficient transgenic and control mice such that
surface biotinalytion or PIPLC digestion of surface PrP could be used. Alternatively
cell-fractionation techniques could be used determine the relative proportion of PrP
within each cellular compartment.
4.5.2 Discussion of experimental results
p
These data show that the overall pattern of PrP localisation is altered in G3 PrP
glycosylation deficient transgenic mice, in a manner consistent with a significant
C • •reduction but not a complete elimination of PrP within the neuropil. This work is
consistent with previous reports of the intracellular localisation of un-glycosylated
PrP both in transgenic animals and cell culture (DeArmond et al., 1997; Neuendorf
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et al., 2004; Rogers et al., 1990). However, un-glycosylated PrP has been observed
at the surface of cultured cells (Borchelt et al., 1990; Caughey et al., 1989; Lehmann
and Harris, 1997; Neuendorf et al., 2004; Petersen et al., 1996). However, in these
cases un-glycosylated PrP , was expressed in the presence of endogenous
p #
glycosylated PrP , which may facilitate trafficking of the un-glycosylated form to the
ccell surface, as PrP may form dimers in vivo (Bendheim and Bolton, 1986).
A reduction in anti-PrPc staining in the neuropil was observed in some sections from
G2 PrP glycosylation deficient transgenic mice. However this result was not
consistently observed, suggesting that N-glycan attachment at the second site may
p t
facilitate localisation of PrP to the neuropil in some situations but that it is not
absolutely required. The majority of previous work has suggested that glycosylation
cof the second N-glycan site is not required for the localisation of PrP (DeArmond et
al., 1997; Korth et al., 2000; Lehmann and Harris, 1997; Neuendorf et al., 2004).
However, one paper has reported intracellular localisation of PrP in the absence of
the second site (Rogers et al., 1990). Differences between the model systems
c
employed may underlie the differences in the importance of the second site to PrP
location in these studies. This is in accordance with our finding that the relative
importance of the second N-glycan site varied, suggesting that factors such as the
expression of other cellular components may modify the importance of the second N-
glycan attachment site to the protein's localisation. Further investigation is required
to determine what these modifying factors are and how they mediate the localisation
of PrPc.
No consistent difference in PrP staining was observed in sections from G1 PrP
glycosylation deficient transgenic mice, suggesting that glycosylation of the first site
is not required for the normal localisation of PrP . A number of published works have
demonstrated the contrary (DeArmond et al., 1997; Lehmann and Harris, 1997;
Rogers et al., 1990). However, all these works disrupted glycosylation at the first site
by the pathogenic T182A mutation that has been shown in three independent studies
to alter cellular localisation of PrPc independently of the prevention of glycosylation
at the first site (Capellari et al., 2000b; Korth et al., 2000; Neuendorf et al., 2004).
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Thus this work supports the hypothesis that glycosylation of PrP at the first site is
not required for the localisation of the protein to the plasma membrane, in agreement
with the work of Capellari (2000), Korth (2000) and Neuendorf (2005). However,
p t •
small changes in the localisation of PrP which are below the detection limit may
occur.
Despite the reduced level of PrP detected in the neuropil of sections from G3
transgenic mice, the location of intracellular PrP was similar in the PrP glycosylation
deficient transgenic and 129/Ola control mice. In all sections examined intracellular
f"*
PrP was excluded from the ER and a proportion of the total was associated with a
marker of the Golgi. A similar pattern of localisation has been previously reported
p
for wild type PrP in vivo validating this finding (Laine et al., 2001; Mironov et al.,
2003). Thus the alteration of localisation of un-glycosylated PrP is not caused by an
accumulation of the protein in the ER or Golgi. Moreover, the data presented here
suggest that complete absence of PrP N-glycans does not prevent transport of the
protein through the ER and into the Golgi. Furthermore, the amount of PrP observed
within the Golgi in G3 transgenic mice does not appear to be reduced compared to
murine controls, suggesting that ER to Golgi trafficking of PrP may not be greatly
altered in the absence of PrP N-glycans. However further experimentation is required
to test this hypothesis.
C iThere are a number of possible explanations for the decreased level of PrP detected
in the neuropil of the G3 PrP glycosylation deficient transgenic mice. PrP may not
be correctly trafficked post-Golgi to the plasma membrane, perhaps being miss-
directed to the endosomal or lysosomal compartments. Alternatively, much reduced
levels of PrPc may reach the membrane because of an enhancement of intracellular
degradation. This may occur if un-glycosylated PrP has a higher probability of
misfolding in the ER and hence a greater proportion of it is subjected to
retrotranslocation and protease degradation via the ERAD pathway. The ERAD
pathway has also been suggested to be important to the normal regulation of
glycosylated PrPc (Jin et al., 2000; Ma and Lindquist 2001; Yedidia et al., 2001).
Un-glycosylated PrPc may be correctly trafficked to the plasma membrane but there
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may be subject to an increased rate of turnover or release, perhaps because of the
exposure of an enzymatic site usually shielded by the N-glycans. As the level of PrP
detected by DELFIA are similar between G3 and 129/Ola controls (Chapter 3), any
• f1
increase in degradation in vivo must be linked to an upregulation of PrP synthesis.
Only one anti-PrP monoclonal was suitable for detection of PrP by
Immunofluorescence, despite the large number investigated. Thus the observed
decrease in G3 PrPc may be caused by a specific alteration in the un-glycosylated PrP
8H4 epitope availability at the membrane. This could conceivably occur, as G3 un-
glycosylated PrP may interact differently from the glycosylated form with a range of
different molecules. G3 PrPc may even interact differently with the plasma membrane
or be localised differently within it, as the regional localisation of GPI anchored
proteins within membrane is thought to be mediated via interactions with other
membrane proteins. Further experimentation is required to investigate whether G3
PrP is located within the same membrane domain as the normally glycosylated
protein, and to define the mechanism which underlies the observed difference in PrP
distribution in the G3 transgenic mice.
The observation of high levels of cytoplasmatic PrP (cytPrP) within a subset of cells
in the hippocampus is consistent with previous reports (Barmada et al., 2004;
Mironov et al., 2003). CytPrP has been suggested to be neurotoxic (Ma et al., 2002).
However, the observation presented here of high levels of cytoplasmatic PrP, in
apparently healthy cells, with intact nuclei, in wild type mice, suggests the contrary.
However, further work is required to investigate whether these cells lack signs of
apoptosis/necrosis in vivo, as has been previously demonstrated in another system
(Mironov et al., 2003). The previous reports of cytPrP cells recorded a higher
frequency of such cells than observed here (Barmada et al., 2004; Mironov et al.,
2003). This may be attributable to the different strains of mice used in this study,
129/Ola compared to FVB and C57/B6 X CBA/J, differences in environmental
factors or circadian fluctuations in cytPrP expression. In this regard it important to
note that all mice used in the experiments presented here were sacrificed between
08.30-10.00 hours, at the start of the light cycle.
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5.0 The role of glycosylation of PrP in a TSE species barrier
5.1 Aim To determine if glycosylation of PrP influences cross-species TSE
transmission.
5.2 Introduction and experimental method
Like many infectious diseases, TSE transmission between species is notably less
efficient than that observed within a species. However, cross-species transmission
does occur with devastating consequences (Chapter 1). The molecular mechanisms
that underlie the barrier to cross-species transmission are poorly understood. Thus it
is currently not possible to make accurate predictions about the risk of cross-species
transmission of novel TSEs and hence to which host species they pose a threat.
The species barrier to transmission is characterised by a decrease in susceptibility,
and an increase in length and variability of the incubation period, in the novel host
species (Pattison, 1965). A number of factors are thought to contribute to the barrier,
most notably PrP and its interaction with species specific factors (Chapter 1) (Barron
et al., 2005; Barron et al., 2001; Manson et al., 1999; Scott et al., 1989; Telling et al.,
1994; Telling et al., 1995). The degree of homology of the amino acid sequence of
host PrPc and donor PrPSc has been reported to influence the extent of the species
barrier (Scott et al., 1989). However, PrP also influences cross-species TSE
transmission independently of PrPc-PrPSc sequence similarity (Barron et al., 2005;
Barron et al., 2001; Manson et al., 1999). Current data suggest that conformational
compatibility between PrPc and PrPSc is a key determinant of the barrier: firstly
because of the TSE strain dependence of the barrier and secondly because of the
correlation of the transmission barrier effect with an alteration of PrPSc conformation
(Peretz et al., 2002; Scott et al., 1993). However, the observed complexity of the TSE
species barrier suggests that it may be composed of multiple mechanisms (Chapter 1).
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The TSE species barrier effect is partially replicated in cell-free PrP misfolding
reactions (Kocisko et al., 1995). This suggests that innate convertibility of PrP may
contribute to the observed transmission barrier, consistent with the conformational
compatibility model. In these in vitro systems, conversion of PrP to a proteinase
resistant form is induced by the introduction of PrPSc, derived from a TSE infected
animal (Kocisko et al., 1994). The observed conversion efficiency approximately
correlates with the relatedness of the amino acid sequence of PrPc and PrPSc, such
that within species conversions occur more readily than cross-species reactions
(Kocisko et al., 1995). Glycosylation of PrP has been suggested to have a specific
role in the observed reduced efficiency of cross-species conversion, since removing
c
PrP 's N-glycans specifically elevates the efficiency of cross-species seeded reactions
p
(Priola and Lawson, 2001). This suggests that the glycosylation of host PrP may
specifically hinder cross-species TSE infection in vivo.
The postulated effect of PrP's glycosylation state on cross-species TSE transmission
may be mediated by a number of mechanisms. Firstly, reported differences in the
glycans attached to PrPSc between species (Xanthopoulos et al., 2006) may indicate
an adaptation or preference of the TSE agent to the predominant PrP glycotypes of a
particular host species. Thus the glycosylation of PrPc in other host species may
restrict replication of the agent. Alternatively, PrP's N-glycans may have a generic
effect on the protein's conformational flexibility, as proposed by (Zuegg and Gready,
2000), such that a glycosylated molecule is less able to adopt the novel conformation
of PrPSc from a different species. Alternatively, glycosylation of PrPc may directly
interfere with the protein's ability to interact with PrPSc (Rudd et al., 2001).
Additionally, the glycosylation state of PrP may mediate the protein's interaction
with other cellular factors that influence the conversion of PrPc to PrPSc in vivo.
Thus the glycosylation status of PrPc could both directly and indirectly influence
PrPc to PrPSc conversion and hence the TSE transmission barrier.
To investigate the hypothesis that glycosylation of PrP retards cross-species TSE
transmission, PrP glycosylation deficient murine transgenics [NPU] and normally
glycosylated mice (CL and 129/Ola) were challenged with the hamster model TSE
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strain, 263K, by intracerebral (ic) inoculation. Data presented in chapter 3
demonstrate that these transgenic mice are a valid model in which to investigate the
influence of PrP's glycosylation state on cross-species TSE transmission. Direct ic
injection is the most efficient route of TSE challenge and thus was used to minimise
the number of experimental animals required. However, this method circumvents the
peripheral transmission and replication phase of the TSE agent. Thus in these
experiments the importance of glycosylation of PrP to the peripheral stage of TSE
infection is not investigated. Although this phase is a key part of natural cross-
species TSE transmissions, the hypothesised influence of glycosylation of PrP on the
TSE species barrier is via its effect on PrP misfolding efficiency, which will directly
effect CNS pathogenesis (Priola and Lawson, 2001). However, further experiments
are necessary to investigate if the glycosylation state of PrP has a specific effect on
peripheral pathogenesis.
Hamster passaged scrapie strain 263K, and the putative equivalent strain Sc237 (Scott
et ah, 1989), are much studied TSE models. A strong barrier to transmission exists
between 263K and wild type mice. The 263K incubation period is in excess of 700
days in murine hosts in contrast to around 60 days in hamsters and susceptibility is
also much reduced in mice (Kimberlin and Walker, 1978a; Race et al., 2001). Thus
transmission of 263K to mice provides a model reflecting a classic species barrier, as
defined by Pattison in 1965 (Pattison, 1965). Additionally, although clinical disease
incidence in 129/Ola mice after challenge with 263K is low, subclinical pathology is
observed in a higher proportion of challenged animals (personal communication R.
Barron). Thus by comparing the extent of subclinical deposition of misfolded PrP
and TSE specific vacuolar pathology between the normally glycosylated control and
glycosylation deficient transgenic mice, the influence of PrP glycosylation state on
cross-species transmission of 263K can be determined, even in the absence of clinical
disease. Therefore, inoculations of 263K into the glycosylation transgenic mice will
# p
be a useful model to test the hypothesis that glycosylation of PrP retards cross-
species transmission of the TSE agent. In particular, given that cell-free conversion
work suggests an effect that is equivalent to a two-three log change in titre (Priola and
Lawson, 2001; Raymond et al., 2000).
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263K was used by Priola and Lawson to demonstrated that glycosylation of PrPc
reduces the efficiency of cross-species TSE misfolding in vitro (Priola and Lawson,
2001). Thus, it is of particular relevance to this study of the in vivo effects of PrPc's
N-glycans on cross-species TSE transmission. Additionally, 263K/Sc237 haa been
used in many previous investigations into the species barrier. It was the strain used to
identify the importance of amino acid sequence homology of PrPc and PrPSc to cross-
species transmission (Scott et al., 1989). Notably it has been used to demonstrate the
phenomenon of adaptation of the agent in new hosts, as illustrated by an alteration of
strain characteristics (Kimberlin and Walker, 1978a). More recent work has built on
this finding and has shown, using the 263K model, a correlation of conformational
change of PrPSc and the species barrier effect (Peretz et al., 2002).
Hamster PrP and hence 263K PrPSc differs from murine PrP at fourteen amino acid
residues (Locht et al., 1986). Three of these differences lie within the N-terminal
signal sequence or the C-terminal GPI anchorage motif, and are hence absent from
the fully mature protein. Previous work has suggested that the difference in the PrP
amino acid sequence between hamster and mice mediates the species barrier (Scott et
al., 1989). It is interesting to note that the amino acid sequence surrounding the first
glycan attachment site is highly conserved between hamster and mouse. In contrast,
proximal to the second site, hamster and mouse PrP differ at amino acids 203 and 205
(hamster sequence). These differences in local amino acid sequence homogeneity
may affect the relative importance of the two N-glycan attachment sites to cross-
species TSE transmission.
The 263K challenged murine transgenics and normally glycosylated control mice
were observed blind to genotype, for 700 days post inoculation, for clinical TSE
disease incidence using standard criteria (Dickinson et al., 1968). Thus, the influence
of glycosylation of PrP on TSE disease transmission and hence the extent of the
species barrier was experimentally assessed. Additionally, the incidence and extent
of subclinical TSE specific pathology, including vacuolar pathology, deposition of
disease associated misfolded PrP (PrPd) within the brain and formation of PK
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resistant PrP (PrPSc) were also examined by standard methods (Bruce et al., 1989;
Fraser and Dickinson, 1968), since significant subclinical disease was anticipated.
The disease associated PrP (PrPd) detected by immunohistochemistry (IHC) was not
always demonstrated to be PK resistant, hence the term PrPd was used to differentiate
it from PK resistant PrPSc. If PrPSc was not detected by the standard extraction
technique it was concentrated by ultracentrifugation or sodium phosphotungstic acid
(NaPTA) precipitation (Safar et al., 1998). In addition to providing information about
the extent of TSE infection in the challenged mice, these data also provide
mechanistic insight into the role of PrPc glycosylation in formation of PrPSc in vivo
after cross-species challenge with 263K.
To further examine the role of glycosylation of PrP on the TSE disease process,
astrocytosis, which is a common but not exclusive TSE pathological hallmark, was
also investigated by IHC using an antibody to glial fibrillary acid protein (GFAP) to
label activated astrocytes. The glycosylation state of PrP may influence the activation
of astrocytes via an effect on the type of PrPSc formed in vivo or by a direct effect on
their role in pathogenesis.
Moreover, by comparing the pattern of vacuolation and PrPd deposition, and the type
of PrPSc formed in control and transgenic mice, the influence of PrPc's N-glycans on
TSE strain characteristics could be determined. Passage of TSE in new hosts is
linked to the emergence of novel strains which differ in their disease characteristics,
including incubation time. Moreover some have postulated that the correlation of
PrPSc glycoform and TSE strain reflects the encryption of TSE strain characteristics
by PrPSc glycoform (Collinge et al., 1996). Thus the alteration of PrPc glycosylation,
and hence also that of PrPSc produced in the murine PrP glycosylation deficient
transgenics, may directly cause a change in TSE strain. Hence it is important to
determine whether any observed changes in disease incidence or onset occur purely
because of a host effect on disease progression (i.e. same pathogen strain, with a
species barrier), or owing to an effect of host on the TSE strain able to infect it.
Furthermore, it is important to consider that TSE strain and the transmission barrier
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may be mechanistically linked and hence it may be artificial to separate them (Hill
and Collinge, 2003).
Subpassage of material from glycosylated controls and G2 transgenic mice infected
with 263K has been undertaken to further compare which TSE strain caused the
disease observed in these mice. TSE vacuolar pathology positive murine brains (two
G2 and one CL) were used to challenge G2 transgenic mice, normally glycosylated
control mice (CL and 129/Ola) and three additional inbred strains of wild type mice
which have been classically used to define TSE strain (Chapter 1.). This work is
currently ongoing and not available for analysis.
5.3 Optimisation of experimental methods
5.3.1 CSA kit for the detection of disease associated PrP
To permit analysis of TSE specific vacuolar targeting, all TSE challenged brain tissue
was subjected to prolonged fixation in formol-saline, alcohol dehydration and the
paraffin embedding process that is required for observation of TSE vacuolation. The
fixation and embedding strategy used is known to remove PrP epitopes and reduce
the levels of detectable PrPd owing to the extensive cross-linking of proteins that
occurs during fixation (Brown et al., 2003; Laine et ah, 2001; Mironov et al., 2003).
Thus it was necessary to use antigen retrieval (wet autoclaving sections at 115 °C for
15 minutes and 5 minutes in 98 % formic acid) to maximise the amount of PrPd
detectable by IHC to ensure that all subclinical TSE cases were detected, which is key
given the low rates of transmission anticipated in this cross-species transmission
experiment (Bruce et al., 1989).
To further increase the detection of PrPd, a catalyzed signal amplification kit from
DAKO was used in which an extra amplification step is used. In this system the
primary antibody is recognised by a biotinylated secondary antibody, to which a
streptavidin-biotin-peroxidase complex then binds. The amplification step is then
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mediated by this peroxidase which catalyses the deposition of biotinylated phenol
increasing the number of biotins bound at the site of the original antibody binding by
approximately fifty-fold. This deposited biotin can then be recognised by a standard
streptavidin peroxidise diaminobenzidine/hydrogen peroxide reaction. Normal brain
homogenate inoculated PrP373 mice and PrP null [NPU] mice were used as negative
controls to ensure that all signal detected was specific to the TSE challenged animals
(PrPd), however these were not aged matched to the experimental TSE challenged
aged mice. Two anti-PrP mouse monoclonal antibodies (6H4 and 8H4) were used
with the kit, the concentrations of which were determined by titration (appendix iv,
v). These monoclonal antibodies recognise epitopes in the central region of the
protein and thus should be effective at detecting both C and N terminal truncated
forms of PrP (appendix vi). No significant difference in the pattern of normally
glycosylated wild type PrPd was observed when the antibodies were used at their
optimised concentrations (8H4 (1/5,000) and 6H4 (1/20,000)); indicating that these
antibodies are effective at recognising all forms of PrPd. However, in general the
level of PrPd detected with 8H4 was lower than 6H4.
5.4 Experimental results
5.4.1 TSE incubation periods and incidence of disease
Age and sex matched PrP glycosylation deficient transgenic [NPU] and normally
glycosylated control mice were challenged by ic injection, to a depth of 2-3 mm in the
right brain hemisphere, with 20 pi of clinical endpoint 263K infected hamster brain
(10 %). Animals were anesthetised for the duration of the experimental procedure,
coded after inoculation and examined blind to mouse genotype, daily for general
good health and formally assessed by TSE scoring criteria weekly using the
definitions of Dickinson and Fraser (1968). All animals which died at time of
injection were excluded from the analysis. After the termination of the experiment,
mice, for which no material was available for post-mortem genotyping or if the brain
material was unsuitable for pathological study, were excluded from experimental
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analysis. All these animals were clinical negatives and those for which pathological
analysis was possible were also negative for TSE specific vacuolation. Exclusions
were necessary because of an excessive post-mortem interval and/or damage during
tissue removal which rendered tissue inappropriate for examination of vacuolation or
because of accidental discards or inappropriate treatment of CNS material.
No symptoms of clinical disease were observed in either the murine PrP glycosylation
deficient transgenics or normally glycosylated control mice challenged with 263K,
consistent with a strong 263K/murine species barrier (Table 5.1) (Kimberlin and
Walker, 1978a). Animals were sacrificed on welfare grounds during the course of the
experiment with non-TSE ailments. These included two scratched eyes, skin
abscesses and breathing difficulties in young and middle aged mice. In older animals
(550 dpi) profound weight loss and associated loss of condition were the most
common reasons for sacrifice; as the animals reached the end of their normal
lifespan the rate of sacrifice increased in all genotypes, consistent with normal
aging (Figure 5.1 A). No differences in reason for sacrifice were observed between
genotypes.
Table 5.1 Summary of TSE disease status in 263K challenged PrP glycosylation
deficient transgenic and control mice
TSE disease status key
0, negative for signs of TSE
disease (PrPd deposition,
vacuolation, clinical signs)
1, only positive for PrPd
deposition
2, positive for both PrPd
deposition and TSE specific
vacuolation
* In these groups, in one animal,
PrPd was limited to a plaque in
the corpus callosum.
TSE disease status
Genotype 0(.) 1 (■) 2(A)
(dpi +/- SEM)
G1 9 8 0
G2 2 5* 11
(552+/- 16.3)






Figure 5.1 Survival and TSE disease status of PrP glycosylation deficient
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(A) The number of G1, G2, G3 transgenic and normally glycosylated control
mice surviving after TSE challenge was plotted against time from inocula¬
tion, to determine if life expectancy after 263K exposure differed between
host genotypes. (B) The TSE disease status (clinical signs, vacuolar pathol¬
ogy and PrPd deposition +/-) of G1, G2, G3 transgenic and normally glyco¬
sylated control (CL or 129/Ola) mice after challenge with 263K was plotted
against the number of days post inoculation at which the animal was eutha¬
nized, to demonstrate the effect of PrP's N-glycans on TSE disease inci¬
dence and onset. The incidence of sub-clinical TSE disease is signifi¬
cantly lower in the G3 (p < 0.001) and G1 (p < 0.025) transgenic mice than
in normally glycosylated control mice, and the incidence of subclinical TSE
disease is significantly higher in G2 transgenic mice than in normally glyco¬
sylated control animals (p < 0.001).
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Within the normally glycosylated control group (CL = 16, 129/Ola = 5) three of the
twenty-one challenged mice exhibited no evidence of TSE pathology or PrPd
deposition, fifteen mice exhibited PrPd deposition in the absence of pathology and
only three of the challenged mice developed specific TSE vacuolar pathology (Table
5.1, Figure 5.1 B). Thus overall, eighteen of the twenty-one normally glycosylated
controls challenged with 263K and available for analysis exhibited evidence of TSE
infection.
No TSE specific vacuolation was observed in the 263K challenged G3 transgenic
mice. A small PrPd deposit was visible in the corpus callosum of one 263K
challenged G3, this may be an injection related accumulation of PrPSc as this region is
proximal to the site of injection in the hippocampus (5.4.3). PrPd was not detected in
any other 263K challenged G3 transgenic mice. Thus G3 mice have enhanced
resistance to 263K, or greatly increased incubations after infection with this agent,
compared to normally glycosylated murine controls (Chi-squared = 28.742, degrees
of freedom = 2, p < 0.001). Thus glycosylation of PrP facilitates the successful
transmission of hamster passaged scrapie strain 263K across a species barrier.
Reduced 263K disease incidence or significantly extended incubation periods were
also apparent in the G1 transgenic mice which lack the first N-glycan attachment site
(Table 5.1) (Chi-square = 7.796, degrees of freedom = 2, p < 0.025). Nine G1
transgenic mice neither displayed deposition of PrPd nor vacuolar pathology; in eight,
limited deposition of PrPd was observed and no G1 mice displayed any specific TSE
vacuolar pathology or signs of CNS dysfunction (Figure 5.1 B). The absence of
vacuolation and the reduced incidence and extent of PrPd deposition (5.4.3) in the G1
compared to the control mice, demonstrates that glycosylation of PrP at the first N-
glycan attachment site specifically mediates transmission of hamster TSE strain 263K
to mice.
In contrast to the enhanced resistance apparent in G1 and G3 transgenic mice, G2
murine transgenics were more susceptible to or had significantly shortened times to
disease onset after 263K challenge than normally glycosylated control mice (Table
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5.1) (Chi-squared = 10.264, degrees of freedom = 2, p < 0.001). The incidence of
TSE specific vacuolation was significantly higher (eleven of the eighteen animals
challenged) and the first case of vacuolation was observed earlier in the G2 transgenic
mice than in normally glycosylated murine controls. However, as animals were not
sacrificed at serial time points, it is not possible to precisely define when the onset of
vacuolar pathology occurred in the two genotypes and the differences observed in the
current data set are not significant. In addition to the cases exhibiting subclinical
vacuolation, a further five G2 transgenic mice exhibited PrPd deposition in the
absence of pathology. Overall, sixteen of the eighteen challenged G2 animals
available for analysis exhibited signs of TSE infection. The G2/263K challenge
experiment suggests that glycosylation of PrP at the second site retards the cross-
species transmission of hamster passaged scrapie strain 263K.
However a barrier to the cross-species transmission of 263K is still observed in the
complete absence of glycosylation at the second site since G2 transgenic mice do not
develop clinical disease, even after 700 days, in contrast to the approximately 60 day
incubation period observed in hamsters after 263K challenge (Kimberlin and Walker,
1978a). This indicates that factors in addition to the glycosylation state of PrP are
important to the murine species barrier to 263K infection. To further investigate the
extent of the barrier, material from two vacuolation positive G2 mice and a normally
glycosylated control mouse are being subpassed into G2 transgenic and normally
glycosylated wild type mice.
The differences in the disease incidence observed in G1 and G2 transgenic mice after
263K challenge, indicates that the site ofN-glycan attachment greatly influences the role
that glycosylation of PrP plays in cross-species TSE transmission. Indeed the
attachment of an N-glycan to asparagine 180 appears to facilitate the cross-species
transmission of 263K to mice, whereas attachment at the second site reduces the
incidence and decreases the time to disease onset after 263K challenge. Moreover, the
apparent resistance of G3 transgenic mice and enhanced susceptibility of G2 transgenic
mice to 263K, suggests that absence of glycosylation of the second site only promotes
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cross-species transmission of 263K to mice in the presence of an N-glycan at the first
site.
5.4.2 The pattern of TSE vacuolar pathology
The correlation of PrPSc glycoform and TSE strain characteristics, such as the targeting
of vacuolar pathology, has led some to suggest that TSE strain maybe encrypted by the
glycoform of PrPSc (Collinge et al., 1996). Thus the observed differences in the disease
incidence in the murine PrP glycosylation deficient transgenics after cross-species
transmission may be caused by differences in the TSE strains able to colonise the
transgenic hosts, rather than a direct effect of glycosylation on disease progression. To
investigate this possibility, the targeting of TSE vacuolar pathology was examined. The
brains of TSE challenged animals were removed post-mortem and saggitally divided in
two asymmetrically. The larger right halves into which the inoculum was originally
introduced were assessed for TSE vacuolar pathology, by standard methods (Fraser and
Dickinson, 1967; Fraser and Dickinson, 1968).
The pattern of sub-clinical vacuolar pathology observed after 263K challenge appeared
similar in G2 and normally glycosylated control animals, (Figure 5.2 A), although a
slightly lower pathology score was observed in the hypothalamus in the control group
(Figure 5.2 A, B and D). This may be due to differences in the stage of TSE disease
development between the groups; given the later onset of pathology in the CL group, it
is also likely that these mice died at an earlier stage of the sub-clinical disease. In both
groups particular targeting to the dorsal medulla (grey area 1) and septum (7) (Figure 5.2
C and E) was observed and little pathology was observed in the cerebellar cortex (2),
hippocampus (6), or cerebral cortex (8 & 9). The pattern of targeting observed was
comparable to previous reports of the transmission of murine passaged/263K to
normally glycosylated 129/Ola mice, (Barron et al., 2001). This further validates the
interpretation that the absence of glycosylation of PrPc at the second site does not
influence the targeting of 263K TSE specific vacuolation.
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Figure 5.2 Lesion profile and examples of vacuolar pathology in 263K
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The pattern of TSE specific vacuolar pathology evident in G1, G2, G3 transgenic and
normally glycosylated control mice after 263K challenge was semi-quantatively
scored, blind to mice genotype and TSE agent, on a scale of 0-5 in nine grey areas (1
dorsal medulla; 2 cerebellar cortex; 3 superior colliculus; 4 hypothalamus; 5
thalamus; 6 hippocampus; 7 septum; 8 retrosplenial and adjacent motor cortex; 9
cingulate and adjacent motor) and three white matter areas of the brain (1* inferior
and middle cerebellar peduncles; 2* decussation of the superior cerebellar
peduncles; 3* cerebral peduncles) by standard methods. The experiment was then
decoded and a lesion profile of the mean vacuolation score for each genotype
constructed. This demonstrates that the pattern and density of vacuolation in G2 and
normally glycosylated control mice is similar apart from in the hypothalamus (A). No
vacuolation was detected in the G1 or G3 transgenci mice. B-E) Examples of
haematoxylin and eosin stained brain sections showing TSE vacuolar pathology in
the hypothalamus (B & D) and septum (C & E) of normally glycosylated (B & C) and
G2 transgenic (D & E) mice. Scale bar 50 pm (B-E).
The intensity of vacuolation observed was lower than that previously reported for
clinically sick animals infected with murine passaged 263K, consistent with the
subclinical TSE state of the mice studied here (Barron et al., 2001).
The similarity of the targeting of TSE vacuolar pathology in the G2 transgenic and
normally glycosylated control mice suggests that they were infected with the same TSE
strain. Further experimental investigation, including an examination of the pattern of
PrPd deposition and strain typing by bioassay, is required to support this conclusion.
However, the observed conservation of the pattern of vacuolar targeting between the G2
transgenic and normally glycosylated control mice infected with 263K suggests that the
observed alteration of disease incidence and onset is the result of a specific role of
second site glycosylation of PrPc on disease progression in mice.
5.4.3 Pattern of TSE associated PrP deposition in the CNS
To further investigate if other TSE strain characteristics differed between the murine PrP
glycosylation deficient transgenics and normally glycosylated controls, the pattern of
disease associated PrP (PrPd) deposition was determined. PrPd deposition was examined
at five defined levels at which vacuolar pathology was scored (Chapter 2) using an anti-
PrP antibody 6H4. Normal brain inoculated Prnp37"1 mice and PrP null mice were used as
negative controls, although these controls were not aged matched to experimental mice.
A subset of brains were stained with an additional anti-PrP antibody 8H4. to determine if
the results were antibody dependent. Furthermore, the extent of PrPd deposition was
used to assess the relationship between PrPd accumulated in vivo and the extent of other
TSE pathological features.
The pattern of early PrPd deposition was broadly similar between vacuolation positive
G2 transgenic and normally glycosylated control mice challenged with 263K as assayed
by 6H4 and 8H4 (Figure 5.3 (i, ii)). Targeted synaptic type PrPd deposition was
observed in the thalamus, habenula and in some cases in the septum at the early stages in
both G2 (Figure 5.3 E-H, I) and normally glycosylated controls (Figure 5.3 A-D, J).
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Figure 5.3 Early stage PrPd deposition in vacuolation positive G2
transgenic and control mice challenged with 263K. Early stage PrPd
deposition after 263K challenge was examined at five defined brain levels of
which four are shown here (A & E) medulla and cerebellum, (B & F)
midbrain including superior collicullus (Sc) (just seen B), cerebral cortex
and hippocampal formation, (C & G) hippocampus (Elp), habenula (Hb),
thalamus (Th), hypothalamus, cerebral cortex and corpus callosum (cc), (D
& H) forebrain including corpus callosum and septum (Sp). PrPd was
detected after wet autoclaving and formic acid treatment using anti-PrP
antibodies 6H4 (i) and 8H4 (ii). The signal was amplified using a CSA kit
and visualised with DAB; nuclei were counter stained with haematoxylin.
Synaptic PrP deposition can be observed in habenula and thalamus (C & G)
using both antibodies (i, ii) and the septum (D & H) using 6H4 (i) in both
G2 transgenic (E-H) and normally glycosylated control mice (A-D). Pattern
of synaptic staining in the thalamus is similar in normally glycosylated
controls (ii enlargement of C) and G2 transgenic mice (iJ, enlargement of
G). Specificity of signal was determined using PrP null [NPU] and normal
brain homogenate challenged PrP373 negative control sections (i-K) and (ii-
I). Sections (A-D) from a single CL mouse, (E-H) two G2 transgenic mice
were analysed (E, G & H animal one; F animal two). Scale bar 500 pm (A-
H), scale bar 25 pm (I & J).
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Figure 5.3 (i) Early stage PrPddeposition in vacuolation positive G2 transgenic
and control mice challenged with 263K (6H4)














Figure 5.3 (ii) Early stage PrPddeposition in vacuolation positive G2 transgenic




















Additionally, more extensive synaptic type deposition was also observed in the cerebral
cortex and forebrain in some G2 and control animals that were sacrificed at later time
points (more than 600 days post ic challenge) (Figure 5.4, 5.5). Despite this variability,
G2 transgenic mice challenged with 263K appeared to exhibit more extensive PrPd
deposition than controls (Figure 5.5, table 5.2), however this difference was not
statistically significant (Chi square = 2.09, df = 3, p < 1). PrPd amyloid plaques were
observed in five G2 transgenics in the thalamus, septum, cerebral cortex and
hippocampus as confirmed by thioflavin-s treatment (Figure 5.6). This formation of
amyloid plaques within these G2 transgenic mice may be a result of the higher density of
PrPd deposition observed, which may favour the formation of higher order aggregates.
These data suggest that glycosylation of PrPc at the second site influences the
amount/rate but not the pattern of PrPd accumulation after cross-species TSE challenge
with 263K. This further supports the hypothesis that TSE strain does not differ between
the G2 transgenic and normally glycosylated control mice but that the rate and
probability of disease progression is changed, indicative of an alteration in the TSE
species barrier.
Table 5.2 Extent of PrPd deposition in the brains of 263K challenged mice
Murine Extent of PrPd deposition (semi-quantitatively scored)
Genotype None Limited Moderate Extensive
G1 9 8 0 0
G2 2 6 4 6
G3 21 1 0 0
CL/129/Ola 3 10 5 3
The brain regions in which PrPd was detected using anti-PrP antibody (6H4), in 263K
challenged mice, was scored blind to genotype. Then the extent of PrPd deposition was
categorised as limited (PrPd observed in the habenular and associated neuropil; ventral
midbrain and midline of the medulla and/or pons), moderate (PrPd observed additionally
in the thalamus) or extensive (PrPd additionally observed in the cerebral cortex, septum,
and caudate-putamen). The experiment was decoded and tabulated.
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Figure 5.4 More extensive PrPd deposition is observed in control mice
after challenge with 263K at later time points. Early stage PrPd
deposition in a normally glycosylated control after 263K challenge was
examined at five defined brain levels of which four are shown here (A &
E) medulla and cerebellum, (B & F) midbrain including superior
collicullus (Sc) (just seen B), cerebral cortex and hippocampal formation,
(C & G) hippocampus (Elp), habenula (Hb), thalamus (Th), hypothalamus,
cerebral cortex and corpus callosum (cc), (D & H) forebrain including
corpus callosum and septum (Sp). PrPd was detected after wet autoclaving
and formic acid treatment, using anti-PrP antibody 6H4. The signal was
amplified using a CSA kit and visualised with DAB; nuclei were counter
stained with haematoxylin. Synaptic-type PrPd deposition can be observed
in habenula, medulla, cerebral cortex (C & G) the septum and caudate
putamen (D & H). Boxed area in A = B, C = D, E = F and G = El.
Sections shown are from a single normally glycosylated control mouse a
further two animals also exhibited a similar pattern of extensive
deposition. Specificity of signal was determined using PrP null [NPU] and
normal brain homogenate challenged PrP373 negative control sections (I).
Scale bar 500 pm (A, C, E, G), 25 pm (B, D, F, H).
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Figure 5.4 More extensive of PrPd deposition is observed in control mice after
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Figure 5.5 Extensive PrPd synaptic-type deposition and plaques were
observed in G2 transgenic mice challenged with 263K. PrPd deposition
in G2 transgenic mice after 263K challenge was on average more
extensive than that observed in normally glycosylated controls. The
deposition of PrPd was examined at five defined brain levels of which four
are shown here (A & B) medulla and cerebellum, (C & D) midbrain
including superior colliculus (Sc), cerebral cortex and hippocampal
formation, (E & F) hippocampus (Hp), habenula (Hb), thalamus (Th),
hypothalamus, cerebral cortex and corpus callosum (cc), (G & H)
forebrain including corpus callosum and septum. Extensive PrPd
deposition was detected throughout the brain, after wet autoclaving and
formic acid treatment, using anti-PrP antibody 6H4. The signal was
amplified using a CSA kit and visualised with DAB; nuclei were counter
stained with haematoxylin. Large PrPd plaques can be observed in the
thalamus (E). Boxed area in A = B, C = D, E = F and G = H. Figures
show the results from a single G2 transgenic mouse, a further five G2
animals exhibited a similar extent of deposition. Specificity of signal was
determined using PrP null [NPU] and normal brain homogenate
challenged PrP373 negative control sections (I). Scale bar 500 pm (A, C, E,
G), 25 pm (B, D, F, H).
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Figure 5.5 Extensive PrPd synaptic-type deposition and plaques were observed




Figure 5.6 PrPd amyloid plaques are formed in the thalamus and hippocampus
in G2 transgenic mice after challenge with 263K.
PrPd plaques were observed in the thalamus (A) and hippocampus (C) of
G2 transgenic mice that were challenged with 263K, using the anti-PrP
antibody 6H4, on brains sections that had be treated with formic acid and
wet autoclaving to mediate antigen detection. To determine if these
plaques contained amyloid protein, serial sections were treated with
thioflavin-s (B & D). The plaques interacted with thioflavin-s
demonstrating the formation of amyloid in vivo. Scale-bar 50 pm.
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The extent of PrPd deposition was reduced in the G1 glycosylation deficient transgenic
mice compared to the normally glycosylated controls (Figure 5.7, table 5.2) (Chi-square
= 10.922, degrees of freedom = 3, p < 0.25). In the majority of G1 transgenic mice, PrPd
was only observed in the habenula and surrounding thalamic neuropil; occasionally,
very limited synaptic staining was also observed in the hypothalamus or medulla. This
pattern of deposition is similar to the earliest deposition observed in 263K challenged
G2 transgenic mice and normally glycosylated controls (data not shown). These data
demonstrate that the absence of the first glycosylation site retards the accumulation of
PrPd in the brain after cross-species 263 K challenge, but does not appear to alter its
pattern. This is consistent with the hypothesis that the strain of TSE does not differ
between the G1 transgenic and normally glycosylated mice. The contrasting effect ofN-
glycans attached at the first site (G2), which may promote PrPd accumulation and at the
second site (Gl) that inhibits the accumulation, of PrPd in vivo after 263K challenge,
suggests that the N- glycans attached to the two sites play very different roles in the
accumulation of PrPd.
Apart from a single corpus callosum PrPd plaque in one G3 transgenic mouse (Figure 5.8
I) no other PrPd deposition was observed in 263K challenged G3 transgenic mice as
assayed by 6H4 or 8H4 (Figure 5.8 A-G). These data suggest that glycosylation of PrP
facilitates the accumulation of PrPd in vivo. Furthermore, this demonstrates that the
effect of absence of glycosylation at the second site on the promotion of PrPd
accumulation in vivo requires that the first site is glycosylated.
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PrPd deposition in G1 transgenic mice after 263K challenge was very
limited, deposition was examined at five defined brain levels of which four
are shown here (A) medulla and cerebellum, (B) midbrain including
superior colliculus, cerebral cortex and hippocampal formation, (C)
hippocampus, habenula, thalamus, hypothalamus cerebral cortex and
corpus callosum, (D) forebrain including corpus callosum and septum,
close up of deposition in habenula (Hb) (F). PrPd deposition was only
detected in the habenula and surrounding thalamus using anti-PrP
antibody 6H4 (C and F) but not in normal mouse serum negative control
(E). Tissue was pretreated by wet autoclaving and formic acid treatment,
anti-PrP signal was amplified using a CSA kit and visualised with DAB,
nuclei were counter stained with haematoxylin. Specificity of signal was
determined using PrP null [NPU] and normal brain homogenate
challenged PrPa negative control brain sections. Scale bar 500 pm (A-E),
25 pm (F).
161
Figure 5.8 PrPd deposition was generally not observed in G3
transgenic mice challenged with 263K. PrPd deposition in G3 transgenic
mice after 263K challenge was examined at five defined brain levels of
which four are shown here (A & E) medulla and cerebellum, (B & F)
midbrain including superior colliculus (B), cerebral cortex and
hippocampal formation, (C & G) hippocampus, habenula, thalamus,
hypothalamus, cerebral cortex and corpus callosum, (D & H) forebrain
including corpus callosum and septum. PrPd deposition was generally not
detected, even after PrP antigen retrieval by wet autoclaving and formic
acid treatment, using anti-PrP antibody 6H4 (A-D) or 8H4 (E-H), and use
of signal amplification by CSA kit. Sections from two G3 transgenic mice
(animal one, A-D; animal two, E-H) did not exhibit detectable PrPd but in
one G3 transgenic mouse, PrPd was detected in the corpus callosum (I).
Nuclei were counter stained with haematoxylin. A 263K challenged G2
transgenic mouse was used as a PrPd positive control (6H4-J, 8H4-K).
Scale bar 500 pm (A-EI).
162
Figure 5.8 PrF^ deposition was generally not observed in G3 transgenic mice
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5.4.4 TSE associated PK resistant PrPSc
To further investigate the effect of host PrP glycosylation state on TSE strain, the PrPSc
type was examined by limited PK digestion and western blot, after cross-species
challenge with 263K. This allowed the molecular weight of the PK resistant core to be
compared between 263K challenged glycosylation transgenic and normally glycosylated
control mice. This parameter correlates with a number of TSE strains and is proposed to
reflect the conformation of PrPSc (Bessen and Marsh, 1992a; Collinge et ah, 1996;
Parchi et ah, 1996; Somerville et ah, 1997). These experiments also permitted an
estimate of the amount of misfolded PrP that had accumulated after 263K challenge.
Brain material was either prepared in sterile physiological saline (for subpassage) then
extracted in detergent containing Tris buffered lysis solution (NP40 lysis buffer) or
directly in NP40 lysis buffer to facilitate isolation of PrPSc. The same batch of PK
(aliquoted and stored a -20 °C) was used for all digestion under standard conditions (20
pg/ml, 37 °C for 1 hour) to ensure enzyme consistency; uninfected negative controls of
the appropriate genotype and corresponding PrPSc positive controls were used for all
digestions.
The PK resistance of PrPSc in 263K challenged animals was determined using standard
digestion conditions and western blotting under denaturation conditions. PrP was
detected using anti-PrP monoclonal antibodies 8H4 and 7A12; similar results were
observed with both antibodies (Figure 5.9 and data not shown). Proteinase K resistant
PrP (PrPSc) was observed in 263K challenged G2 transgenic mice (n = 5) and normally
glycosylated control mice (n = 7), but not in 263K challenged G1 (n = 5) or G3 (n = 5)
transgenic mice or uninfected murine controls, even after twenty fold concentration by
NaPTA precipitation or high speed centrifugation (Figure 5.9 B-E). This would suggest
that either the G1/263K PrPd observed by IHC is PK sensitive or below the level of
detection possible by these techniques. Further investigation is required using a more
sensitive assay and lower concentrations of PK to assess these possibilities
experimentally.
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Figure 5.9 Western blots of PrPScfrom PrP glycosylation deficient transgenic
mice, murine and hamster controls challenged with 263K
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PrPSc was isolated from three 263K challenged G2 transgenic mice and
three normally glycosylated control mice (CL or 129/Ola) and one hamster,
that exhibited TSE specific vacuolation and/or PrPd deposition, by standard
PK digestion (20 pg/ml, 37 °C, one hour) of total brain homogenate (A) that
ahd been prepared in saline (S) or NP40 tissue lysis buffer (N). No
consistent difference in electrophorectic mobility of un-glycosylated PrPSc
(blue arrow unSc) is observed between G2 transgenic and normally
glycosylated control mice, however differences in the mobility of
mono-glycosylated PrPSc (blue arrow monoSc) between the G2 transgenic
and control mice are apparent. In five G1 transgenic mice (B and C) in
which PrPd was observed and five G3 transgenic mice (D and E) in which
no PrPd was observed, PrPSe was concentrated twenty-fold by NaPTA
mediated precipitation (B and D) or high speed centrifugation (C and E);
after standard PK digestion (20 MQ/ml. 37 °C, one hour). No PrPSc was
detected in any of these samples, despite clear PrPc signal . PrP was
detected with anti-PrP antibody 8H4 and horseradish conjuagated
anti-mouse secondary antibody (Jackson ImmunoResearch, West Grove,
USA). Secondary was detected using POD solution (Roche Diganostics,
Basel, Switzerland) and the resultant chemiluminescence was detected
using X-ray film. 165
Slight variation was observed in the electrophoretic mobility of PrPSc between samples.
In particular, tissue that was prepared for inoculation by homogenisation in
physiological saline produced un-glycosylated PrPSc after PK digestion of a slightly
lower electrophoretic mobility, which may indicate a greater molecular weight than that
directly homogenesised in NP40 buffer. However, PrPSc isolated from 263K challenged
G2 transgenic mice was not of a consistently different molecular weight than that from
normally glycosylated controls. This is consistent with the observed similarity of
deposition pattern of PrPd in G2 and control mice in vivo and suggests that the
conformation of PrPSc is similar in the transgenic and control mice, which is indicative
of these animals being infected with the same TSE strain.
However, the mono-glycosylated PrPSc from G2 transgenic mice consistently exhibited
significantly higher electrophoretic mobility than that from normally glycosylated
animals. This indicates that the combination of sugars attached to mono-glycosylated
PrPSc differs between G2 transgenic and normally glycosylated control mice. Further
investigation is required to determine how the glycans attached to G2/263K PrPSc and
CL/263K PrPSc differ, and if these differences affect the conformation of PrPs\
In both G2 and normally glycosylated controls, the ratio of glycotypes appeared to be
shifted towards the less glycosylated forms when compared to that of hamster 263K
glycoform (Figure 5.9). However, this result is compounded by known differences in
the amino acid sequence and putative differences in the N-glycans attached to hamster
and mouse PrP, which may alter antibody binding to the different glycotypes of protein
as highlighted by results presented in Chapter 3. Hence although this observation does
not provide strong evidence for preferential conversion of un- and mono-glycosylated
murine PrPc by hamster 263K PrPSc, it further supports the hypothesis that PrP's N-
glycans may retard the conversion of murine PrP by hamster 263K.
Furthermore, G2/263K CNS material appeared to contain more PrPSc than was observed
in 263K challenged normally glycosylated mice, as higher dilution factors were required
to produce equivalent western blot signals (Figure 5.9 A). This is consistent with the
observation of heavier and more extensive PrPd deposition in the murine G2 transgenics
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than in normally glycosylated mice. Thus providing further evidence that glycosylation
of PrP's second site reduces the rate of PrPd accumulation in mice after cross-species
infection with hamster passaged scrapie strain 263K. However, differential antibody
recognition of misfolded PrP from G2 transgenic and normally glycosylated control
mice could conceivably also explain these observations. Moreover, the concentration of
PrPSc isolated from 263K/G2 transgenic mice was always lower than that observed in the
clinical endpoint 263K hamsters. Thus, even in the absence of glycosylation at the
second site, a strong barrier to in vivo 263K seeded PrPSc accumulation is apparent in
mice.
5.4.5 TSE associated astrogliosis
Astrogliosis is a typical pathogenic response to TSE infection, although it is not observed
in all types of disease. To determine if its occurrence after cross-species TSE challenge
was influenced either directly or indirectly by the glycosylation state of PrPc, its extent
was examined in 263K challenged glycosylation deficient transgenic mice and normally
glycosylated controls. What mediates the observed up regulation of astrocytes in TSE
disease is currently unclear; they may be responding to the deposition of misfolded PrP. a
subset of PrP forms (PrP*), directly to neuronal damage or dysfunction independently of
PrP, or may be independently interacting with the TSE agent. An antibody against glial
fibrillary acid protein (GFAP) was used. In a healthy brain nascent astrocytes express
GFAP at low levels, however during the astrocytic response the number of astrocytes
increases, their morphology alters and the level of GFAP they express rises (Sofroniew,
2005). A subset of brains was selected from each experiment and the presence of an
astrocytic response was scored blind using three possible categories (no response, limited
response, extensive response). Brain sections from normal murine brain homogenate
inoculated and uninfected wild type mice were used as negative controls for astrogliosis.
Brain sections from clinical endpoint mice infected with ME7 were used as the positive
control for astrogliosis
Vacuolation positive 263K challenged G2 transgenic and normally glycosylated control
mice exhibited extensive astrocytosis throughout the brain suggesting that glycosylation
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of PrP at the second site is not required for the TSE disease activation of astrocytes
(Figure 5.10). G1 transgenic mice, in which only PrPd was observed in the absence of
vacuolation, did not exhibit detectable astrogliosis (Figure 5.10 E, F). This suggests that
either the misfolded PrP deposited in the G1 transgenic mice was of an insufficient
quantity to induce an astrocytic response or it was of a different type to that which
formed in the G2 transgenic mice. Alternatively, the absence of astrogliosis in the G1
transgenic mice may also occur independently of misfolded PrP, perhaps via a direct
effect of PrP glycosylation state on astrocytes or via a change in neuronal damage or
dysfunction. No astrocytosis was observed in G3 263K challenged transgenic mice
consistent with absence of other TSE signs in these animals (data not shown)
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Figure 5.10 Extent of astrocyte activation in glycosylation deficient
transgenic and control mice challenged with 263K
Astrogliosis in 263 K challenged mice was examined using
immunohistochemistry for GFAP. Clinical endpoint ME7 challenged
mice were used a positive control and normal brain homogenate
challenged and unchallenged mice were used to determine baseline level
of astrocyte activation in healthy brains. Extensive astrogliosis was
observed in TSE vacuolation positive normally glycosylated controls (A
and B) and G2 transgenic mice (G and H). In G1 transgenic mice (E and
F) in which limited PrPd was observed in the absence of vacuolation, the
distribution of astrocytes was comparable to that observed in uninfected
control (C and D). Scale bar 500 pm (A, C, E, G), 50 pm (B, D, F, FT).
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Figure 5.10 Extent of astrocyte activation in glycosylation deficient transgenic
and control mice challenged with 263K
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5.4.6 Results summary
These data demonstrate that the glycosylation state of host PrP greatly influences the
incidence and progression of TSE disease after cross-species transmission of 263K to
mice. However, other strain characteristics of the resultant infection do not appear to be
altered by the glycosylation state of host PrP. Moreover, the effect of glycosylation is
dependent on the site of N-glycan attachment.
- Mice expressing only un-glycosylated PrP are resistant to 263K transmission and do
not form significant PrPSc.
- Absence of the first N-glycan attachment site increases resistance to, or extends the
incubation period, of 263K but does not completely prevent the formation of misfolded
PrP in mice.
- Absence of the second N-glycan attachment site enhances the susceptibility of mice to
263K, as illustrated by the higher attack rate and decreased time to disease onset.
Additionally, the accumulation of PrPSc in vivo appears to be promoted.
- Glycosylation of host PrP does not influence the pattern of vacuolar pathology,




A number of hamster scrapie challenged mice, particularly G2 transgenic mice,
exhibited relatively severe TSE specific pathology (PrPd deposition and widespread
vacuolation) and extensive astrocytosis in the absence of any neurological signs or
significant reduction in life span. This sub or preclinical disease state is consistent with
previous reports of cross-species TSE transmissions (Hill et ah, 2000; Race et ah, 2001).
These data also support the hypothesis that the neurotoxic PrP species may not be PrPs<*
(Weissmann, 1991), given the substantial amounts tolerated in clinically unaffected
mice. Additionally, this work questions a direct link between TSE specific vacuolation
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and neuronal dysfunction as has been previously postulated (Laszlo et al., 1992).
Equally, these data may be explained by compensation of a damaged neurons function
by surrounding cells. However, as only standard clinical signs were assessed, subtle
changes in behaviour, as have been previously reported associated with the pre-clinical
TSE phase (Deacon et al., 2001; Guenther et al., 2001), may have been overlooked.
Thus the observed pathological changes may have resulted in undetected alterations in
the behaviour of infected mice.
5.5.2 Discussion of experimental results
These data demonstrate that glycosylation of PrP specifically affects the cross-species
transmission of hamster scrapie strain 263K, as indicated by an alteration in the
incidence and time to development of TSE specific pathology. However, other TSE
strain characteristics such as the pattern of vacuolar targeting and PrPd deposition are not
significantly affected by changes in the glycosylation status of PrPc. Moreover, the
influence of PrP's glycosylation state on disease is dependent upon the site of N-glycan
attachment. Glycosylation of asparagine 180 is linked to the facilitation of cross-species
transmission of 263K, as demonstrated by the reduced incidence and extent of TSE
disease observed in challenged G1 and G3 transgenic mice. In contrast, glycosylation of
asparagine 196 retards the cross-species transmission of hamster 263K to murine hosts,
but only in the presence of a glycan at the first site, as demonstrated by the higher
disease incidence in G2 transgenic mice compared to wild type murine controls and the
G3 transgenics. These data raise the question of why glycosylation of the two sites has
such dramatically different effects on 263K transmission, and why the glycosylation
state of first site modifies the importance of glycan attachment to the second.
Importantly, the facilitating effect of the absence of glycosylation of PrP 's second site
on TSE transmission appears to be limited to cross-species challenge, as G2 transgenic
mice and comparable conventional murine transgenics are not more susceptible to
murine passaged scrapie or murine passaged BSE (Neuendorf et al., 2004) (Tuzi et al, in
preparation, appendix ii). Indeed, extensive prolongation of the incubation period has
been observed in G2 transgenic mice challenged with the murine TSE strains 301C,
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ME7 and Chandler (appendix ii.). This suggests that the mechanism underlying the
inhibitory role of second site PrP glycosylation in TSE transmission is dependent upon a
species barrier specific function. However, the inhibitory effect of disrupting the first
glycosylation site, or both sites, on TSE disease is not limited to cross-species
transmissions (Tuzi et al, in preparation, appendix ii), suggesting that the observed
reduced disease incidence and the apparent extended time to disease onset in the G1 and
G3 transgenic mice may be the result of a generic effect on TSE disease.
The extent of the species barrier to 263K transmission correlates with the observed
accumulation of PrPSc in vivo, for example the TSE pathology negative G3 transgenic
mice also exhibit no significant misfolded PrP. Thus, either G3 PrPSc does not form in
vivo, or it forms but does not accumulate or is undetectable by conventional methods.
These results differ from in vitro PrPc to PrPRes conversion assay data presented by
Priola and Lawson, which showed that un-glycosylated murine PrP was more readily
converted to PrPRcs by hamster scrapie (263K) than the normally glycosylated protein
(Priola and Lawson, 2001). This discrepancy may be the result of the experimental
differences between the work presented here and the in vitro conversion assay, such as
the method of producing un-glycosylated PrP or the amino acid sequence of murine PrP
used. Alternatively this difference may be the result of an in vivo specific effect of PrP's
N-glycans on TSE disease pathogenesis and PrPSc accumulation. Further
experimentation is required to determine if the innate convertibility of G3 un-
glycosylated PrP resembles or differs from that of Priola and Lawson's construct, and
hence if the absence of PrPSc formation in the G3 transgenic mice reflects an inability of
G3 PrP to misfold (Chapter 7).
Similarly, the differences in the role of the first and second site of N-glycosylation on
the cross-species transmission of 263K to mice correlated with the accumulation of
misfolded PrP in vivo. This may be related to the differing effect of glycosylation of the
two sites on the efficiency of PrPSc formation. Computational modelling experiments
have suggested that N-glycan attachment to PrPc at the second site may enhance the
protein's conformational stability (Zuegg and Gready, 2000). Thus in the absence of
glycosylation at the second site, the energy barrier to generate the misfolded
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conformation may be reduced and hence conversion may occur more readily. This
mechanism may be specific to cross-species TSE challenge because of the unique
conformational transition of PrPSc which is proposed to underlie the species barrier
(Peretz et ah, 2002). Equally, the relative proximity of the second site to two
murine/hamster amino acid differences may underlie the observed inhibitory effect of
glycosylation at this site on the cross-species transmission of 263K to mice. Further
experimentation is required to explore the feasibility of these scenarios.
The effect of PrP glycosylation state on the accumulation of PrPSc in vivo may be
mediated by an effect on the stability of PrPSc, such that its rate of clearance in the CNS
is modified. This could occur if the sensitivity of the N-glycan deficient forms to
enzymatic digestion was directly changed or if they are differently targeted for
clearance. The absence of glycosylation of the second site does not appear to alter the
conformation of PrPSc, as assayed by PK digestion. However, the effect of the absence
of glycosylation at the first or both sites on the conformation of misfolded PrP unknown
since no detectable PrPSc formed in either the G1 or G3 transgenic mice. A change in
conformation may affect the stability of PrPSc, as has been experimentally suggested for
different TSE strains (Safar et ah, 1998), and hence its ability to accumulate in vivo.
The glycosylation state of PrPSc may equally affect the protein's ability to aggregate that
could result in a change in its in vivo stability. All these possible effects could feasibly
result as a direct effect on the behaviour of an individual PrP molecule or via higher
order interactions between PrP and itself or other cellular components.
Alternatively, the difference between the in vitro and in vivo data may reflect a TSE
specific role of the glycosylation state of PrP independent of its TSE disease associated
misfolding. This putative function may either be upstream of the in vivo formation of
PrPSc, or it may act in addition to a change in convertibility. Glycosylation of PrPc may
influence the turnover or trafficking of the protein, despite the comparable steady state
of the PrP in the CNS in the PrP glycosylation deficient transgenic and normally
glycosylated mice (Chapter 3). These factors could directly affect the ability of PrP to
play its essential role in TSE pathogenesis. Equally they may affect the subcellular
distribution of PrPc in the murine PrP glycosylation deficient transgenics, as has been
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previously demonstrated in other systems (DeArmond et al., 1993; Neuendorf et al.,
2004). Cellular localisation of PrPc has been suggested as important to both PrP
misfolding and TSE pathogenesis (Chesebro et al., 2005; Taraboulos et al., 1995; Trifilo
et al., 2006). The localisation of PrPc may be altered in the G3 PrP glycosylation
deficient transgenics (Chapter 4) and this may contribute to the resistance of these mice
to cross-species TSE transmission.
Transgenic mice which express PrP that lacks the GPI anchor also do not develop
classical TSE disease, but do form PrPSc after TSE challenge (Chesebro et al., 2005;
Trifilo et al., 2006). The PrP in this transgenic model is also not fully glycosylated,
presumably because of the known requirement for a specific distance between the N-
glycan attachment site and PrP's C-terminus (Walmsley and Hooper, 2003). The
formation of PrPSc in the GPI anchor deficient transgenic mice suggests that the
mechanisms underlying TSE disease resistance differ between the PrP glycosylation and
GPI anchor deficient transgenic mice. Enhanced resistance to cross-species transmission
is also caused by the endogenous expression of murine PrP in over-expressing hamster
PrPc transgenic mice (Telling et al., 1994; Telling et al., 1995). The authors of this
paper suggested that this result occurred because of a requirement for a species specific
PrP conversion factor, which they postulate interacts with an area of the C-terminus of
PrP that is not normally shielded by the protein's N-glycans (Telling et al., 1995). Thus
interactions with this proposed factor would be anticipated to be equivalent in the G1
and G3 murine transgenics to those in wild type mice, although interaction of conversion
factors with other regions of PrP may be affected by the absence of glycosylation of the
protein in the transgenic mice.
Alternatively, the results of Telling and colleagues can be explained by heterologous PrP
conversion interference, as has been observed in vitro systems (Horiuchi et al., 2000).
Similarly, heterozygosity for PrP polymorphisms is linked to enhanced resistance to
TSE transmission (reduced disease incidence and increased incubation periods) (Barron
et al., 2005; Collinge et al., 2006). The G1 and G3 transgenic mice used in these
experiments were homozygous for the introduced changes in the first and second glycan
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attachment site and thus heterologous interference would not have contributed to the
observed changes in cross-species transmission.
These data demonstrate that the absence of glycosylation of PrP at the first or both N-
glycan attachment sites greatly reduces the formation of PrPSc and prevents the
development of TSE disease after cross-species challenge with hamster scrapie strain
263K. Replication of TSE infectivity in the absence of detectable PrPSc or the
development of TSE pathology has been previously observed (Barron et ah, 2001; Hill
et ah, 2000; Lasmezas et ah, 1997; Race et ah, 2001). Thus, subpassage of material
from TSE challenged G3 and G1 transgenic mice into the G3 mice, G1 mice, wild type
mice and hamsters is required to experimentally assess whether the complete lack of
PrP's N-glycans prevents the replication of TSE infectivity in addition to its influence on
PrP misfolding and development of TSE disease.
In conclusion these data demonstrate that the glycosylation state of murine PrP can have
a dramatic influence on disease incidence and time to disease onset after challenge
across a species barrier with hamster scrapie strain 263K. The effect of PrP 's N-
glycans on the rate of disease progression occurs in the absence of an alteration of other
strain characteristics. Further experimentation is required to determine the mechanism
by which this modification of transmission occurs and if PrP's glycosylation state also
affects transmission of other TSE strains between species.
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6.0 TSE strain and the effect of glycosylation of PrPc on cross-species
transmission
6.1 Aim To determine if the proposed role of PrP's N-glycans in the TSE species
barrier is dependent upon TSE strain.
6.2 Introduction and experimental method
Data presented in Chapter 5 demonstrates that the N-linked glycosylation of PrP has
a major influence on the transmission of hamster scrapie, strain 263K to mice. In
particular, glycosylation of asparagine 180 enhances the cross-species transmission of
263K, whilst N-glycan attachment to asparagine 196 hindered it. Thus the
glycosylation state of host PrPc modulates the ability of a TSE agent to elicit disease
in a novel host species. Previous host factors that influence the cross-species
transmission of TSE disease, such as PrP amino acid sequence, have exhibited TSE
strain dependence (Manson et al., 1999; Prusiner et al., 1990). Additionally the effect
of PrP's glycosylation state on within species transmission is also affected by TSE
strain (DeArmond et al., 1997; Neuendorf et al., 2004; Tuzi et al., in preparation)
(appendix ii). Thus the effect of N-glycan attachment to PrP on cross-species
transmission may be similarly influenced by TSE strain.
The potential strain dependence of the role of PrP's N-glycans in the TSE species
barrier may be mediated by a number of mechanisms. Experimental work has
suggested that the extent of the species barrier may reflect the conformational
compatibility between host PrPc and donor PrPSc, which will be unique for each
strain/host combination (Peretz et al., 2002). This model suggests that the ability of
PrPc from a host species to adopt the misfolded conformation of the challenging TSE
strain determines the extent of the species barrier. Thus host factors that influence the
conformational flexibility of PrPc and its ability to misfold may be particularly
important to the species barrier. Equally the specific PrPc glycotypes required for
efficient transmission may vary between different strains, as the glycoform of PrPSc
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has been reported to reproducibly correlate with strain (Collinge et al., 1996; Parchi et
ah, 1996). Moreover other strain specific factors, such as the cells targeted during
disease or the method of cell to cell spread of infectivity may also be differentially
p m p
influenced by the glycosylation state of PrP . Hence the glycosylation state of PrP
may also influence the barrier, independent of an effect on the accumulation of PrPSc.
The role of N-glycans in the TSE species barrier may depend upon the relatedness of
host and donor of infectivity. In particular, the degree of amino acid sequence
homology between the two species may determine the relative importance of N-
glycosylation to cross-species transmission. Alternatively the degree of the barrier to
cross-species transmission may also modify the importance of N-glycans.
Additionally, recent work has suggested that the combination of N-glycans attached
to PrPSc differs between host species (Xanthopoulos et al., 2006). This may reflect an
adaptation of the TSE agent to the N-glycans of a particular host, which may also
contribute to a specific effect of glycosylation on cross-species transmission.
To investigate if TSE strain influences the role of glycosylation of PrP in the TSE
species barrier, PrP glycosylation deficient murine transgenics [NPU] and normally
glycosylated mice (CL) were independently challenged with two human TSE sources,
variant CJD and sporadic CJD MM-cortical (type 2). Comparison of these data with
that presented in chapter 5 will provide further insight into the importance of TSE
donor species and strain. The patients from which the variant CJD and sporadic CJD
(MM type 2) TSE sources were derived were methionine homozygote at PrP codon
129 and did not carry other changes in their PrP amino acid sequences. Additionally,
the size of PK resistant un-glycosylated PrPSc is not distinguishable between these
patients, suggesting that the conformation of PrPSc may be similar in these two
diseases. Despite having an identical PrP amino acid sequence and PK resistant core
size, variant and sporadic CJD (MM type 2) markedly differ in a number of aspects,
most notably their clinical and neuropathological features, the glycoform of PrPSc and
their transmissibility to new hosts differs (Brown et al., 1997; Collinge et al., 1996;
Ironside et al., 2000; Parchi et al., 1999; Will et al., 1996) (Table 6.1).
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Table 6.1 Variant and Sporadic CJD Summary Table (based upon data
presented in (Bruce et al., 1997; Ironside et al., 2000; Parchi et al., 1999; Will et
al., 1996)
Strain/Isolate Variant CJD Sporadic CJD MM-cortical
(type 2)





associated with myoclonus &
pyramidal signs
Neuropathology Severe spongiform change
(caudate nucleus & putamen)
absent in the hippocampus
PrP deposited in florid plaques
(cerebral and cerebellar
cortex) & wide spread
pericellular deposition
Coarse spongiosis (cerebral
cortex & thalamus) absent in




PrP codon 129 methionine/methionine methionine/methionine
Glycoform
of PrPSc







The TSE agent which causes variant CJD and the related disorders of BSE and FSE is
unusually transmissible to other host species, including to a number of strains of wild
type mice (Bruce et al., 1997). Clinical disease is observed in a relatively high
proportion of challenged 129/Ola mice and onset is observed from around 400 days
after intra-cerebral (ic) inoculation of a 10~2 homogenate. The characteristics of vCJD
are generally very stable upon passage through novel host species, suggesting it is
able to invade a range of hosts without undergoing significant adaptation (Bruce et
al., 1997). Consistent with this is the observation of the maintenance of the PrPSc
glycoform (predominantly di-glycosylated) after passage in new host species
(Collinge et al., 1996; Hill et al., 1997a). However, the molecular mechanisms that
permit the wide host range of this TSE strain are not well understood. In contrast,
sporadic CJD MM-cortical (type 2) is relatively untransmissible to wild type or
humanized transgenic mice (Korth et al., 2003; Taguchi et al., 2003) (Personal
communication, Professor Moira Bruce and Mr. Matthew Bishop). Thus a classical
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species barrier to the transmission of sporadic CJD (MM type 2) to mice is observed;
where as the murine barrier to variant CJD transmission appears far weaker.
Both variant and sporadic (MM type 2) CJD generally exhibit a relatively long
clinical phase that is in excess of one year. However, on average variant CJD patients
are far younger than those with sporadic CJD (MM) type 2 (Parchi et al., 1999; Will
et al., 1996). The clinical features and neuropathology also differ between the two
diseases, although the age distribution of the two patients groups may also contribute
to the observed variation in the pattern and progress of disease. The distribution and
pattern of PrPSc deposition also varies between the two conditions (Ironside et al.,
2000; Parchi et al., 1999). This difference suggests that the conformation of PrPSc
may also differ, consistent with the radically different PrPSc glycoform observed in
variant and sporadic CJD (MM type 2) patients (Figure 6.1). Despite these diseases
occurring in individuals with identical PrP amino acid sequences, they have
dramatically different phenotypes and are likely to be caused by different TSE strains.
Thus by transmitting these two TSE sources to the PrP glycosylation deficient
transgenic and control mice, the importance of TSE strain to the role of PrP's N-
glycans in the TSE species barrier can be specifically investigated. Furthermore, as
the PrPSc from both TSE sources differ from murine PrPc at the same twenty-seven
amino acids, these experiments will be independent of the known effect of PrPc/PrPSc
amino acid sequence homology on the barrier.
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Figure 6.1 Variant CJD and sporadic CJD MM type 2 differ in PrPSc glycoform
but not size of the un-glycosylated band
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Western blots of PrPSc isolated from sporadic and variant CJD patients
by limited PK digest (50 pg/ml 1 hour 37 °C) (A, all lanes but 2, and B,
all lanes but 2 and 9). PrPSc type 1 (un-glycosylated PrPSc
approximately 19 kDa) and type 2 (un-glycosylated PrPSc
approximately 21 kDa) reference samples were used to determine the
electrophoretic mobility of PrPSc found in (A) variant CJD NIBSC
remainder inocula (lane 4 and 7) and (B) sporadic CJD type 2
remainder inocula (lane 5). Both samples have type 2,
un-glycosylated, PrPSc. The PrPSc glycoform differs between variant
and spordic CJD MM type 2. PrPSo from the variant CJD patient is
predominately di-glycosylated and PrPSc from the sporadic CJD
patient is predominately mono-glycosylated. The sporadic CJD
sample was concentrated ten-fold compared to references samples,
by high speed centrifugation. PrP detected with anti-PrP specific
antibodies 6H4 (A, lanes 1-5, and B) and 3F4, (B, lanes 6-9).
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The WHO reference vCJD isolate supplied by National Institute of Biological
Standards as a 10 % homogenate was used as the source of vCJD challenge material
(Minor et ah, 2004). This isolate has full ethical approval for research. The sporadic
CJD isolate used was kindly provided by Professor Ironside, The National CJD
Surveillance Unit, Edinburgh, and also has research use ethical approval. The NIBSC
sporadic CJD reference cases are unsuitable for this study because of their mixed
PrPSc type, which may represent the coexistence of multiple TSE strains that would
compound the study presented here (Minor et al., 2004). The sporadic CJD MM type
2 sample selected has been previously studied on multiple occasions and had been
shown to only contain type 2 PrPSc of predominate mono-glycosylated glycotype
(personal communication, Dr. Mark Head). This was reconfirmed experimentally for
the frontal cortex sample used in these transmission experiments (Figure 6.1).
Previous transmission of the NIBSC vCJD isolate to mice by inter-cerebral (ic)
inoculation at the concentration supplied, lead to ethically unacceptable levels of
injection related deaths (personal communication Irene McConnell). This may be
linked to the previously reported bacterial bioburden of 200-600 colony forming
units/ml in the NIBSC sources (Minor et al., 2004). A further ten-fold dilution of the
inoculum was required to remediate this toxicity problem. The sporadic CJD isolate
was likewise inoculated as a 1 % homogenate so that the two human transmissions
would be directly comparable. Full ethical approval for the use of the experimental
animals was granted by the local review panel.
6.3 Experimental results
6.3.1 TSE incubation periods and incidence of disease
Aged and sex matched PrP glycosylation deficient transgenic [NPU] and normally
glycosylated control line (CL) mice were challenged by intracerebral (ic) injection
with 20 pi of TSE source infected brain homogenate (1 %) and monitored for the
development of TSE clinical disease (Chapter 2 and 5). Only challenged animals that
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exhibited clinical signs and TSE vacuolar pathology were classified as confirmed
TSE clinical cases, as other non-TSE conditions may lead to the development of
neurological signs. All challenged animals were examined for TSE specific
vacuolation and the deposition of misfolded PrP within the brain.
Table 6.2 Summary of the outcome of cross-species transmissions to the PrP
glycosylation deficient transgenic mice
TSE Genotype
TSE Disease status




CL 18 0 If 0
Sporadic CJD
type 2
G3 17 0 0 0
Sporadic CJD
type 2
G2 5 2 6 7
(404 +/- 7.8)
Variant CJD CL 2 10 2 9
(491+/-24.5)
Variant CJD G3 22 0 0 0
Variant CJD G2 9 8* 0 5
(536 +/- 16.3)
TSE disease status key (Corresponds to data presented in Figure 6.2)
0, negative for signs of TSE disease (PrPd deposition, vacuolation, clinical signs)
1, only positive for PrPd deposition
* In these experiments, in one animal, PrPd was limited to a plaque in the corpus collosum
2, positive for both PrPd deposition and TSE specific vacuolation
tNo PrPd was visible in the brain of this animal.
3, confirmed TSE clinical case (clinical signs and vacuolation)
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6.3.1.1 Sporadic CJD
Sporadic CJD MM type 2 did not appear to transmit to normally glycosylated (CL)
mice. Animals were observed for 707 days after challenge and none displayed TSE
clinical signs (Table 6.2, Figure 6.2 A). Limited TSE specific vacuolation in the
thalamus was observed in one sporadic CJD challenged normally glycosylated
control, however PrPd deposition was not observed in this or any other normally
glycosylated control. These results are consistent with previous findings that have
shown this TSE source is poorly transmitted to wildtype and transgenic mice (Korth
et al., 2003; Taguchi et al., 2003) (Personal communications Mr. Matthew Bishop and
Professor Moira Bruce).
No sporadic CJD challenged G3 transgenic mice developed clinical signs, TSE
vacuolar pathology or PrPd deposition during 707 days of observation post
inoculation (d.p.i.). Survival of CL sporadic CJD challenged mice and G3 transgenic
mice was comparable (Figure 6.2 C). Thus, the complete absence of PrP's N-glycans
does not appear to reduce the resistance of mice to sporadic CJD challenge or reduce
the incubation period of disease.
In contrast, the absence of glycosylation at the second site only (G2) permitted the
development of clinical TSE disease after sporadic CJD challenge (Figure 6.2 A).
Seven of the G2 challenged mice developed clinical TSE (mean 404 d.p.i., +/- 7.8
days (SEM)). Fourteen of the twenty-four challenged G2 mice survived until the first
clinical case. Thus the incidence of sporadic CJD transmission at 10" dilution was 50
% (7/14). Three of these G2 mice were found dead, unexpectedly soon after
exhibiting clinical symptoms. Additionally, a further seven sporadic CJD challenged
G2 animals with no definite signs of TSE clinical disease were also found dead. TSE
vacuolar pathology and PrPd was detected in five of these animals and PrPd in the
absence of vacuolation was observed in the sixth. Therefore these animals may have
died of undetected TSE disease. Thus the G2 transgenic mice may have hi gher
susceptibility to sporadic CJD than was experimentally observed. Elowever, animals
were also found dead in genotypes of mice that were resistant to TSE challenge.
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Figure 6.2 TSE status and survival-time of challenged animals
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The TSE disease status (clinical signs, vacuolar pathology and PrPd deposi¬
tion +/-) of G1, G2, G3 transgenic and normally glycosylated control (CL )
mice after challenge with (A) sporadic CJD MM type 2 or (B) variant CJD
was plotted against the number of days post inoculation at which the animal
was euthanized. The incidence of TSE disease after challenge with sporadic
CJD was significantly higher in G2 transgenic mice than in control mice (p <
0.001). The incidence of disease after challenge with vCJD was signifi¬
cantly lower in G2 (p = 0.032) and G3 (p < 0.001) transgenic mice than in
controls. Percentage of animals surviving after challenge with (C) sporadic
CJD MM type 2 or (D) variant CJD was plotted against the number of days
since TSE challenge .
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Thus it is only possible to speculate that the G2 transgenics that did not exhibit overt
TSE clinical signs, died as a result of their TSE pathology.
A number of sporadic CJD challenged G2 animals, including three animals which
survived for more that 650 days post inoculation, did not exhibit clinical disease,
vacuolar pathology or PrPd deposition. Although the barrier to the cross-species
transmission of sporadic CJD to mice was greatly reduced by the absence of
glycosylation of PrP's second site, the incidence of disease was not 100 % indicating
that the species barrier was not completely eliminated. Subpassage of sporadic CJD
affected G2 transgenic mice into G2 transgenic and normally glycosylated, wild type
mice are being undertaken to determine the extent of the species barrier (6.4.8).
6.3.1.2 Variant CJD
TSE clinical disease signs was observed in nine of the twenty-three vCJD challenged
normally glycosylated controls (CL) between 386 and 616 d.p.i. with a mean
incubation period of 491 days (+/- 24.5 days SEM) (Table 6.2, Figure 6.2 B). Two of
the control mice died prior to the first clinical case thus the CL disease incidence was
43 % (9/21) for a 10"2 vCJD challenge. This moderate disease incidence and the high
variance in incubation period are attributable to the murine species barrier to infection
with a human TSE agent and are consistent with previous reports. Two additional CL
transgenic mice had TSE specific vacuolation in the brain but did not show clinical
signs. In both cases the vacuolation was less dense and extensive than that observed
in brain sections from clinical end point mice. This suggests that had these mice lived
they may have gone on to develop clinical signs (data not shown). In ten of the vCJD
challenged mice PrPd deposition was observed in the absence of significant vacuolar
pathology.
Both the G2 and G3 transgenic mice had a lower disease incidence or longer
incubation period after vCJD challenge than the CL mice (Figure 6.2 B, Figure 6.2 D)
(G2 versus CL control Chi-sq = 6.908, df = 2, p = 0.032; G3 versus CL control Chi-sq
= 37.663, df = 2, p < 0.001). No vCJD challenged G3 mice exhibited signs of TSE
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clinical disease, nor was vacuolation or PrPd deposition seen in brain sections from
r<
these mice. Thus glycosylation of host PrP is required for the successful cross-
species transmission of vCJD from humans to mice. There were only five clinical
cases in the twenty-two G2 transgenic mice challenged with vCJD. Sixteen of the
total twenty-two challenged mice survived after the first clinical case, givin g an
disease incidence of 31 % (5/16). The mean incubation period in the G2 transgenic
mice (536 days +/- 16.3 (SEM)) after vCJD challenge was 45 days longer than that
observed in the CL mice. However, this difference in incubation period is not
statistically significant. In addition to the clinically sick G2 transgenic mice a further
eight G2 animals exhibited PrPSc deposition in the absence of vacuolar pathology.
In summary, thirteen of the twenty-two vCJD challenged G2 transgenic mice
exhibited evidence of TSE disease, in contrast to twenty-one of the twenty-three
vCJD challenged normally glycosylated controls. Therefore the G2 transgenics
which lack the second glycosylation site have a lower disease incidence after vCJD ic
inoculation than normally glycosylated controls. This suggests that glycosylation of
PrP at the second site facilitates the cross-species transmission of vCJD, in contrast
to its inhibitory effect on the transmission of 263K and sporadic CJD to mice. Thus
the role of the second glycosylation site in cross-species TSE transmission is
dependent upon TSE strain.
6.3.2 The pattern of TSE vacuolar pathology
To examine if the change in disease incidence and incubation period observed in the
G2 transgenic mice compared with the CL mice after cross-species TSE challenge,
was linked to an alteration of other disease characteristics, the pattern of TSE
vacuolar pathology was investigated. The brains of clinically sick animals challenged
with variant and sporadic CJD (MM type 2), were analysed, blind to mouse genotype
and TSE agent, for the extent and distribution of vacuolation by standard methods
(Fraser and Dickinson, 1967; Fraser and Dickinson, 1968) (2.7.6). The mean results
were compared between the normally glycosylated control (CL) and G2 transgenic
mice.
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6.3.2.1 Sporadic CJD MM type 2
TSE vacuolar pathology was relatively evenly spread through-out the brains of
sporadic CJD challenged G2 transgenic mice and was of a relatively low intensity
(Figure 6.3). Some targeting to the superior colliculus and the hippocampus was
observed (Figure 6.3 A, B, C). The posterior brain areas such as the dorsal medulla
(1) and cerebellar cortex (2) were relatively spared and little vacuolation was
observed in the hypothalamus (4). Vacuolation in the cerebral cortex (8 and 9) was
unusually coarse (large vacuole size) and was predominately localised in the inner
layers. Cortical vacuolation was associated within regions in which deposition of
plaques was also observed, although direct association of plaques and vacuoles, i.e.
florid plaques, was not apparent (Figure 6.3 D and E).
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Figure 6.3 Lesion profile and examples of vacuolar pathology in sporadic CJD
challenged G2 transgenic mice at clinical endpoint
A 5
The pattern of TSE specific vacuolar pathology in G2, G3 transgenic and normally
glycosylated control (CL) mice after sporadic CJD MM type 2 challenge was
semi-quantatively scored, blind to genotype and TSE agent, on a scale of 0-5 in nine
grey areas (1 dorsal medulla; 2 cerebellar cortex; 3 superior colliculus; 4
hypothalamus; 5 thalamus; 6 hippocampus; 7 septum; 8 retrosplenial and adjacent
motor cortex; 9 cingulate and adjacent motor cortex) and three white matter areas of
the brain (1* inferior and middle cerebellar peduncles; 2* decussation of the superior
cerebellar peduncles; 3* cerebral peduncles). The experiment was then decoded and
a lesion profile of the mean vacuolation score for G2 transgenic mice that developed
clinical TSE disease was plotted (A). Error bars indicate standard error of the mean.
B-E) Examples of haematoxylin and eosin stained brain sections showing TSE
vacuolar pathology in the superior colliculus (B), hippocampus (C) and cerebral
cortex (D & E) of G2 transgenic mice. Scale bar 50 pm (B-E).
6.3.2.2 Variant CJD
The targeting and density of vacuolar pathology at clinical endpoint was similar in
vCJD challenged G2 and CL transgenic mice, and to previous reports (Figure 6.4 A)
(Barron et ah, 2001; Bruce et ah, 1997). Vacuolation was particularly targeted to the
dorsal medulla (1) and the hypothalamus (4) in both genotypes; whereas the superior
colliculus (3), the hippocampus (6) and the cerebral cortex (8 and 9) were not
significantly vacuolated (Figure 6.4 A-E). Vacuolation targeted to the cochlear
nucleus was observed in both G2 and CL mice (data not shown), as has been
previously reported for PrP373 mice challenged with the analogous source BSE
(Brown et ah, 2003). However, it was not possible to examine this nucleus in a
number of animals because of damage to the area or sections at the correct level not
being available. Despite decreasing the disease incidence after vCJD challenge,
absence of glycosylation at PrPc's second N-glycan attachment site does not appear
to alter the pattern of targeting or intensity of vacuolation at clinical endpoint. This
suggests that the TSE strain was not altered by the absence of PrP's second
glycosylation site.
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Figure 6.4 Lesion profile and examples of vacuolar pathology in vCJD
challenged G2 transgenic and control mice at clinical endpoint
A
Scoring Area of Brain
The pattern of TSE specific vacuolar pathology in G2, G3 transgenic and normally
glycosylated control (CL) mice after vCJD challenge was semi-quantatively
scored, blind to mice genotype and TSE agent, on a scale of 0-5 in nine grey areas
(1 dorsal medulla; 2 cerebellar cortex; 3 superior colliculus; 4 hypothalamus; 5
thalamus; 6 hippocampus; 7 septum; 8 retrosplenial and adjacent motor cortex; 9
cingulate and adjacent motor) and three white matter areas of the brain (1* inferior
and middle cerebellar peduncles; 2* decussation of the superior cerebellar
peduncles; 3* cerebral peduncles). The experiment was decoded and a lesion
profile of the mean vacuolation score observed in animals with clinical TSE
disease was plotted by mouse genotype (A). Error bars indicate standard error of
the mean. This demonstrates that the pattern and density of vacuolar targeting in
G2 transgenic and CL control mice challenged with vCJD are indistinguishable.
Examples of haematoxylin and eosin stained brain sections showing vacuolar
pathology in the medulla (B & D) and hypothalamus (C & E), of normally
glycosylated (B & C) and G2 transgenics (D & E). Scale-bar 50 pm (B-E).
6.3.3 The pattern of TSE associated PrP deposition in the CNS
To investigate if the glycosylation state of PrP affected the deposition of misfolded
PrP in the CNS after cross-species TSE challenge with variant or sporadic CJD, brain
sections from all TSE challenged animals were examined blind for disease associated
PrP (PrPd) at five defined levels (Chapter 2). PrP was detected using anti-PrP
antibody 6H4. Normal brain inoculated PrP373 mice and PrP null mice [NPU] were
used as negative controls, using the CSA method (Chapter 2 and 5). Sections from a
subset of the brains were independently stained using the anti-PrP antibody 8H4, to
determine whether the results were antibody dependent. Antibody concentrations
were determined by titration (appendix vii-x).
6.3.3.1 Sporadic CJD type 2
PrPd deposition in G2 mice challenged with type 2 sporadic CJD exhibited a distinct
pattern, which was similar for both 6H4 and 8H4 stained sections, although
significantly higher non-specific background staining was observed with 8H4 (Figure
6.5 i and ii). Aggregated PrPd deposition was observed in the thalamus in all G2
animals in which PrPd was detected. Additionally, multicentric plaque-like deposits
were observed in the cerebral cortex in the majority of PrPd positive animals and in
the hippocampus in some G2 mice (Figure 6.5). A similar pattern of deposition was
observed in all PrPd positive sporadic CJD challenged G2 transgenic mice, whether or
not clinical signs or vacuolation were apparent. Extensive deposition was observed
even at early time points (data not shown).
The plaque-like deposits in sporadic CJD challenged G2 mice interacted weakly with
thioflavin-s compared to the plaques observed in G2 animals that were challenged
with 263K (Figure 6.6). This suggests that the plaques which formed in G2 mice
affected with sporadic CJD did not contain significant amounts of amyloid. Limited
synaptic PrPd deposition was also observed in G2 sporadic CJD challenged brains in
association with these plaque-like deposits (Figure 6.5 i F).
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Figure 6.5 (i, ii) PrPd deposition was observed in G2 transgenic mice
after challenge with sporadic CJD MM type 2. The deposition of PrPd
was examined in G2 transgenic mice challenged with sporadic CJD MM
type 2, at five defined brain levels of which four are shown here (A)
medulla and cerebellum, (C) midbrain including superior collicullus,
cerebral cortex and hippocampal formation, (E hippocampus, habenula,
thalamus, hypothalamus, cerebral cortex and corpus callosum, (G)
forebrain including corpus callosum and septum. Aggregated PrPd
deposition was detected in the thalamus (Th) and multicentric plaques
were observed throughout the cerebral cortex (A and C); after wet
autoclaving and formic acid treatment using anti-PrP antibody 6H4 (i) or
8H4 (ii); signal was amplified using a CSA kit and visualised with DAB,
nuclei were counter stained with haematoxylin. Upper boxed area in C
corresponds with A, lower boxed area in C with D, upper boxed area in E
with F and the lower boxed area in E with H. Specificity of signal was
determined using negative control sections from a PrP null [NPU] mouse
and a normal brain homogenate challenged normally glycosylated control
mouse (I). Sections shown are from one G2 transgenic mouse (A-H).
Scale-bar 500 pm (A, C, E, G) and 25 pm (B, D, F, H).
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Figure 6.5(i) PrPd deposition was observed in G2 transgenic mice after
challenge with sporadic CJD (MM type 2) (6H4)
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Figure 6.5(ii) PrPd deposition was observed in G2 transgenic mice after





Figure 6.6 PrPd plaque like deposits in G2 transgenic mice after sporadic
CJD challenge did not interact strongly with thioflavin-s













Multicentric PrPd plaque-like deposits in the cerebral cortex (A, C), were
detected with anti-PrP antibody 6H4 in brain sections subjected to formic acid
and wet autoclaving, in G2 transgenic mice (results from two individual mice
shown) that were challenged with sporadic CJD. To determine if these
deposits contained amyloid, serial sections were treated with thioflavin-s. G2
transgenic mice that were challenged with 263K and contained amyloid
plaques were used as a positve control (Figure 5.6). The PrPd deposits in the
sporadic CJD challeged mice did not strongly interact with thioflavin-s (B, D).
Scale-bar 35 pm.
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No PrPd deposition was observed in either CL normally glycosylated
control or G3 transgenic mice challenged with sporadic CJD (Figure 6.7,
6.8).
Figure 6.7 PrPd deposition was not observed in normally glycosylated
control mice challenged with sporadic CJD The deposition of PrPd was
examined in normally glycosylated controls challenged with sporadic CJD
MM type 2, at five defined brain levels of which four are shown here (A &
E) medulla and cerebellum, (B & F) midbrain including superior
collicullus (B), cerebral cortex and hippocampal formation, (C & G)
hippocampus, habenula, thalamus, hypothalamus cerebral cortex and
corpus callosum, (D & H) forebrain including corpus callosum and
septum. PrPd deposition was not detected even after PrP antigen retrieval
by wet autoclaving and formic acid treatment using anti-PrP antibodies
6H4 (A-D) or 8H4 (E-H), anti-PrP signal was amplified using a CSA kit
and visualised with DAB, nuclei were counter stained with haematoxylin.
Sections shown are from one normally glycosylated control mouse (CL).
A sporadic CJD challenged G2 transgenic mouse was used as a PrPd
positive control (figure 6.5 i and ii). Scale bar 500 pm.
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Figure 6.7 PrPd deposition was not observed in normally glycosylated control
mice challenged with sporadic CJD
A B
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Figure 6.8 PrPd deposition was not observed in G3 transgenic mice
challenged with sporadic CJD MM type 2. The deposition of PrPd was
examined in G3 transgenic mice challenged with sporadic CJD MM type
2, at five defined brain levels of which four are shown here (A & E)
medulla and cerebellum, (B & F) midbrain including superior collicullus
(B), cerebral cortex and hippocampal formation, (C & G) hippocampus,
habenula, thalamus, hypothalamus cerebral cortex and corpus callosum,
(D & H) forebrain including corpus callosum and septum. PrPd deposition
was not detected when PrP antigen retrieval, by wet autoclaving and
formic acid treatment, using anti-PrP antibodies 6H4 (A-D) or 8H4 (E-H).
Anti-PrP signal was amplified using a CSA kit and visualised with DAB,
nuclei were counter stained with haematoxylin. Sections shown are from
one G3 transgenic mouse. A sporadic CJD challenged G2 transgenic was
used as a PrPd positive control (figure 6.5 i and ii). Scale bar 500 pm.
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Figure 6.8 PrPd deposition was not observed in G3 transgenic mice
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6.3.3.2 Variant CJD
The pattern of disease associated PrPd deposition in the variant CJD inoculated
normally glycosylated controls (CL) at clinical endpoint was similar to that
previously reported in 129/Ola wild type mice using both anti-PrP monoclonals
(Figure 6 .9 and 6.10) (Barron et ah, 2001). Extensive synaptic type deposition
throughout the thalamus, hypothalamus, pons and medulla, with particular targeting
to the habenula, weaker synaptic type deposition in the forebrain and the hallmark
targeting to the neuropil of the CA2 hippocampal cell layer was observed.
Additionally, animals with the heaviest PrPd deposition also exhibited limited
synaptic type deposition in the cortex; no plaques were observed (Figure 6.9 E). PrPd
deposition in pre/subclinical CL controls was in general less extensive but of a similar
pattern compared to that observed at clinical endpoint (data not shown). Earliest
deposition occurred in the habenula and the ventral midbrain (data not shown).
In contrast, the pattern of PrPd in clinical end point G2 glycosylation deficient
transgenic mice was markedly different from that in normally glycosylated controls,
as detected both by 8H4 and 6H4 (Figure 6.10, Figure 6.11). Extensive small focal
deposits were seen throughout the pons, medulla, thalamus, septum and
hypothalamus, and occasionally in the cortex. Additionally to the presence of focal
deposits, clinical endpoint G2 mice exhibited lighter and less extensive synaptic type
deposition than control mice in the hypothalamus, the thalamus, and occasionally the
medulla and pons. Significantly, targeted PrPd deposition in the CA2 associated
neuropil was completely absent in all clinical endpoint G2 cases. The pattern of PrPd
was generally similar in the TSE vacuolation negative animals, although often it was
far less extensive. In several G2 transgenic mice deposition was only observed in the
habenula. Overall these data demonstrate that the absence of glycosylation of PrP at
the second attachment site can modify the pattern of PrPd accumulation in vivo.
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Figure 6.9 PrPd deposition was observed in normally glycosylated
control mice challenged with variant CJD. The deposition of PrPd was
examined in normally glycosylated controls challenged with variant CJD,
at five defined brain levels of which four are shown here (A) medulla and
cerebellum, (C) midbrain including superior collicullus, cerebral cortex
and hippocampal formation, (E) hippocampus, habenula, thalamus,
hypothalamus cerebral cortex and corpus callosum, (G) forebrain
including corpus callosum (cc) and septum (Sp). Synaptic-like PrPd
deposition was detected in the medulla, pons (data not shown), habenula
(Hb), ventral midbrain, hypothalamus (Hy), thalamus (Th) and CA2
region of the hippocampus (Hb); after wet autoclaving and formic acid
treatment using anti-PrP antibody 6H4, signal was amplified using a CSA
kit and visualised with DAB, nuclei were counter stained with
haematoxylin. Boxed areas in A corresponds with B, C with D, E with F
and G with H. Sections (A,B E-H) are from one normally glycosylated
control mouse (CL) and sections (C and D) from another CL animal. Both
CL animals were sacrificed at TSE clinical endpoint and exhibited
vacuolar pathology. Specificity of signal was determined using negative
control sections from a PrP null [NPU] mouse and a normal brain
homogenate challenged normally glycosylated control mouse (I). Scale
bar 500 pm (A, C, E, G) and 50 pm (B, D, F, H).
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Figure 6.9 PrPd deposition was observed in normally glycosylated control
mice challenged with variant CJD
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Figure 6.10 PrPd deposition pattern observed in G2 transgenic mice
challenged with variant CJD. PrPd deposition in G2 transgenic was
examined at five defined brain levels of which four are shown here (A)
medulla and cerebellum, (C) midbrain including superior collicullus,
cerebral cortex and hippocampal formation, (E) hippocampus, habenula,
thalamus, hypothalamus cerebral cortex and corpus callosum, (G)
forebrain including corpus callosum and septum. Focal PrPd deposits
were detected in the medulla, pons, ventral midbrain, hypothalamus,
thalamus and septum. Light synaptic-type deposition was observed in the
medulla, ventral midbrain, hypothalamus (Hy) and septum (Sp).
Deposition of PrPd in the habenula (Hb) of G2 transgenic mice was
indistinguishable from that observed in normally glycosylated controls.
PrP was detected after antigen retrieval by wet autoclaving and formic
acid treatment using anti-PrP antibody 6H4, signal was amplified using a
CSA kit and visualised with DAB, nuclei were counter stained with
haematoxylin. The boxed area in A corresponds with B, C with D, E with
F and G with H. All sections shown are from a single G2 transgenic that
was sacrificed with clinical TSE disease and exhibited vacuolar pathology.
Specificity of signal was determined using brain sections from a PrP null
[NPU] mouse and a normal brain homogenate challenged mouse (I).
Scale-bar 500 pm (A, C, E, G) and 50 pm (B, D, F, H).
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Figure 6.10 PrPd deposition pattern observed in G2 transgenic mice
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Figure 6.11 The PrPd deposition pattern observed in G2 transgenic
and control mice after variant CJD challenge did not depend on anti-
PrP antibody PrPd deposition was examined at five defined brain levels
of which four are shown here (A) medulla and cerebellum, (C) midbrain
including superior collicullus, cerebral cortex and hippocampal formation,
(E) hippocampus (Hp), habenula (Hb), thalamus (Th), hypothalamus (Hy),
cerebral cortex and corpus callosum, (G) forebrain including corpus
callosum and septum (Sp). PrP was detected after antigen retrieval by wet
autoclaving and formic acid treatment, using anti-PrP antibody 8H4,
signal was amplified using a CSA kit and visualised with DAB, nuclei
were counter stained with haematoxylin. Clear differences in the PrP
deposition pattern can be observed between a G2 transgenic (E-H) and a
normally glycosylated control mouse (CL) (A-D), figures shown are
representative of four further vCJD challenged G2 transgenics, which
developed clinical TSE disease, and the further eight CL animals that
developed TSE clinical disease after challenge with vCJD. Specificity of
signal was determined using negative control brains sections from a PrP
null [NPU] mouse and a normal brain homogenate challenged normally
glycosylated control mouse (I). Scale bar 500 pm.
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Figure 6.11 The PrPd deposition pattern observed in G2 transgenic and
control mice after variant CJD challenge did not depend on anti-PrP antibody
























However, PrPd deposition in the habenula was indistinguishable in the CL and G2
transgenic mice (compare figure 6.9 E and F with 6.10 E and F), demonstrating that
brain region specific factors modify the importance of glycosylation of PrP to its TSE
disease associated accumulation in vivo. This difference in PrPd deposition may
indicate that a different conformation of misfolded PrP is accumulating in the G2
transgenic mice challenged with variant CJD than in normally glycosylated controls.
No deposition of PrPd was observed in any vCJD challenged G3 mice (6.12),
demonstrating that the absence of PrPc's N-glycans prevents the formation of
misfolded PrP after vCJD challenge.
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Figure 6.12 No PrPd deposition was observed in G3 transgenic mice
challenged with variant CJD. PrPd deposition was examined at five
defined brain levels of which four are shown here (A and E) medulla and
cerebellum, (B and F) midbrain including superior collicullus, cerebral
cortex and hippocampal formation, (C and G) hippocampus, habenula,
thalamus, hypothalamus cerebral cortex and corpus callosum, (D and H)
forebrain including corpus callosum and septum. PrP signal was
recovered using antigen retrieval by wet autoclaving and formic acid
treatment and detected using anti-PrP antibody 6H4 (A-D) and 8H4 (E-H)
on sections from two G3 transgenics (animal one A-D, animal two E-El)),
signal was amplified using a CSA kit and visualised with DAB, nuclei
were counter stained with haematoxylin. Variant CJD challenged normally
glycosylated control (CL) was used as positive controls for the detection
of PrPd using 6H4 (I) and 8H4 (J) antibodies. Scale bar 500 pm.
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Figure 6.12 No PrPd deposition was observed in G3 transgenic mice
challenged with variant CJD
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6.3.4 TSE associated PK resistant PrPSc
To investigate if the conformation of misfolded PrP differed between the G2
transgenic and normally glycosylated control mice challenged with variant CJD the
size of PK resistance core of PrP was investigated by standard methods, as outlined in
chapters 2 and 5 Additionally the PK resistance of the misfolded PrP observed in G2
transgenic mice challenged with sporadic CJD and in a subset of PrPd negative
animals was also determined. When PrP signal was not low or undetectable by
standard methods, PrPSc was concentrated by NaPTA precipitation. High speed
centrifugation was not used, as preliminary experiments demonstrated that this
method did not sufficiently separate PrPSc from other PK resistant components
resulting in electrophorectic artefacts because of protein overloading of the gel
(appendix xi).
6.3.4.1 Sporadic CJD MM type 2
PrPSc was isolated from one early preclinical and three clinical endpoint sporadic CJD
G2 transgenic mice, by standard PK digestion and NaPTA precipitation (Figure 6.13
A; n = 4, 8H4). Similar to the result observed for murine PrPSc produced after 263K
challenge (chapter 5) un-glycosylated PrPSc isolated from brains prepared in
physiological saline for subpassage appeared to have lower electrophoretic mobility
to that isolated directly in NP40 lysis buffer (Figure 6.13 A). No PrPSc was observed
600 d.p.i. in G3 or CL mice that were challenged with sporadic CJD, even after forty-
fold NaPTA mediated concentration (Figure 6.13 B and C; n = 5, 8H4). This is
consistent with the absence of detectable PrPd by IHC. However, some undigested
PrP was apparent in a number of samples.
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Figure 6.13 Western blots of PrPSc from PrP glycosylation deficient
transgenic and control mice challenged with sporadic CJD.
(A) PrPSc was isolated from four sporadic CJD challenged G2 transgenic
mice; one vCJD challenged G2 transgenic (assayed in duplicate), one
vCJD challenged normally glycosylated control (CL) (assayed in
duplicate), one 263K normally glycosylated challenged control (CL), one
uninfected CL mouse and one uninfected G2 transgenic mouse by
standard PK digestion (20 pg/ml, 37 °C, one hour). PrPSc was concentrated
by NaPTA mediated precipitation. Original brain samples were prepared
in physiological saline (S) or NP40 lysis buffer (N). The electrophoretic
mobility of PrP differed between samples prepared by the two methods.
(B) Brain samples from five PrPd and vacuolation negative normally
glycosylated controls and (C) five G3 transgenic mice which had survived
for at least 600 dpi, were concentrated forty-fold, by NaPTA mediated
precipitation, after standard PK digestion (20 pg/ml, 37 °C, one hour).
However, no PrPSc was detected in any of these samples, despite a clear
PrPc signal prior to concentration and the concentration of PrPSc from a
sporadic CJD challenged G2 transgenic brain sample. PrP was detected
with anti-PrP antibody 8H4 and horseradish conjugated anti-mouse
secondary antibody (Jackson ImmunoResearch, West Grove, USA).
Secondary was detected using POD solution (Roche Diagnostics, Basel,
Switzerland) and the resultant chemiluminescence was detected using X-
ray film.
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Figure 6.13 Western blots of PrPScfrom PrP glycosylation deficient transgenic
and control mice challenged with sporadic CJD
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PrPSc could be isolated from clinical endpoint vCJD normally glycosylated control
mice (CLs) by standard methods without the need for NaPTA precipitation (n = 5,
data not shown). However, PrPSc was only detected in one of the four vCJD
challenged G2 clinical endpoint animals (Figure 6.13 A and data not shown). Ten¬
fold NaPTA mediated concentration was required to detected PrPSc in the other G2
clinical endpoint animals; such that the equivalent of 5 pg of total brain (wet weight)
was run per G2 well (Figure 6.14 A). Both vCJD challenged G2 and CT brain
homogenates were concentrated after PK digested by NaPTA precipitation, to ensure
equivalent populations of PrPSc were compared. Equal PrP signal was then achieved
by diluting CL PrPSc ten-fold prior to electrophoresis. This data demonstrates that a
lower level of PrPSc accumulates at clinical endpoint after vCJD challenge in G2
transgenic mice despite the longer incubation period in these animals.
However, by Ponceau-s staining it was apparent that the total protein loaded per G2
lane was significantly higher than that loaded for the CL controls, which may have
effected the electrophoretic separation of the proteins. This indicates that NaPTA
precipitation was not completely selective for PrPSc and that other PK resistant
proteins were also concentrated by this method. Additionally, significant carry-over
of undigested PrPSc or PrPc during NaPTA precipitation was apparent in both the G2
and CL vCJD challenged brain homogenates but not in uninfected controls.
In one subclinical and one clinical endpoint G2 transgenic mouse the size of un-
glycosylated PrPSc was similar to that observed in the CL control mice (Figure 6.14
A, lanes 7 and 9). In the other clinical G2 animals the un-glycosylated PrPSc
exhibited slower electrophoretic mobility than that of the CL controls which may
indicate that the PK resistant PrP core was larger in these samples. Although all
samples were prepared by identical methods, the greater amount of protein loaded per
well for the G2 PrPSc samples may have affected the electrophoretic mobility of
PrPSc.
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Figure 6.14 Western blots of PrF6cfrom PrP glycosylation deficient transgenic
and control mice challenged with variant CJD
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(A) PrPSc was isolated from vCJD challenged pre-clinical and clinical endpoint G2
transgenic and normally glycosylated control (CL) mice by standard PK digestion (20
pg/ml, 37 °C, one hour) and NaPTA mediated concentration from total brain
homogenate. Amount of PrPSc was equalised between lanes by dilution of samples
after NaPTA precipitation to permit comparison of samples. In two G2 transgenic
mice (A, lane 7 & 9) electrophoretic mobility of un-glycosylated PrPSc was comparable
to that in normally glycosylated control mice, in three G2 transgenic samples (A, lane
3, 5 & 11) the electrophoretic mobility of un-glycosylated PrPSc was reduced
compared to that of controls, suggesting that the conformation of PrPSc may also
differ. In five PrPd and vacuolation negative variant CJD challenged G3 transgenic
mice (B), total brain proteins were concentrated forty-fold by NaPTA mediated
precipitation after standard PK digestion; no PrPSc was detected in any of these
samples, despite clear PrPc signal in all samples and a clear PrPSc signal in the
CL/vCJD postive control (B, lane 12). PrP was detected with anti-PrP antibody 8H4
and horseradish conjugated anti-mouse secondary antibody (Jackson
ImmunoResearch, West Grove, USA). Secondary was detected using POD solution
(Roche Diganostics, Basel, Switzerland) and the resultant chemiluminescece was
detected using X-ray film.
Thus although the difference in size of PrP after PK digestion may reflect a difference
in the conformation of PrPSc, this could also be an artefact caused by the difference in
the amount of PrPSc between the samples. Glycosylation of the second site may
mediate the maintenance of the misfolded conformation of PrP/vCJD in murine hosts,
however further investigation is required to confirm this.
No PrP was detected in G3 transgenic mice challenged with vCJD after 600 d.p.i.,
even after forty-fold by NaPTA mediated concentration (Figure 6.14 B; n = 5)
consistent with the absence of detectable PrPd by IF1C.
6.3.5 TSE associated astrogliosis
The number and distribution of astrocytes in the brains of cross-species TSE
challenged murine PrP glycosylation deficient transgenics and normally glycosylated
control mice was investigated to determine if PrPc's glycosylation state influenced
the development of astrogliosis (for method see chapters 2 and 5).
6.3.5.1 Sporadic CJD MM type 2
Astrocytosis was observed throughout the cerebral cortex, hippocampus, thalamus
and hypothalamus of clinical endpoint sporadic CJD challenged G2 transgenic mice
but not in challenged normally glycosylated controls or G3 transgenic mice consistent
with the absence of TSE pathology in these mice (Figure 6.15). Interestingly, the
astrocytosis observed in the clinical endpoint sporadic CJD challenged G2 was less
extensive than that observed in 263K vacuolation positive G2 transgenic mice which
exhibited no overt signs of clinical disease (Chapter 5).
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D (Uninfected control)
Figure 6.15 Astrogliosis was apparent at clinical endpoint in sporadic CJD
challenged G2 transgenic mice but not in control mice
Extensive astrogliosis was apparent in sporadic CJD challenged clinical
endpoint G2 transgenics (A, B and E) as compared to uninfected controls (C,
D & F); assayed by IFIC using anti-GFAP antibody. Figures show sections
taken from one G2 transgenic mouse and one uninfected control. Boxed area
in B = E and in D = F. Scale bar 500 pm (A-D), 50 pm (E & F).
C (Un Infected control)
: «
■ v ~ v ■
.V L «




At clinical endpoint, extensive astrocytosis was observed in all normally glycosylated
(CL) vCJD challenged controls examined (n = 7) (Figure 6.17 A and B). Astrocyte
activation was observed in the thalamus and throughout the mid-brain and to a more
limited extent in the hippocampus and cerebral cortex. In contrast, extensive
astrocytosis was not consistently observed in vCJD challenged G2 transgenic mice at
clinical endpoint (4/5 astrocytosis negative, 1/5 limited astrocytosis) (Figure 6.17 E
and F).
This demonstrates that not only is disease incidence and the pattern of PrPd deposition
altered by the absence of an N-glycan at the second site, but other elements of the
pathological response to TSE infections are changed. Interestingly these data also
demonstrate the independence of the development of vacuolar pathology and the
astrocytic response.
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Figure 6.16 Astrogliosis was apparent in clinical endpoint variant CJD
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Extensive astrogliosis was apparent in variant CJD challenged clinical
endpoint normally glycosylated controls (CL) (A, B & G) but not clinical
endpoint G2 transgenics (E, F & I) nor uninfected controls (C, D & H), as
assayed by IHC using an anti-GFAP antibody. Figures show results from one
vCJD challenged CL control, one vCJD challenged G2 transgenic and one
uninfected normally glycosylated control. Boxed area in A = G, in C = H and
in E = I. Scale bar 500 pm (A-F), 50 pm (G-l).
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6.3.6 Subpassage of CNS material from cross-species challenged G2 transgenic
and normally glycosylated control mice
To define the extent of the species barrier between murine hosts and the human TSE
agents studies subpassage experiments were undertaken. Material from G2
transgenic and normally glycosylated control mice challenged with vCJD or sporadic
CJD MM type 2 was inoculated ic into normally glycosylated and G2 transgenic
mice, by standard methods, such that any difference in incubation period between
first and second passaged could be defined. A reduction in the incubation period
between the first and second passage formally demonstrates that a species-barrier to
transmission was observed during the primary passage.
In a complementary experiment, material from the first passage was used to challenge
two strains of wild type mice (C57BL, VM) and their F1 cross (CV) [TSE strain
typing panel]. The primary amino acid sequence of PrPc differs between C57 (PrP373)
and VM mice (PrPb/b) (Moore et ah, 1998; Westaway et ah, 1987). TSE disease
develops differently in these mouse strains (Bruce, 1993). Thus by comparing the
incubation period and lesion profile in these mice, the TSE strain isolated during the
primary passage can be classified (Chapter 1). This experiment will examine whether
the strain of TSE infecting the murine PrP glycosylation deficient transgenic and
control mice at first passaged differed, and hence if the observed differences in
transmission are attributable to strain selection rather than a direct effect on the extent
of the species-barrier.
For secondary passage animals were challenged with 1 % brain homogenate from
clinical endpoint sporadic CJD challenged mice. Material from two G2 transgenics
that exhibited similar CNS pathology and clinical disease symptoms were used.
Experimental procedures were identical to those for primary challenge, as described
in chapters 2 and 5. This experiment is ongoing and is currently not available for
complete analysis.
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However, ic inoculation of brain material from the G2/sporadic CJD clinical-endpoint
animals led to the development of TSE clinical disease in all challenged G2 mice.
For the two samples assayed, the incubation period observed upon second passage
was reduced approximately three fold compared to that of the primary transmission
(Table 6.3). This is consistent with the existence of a substantial barrier to the
transmission of this source to the G2 transgenic mice, despite their dramatically
increased disease incidence compared to normally glycosylated controls at first
passage. The mean incubation period was slightly longer for one sample (Table 6.3).
This may reflect a marginally lower infectious titre in this sample, titration
experiments will be required to investigate this possibility.
Table 6.3 Subpassage of CNS material from G2 transgenic and normally
glycosylated control mice
Inoculum Second passage host
number of clinical animals/ total
number challenged animals
(incubation period +/- SEM)
129/Ola G2
G2/sporadic CJD-1











Importantly no disease has yet been observed in the normally glycosylated controls
challenged with G2/sporadic CJD (200 dpi); this demonstrates that G2 transgenic
mice are particularly permissive for the strain of TSE isolated after sporadic CJD
challenge. Absence of glycosylation at the second site appears to produce an intra-
species transmission barrier as has been previously observed for PrP polymorphisms
(Barron et al., 2005).
The pattern of TSE vacuolar targeting was very similar between the groups but
differed from that observed at first passage (Figure 6.17).
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Scoring Area of Brain
The pattern of TSE specific vacuolar pathology was semi-quantatively
scored blind on a scale of 0-5 in nine grey areas (1 dorsal medulla; 2 cere¬
bellar cortex; 3 superior colliculus; 4 hypothalamus; 5 thalamus; 6 hippo¬
campus; 7 septum; 8 retrosplenial and adjacent motor cortex; 9 cingulate
and adjacent motor) and three white matter areas of the brain (1* inferior
and middle cerebellar peduncles; 2* decoction of the superior cerebellar pe¬
duncles; 3* cerebral peduncles) by standard methods, the experiment was
then decoded and a lesion profile of the mean vacuolation score con¬
structed. This demonstrates that the pattern and density of vacuolation in
G" transgenic mice infected with the two G2/sporadic CJD samples investi¬
gated is very similar but that the patterns differs from that observed at pri¬
mary passage of sporadic CJD in G2 mice.
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This provides strong evidence that the same TSE strain was isolated in both the G2
transgenic mice after sporadic CJD challenge, although this conclusion awaits the
results of the TSE strain typing experiment which has yet to be finalised.
Furthermore, the alteration of lesion profile between primary and secondary passage
suggests that TSE agent has undergone a process of adaptation to the G2 transgenic
mice; as has previously occurred in other cross-species TSE transmissions (Bruce et
al., 2002). This further supports the existence of a species barrier in the G2
transgenic mice to sporadic CJD transmission, despite the greatly elevated disease
incidence observed in these mice compared to normally glycosylated controls.
6.4.7 Results summary
These data demonstrate that the role of PrP 's N-glycans in the cross-species
transmission of TSE disease in greatly influenced by TSE strain and can not be
predicted by the amino acid homology of PrPc and donor PrPSc.
- Mice expressing only un-glycosylated PrP are resistant to vCJD and sporadic CJD
transmission and do not permit the accumulation of PrPSc.
- Glycosylation of the second attachment site alters disease incidence and/or
incubation period after cross-species TSE transmission in a strain dependent manner.
- Glycosylation of host PrPc does not influence the strain specific targeting of
vacuolar pathology but does alter the rate and pattern of accumulation of PrPSc in vivo
after cross-species transmission for some TSE strains





6.4.1.1 Disparity of clinical symptoms, vacuolation and PrPd
Clinical signs were observed in a number of animals (11/136) in the absence of TSE
specific vacuolar pathology. For experimental analysis all of these animals were
defined as false positives, as vacuolation is a diagnostic criterion for TSE disease and
the neurological signs in these mice are non-specific. In five of these animals no PrPd
was detected adding further support to these animals being false positives. Non-TSE
CNS diseases or a dysfunction of unknown aetiology may have caused the clinical
signs in these mice in the absence of TSE pathogenesis. In the remaining six animals
PrPd deposition was apparent, although relatively scant. It remains a theoretical
possibility that the clinical signs observed in these animals were caused by misfolded
PrP, however for the purposes of this study this scenario was not further explored.
The density of vacuolation varied between the different challenge experiments. In
particular the density of subclinical vacuolation after 263K challenge (chapter 5) was
much greater than the density observed at clinical endpoint in either the variant or
sporadic CJD challenges. The extent and amount of vacuolation in identical hosts is
known to vary among different strains of TSE disease (Bruce, 2003). The data
presented here is consistent with this, and the hypothesis that vacuolation itself is not
the principal cause of clinical signs during TSE disease.
Despite the significant difference in the pattern of PrPd deposition and type of PrPSc in
G2 transgenic mice as compared to normally glycosylated controls challenged with
vCJD the targeting of vacuolar pathology was unchanged. This suggests that PrPd is
not directly responsible for the generation of vacuolation in agreement with previous
reports (Barron et al., 2001; Foster et al., 2001). These data support the hypothesis of
the existence of a subtype of misfolded PrP that is neurotoxic.
224
6.4.1.2 Variation in size of PrPSc
Slight variation in the electrophoretic mobility of un-glycosylated PrPSc between
animals in the same experimental group was observed. In particular, a clear
difference in the electrophoretic mobility of the PrPSc was apparent between the
samples which were prepared for subpassaged by homogenisation in physiological
saline and those directly extracted in NP40 buffer. The different history of detergent
exposure may have altered the binding of PrPSc to SDS, and hence altered its charge
and electrophoretic migration. Additionally, the material prepared for subpassage in
physiological saline was disrupted by repeated passage through a 26 gauge needle,
resulting in disruption of nuclei and mixing of its contents (DNA and nuclear
proteins) with PrPSc. Interaction of PrPSc with these components may also have
altered its electrophoretic mobility.
Equally, electrophoretic mobility will also be influenced by the ratio of protein to
SDS or the amount of protein per lane. In particular, the significant concentration of
G2/vCJD samples may have also resulted in electrophoresis artefacts. NaPTA
precipitation was not totally selective for PrPSc and other partially PK resistant
proteins were also concentrated. Hence in the G2 lanes approximately ten-fold more
protein was loaded than in the normally glycosylated PrP control lanes. This larger
amount of total protein may reduce the separation all proteins, including PrP, during
electrophoresis. Thus the difference in electrophoretic mobility observed may not be
a consequence of differential PK digestion but reflect the ratio of PrPSc to total
protein.
Alternatively, the observed differences in electrophorectic mobility of PrPSc may have
resulted from differences in the extent of PK digestion. The extent of PK digestion of
PrPSc is dependent on a number of experimental factors particularly the pH and PK
concentration (Notari et al., 2004). The samples were prepared with 50 mM tris
which may be an insufficient concentration to fully buffer variation in pH between
samples (Notari et al., 2004). Concentration of PK used should be uniform between
all reactions as a single batch of PK which was aliquoted and stored at - 20 °C, was
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used for all digestions. However the ratio of PK to protein will have differed between
5 and 10 % homogenates, as the amount of PK which was added was determined by
reaction volume rather than the total amount of protein in each sample. Additionally,
differences in the pH of homogenates may have contributed to the observed variation
in PK digestion. However pH variation is unlikely to have affected the size of PrPSt
in the NaPTA prepared samples, as PK digestions were carried out in the presence of
2 % sarkosyl which eliminates the effect of pH on PrPSc digestion size (Notari et al.,
2004). If additional material were available, it would be desirable to repeat the
preparation of infected brain material in a buffer containing 100 mM tris and monitor
the pH of homogenates prior to digestion to investigate whether the variation
observed was attributable to variation in the pH of samples.
6.4.2 Discussion of experimental results
6.4.2.1 Enhanced resistance of G3 transgenic mice to cross-species TSE challenge
Similarly to the enhanced resistance/increased incubation period of G3 transgenic
mice to hamster scrapie 263K challenge (Chapter 5), these murine PrP glycosylation
deficient transgenics did not exhibit any sign of TSE disease after cross-species
challenge with vCJD or sporadic CJD (MM type 2). These data demonstrate that
both the 263K-hamster/murine and human/murine TSE species barriers are enhanced
in the absence of glycosylation of host PrP . However, as only three cross-species
TSE sources have been investigated here, it is not possible to determine if the
resistance of G3 transgenic mice to cross-species TSE infection is a generic effect or
dependent on TSE source or strain. The evidence to date however would suggest the
G3 transgenic mice are resistant to cross-species TSE infection irrespective of strain
of agent. Transmission of hamster adapted 79A (79A-H) to the G3 transgenic mice
may provide data pertinent to this issue (Kimberlin et al., 1989); as G3 mice are




Additionally, further investigation is required to determine if the absence of PrP 's N-
glycans has a similar effect on cross-species transmission of TSE to other host
species. In particular, in longer lived animals absence of glycosylation of PrP may
not be sufficient to prevent TSE disease development altogether, although it is likely
to significantly extend the TSE incubation period, given its dramatic effect in mice.
PrPd deposition and PrPSc formation was also dramatically reduced in G3 transgenic
mice compared to normally glycosylated murine controls after cross-species TSE
challenge. The absence of accumulated misfolded PrP in G3 transgenic may underlie
the observed barrier to TSE transmission.
A strong intra-species transmission barrier has also been observed in the G3
transgenic mice and comparable conventional PrP murine transgenics (DeArmond et
al., 1997; Tuzi et al., in preparation) (appendix ii). Elowever, clinical disease in the
G3 transgenics has been observed, albeit with greatly increased incubation periods
and reduced disease (Tuzi et ah, in preparation). Thus the influence of PrP's N-
glycans on TSE transmission is not unique to the species barrier. These factors may
include the effect of PrP's N-glycans on the subcellular localisation of the protein
(chapter 4) or the interaction of the protein with in vivo factors that promote its
misfolding (chapter 7) or clearance.
Replication of TSE infectivity in the absence of detectable PrPSc or the development
of TSE pathology has been previously observed (Barron et ah, 2001; Hill et ah, 2000;
Lasmezas et ah, 1997; Race et ah, 2001). Therefore despite the absence of TSE
pathology or PrPSc in the G3 transgenic mice challenged with variant CJD and
sporadic CJD, subpassage of CNS material is required to experimentally assess
whether replication of TSE infectivity also did not occur in these mice.
6.4.2.2 The effect of glvcosvlation at the second site on cross-species transmission
is TSE source dependent
G2 transgenic mice which lack the second N-glycan attachment site display an altered
disease incidence and/or incubation time after cross-species TSE challenge with three
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TSE sources (chapter 5 and this chapter). For two sources (hamster 263K and
sporadic CJD MM type 2) disease incidence was greater than in CL mice and time to
disease onset appeared to be reduced; conversely in the case of vCJD, absence of the
second site led to a reduction in disease incidence. Thus the role of glycosylation of
PrP's second site in cross-species TSE transmission is dependent upon TSE strain.
However, neither the species from which the TSE agent is derived nor the glycoform
of the infecting PrPSc predicts the role of PrPc glycosylation status in transmission
between species.
Importantly, as previously discussed in Chapter 5, the absence of second site
glycosylation specifically promotes cross-species TSE transmissions. However, an
extension of the incubation period in G2 transgenic mice is observed for both vCJD
and the related mouse passaged BSE strain, 301C (Tuzi et al, in preparation; appendix
ii). Therefore the strain dependence of the role of the second site in cross-species
TSE transmission observed here may reflect a common effect of a strain requirement
for the second site, independent of the species barrier.
Glycosylation of asparagine 196 significantly contributes to the barrier to
transmission of hamster 263K and sporadic CJD (MM type 2) to mice. However, the
species-barrier to these agents is not completely eliminated by absence of the second
site, as G2 transgenic mice are not 100% susceptible to these agents and a shortening
in the incubation period is observed at second passage. This suggests that
glycosylation of PrPc's second site contributes to the barrier to cross-species TSE
transmission for some strains, but that other factors are also key to limiting the cross-
species spread of the TSE agent.
The data also suggest that the rate of PrPd deposition in the CNS in response to
challenge with 263K or sporadic CJD is increased in the absence of glycosylation of
PrP's second site. Thus glycosylation of the second N-glycan attachment site appears
to inhibit the accumulation of some conformations of misfolded PrP in vivo. In
contrast, the amount of PrPd detected by IHC and PrPSc by western blot is reduced in
clinical endpoint G2 transgenic mice compared to normally glycosylated controls
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challenged with vCJD. Therefore for this TSE strain the second site glycosylation
appears to promote the accumulation of PrPSc in vivo. These techniques discriminate
TSE disease associated misfolded PrP from PrP by different methods (fixation-
denaturation and PK digestion), and thus the lower amount of misfolded PrP observed
is unlikely to be an experimental artefact, although the possibility of the G2/PrPSc
being more liable to degradation by both methods can not be formally discounted.
These data suggest that the kinetics of accumulation of PrPSc after vCJD challenge is
altered by the absence of glycosylation of PrP at the second site.
PrPSc may be a surrogate marker for the neurotoxic form of PrP. Therefore the low
level of PrPSc detected in clinical endpoint G2 transgenic mice challenged with vCJD
may not reflect a lower level of neurotoxic PrP (Hill et ah, 2000). Further
investigation is required to ascertain if the misfolded PrP generated in this challenge
is more neurotoxic than that which is normally glycosylated. This could be achieved
by comparison of the neurotoxicity of the two forms in neuronal cell cultures.
Titration of TSE affected brain in G2 and wild type mice is required to ascertain if the
titre of TSE infectivity produced after vCJD challenge is equivalent in G2 and
normally glycosylated control mice.
The size of the PK resistant PrP core appears to be altered in some G2 transgenic
mice compared to normally glycosylated controls after vCJD challenge, although this
result may be an experimental artefact (6.4.2.2). Alteration in the size of the PK
resistant core is thought to be caused by differences in the conformation of PrPSc,
such that less of the N-terminal is available for PK digestion (Bessen and Marsh,
1992a). Thus glycosylation of PrP at the second site may alter the conformation of
PrPSc generated after vCJD challenge. Previous work has suggested that
glycosylation may influence PrP conformation, indeed some have suggested that
PrPSc's N-glycans may encode TSE strain information (Collinge et ah, 1996; Rudd et
ah, 2001). Transmission of murine scrapie strain 79A through the G2 transgenic mice
has been shown to alter some strain characteristics (Tuzi et al, in preparation).
Further investigation is required to determine if the conformation of PrPSc has been
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altered upon cross-species transmission of TSE in the PrP glycosylation deficient
transgenic mice. A similar change in PrPSc type has been reported upon passage of
vCJD in normally glycosylated transgenic mice (Asante et ah, 2006; Hill et al.,
1997a; Korth et ah, 2003). In these reports, the electrophoretic mobility of the un-
glycosylated PK resistant core was observed to be lower in a proportion of the
challenged animals. However, no difference in the amount of PrPSc was reported in
these studies in contrast to the dramatic results observed here.
In addition to the amount and size of PK resistant PrP varying, the pattern of PrPd
deposition was also significantly different in G2 transgenic mice as compared to
normally glycosylated murine controls challenged with vCJD. Similarly, within
species TSE transmission to a conventional murine transgenic lacking the second
glycosylation site was reported to result in an altered pattern of misfolded PrP
deposition (DeArmond et al., 1997). In this experiment both the targeting and type of
PrPSc deposition was changed, in particular the specific formation of amyloid plaques
in the murine transgenics was reported. In contrast to the model used here the pattern
of PrPc localisation in the CNS also differed in the murine glycosylation deficient
transgenics compared to normally glycosylated controls, which may have contributed
to the change in deposition observed (DeArmond et al., 1997).
The pattern of PrPd deposition in vivo is influenced by PrP's amino acid sequence and
attachment of the GPI anchor (N-glycan attachment) (Bruce et al., 1991; Chesebro et
al., 2005). The glycosylation of PrP's second site plays a key role in determining the
PrPd deposition after cross-species transmission of some strains of TSE. Differences
in the type of PrPd deposited may be caused both by its conformation and rate of
formation in vivo. Indeed in some TSE models a longer incubation period is
associated with the formation of PrPd plaques (Brown et al., 2003). Similarly here in
the longer incubation period model (vCJD challenged G2's) focal deposits were
observed in contrast to the more diffuse or synaptic pattern of PrPd in the normally
glycosylated controls. Alternatively, the absence of glycosylation at the second site
may have directly altered the deposition of PrPd and may even have caused the
observed change in incubation period.
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Different TSE sources have different pathogenic requirements and target different
regions of the brain, peripheral nerves and lymphoid tissue (Bruce, 1993).
Glycosylation of PrPc differs between regions of the brain and in the periphery; both
in terms of the combination of sugars attached and the relative occurrence of the un-,
mono- and di-glycosylated forms (Russelakis-Carneiro et ah, 2002; Somerville,
1999). Equally the expression and localisation of other cellular components
important to cross-species TSE pathogenesis or PrP conversion may differ between
TSE target regions. The requirement for PrPc's N-glycans for successful TSE
pathogenesis may regionally differ because of variation in the availability of
cofactors. Thus the difference in the importance of the second site to TSE
transmission between TSE sources may be the result of differences in the
pathogenesis and the tissues targeted by each source. In particular, th e apparent
requirement for a replication phase in peripheral lymphoid tissue prior to the
development of full CNS disease, even after direct inter-cerebral inoculation, differs
between sources (Bruce et al., 1994). Peripheral pathogenesis may be altered in the
G2 glycosylation deficient transgenic mice.
The glycosylation state of PrPc may also impact on other aspects of TSE
pathogenesis that are known to differ between TSE sources, such as the extent of
neuronal death, microglial activation or astrogliosis. Indeed, after vCJD challenge,
the glycosylation state of murine PrP clearly influenced the activation of astrocytes.
This effect may be mediated indirectly via a change the conformation of PrPSc.
However, an effect on astrocyte function directly via the change in PrP glycosylation
state may also occur; as work has suggested that PrPc is expressed at low levels in
astrocytes, although this has not been replicated in all studies (DeArmond et al., 1987;
Ford et al., 2002a; Laine et al., 2001; Manson et al., 1992a; Mironov et al., 2003;
Verghese-Nikolakaki et al., 1999). Thus it is feasible that the global alteration of the
glycosylation of PrPc in these studies may alter astrocyte activation in a TSE source
specific manner, although given the massive effect on PrPSc deposition in this model
it appears a rather unlikely scenario. PrPc has been reported to have both pro- and
anti-apoptotic functions in cell culture systems (Bounhar et al., 2001; Brown et al.,
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2002; Milhavet and Lehmann, 2002; Solforosi et al., 2004). The glycosylation state of
host PrP may alter the proteins role in TSE disease related apoptosis. The extent and
pattern of cell death differs between TSE strains. The importance of glycosylation of
PrP to the protein's pro- or anti-apoptotic role may also differ between TSE strains.
Surprisingly, G2 transgenic mice are more susceptible to variant CJD and sporadic
CJD than comparable gene-targeted murine transgenics which express the human PrP
under control of the murine PrP promoter (Bishop et al., 2006; Personal
communication Matthew Bishop), despite the comparable level of PrPc in the G2 and
humanised transgenic mice. This provides strong evidence that amino acid sequence
homology does not determine the barrier to infecting mice with human TSE sources.
Furthermore these data emphasise the likely existence of murine specific PrP
conversion factors which facilitate PrP misfolding or accumulation in vivo.
Importantly, both the targeting of vacuolation and the clinical signs were not
significantly altered in G2 transgenic mice compared to normally glycosylated murine
controls after vCJD challenge, despite the differences in PrPd deposition. This
demonstrates that not all aspects of TSE pathogenesis correlate with PrPd deposition.
However, the activation of astrocytes was not detected in the G2 clinical endpoint
vCJD animals, suggesting that the alteration in PrPd deposition does alter disease
pathogenesis. Astrocytosis has been clearly observed in G2 animals challenged with
both sporadic CJD and 263K indicating that in this case the absence of astrocyte
activation must a specific to the TSE source.
In conclusion, the PrP's N-glycans greatly influence the cross-species transmission of
a number of TSE agents, demonstrating that this post-translational modification has
an important species barrier role. However, the nature of this role is strain dependent.
Additionally, the N-glycosylation state of PrPc alters both the rate of accumulation
and the pattern of misfolded PrP deposition in vivo. Further investigation is required
to determine if the observed changes in PrPSc directly underlie the effect of PrP's
glycosylation status on cross-species TSE transmission.
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7.0 The role of PrP 's N-glycans in the protein's misfolding
determined using Protein Misfolding Cyclic Amplification (PMCA)
7.1 Aim To determine if the role of PrPc glycosylation state in the TSE transmission
barrier can be attributed to a direct influence of the N-glycans on the conversion of
PrPc to PrPRes.
7.2 Introduction and experimental technique
Glycosylation of PrPc has a dramatic influence on TSE transmission both within and
between species (Chapter 4 and 5; Tuzi et ah, in preparation; DeArmond et ah, 1997;
r>
Neuendorf et ah, 2004). However the nature of the influence of PrP 's N-glycans
varies both with TSE strain and the site of attachment. The role of glycosylation of
PrPc in TSE transmission may occur via a number of potential mechanisms. In
particular, the glycosylation state of PrPc may alter its interaction with other
molecules and may influence the key PrPc to PrPSc conversion event, which is
thought to lie at the heart of TSE disease.
Some studies have suggested that the glycosylation state of PrPc has little influence
on its in vitro convertibility (Kocisko et ah, 1994; Kocisko et ah, 1995). Others have
suggested that un-glycosylated PrPc is more readily converted than the normally
glycosylated protein (Bossers et ah, 1997; Lawson et ah, 2001; Priola and Lawson,
2001; Raymond et ah, 1997; Vorberg and Priola, 2002). In some cases this
inhibitory effect of glycosylation was only observed for cross-species conversions or
when the N-terminus of PrPc was truncated (Lawson et ah, 2001; Priola and Lawson,
• c
2001). However all these in vitro investigations utilised cell culture derived PrP
and/or global glycosylation inhibition strategies such as the use of tunicamycin.
Glycosylation of PrPc in cell culture differs from that in vivo and is greatly
influenced by the culture conditions (Monnet et ah, 2003). In particular PrP
produced in N2a cells has been reported to be overglycosylated and under sialyated
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c
(Bossers et al., 1997). Thus, studies using cell-culture-derived PrP , which will not
r-
be natively glycosylated, may not reflect the true role of glycosylation of PrP in
vivo. Global inhibition of glycosylation may alter conversion efficiency
independently of the role of PrP N-glycans, as the glycosylation state of other
cellular factors including any involved in conversion will also be altered. Moreover,
use of tunicamycin in cell cultures both increases the incidence of protein misfolding
and greatly alters cellular expression pattern, both of which may affect PrP
convertibility independently of the role of the glycosylation (Benedetti et al., 2000).
cUse of the PrP glycosylation deficient transgenic mice [NPU] as the source of PrP
p
circumvents these issues, as partially and completely un-glycosylated PrP can be
produced without the use of enzymatic or chemical deglycosylation. Additionally,
the relative importance of glycosylation, at each attachment site, to conversion can
cbe investigated by a comparison of G1 and G2 derived PrP . Furthermore, the in
vitro data generated can be directly comparable to the in vivo transmission
experiments to these PrP glycosylation deficient transgenic mice.
To examine the role of PrP's N-glycans in the conversion of PrPc to PrPRes the in
vitro conversion technique Protein Misfolding Cyclic Amplification (PMCA) was
used (Saborio et al., 2001). Unpurified murine brain homogenate was used as the
source of PrPc, mixed with PrPSc and subjected to PMCA. This conversion
technique utilises repeat round of incubation at 37 °C and sonication to induce the
amplification of the misfolded conformation of PrP. During the incubation step
PrPSc from a TSE infected host binds to and induces the conformational conversion
of the normally folded PrP substrate, leading to an amplification of the misfolded
PK resistant form. To increase the amplification level the reaction is sonicated after
each 37 °C incubation period, to break-up the misfolded PrP aggregates into smaller
c
fragments which are then able to bind and induce further conversion of PrP to a PK
resistant form (Figure 7.1 adapted from Saborino et al 2001).
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Figure 7.1 Schematic representation of PMCA (Adapted from Saborino et al
2001)
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The PMCA technique requires that PrP misfolding is seeded by the presence of
PrPSc, as has been previously demonstrated by conventional in vitro conversion
assays (Kocisko et ah, 1994). Additionally the theory underlying PMCA would
suggest that seeded misfolding leads to an increase in the size of PrPRes aggregates,
as the application of ultrasound, which mechanically breakdowns large molecules,
facilitates amplification. This apparent requirement for aggregate breakdown
suggests that seeding efficiency is proportional to the surface area of
misfolded protein, perhaps because of a requirement for a direct interaction between
PrPSc and PrPc. This may be consistent with the observations of Silveira and
colleagues who demonstrated that oligomeric PrPSc was associated with higher levels
of TSE infectivity than larger aggregates (Silveira et ah, 2005). However the
optimum size of PrPRes aggregate to mediate PMCA conversion has yet to be
determined.
The standard in vitro conversion method is relatively inefficient and requires a great
excess of PrPSc to seed conversion (Kocisko et al., 1994). Thus, in order to detect the
newly formed PrPRes, PrPc must either be radiolabeled or have a specific epitope
which is not present in the seeding PrPSc. Radiolabelling of in vivo derived protein is
not experimentally viable and the introduction of a novel antibody epitope into PrP
may alter the behaviour of the protein, as has been previously highlighted (Barron et
al., 2005). Thus the standard conversion technique is not suitable for the study of
the role of in vivo glycosylation of PrP in the convertibility of the protein to PrPRes.
In contrast in vivo derived PrP can be utilised as a substrate for PMCA mediated
conversion. Higher PrPRcs amplification levels are possible using PMCA rather than
standard in vitro conversion. Therefore, it is possible to identify newly formed
PrPRes purely on the basis of its resistance to PK because it is formed in excess of the
seeding PrPSc (Castilla et al., 2004). Therefore, it is not necessary to specifically label
the PrPc substrate.
PMCA mediates the seeded misfolding of PrP to the disease associated form in the
presence of all cellular components of the central nervous. In fact these components
are essential for successful PMCA mediated PrPRcs amplification (Saborio et al.,
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1999). This demonstrates that the PrPc to PrPRes conversion event is mediated by
other cellular factors. In the PMCA system all cellular components can freely mix
and thus novel interactions may occur between molecules from different cell types
and subcellular compartments which would not normally occur in vivo. Thus the in
vitro mechanism of PrPc to PrPRes conversion may differ from that in vivo because of
the influence of non-specific factors or the absence of a sufficient concentration of a
required factor. Equally, sonication is known to mediate the misfolding of a number
of proteins that are not amylogenic in vivo, which may alter their role in conversion
(Stathopulos et ah, 2004). Despite these caveats, PMCA generated PrPRes has similar
physical properties to PrPSc including its secondary structure (Castilla et al., 2005).
Furthermore, PMCA does appear to mimic a number of in vivo TSE characteristics,
most notably the replication of infectivity and also some aspects of the species
barrier (Castilla et al., 2005; Piening et al., 2006), suggesting that fundamental
aspects of TSE disease are dictated at the molecular, rather than the cellular level and
validating the use of PMCA to investigate the importance of PrP's N-glycans to TSE
transmission.
For all the experiments performed in this chapter, automated PMCA was carried-out
in tubes which were sealed for the duration of the experiment, such that sonication
was applied indirectly via a water bath (Castilla et al., 2004). Uninfected brain
homogenate was prepared by standard procedures to ensure of retention of cellular
membranes, as this has been suggested to be important for successful PMCA
amplification (Castilla et al., 2004). This PrPc containing substrate was then seeded
by an experimentally determined ratio of infected brain homogenate that contained
PrPSc. This master mix was divided into aliquots after vigorous vortexing to ensure
homogeneity. Control aliquots were frozen or incubated at 37 °C in the absence of
sonication for the duration of the experiment, multiple aliquots were then subjected
to PMCA. Each PMCA cycle consisted of a 30 minute incubation at 37 °C followed
by 30 second pulse of sonication, multiple cycles were undertaken as determined by
optimisation experiments.
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The amount of newly formed PrPRes was assayed by standard proteinase K digestion
and western blot densitometry, which permitted the separate quantification of the un-
, mono- and di-glycosylated PrP glycotypes. Bands were delineated manually using
peak minima to determine band limits. The level of PrPRes amplification was
calculated by dividing the amount of PrPRes detected after experimental treatment by
the amount of PrPSc used to seed the reaction, as detected in the frozen sample. In
this way both the relative amplification level of each individual glycotypes and the
total increase in PrPRes could be determined. Thus the specificity of amplification
could be checked by comparing the amplification level of the PrP glycotypes which
were present in the uninfected brain homogenate with those which were not. For
example, when using a G3 PrP homogenate, non-specific amplification of the
mono- and di-glycosylated forms can be compared against the specific amplification
of the un-glycosylated PrPRes, to confirm that any observed reaction was specific to
the PrP supplied.
Additionally, it was also possible to score the reactions as positive or negative for
PrPRes amplification by comparison with the experimental controls. Positive
reactions were those which exhibited a two-fold increase of the predominate PrPRes
glycotype over that observed in the PrP null [NPU] control, as determined by
western blot densitometry. This allowed low but specific amplification of un-
glycosylated PrPRes to be detected. Amplification occurrence may reflect the
likelihood of a PrP to PrPRes nucleation event occurring, whereas the total
amplification level may reflect the efficiency of PrPRes generation after nuclcation.
To investigate the importance of PrP N-glycans to TSE transmission, two murine
TSE strains (ME7 and 79A) and one hamster TSE strain (263K) were used to seed
PMCA reactions. This was performed to investigate both the role of TSE strain and
the species barrier on conversion. ME7 and 79A differ in PrPSc glycoform, in
addition to the pattern vacuolar pathology in the brain and disease incubation periods
(Somerville et al., 1997) (Figure 7.2 B and C). The glycoform of 263K is similar but
not identical to that of ME7, as both are predominantly di-glycosylated (Bruce and
Dickinson, 1987; Somerville et al., 1997) (Figure 7.2 A). 263K is poorly
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transmissible to wild type normally glycosylated mice (Chapter 5) (Kimberlin and
Walker, 1978a). In contrast the murine adapted strain like ME7 and 79A are readily
transmitted to mice (appendix ii). Additionally, all these strains have different
transmission characteristics to the glycosylation deficient transgenic mice (Chapter 4;
Tuzi et ah, in preparation; appendix ii). 263K is more readily transmitted to G2
transgenic mice and less readily transmitted to G1 and G3 transgenic mice than to
normally glycosylated mice (Chapter 5). Whereas, 79A is transmissible to G1
transgenic mice but ME7 is not (Tuzi et ah, in preparation; appendix ii). These
differences may be caused by innate differences in the ability of the different PrP
glycotypes to adopt the misfolded conformation of each of these strains.
It was not possible to investigate the relative convertibility of variant and sporadic
CJD MM type 2 PrPSc seeded PMCA reactions because of USDA restrictions on the
import and work with category three TSE material in the United States, and the lack
of a category three located automated sonicator in the United Kingdom at the time of
investigation. Additionally, to address the role of PrP's N-glycans in the variant and
sporadic CJD seeded PMCA reactions, a relatively large amount of infected brain
material would have been required. Approximately 1 gram of infected brain material
of each TSE strain was used in the experiments presented here and a larger amount
may have been required for variant or sporadic CJD seeded reactions as a higher
ratio of PrPSc to PrPc or additional optimisation experiments may have been required.
Using such a large volume of category three infected brain material would have
posed both a health and safety risk and ethical issues.
7.3 Optimisation of experimental technique
7.3.1Characterisation of PrPSc containing seed
Half brains from murine passaged scrapie strains ME7 and 79A clinical end point
129/Ola murine brain were a kind gift of Dr. Nadia Tuzi (NPU). TSE strain was
confirmed by incubation period and lesion profile. Two whole brains from a clinical
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end point hamster infected with TSE strain 263K were sourced from the NPU-IAH
strain bank. All TSE infected brains were homogenised in PBS/proteinase inhibitors
(PI) by standard methods (Castilla et ah, 2004). The expected PrPSc glycoform for
these strains was confirmed by western blot densitometry (Figure 7.2 and 7.3).
Preliminary PMCA studies demonstrated variable background non-specific
amplification of PrPRes for all TSE strains investigated. An apparent amplification of
PrPRes was observed in some PrP null controls, which lack any PrPc conversion
substrate (data not shown). Additionally, amplification of non-specific PrP
glycotypes that were not present in the PrPc containing substrate from the
glycosylation deficient transgenic mice was observed (e.g. di-glycosylated PrPRes
amplification in a G2 substrate (data not shown). This could be attributable to either
amplification of the PrP contained in the unpurified infected brain homogenate or
variability in the amount of PrPSc in each reaction.
7.3.2 Purification of ME7 and 79A seed
The ME7 and 79A clinical endpoint infected brain 10 % homogenate that were
p
prepared in sterile PBS/PI, were then centrifuged in 10 % sarkosyl to separate PrP
from PrPSc. Purification of PrPSc prevents contamination of the reaction with
normally glycosylated PrP from the infected brain homogenate, which may convert
to PrPRes elevating the non-specific signal. Not all PrPSc was recovered by the
technique, as demonstrated by the higher concentration of purified sample required
to obtain detect similar levels of PrPRes by western blot (Figure 7.2). Elowever, the
glycoform of PrPSc was unchanged by this purification procedure, suggesting that
purification did not lead to enrichment for a subset of PrPSc (Figure 7.2 A, B and
7.3). Furthermore the pattern of amplification observed did not differ between the
reactions seeded with purified or unpurified PrPSc such that these data sets could be
validly combined for analysis (Tables 7.1 and 7.2). This purification procedure did
not significantly reduce the background for either the ME7 nor 79A seeded PMCA
reactions, suggesting that the background observed in the preliminary reactions was
not caused by conversion of PrP associated with the seed.
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Figure 7.2 Western Blots of PrPSc used to seed PMCA reactions
A Hamster (263K) Hamster
1:2 1:5 1:10
PK + + +
- 27
B Murine scrapie 79A
Unpurified Purified Old Supernatant Wash Mouse





C Murine scrapie ME7
Unpurified Purified Supernatant Wash Mouse
1:5 1:10 1:5 1:10
PK + + + + + - + -
-36
-27
Western blots of total brain proteins, treated with 50 pg/ml PK at 55 °C (A) or
37 °C (B & C) for 1 hour shaking at 300 rpm, as indicated to isolate PrPSc from
total brain homogenate from a (A) clinical endpoint 263K infected hamster, (B)
clinical endpoint 79A infected 129/Ola mouse or (C) ME7 clinical endpoint
129/Ola mouse. Infected brain homogenates were diluted in PrP null brain ho¬
mogenate at the ratio indicated prior to PK digestion. Western blots were




Figure 7.3 Densitometry was carried out on western blots to quantify
the glycoform of murine PrPSc before and after purification
A (79A)
B (ME7)
Y-scale intensity of signal, X-scale relative distance from top of lane.
PrPSc concentration and purification state as indicated. A) clinical end-
point 79A infected 129/Ola murine brain homogenate, used to seed
PMCA reactions. B) ME7 clinical endpoint 129/Ola murine brain homoge¬
nate, used to seed PMCA reactions.
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^Amplification was calculated by dividing amount of total amount of PrPRes after
PMCA by the total amount of PrPRes in the frozen control, as detected by western
blot densitometry (anti-PrP antibody 6D11).
f Positive amplifications were those which exhibited two fold amplification of the
predominant glycotype compared to that observed for the PrP null controls within
that experiment. Additionally, for Gl, G2 and G3 samples amplification level of the
predominant glycotype also exceed 1.5 fold of that of non-specific glycotypes; i.e.
for Gl and G2 samples the amplification level of the mono-glycosylated band had to
exceed that of the di-glycosylated band.
*Each independent control sample (129/Ola and PrP null) was run in triplicate, such
that each could be directly compared to the PrP glycosylation deficient experimental
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samples, thus the 36 samples of 129/Ola seeded with unpurified 79A equate to 12
independent PMCA reactions.
7.3.3 Controlling amplification of hamster PrPc by pre-heat treating the 263K
infected brain homogenate
Consistent with the observed TSE species barrier, in vitro PrP conversion efficiency
is far higher if the PrPSc seed and PrPc substrate are derived from the same species
(Kocisko et ah, 1995; Piening et ah, 2006; Priola and Lawson, 2001; Raymond et al.,
2000; Raymond et al., 1997). Thus hamster PrP , contained in the seeding infected
brain homogenate, may amplify in preference to the murine PrPc, increasing non¬
specific amplification, as was observed in preliminary experiments. To remove
hamster PrP from the infected brain homogenate the material was incubated with
shaking for 10 minutes at 55 °C before each PMCA reaction. This procedure does
not remove PrP from the reaction but renders it incompetent for amplification
(personnel communication, Dr. Joaquin Castilla).
Amplification experiments were carried out with both heat treated and untreated
263K seed. The treatment was observed to reduce background non-specific
amplification. However heat treatment did significantly alter the mean amplification
level observed within each genotype (Table 7.3). The heat treatment appeared to
reduce the amplification level of 263K/hamster PrPRes (Table 7.3). However, the
amplification level of 263K seeded G2, G3 and normally glycosylated murine PrPRcs
was significantly enhanced by heat treatment (REML variance component analysis,
Wald test for fixed effects, Wald statistic = 10.17, degrees of freedom = 1, Chi-pr =
0.001). Despite these changes the overall pattern of amplification of murine PrPRes
was not altered by the heat-treatment (Table 7.3).
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Table 7.3 Total amplification of PrPRcs for reactions seeded with 263K
PrPc PrPRes Amplification^
Genotype Un-heated +/- SEM Heated (55 °C 10 mins) +/- SEM
(# positives!/total number reactions) (# positives/total number reactions)
129/Ola 3.55 +/-0.26 5.44+/-0.98
(14/33 = 5/11*) (26/42 = 9/14*)
G1 1.75 +/-0.17 1.39+/-0.23
(0/11) (1/14)
G2 3.18+/-0.91 5.40+/- 1.73
(6/11) (9/14)
G3 1.36+/-0.12 2.56 +/- 0.58
(6/11) (8/14)
PrP Null 1.47+/-0.11 0.89+/-0.14
(0/9) (0/12)
Hamster 9.98 +/- 4.86 4.00 +/- 2.90
(3/3) (1/3)
^Amplification was calculated by dividing amount of total amount of PrPRes after
PMCA by the total amount of PrPRes in the frozen control, as detected by western
blot densitometry (anti-PrP antibody 6H4).
f As greater variability between individual samples within each group was observed
for the 263k seeded PMCA reactions and the amplification level within each null
control was only assayed once, background levels where set using the highest
background observed for the experimental conditions rather than on an within
experiment basis.
To determine if amplification of hamster PrPRes occurred in the 263K seeded PMCA
reactions, a further control step was used. After detection of PrPSc using the PrP
specific antibody 6H4, western blots were stripped and reprobed with a hamster
specific antibody 3F4. Thus the generation of hamster PrPRes could be assessed
(Figure 7.4). Variability in the amount of hamster PrPRes was observed and it was
reduced but not eliminated by heat pre-treatment. Overall, hamster specific
amplification levels were low compared to the total amplification detected;
demonstrating the specific amplification of murine PrPRcs.
245
Figure 7.4 Western blots of optimisation of 263K seeded PMCA reactions
A (1:20, 1 mM EDTA) 6H4
24 hours 48 hours
I si S'2 F 1 si S2 129/ola
PK++ + + + + +
B (1:20, 5 mM EDTA) 6H4
24 hours 48 hours
I SI S2 F 7 S1 S2 129/Ola
PK+ + + + + + +
I PrPRe;
C (1:20, 1 mM EDTA) 3F4
iiiy-Mii'iiitii 4
D (1:20, 5 mM EDTA) 3F4
prPRes
E (1:40, 1 mM EDTA) 6H4
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Western blots of PMCA reactions in duplicate (lanes S1, S2), non-sonicated controls incubated
at 37 °C (lane I) or frozen (lane F); time on sonicator as indicated. PMCA carried out in the
presence of (A, C, E, G, I, K) 1 mM EDTA or (B, D, F, H, J, L) 5 mM EDTA. Ratio of 263K infected
brain homogenate to uninfected 129/Ola brain homogenate (A, B, C, D) 1:20, (E, F, G, H) 1:40,
(I, J, K, L) 1:80. Samples treated with 50 pg/ml PK at 37 °C for 1 hour shaking at 300 rpm, as
indicated. Maximal amplification of PrPRes (F) (5 mM, 1:40, 48 hours). A, B, E, F, I, J) probed with
murine and hamster PrP specific antibody 6H4. C, D, G, H, K, L) correspond to membrane above
(i.e C = A) which had been stripped and reprobed with hamster specific PrP antibody 3F4 and
thus shows minimal amplification of hamster PrPRes.
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7.3.4 Use of EDTA in the uninfected brain homogenate
Murine brains were not perfused prior to sacrifice; thus the brain homogenate
contained blood in addition to cells of the central nervous system. A constituent of
blood is thought to inhibit the PMCA mediated conversion of PrPc to PrPRes (Castilla
et ah, 2004). The metal chelator EDTA has been shown to reverse this inhibitory
effect. To investigate the impact of EDTA concentration on PMCA conversion
efficiency, reactions were carried out in presence of either 5 mM or 1 mM EDTA.
For 263K seeded reactions, both the amplification efficiency and frequency were
higher in the presence of 5 mM EDTA (Figure 7.4). Thus all 263K seeded PMCA
reactions were carried out at this EDTA concentration. No effect of EDTA
concentration was discernible for reactions seeded by either ME7 or 79A and all
reactions were carried out at 5 mM EDTA (Figure 7.5 and 7.6).
7.3.5 Optimisation of the ratio of infected brain homogenate to uninfected brain
homogenate
Optimisation of PMCA experimental conditions was carried out using normally
glycosylated PrPc from 129/Ola mouse brain homogenate. The optimum ratio of
263K infected brain homogenate to uninfected was experimentally determined to be
1:40 (Figure 7.4). At the lower 1:20 dilution, amplified PrPRes was swamped by the
signal from the starting material and at a higher dilution (1:80) a lower proportion of
total PMCA reactions exhibited PrPRes amplification. The amplification of PrPRes
seeded by 263K, was greater after 48 hours (96 PMCA cycles), compared to the level
of amplification observed after 24 hours (48 cycles). The optimum ratio of both
ME7 and 79A purified PrPSc seed to uninfected homogenate was determined to be
1:100 (Figure 7.5 and 7.6). In contrast to the 263K experiments, increasing the
number of PMCA cycles performed did not increase the PrPRes amplification level
for either of the murine scrapie strains investigated (7.6 and data not shown). Thus
ME7 and 79A seeded PMCA reactions were carried out for 24 and 48 cycles
respectively.
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Figure 7.5 Western blots of optimisation of ME7 seeded PMCA reactions
A (Unpurified) B (Purified PrPSc) 1:100
129/Ola NulL _ -too/nia 129/Ola Null 129
DL, F I S1 S2 S3 F I SI S2 '^a,uia nL.F I Si S2 S3 F I S1 S2 S3 /OlaPK+ + + + + + ++ + - PK+ + + + + + + + + +-
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C (Unpurified) D (Purified PrPSc)
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E (Purified PrPSc) 24 hours 48 hours ^ .100
129/Ola Null 129/Ola Null 129
F I S1S2 F I S1 F I S1 S2 F I S1/Ola
PK++ + + + + + + ++ + ++ + -
Pf-pRes "36 kDa
m m ** §§ |p
"*» MP !■ *<t
- 27
Western blots of PMCA reactions in triplicate (lanes S1, S2, S3), non-sonicated
controls incubated at 37 °C (lane I) or frozen (lane F) for duration of experiment;
time on sonicator as indicated or if not indicated 12 hours. PMCA substrate
PrPc containing normal brain homogenate from 129/Ola mice or PrP null mice
as indicated, seeded with unpurified ME7 brain homogenate (A& C) or purified
PrPSc/ME7 (B, D & E). PMCA carried out in the presence of (A, B C, D) 5 mM
EDTA or (E) 1 mM EDTA. Ratio of seed to uninfected 129/Ola brain
homogenate (A, B, E) 1:100 or (C, D) 1:200. Samples treated with 50 pg/ml PK
at 37 °C for 1 hour shaking at 300 rpm, as indicated. Maximal amplification of
prpRes (g) (5 m|\/] purified, 1:100). PrPRes detected with anti- PrP antibody 6D11
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Figure 7.6 Western blot of optimisation of 79A seeded PMCA reactions
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Western blots of 79A seeded PMCA reactions in triplicate (lanes S1, S2, S3), non-sonicated
controls incubated at 37 °C (lane I) or frozen (lane F). PrPc containing normal brain homogenate
129/Ola mice (A-G), C57/BL6 (H & I) or brain homogenate of PrP null mice as indicated, seeded
with unpurified 79A brain homogenate (C & D) or purified PrPSc/79A (A, B, E-l). PMCA carried
out in the presence of (A-D & F-l) 5 mM EDTA or (E) 1 mM EDTA. Ratio of seed to uninfected
129/Ola brain homogenate A, B, E, F-l) 1:100; C, D) 1:200. Time on sonicator as indicated or
A-D, F, H) 24 hours and G & I) 48 hours A-E, H, I) sonicator 1; F & G) sonicator 2. Samples
treated with 50 pg/ml PK at 37 °C for 1 hour shaking at 300 rpm, as indicated. Maximal
amplification of PrPRes (B) (5 mM, purified 1:100) not (A) (5 mM, unpurified 1:100). PrPRes
detected with anti-PrP antibody 6D11.
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Both the predominant di-glycosylated PrPRes glycoforms of 263K and ME7 were
reproduced in the PMCA reactions. However, despite manipulation of a number of
experimental factors, including EDTA concentration, purification of seeding
material, number of PMCA cycles and sonicator used, it was not possible to
reproduce the predominant mono-glycosylated PrPRes glycoform of 79A (Figure 7.6).
To determine if this was attributable to the source of PrPc, 79A seeded PMCA using
an alternative PrP source was undertaken (perfused C57BL/6J uninfected brain
homogenate a kind gift of Dr. Joaquin Castilla UTMB, TX). The predominant
mono-glycosylated glycoform of 79A was also not reproduced using the C57/B6
C iPrP substrate (Figure 7.6 H and I), indicating that the failure to reproduce the
characteristic glycoform of 79A was a general result and was not attributable to the
quality of the 129/Ola derived brain homogenate or strain of mouse used.
Table 7.4 Optimised PMCA conditions
TSE Strain Ratio of Number of PMCA EDTA (mM)
seed: substrate Cycles
79A 1:100 48 5
ME7 1:100 24 5
263K 1:40 96 5
7.4 Validation of experimental technique
7.4.1 Amplification of PrPRes in the absence of seed
Previous cell culture studies have suggested that absence of PrP N-glycans leads to
the spontaneous adoption of PrPSc-like properties; although, no such formation of
PrPRes has been observed in the PrP glycosylation deficient transgenic mice in vivo
(Cancellotti et al., 2005; Lehmann and Harris, 1997) (Chapter 3). To investigate the
possible spontaneous formation of PrPRes during PMCA; PMCA reactions were
undertaken using the optimised experimental conditions without the inclusion of
infected brain homogenate or PrPSc. A preliminary study demonstrated that no
spontaneous formation of PrPRes occurred after 96 PMCA cycles in unseeded
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substrate from the glycosylation deficient transgenic [NPU] or normally glycosylated
129/Ola control mice (two independent brains, assayed in duplicate, data not shown).
A more detailed study was then undertaken, in which samples were also examined
after 24 and 48 cycles. No PrPRes was detected after standard PK digestion and
western blot (Figure 7.7, three independent brains in triplicate), demonstrating that
absence of PrP N-glycans does not lead to the spontaneous formation of the PK
resistant conformation under the experimental conditions used. Thus all PMCA
mediated amplification of PrPRes described here is dependent upon seeding by PrPSc.
7.4.2 Stability of PrP substrate in the reaction conditions used
The removal of PrP N-glycans may render the protein more liable to degradation
(Petersen et al., 1996; Rudd et al., 2001). To investigate the relative stability of PrPc
from the glycosylation deficient transgenic and 129/Ola control mice in PMCA,
PMCA reactions without the addition of infected brain homogenate were undertaken.
The amount of PrP remaining after 24, 48 and 96 PMCA cycles was assayed by
western blot densitometry (Figure 7.8 E, four independent brains assayed in
triplicate). The relative fold-change was calculated by division of the amount of
PrP detected after PMCA by the amount detected in a sample frozen for the
duration of the experiment (Figure 7.8 A-D). Neither the normally glycosylated
controls nor the glycosylation deficient transgenic samples exhibited a decrease in
p p
detectable PrP . Thus the stability of normally glycosylated wild type PrP and
p
partially glycosylated PrP from transgenic murine brains were comparable.
However, although no decrease in detectable PrPc was observed in several
incidences, average PrPc signal was higher than in the frozen control after PMCA.
These changes were significantly different from one but the increases in detectable
PrPc were relatively small (REML variance component analysis Wald test for fixed
effects, Wald statistic = 10.65, degrees of freedom = 3, Chi pr = 0.014). Additionally,
the detected change in PrPc did not correlate positively with the number of PMCA
cycles for either G1 or 129/Ola derived substrates, suggesting that the observed
differences may represent variability in detection rather than a PMCA dependent
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Figure 7.7 Western blot of PrPRes generation in unseeded PMCA reactions
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Western blots of unseeded PMCA in triplicate (lanes S1, S2, S3),
non-sonicated controls incubated at 37 °C (lanes I) or frozen (lanes F) and
ME7 infected brain homogenate, PK resistance controls. A-D) Time on
sonicator as indicated or (E & F) 48 hours. PMCA substrate used; normal brain
homogenate from the G1 (A), G2 (B), G3 (C) glycosylation deficient transgenic
or normally glycosylated 129/Ola mice (D) and as indicated (E & F). All PMCA
reactions carried out in 5 mM EDTA. A-F) probed with anti-PrP specific
antibody 6H4.
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Figure 7.8 PrPc stability in unseeded PMCA reactions
The stability of PrPc under PMCA conditions in the absence of PrPSc seed
was determined by densitometry on western blots using anti-PrP specific
antibody (6H4), on samples that had been subjected to 24 (hatched), 48
(double hatched) and 96 (dotted) PMCA cycles. Error bars indicate stan¬
dard error of the mean (n = 4 assayed in triplicate), a small but significant
difference in PrPc stability is detected between normally glycosylated control
(129/Ola) and G1, G2 and G3 transgenic murine brain homogenate samples
(REML variance components analysis, Chi-pr = 0.014). However, the
change in amount of PrPc detected does not correlate with the number of
PMCA cycles.
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increase in PrP signal. Interestingly, little variability in the amount of G3-PrP
detected after PMCA was observed (Figure 7.8), indicating that PrP's N-glycans may
contribute to the observed western blot detection variability.
7.4.4 263K seeded amplification level of hamster PrP
In accordance with the species barrier effect, previous in vitro conversion reactions
have shown that 263K amplification is more efficient when a hamster rather than
murine PrP is used as substrate (Kocisko et al., 1995; Piening et ah, 2006; Priola
and Lawson, 2001). To investigate this in the system used here, 263K seeded PMCA
reactions using uninfected hamster brain homogenate as substrate (kind gift of Dr.
Paula Prieto Saa) were under taken (Figure 7.9 D, Table 7.3). The mean
amplification level of normally glycosylated hamster PrPRes was higher than that
observed for normally glycosylated murine PrP when the 263K seed had not been
heat treated (REML variance component analysis, Wald statistic = 10.17, degrees of
freedom = 1, Chi pr = 0.001). Thus the experimental system used here replicated the
in vivo hamster-mouse species barrier phenomena. However, heat treatment of the
263K seed appeared to reduce the total level of amplification observed for hamster
PrP, in contrast to the effect on cross-species conversion efficiency.
7.4.5 The effect of sonication on amplification of PrPRes
The level of 263K seeded PrPRes amplification was significantly higher in samples
subjected to sonication as compared to that in the non-sonicated controls incubated at
37 °C (Table 7.7) (REML variance component analysis, Wald statistic = 9.69,
degrees of freedom = 1, Chi pr = 0.002). In contrast, sonication had only a small
facilitating effect on amplification in ME7 and 79A seeded reactions (Table 7.5 and
7.6) (ME7, REML variance component analysis, Wald statistic = 3.81, degrees of
freedom = 1, Chi pr = 0.048; 79A REML variance component analysis, Wald
statistic = 2.24, degrees of freedom = 1, Chi pr = 0.134). This would suggest that
further refinements to the experimental conditions are required for these TSE strains
and underlines the differences in PrPSc derived from different TSE strains.
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Table 7.5 Mean overall amplification of non-sonicated 37 °C controls seeded
with 79A
PrPc Genotype Unpurified +/- SEM Purified +/- SEM
(n) (n)
129/Ola Mouse 2.36+/-0.16 2.07+/-0.16
(12 = 4) (11=4)
G1 Transgenic Mouse 1.72+/-0.24 1.36+/-0.18
(4) (3)
G2 Transgenic Mouse 1.96+/-0.06 1.92+/-0.33
(4) (4)
G3 1.31 +/-0.16 1.18+/-0.11
(4) (4)
PrP Null 0.98 +/- 0.09 0.68+/-0.11
(12 = 4) (11 ~ 4)
Table 7.6 Mean overall amplification of non-sonicated 37 °C controls seeded
with ME7
PrPc Genotype Unpurified +/- SEM Purified +/- SEM
(n) (n)
129/Ola 2.44+/-0.15 2.49+/- 0.17
(3 = 1) (26 = 9)




G3 1.01 1.31 +/-0.10
(1) (8)
PrP Null 1.31 +/- 0.27 1.09 +/- 0.06
(3 = 1) (26 = 9)
Table 7.7 Mean overall amplification of non-sonicated 37 °C controls seeded
with 263k
PrP( Genotype Unheated +/- SEM Heated+/- SEM
(n) (n)
129/Ola 1.74 +/- 0.23 2.48+/- 0.53
(9 = 3) (12 = 4)
G1 1.20+/-0.09 2.00+/-0.61
(3) (4)




PrP Null 1.40+/-0.14 1.03 +/-0.11
(9 = 3) (12 = 4)
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7.5.1 Experimental Results
7.5.1 The ability of mono-glycosylated PrPc to convert PrPRcs
TSE transmission to the PrP glycosylation deficient transgenic mice [NPU] has
demonstrated that the site of PrP N-glycan attachment has a great influence on the
role of glycosylation of PrP in TSE disease (Chapter 5; Tuzi et ah, in preparation,
appendix ii). To investigate the importance of site of N-glycan attachment on the
ability of mono-glycosylated PrP to convert to the disease associated form, PMCA
. C .
using PrP derived from the G2 and G1 transgenic murine brain as the conversion
substrate were undertaken. Strong and specific amplification of PrPRes mono-
glycosylated at the first N-glycan attachment site (G2) was observed for all TSE
strains investigated (Figure 7.9-7.12) (79A REML variance component analysis,
difference between G2 and negative control mean = 0.2097, standard error = 0.0445,
significant at p = 0.05; ME7 REML variance component analysis, difference between
G2 and negative control mean = 0.2321, standard error = 0.0590, significant at p =
0.05; 263K REML variance component analysis, difference between G2 and
negative control mean = 0.4036, standard error = 0.0441, significant at p = 0.05) .
However, the conversion frequency and the overall amplification level differed
between strains. Additionally, for each seeding strain the size of un-glycosylated
PrPRes generated did not differ between the G2 and the 129/Ola substrates. Thus the
conformation of PrPRes, as assayed by the extent of the protein resistant to PK, did
not appear to be altered by the absence of second site glycosylation.
The majority of the within-species conversion reactions, seeded by ME7 or 79A,
produced positive PrPRes amplification of PrP mono-glycosylated at the first site
(79A 16/24, ME7 22/29). The mean overall amplification of PrPRes (irrespective of
glycoform) seeded by ME7 was slightly lower in the G2 derived substrate than in
129/Ola control, in which PrP was normally glycosylated (129/Ola = 2.90 +/-0.18
fold; G2 = 2.46+/-0.25 fold), however this was not significantly different (REML
variance component analysis, difference between G2 and positive control mean =
0.1097, standard error = 0.0586, not significant at p = 0.05).
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Figure 7.9 Western blots of 263K seeded PMCA reactions
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Western blots of example 263K seeded PMCA reactions in quadruplet (lanes
S1, S2, S3, S4), non-sonicated controls incubated at 37 °C (lanes I) or frozen
(lanes F) for duration of experiment. Ratio of 263K clinical endpoint infected
brain homogenate to uninfected brain homogenate (1:40). Normal brain
homogenate derived from a PrP null mouse, the PrP glycosylation transgenic
mice, a normally glycosylated 129/Ola mouse and pooled hamster brain (kind
gift of Paula Prieto Saa) as indicated. PMCA reaction carried out in the
presence of 5 mM EDTA, for 96 cycles over 48 hours. PMCA reactions treated
with PK (50 pg/ml 37 °C, 1 hour). PrPRes detected by western blot using
anti-PrP antibody 6H4.
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Western blots of example 79A seeded PMCA reactions in triplicate
(lanes S1, S2, S3), non-sonicated controls incubated at 37 °C (lanes I)
or frozen (lanes F) for duration of experiment. Ratio of purified
79A/PrPSc to uninfected brain homogenate (1:100). Normal brain
homogenate derived from a PrP null mouse, the PrP glycosylation
transgenic mice and a normally glycosylated 129/Ola mouse as
indicated. PMCA reaction carried out in the presence of 5 mM EDTA,
for 48 cycles over 24 hours. Reactions treated with PK (50 pg/ml 37 °C,
1 hour). PrPRes detected by western blot using anti-PrP antibody 6D11.
258
Figure 7.11 Western blot of ME7 seeded PMCA reactions
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Western blots of example ME7 seeded PMCA reactions in triplicate
(lanes S1, S2, S3), non-sonicated controls incubated at 37 °C
(lanes I) or frozen (lanes F) for duration of experiment. Ratio of
purified ME7/PrPSc to uninfected brain homogenate (1:100).
Normal brain homogenate derived from a PrP null mouse, the PrP
glycosylation transgenic mice and a normally glycosylated 129/Ola
mouse as indicated. PMCA reaction carried out in the presence of
5 mM EDTA, for 24 cycles over 12 hours. Reactions treated with PK














































G1 G2 G3 129/Ola Null
Total amplification of PrPRes by glycotype after PMCA; as determined by
western blot densitometry, using the PrP specific antibodies (6H4 or 6D11).
All reactions carried in the presence of 5 mM EDTA. (A) 1:100 79A to PrPc
brain homogenate, 48 PMCA cycles, (5 independent samples assayed in
triplicate), (B) 1:100 ME7 to PrPc brain homogenate, 24 PMCA cycles, (5
independent samples assayed in triplicate), (C) 1:40 263K to brain ho¬
mogenate, 96 PMCA cycles, (7 independent samples assayed in triplicate/
quadruplet). Error bars standard error of the mean.
260
Similarly, the total amplification levels of PrPRes seeded by 79A PrPSc did not
significantly differ between the G2 and 129/Ola substrates (129/Ola = 2.76 +/-0.21
fold, G2 = 2.72 +/-fold) (REML variance component analysis, difference between
G2 and positive control mean = 0.0341, standard error = 0.0445, not significant at p
= 0.05).
G2 derived PrPc also converted to PrPRes when seeded by PrPSc from a different
species (hamster 263K). Both the overall total amplification of PrPRes (irrespective
of glycoform) and the frequency of positive amplification reactions were not
significantly different between the G2 and the normally glycosylated 129/Ola
substrate (Table 7.3) (REML variance component analysis, difference between G2
and positive control mean = 0.0348, standard error = 0.0441, not significant at p =
0.05). Although the mean amplification level of the predominate mono-glycosylated
PrPRes seeded by 263K is much greater than that observed for the mono-glycosylated
form in the normally glycosylated control (Figure 7.12). This apparent discrepancy is
caused by the majority of seeding 263K PrPSc being di-glycosylated, so that the fold-
change in the mono-glycosylated form is magnified compared to the overall
amplification level.
In contrast, PrP derived from G1 glycosylation deficient transgenic mice, in which
N-glycans can only be attached at the second site, did not convert to PrPRes when
seeded by ME7 and 263K (Table 7.2, 7.3 Figure 7.10-7.12). Two of G1/ME7
PMCA reactions which scored as positives are attributable to the failure of the
control sample to correctly separate during electrophoresis, perhaps because of a sub-
optimum PK digestion (appendix xi). This lead to an unrepresentative low
densitometry reading for the frozen mono-glycosylated glycotype, that resulted in an
apparently higher than background amplification level for the corresponding PMCA
reactions. Thus although these samples scored positive by the densitometric criteria,
they do not represent specific amplification of mono-glycosylated PrPRes.
Furthermore, only weak amplification of G1 PrPRes was occasionally observed in
reactions seeded by 79A (Table 7.1 Figure 7.10). Flowever, owing to the infrequency
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of these conversion events and low amplification levels observed, the mean
amplification level of PrPRes mono-glycosylated at the second site was only slightly
and not significantly above background levels (Table 7.1 Figure 7.10 B) (REML
variance component analysis, difference between G1 and negative control mean =
0.0681, standard error = 0.0490, not significant at p = 0.05). Thus demonstrating that
murine PrP mono-glycosylated at the second N-glycan attachment site has greatly
reduced convertibility to PrPRes. However, at least one TSE strain may induce this
glycotype to adopt the misfolded conformation, albeit with a very low frequency and
amplification level. The differences in convertibility of PrP from the G1 and G2 PrP
glycosylation deficient transgenic mice demonstrate that the site of N-glycan
attachment to PrP greatly affects the role of glycans during PrPc to PrPRes
conversion.
7.5.2 The ability of un-glycosylated PrP to convert to PrPRes in the absence of
other glvcotvnes
In the presence of other converting glycotypes (e.g. when using normally
glycosylated 129/Ola PrPc), un-glycosylated PrP was observed to form PrPRes with
all TSE strains investigated. This is consistent with the formation of un-glycosylated
PrPSc during TSE disease in vivo (Collinge et ah, 1996; Parchi et al., 1996; Rudd et
ah, 1999; Somerville et ah, 1997; Stahl et ah, 1993; Stimson et ah, 1999). To
investigate the ability of un-glycosylated PrPc to convert to PrPRes in the absence of
p p
other PrP glycotypes, PMCA reactions using G3 derived PrP , in which all PrP was
un-glycosylated, were undertaken. Un-glycosylated PrP formed PrPRes when seeded
with either murine passaged scrapie 79A or hamster passaged scrapie 263K but not
when seeded by ME7 (Figure 7.9-7.12 and Table 7.1-3). This demonstrates that the
PMCA mediated conversion of un-glycosylated PrP is dependent upon TSE strain.
Although the frequency of un-glycosylated PrP to PrPRes conversions seeded with
79A or 263K were comparable to those observed with normally glycosylated PrP, the
overall amplification levels (irrespective of the glycotypes) were significantly lower
than the wild type control (Table 7.3) (263K REML variance component analysis,
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difference between G3 and negative control mean = 0.1978, standard error = 0.0441,
significant at p = 0.05; 79A RJEML variance component analysis, difference between
G3 and negative control mean = 0.2125, standard error = 0.0490, significant at p =
0.05). However, total amplification of G3-PrP in 263K seeded reactions was
significantly higher than that observed in the negative control (REML variance
component analysis, difference between G3 and positive control mean = 0.2406,
standard error = 0.0428, significant at p = 0.05). Moreover, G3-PrP amplification in
79A seeded reactions was not significantly higher than background (Table 7.1)
(REML variance component analysis, difference between G3 and negative control
mean = 0.0313, standard error = 0.0490, not significant at p = 0.05). Therefore
although un-glycosylated PrP is as likely to initiate conversion to PrPRes as normally
glycosylated PrP (similar conversion frequency) when seeded by 79A or 263K, it is
unable to sustain significant amplification of PrPRes in the absence of other
glycotypes. Furthermore the size of un-glycosylated PrPRes did not differ between
the 129/Ola and G3 reactions, indicating that complete absence of PrP's N-glycans
did not alter the PrPRes conformation adopted.
7.5.3 Species barrier specificity of the influence of PrP glycosylation on
Rps
conversion to PrP
Previous work had suggested that PrP's N-glycans specifically play a role in cross-
species conversions but not for conversion seeded with PrPSc from the same species
(Priola and Lawson, 2001). In contrast, these data demonstrate that the PrP
glycosylation state is important both to cross-species and within species conversions.
Furthermore, the TSE strain rather than the species of the PrPSc donating TSE host is




These data demonstrate that PrP 's N-glycans do influence the convertibility of the
protein to the disease associated form.
- That the site of N-glycan attachment influences the importance of
glycosylation of PrPc to its conversion to PrPRes, as demonstrated by the differential
convertibility of G1 and G2 PrP.
- That the total absence of PrP 's N-glycans either inhibits or reduces
convertibility to PrPRes, in a TSE strain specific manner.
- That the absence of PrP 's N-glycans did not alter the conformation of
PrPRes generated, as assayed by the size of the un-glycosylated band after PK digest.
- That the importance of PrP 's N-glycans to conversion events does not
display a species barrier specific affect in contrast to previously published work




The use of purified PrPSc as the seeding material did not reduce the background
increase in the PrPRes signal (Table 7.1 and 7.2). This suggests that no detectable
p #
amplification of PrP from the infected brain homogenate occurred for the PMCA
conditions used. The purified and un-purified infected brain homogenates were
manually sonicated (10, 1 second pulses power output 20 %) prior to mixing with the
uninfected substrate. This step was not used during the preliminary tests. Thus the
variability in background levels observed in the preliminary experiments may be
attributable to insufficient dispersal of the infected brain homogenate in the master
mix.
The heat treatment of the 263K infected hamster brain homogenate, used to render
the hamster PrP incompetent for PMCA conversion, was observed to inhibit the
p i
conversion of hamster PrP to the PK resistant form, in accordance with the
observations of others (Dr. Joaquin Castilla, personal communication). However the
opposite was true for murine derived PrPc substrate, as the heat treatment of 263K
facilitated these cross-species conversion reactions. This suggests that the heat-
treated PrP or other cellular components may inhibit the conversion of homologous
hamster PrP but not heterologous murine PrP. Alternatively the heat-treatment may
have specifically modified the conversion ability of 263K/PrPSc. The 55 °C
c .
treatment of normally folded mammalian proteins such as PrP is likely to lead to the
destabilisation of secondary structure and aggregation. Whereas, this mild heat
treatment has been shown to have little effect on TSE infectivity (Somerville et ah,
2002) and thus, by inference, also may have little effect on the ability of PrPSc to
seeded conformational conversion. Thus it appears more probable that the observed
species-specific inhibitory effect is mediated by PrP or another cellular component
rather than a modification of PrPSc.
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The average amplification level for ME7 and 79A seeded reactions was lower than
that observed for cross-species reactions seeded by 263K. This contrasts with the
higher transmissibility of the murine strains to mice and results from conventional
PrP conversion assay (Kimberlin and Walker, 1978a; Kocisko et ah, 1995).
Additionally, for the murine seeded PMCA reactions, mean PMCA amplification
levels were not significantly higher than control reactions incubated at 37 °C. Also,
no increase in amplification level was observed after a greater number of PMCA
cycles or by addition of EDTA for the murine seeded experiments, in contrast to
those seeded by 263K. This evidence would suggest that although amplification was
achieved during the experiments, further optimisation is required for these strains.
This however does not invalidate any conclusions drawn from these data as although
not maximised, significant amplification of PrPRes did occur for both the murine TSE
strains. This result highlights the differing nature of TSE strains.
Despite the manipulation of a number of experimental parameters it was not possible
to reproduce the predominantly mono-glycosylated 79A PrPRes glycoform by PMCA
using normally glycosylated PrP . This was consistent with the experimental data
presented here, which showed that mono-glycosylated PrP does not amplify more
readily than the normally glycosylated protein, when seeded with 79A PrP.
Previous studies have reported reproduction of the seeding PrPSc glycoforms during
in vitro generation of PrPRes (Soto et ah, 2005; Vorberg and Priola, 2002). However,
the glycosylation status of PrPc was also shown to influence PrPRes glycoform in one
study (Vorberg and Priola, 2002). Thus, TSE strain specific in vivo factors other
than innate convertibility of PrP glycotypes govern the generation of the
characteristic PrPRes glycoform of 79A. These may include the abundance of PrP
glycotypes or glycotype specific conversion factors at the site of conversion. This
result does not negate the maintenance of 79A strain characteristics during PMCA
amplification, as maintenance of TSE strain may be independent of PrPSc glycoform.
Although the predominately di-glycosylated glycoforms of ME7 and 263K were
reproduced by PMCA, the failure to reproduce the glycoform of 79A suggests that
this is a generic effect, rather than a true maintenance of strain specific glycoform.
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The apparent preferential formation of di-glycosylated PrPRes during PMCA could
either be because it is innately more convertible or because there is a vast excess in
the normally glycosylated in vivo derived substrate (Chapter 3). Thus it may
dominate the conversion reaction by virtue of its abundance, in normally
glycosylated controls. Convertibility of normally glycosylated PrP was comparable
to that of PrP mono-glycosylated at the first attachment site. However, the
convertibility of normally glycosylated PrP was enhanced compared to un-
c c
glycosylated PrP or PrP mono-glycosylated at the second attachment site. Thus a
higher innate convertibility of the di-glycosylated form could contribute to its
preferential production in vitro. However, as the stoichiometry of the two possible
forms of mono-glycosylated PrP in vivo is unknown, it is not possible to determine
whether the convertibility of mono-glycosylated PrP in normally glycosylated hosts
differs from that of the di-glycosylated form.
7.6.1 Discussion of experimental results
Our data shows that PrP mono-glycosylated at the second site (Gl) is relatively
unable to form PrPRes in vitro', suggesting that this glycotype may not play a role in
TSE disease. However, further experimentation is required to determine if Gl PrP
can form PrPRes in the presence of other glycotypes of PrP that can convert.
Conversion of Gl PrP may be facilitated by the misfolding of more convertible PrP
glycotypes under normal glycosylation conditions. Equally Gl PrP may be more
readily converted by PrPSc from other TSE strains. Alternatively G1 PrP may inhibit
the conversion of other conversion competent glycotypes of PrP. Previous studies
that have investigated the importance of the glycosylation of PrP to conversion, have
not addressed the importance of site of N-glycan attachment to the protein's in vitro
misfolding (Kocisko et al., 1994; Kocisko et al., 1995; Lawson et ah, 2001; Priola
and Lawson, 2001; Raymond et ah, 1997). Although, in vivo transmission studies
using PrP glycosylation deficient mice have highlighted the importance of site of
attachment to TSE disease (Chapter 4; Neuendorf et ah, 2005; Tuzi et ah, in
preparation). Additionally, no study has thoroughly addressed the importance of the
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site of N-glycan attachment to the generation of mono-glycosylated PrPSc in hosts in
which PrP is normally glycosylated.
Several studies have observed variable attachment of N-glycans to PrPSc at both sites
(Rudd et ah, 1999; Stahl et ah, 1993; Stimson et al., 1999), although in these studies
the majority of PrPSc was shown to be di-glycosylated (Rudd et ah, 1999; Stahl et ah,
1993; Stimson et ah, 1999). The latter result is attributable to the strains of TSE
used, ME7 and 263K/Sc237, in which PrPSc is predominately di-glycosylated
(Somerville et ah, 1997). Higher site occupancy of the first N-glycan site compared
to the second has been observed using mass-spectrometry (with N-glycan attachment
detected at greater than 90% of asparagines at the first site, compared to at 80% at
the second) (Stahl et ah, 1993), consistent with the finding that N-glycan attachment
to PrP is determined by the distance from the C-terminus (Walmsley and Hooper,
2003). Others have not observed preferential glycosylation of PrP at the first site;
although no experimental data was shown in this case (Rudd et ah, 1999). Two
prominent mono-glycosylated PrPSc bands are observed in a number of TSE strains,
these may correspond to the first and second site mono-glycosylated forms
(Somerville, 1999). However, this has not been experimentally demonstrated and
these prominent forms may correspond to different combinations of glycans attached
at one site.
However, work on PrPSc/ME7 has clearly demonstrated that the combination of
glycans attached at each site reproducibly differ (Stimson et ah, 1999). This
translates into clear differences in molecular weight; consistent with our observations
of size differences in the G1 and G2 mono-glycosylated form and previous works
(Moudjou et ah, 2004; Stimson et ah, 1999). This is consistent with evidence from
263K infected normally glycosylated hamsters and a conventional transgenic murine
model, which also suggest that site specific glycosylation of PrPSc occurs
(DeArmond et ah, 1997; Endo et ah, 1989). These works are in agreement with the
two PrPSc predominant mono-glycosylated forms observed in vivo corresponding to
site specific glycotypes. Despite this, there is no clear evidence of the existence of
second site mono-glycosylated PrPSc in vivo generated during acquired TSE disease.
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The data presented here would suggest that this form of PrPSc is not readily generated
and thus has little or no role in TSE disease, although there is evidence for the
existence of mono-glycosylated forms of PrP attached at both glycosylation sites, in
normally glycosylated sheep and mice (Moudjou et ah, 2004).
Why PrP mono-glycosylated at the second site is relatively unable to convert to
PrPRes, when both di-glycosylated and un-glycosylated PrP can convert, presents a
conundrum. These data suggest that this failure to convert is neither attributable to
glycosylation at the second site per se, nor owing to absence of N-glycans at the first.
The nature of the N-glycans attached at the second site may vary between G1 and
129/Ola PrP such that those attached to G1 PrP may specifically inhibit conversion.
Alternatively the interaction of N-glycans attached at the first and second site may
alter the behaviour of each. Indeed Moudjou and colleagues have suggested that
repulsion between the N-glycans may lead to the unmasking of a region of the PrP
surface, which would otherwise be covered if only one of the sites was glycosylated
(Moudjou et al., 2004). These potential differences may directly affect both the
conformational flexibility of PrPc, its ability to bind PrPSc or may indirectly effect its
interaction with a secondary molecule. Further experimentation is required to
determine which of these effects underlies the observed poor convertibility of G1
PrP.
Alternatively, un-glycosylated and glycosylated PrP may convert to PrPRes via
P
different mechanisms. As the complete absence of N-glycans on G3 derived PrP
may alter the protein's folding in vivo, as this form of PrP will no longer interact with
glycosylation specific folding pathway/chaperones. Differential interaction of PrP
with chaperones has been previously demonstrated to be dependent on presence or
absence of the di-sulphide bound (Capellari et al., 1999). The G3 PrP folding
pathway may also be different from that of the normally glycosylated form, as has
been shown for other proteins (Oliver et al., 1997; Swanton et al., 2003). If this is
the case the successful conversion of glycosylated forms of PrP may require
glycosylation of the first site. Further experimentation is required to ascertain
whether the conformation of PrPc glycotypes differs and what impact this may have
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on the conversion to PrPSc. Additionally, experiments are required to investigate
whether successful conversion of G1 PrP can be mediated by PrPSc from another
TSE source.
Equally, the conformation or aggregation status of PMCA generated PrPRes may
differ between the glycotypes. TSE strain is often biochemically determined by the
size of the un-glycosylated band after PK digest. According to this parameter,
absence of PrP N-glycans did not alter TSE strain during PMCA (Collinge et ah,
1996; Parchi et ah, 1996). This result could have been further confirmed by either
PNGase digestion or Endman protein sequencing of PrPRes. Additionally, a further
investigated either by a conformational study of PrPRes or strain typing bioassay.
Previous work has suggested that removal of the second glycosylation site is linked
to changes in the strain characteristics of 79A (Tuzi et al., in preparation). The
maintenance of size of G2 PMCA generated un-glycosylated PrPRes presented here is
compatible with this finding, as in vivo the PK resistant band size was also
unchanged despite the alteration of other strain characteristics.
The complete absence of PrP 's N-glycans led to a significant reduction in the level
of PrPRes generated for both within and cross-species conversion reactions.
Additionally, for one TSE strain, ME7, PrPRcs formation was completely inhibited
when the PrP substrate was not glycosylated. Previous in vitro studies using the
standard method have either suggested that the absence of PrP N-glycans increased
or had no effect on conversion efficiency (Kocisko et ah, 1995; Priola and Lawson,
2001; Raymond et ah, 1997). These differences may be attributable to either the in
vivo glycosylation of the PrP substrate used in the experiments outlined here; the
influence of other cellular factors on conversion; or the different TSE strains used in
these experiments to seed the reactions.
Transfection of scrapie infected cell lines with a construct expressing composite
hamster-murine un-glycosylated PrP (MHM2Aiai82/Aiai98) have also demonstrated
lower levels of un-glycosylated PrPRes formation than that observed with normally
glycosylated controls. Interestingly this study also showed that although the level of
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un-glycosylated PrPRes formed was lower, misfolding occurred quicker (Taraboulos
et al., 1990a). Similarly more rapid formation of un-glycosylated PrP was detected
in a cell culture infection experiment, although no data on amount of PrPRes
generated was presented in this paper (Korth et al., 2000). Further studies are
required to investigate if the rate of PrPRes formation is altered in the system
described here. The data presented here demonstrate that the conversion of un-
glycosylated PrP is influenced by the presence of other conversion competent
glycotypes. In previous cell culture experiments un-glycosylated PrP was over-
expressed in the presence of the normally glycosylated PrP (Korth et al., 2000;
Taraboulos et al., 1990a), which may have facilitated the conversion of the un-
glycosylated form.
The complete failure of un-glycosylated PrP to adopt the conformation of
ME7/PrPRes, counter-intuitively suggests that un-glycosylated PrP is less
conformationally flexible than that which is normally glycosylated PrP, in contrast to
previous suggestions (Rudd et al., 2002; Rudd et al., 2001). However, G3-PrP may
have failed to convert because of an indirect mechanism. PrP's N-glycans may
mediate conversion to PrPRes by stabilisation of misfolding intermediates, by
interacting with PrPSc conversion factors or by maintaining the protein in a required
environment for successful conversion, perhaps in association with membranes.
Similarly, the reduced levels of un-glycosylated PrPRes generated in 79A and 263K
seeded reactions demonstrates that although able to initially misfold, un-glycosylated
PrP could not sustain significant PrPRcs amplification. This result suggests that un-
glycosylated PrPRes may not be able to seed further conversion and thus may have
little relevance to the transmission of TSE disease. Further experimentation is
required to explore this hypothesis and to define the structural characteristics of
PMCA PrPRes. Additionally, the seeding ability of un-glycosylated PrP may be
altered in the context of other PrPRes glycotypes when mixed aggregates are likely to
form.
Previous work has suggested that in vitro misfolding of un-glycosylated PrP
generates a number of smaller PK resistant forms of PrP (12-14 kDa) in addition to
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the major 18-21 kDa form (Lawson et al., 2001; Priola and Lawson, 2001). These
works suggest that the misfolded conformation adopted is affected by the
glycosylation state of PrP . In all experiments presented here the size of un-
glycosylated PrPRes generated was unaffected by the glycosylation status of the PrPc
substrate and no smaller PK resistant forms were observed.
The convertibility of un-glycosylated PrP and to a lesser extent PrP mono-
glycosylated at the first site was determined by the strain of TSE used, to seed the
PMCA reaction. This implies that the importance of PrP's N-glycans to conversion
is dependent upon the novel PrPRes conformation to be adopted. These data support
the hypothesis that the precise mechanism and conversion requirements are TSE
strain specific. However, the relative PMCA-convertibility of glycan deficient PrP
by different TSE strains does not exactly mirror the transmissibility of these agents to
the PrP glycosylation deficient transgenics. In particular, no significant difference in
the 79A/PrPSc seeded conversion efficiency of G2/PrP was observed in these studies,
whilst the incubation period of 79A in G2 transgenics was significantly increased
compared to normally glycosylated controls (Tuzi et al., in preparation, appendix ii).
Thus the effect of N-glycan attachment to PrP on TSE transmission is not simply
caused by a direct effect on the innate convertibility of the protein.
In contrast to previously published work, the role of PrP N-glycans in determining
convertibility to PrPRes is not limited to cross-species seeded reactions (Priola and
Lawson, 2001). In particular the experiments presented here demonstrate that PrP's
N-glycans do not pose a barrier to cross-species in vitro conversion, since partial or
total absence of murine PrP N-glycans did not facilitate the formation of PrPRes when
seeded by hamster passaged scrapie. In fact, cross-species conversion was inhibited
(Gl) or reduced (G3) by the partial or complete absence of attached N-glycans.
Previous work had shown that removal of PrP 's N-glycans did not lead to 263K
seeded conversion of murine PrP using standard conversion technique (Kocisko et
al., 1995). However, in contrast to this work, here we show strong conversion of
normally glycosylated murine PrP, thus demonstrating the specific reduction in
conversion owing to the absence of glycosylation. Additionally, few differences in
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the effect of PrP glycosylation state on convertibility of the protein were observed
between cross-species and within-species PMCA seeded reactions. Indeed TSE
• c
strain appeared more important in determining the role of PrP 's N-glycans in
conversion than PrPSc source species. These data suggest that the role of PrPc's
second site N-glycan in the cross species transmission of TSE may be mediated by
factors other than the innate convertibility of PrP.
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8.0 Discussion
8.1 Overview of principal findings
The N-linked glycosylation of PrP at two sites is highly conserved, suggesting that
the N-glycans are important to the protein's normal function, as has been reported
for numerous other glycoproteins (Gils et ah, 2003; Kim et ah, 2004; Lee et al.,
2003; Rudd et al., 1995; Torres et al., 2003). However, the data in this thesis
demonstrate that the absence of glycosylation of PrP's first, second or both sites,
does not compromise the health or survival of transgenic mouse models (Chapter 3)
(Cancellotti et al., 2005). Furthermore these transgenic mice do not develop
spontaneous TSE disease, or accumulate PrPSc in the CNS in the absence of TSE
challenge, counter to previous suggestions based upon findings from a cell culture
system (Lehmann and Harris, 1997). Thus the function of PrP's N-glycans is neither
essential for life nor required to prevent spontaneous misfolding of PrP in vivo.
This is the first systematic examination of the influence of PrP 's glycosylation state
on the spontaneous development of TSE disease, despite the previous generation of
PrP glycosylation deficient transgenic mice, in PrP null backgrounds, by
conventional methods (DeArmond et al., 1997; Neuendorf et al., 2004). Moreover,
glycosylation at either site appears to be sufficient for the normal cellular
localisation of PrPc in vivo (Chapter 4), in contrast to earlier reports (DeArmond et
al., 1997; Rogers et al., 1990) (appendix i).
However, these PrP glycosylation deficient transgenic mice [NPU] exhibit a
dramatic phenotype when challenged with hamster or human TSE agents across the
species barrier (Chapters 5 and 6). Previous work has shown that the glycosylation
of PrP promoted the within-species transmission of TSE disease in a strain
dependent manner (DeArmond et al., 1997; Neuendorf et al., 2004; Tuzi et al., in
preparation). However, the work presented here is the first study to address the role
of PrP's N-glycans in cross-species TSE transmission. The results of a cell-free
conversion assay had previously suggested that glycosylation of PrPc may play a
TSE species barrier specific role (Priola and Lawson, 2001). These in vitro data
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predicted that the total absence of PrP's N-glycans would render a host more
susceptible to cross-species TSE challenge. In contrast, the data presented here
demonstrate that in vivo the absence of PrP's N-glycans inhibited the cross-species
transmission of a range of TSE agents (Chapters 5 and 6). The altered localisation of
PrPc in the G3 transgenic mice may account for the resistance of this model to cross-
species TSE challenge (Chapter 4). Additionally, in vitro conversion in an
independent experimental system failed to replicate Priola and Lawson's findings
(Chapter 7). Indeed the data presented here suggest that the innate convertibility of
G3/PrP is reduced compared to that of the normally glycosylated protein.
To further understand the role of glycosylation in cross-species TSE transmission,
attachment of glycans to the first or second site was also investigated, using the G1
and G2 transgenic mice. Previous studies have demonstrated that the first and
second site of N-glycan attachment have differing effects on the transmission of TSE
within a species (DeArmond et al., 1997; Neuendorf et al., 2004; Tuzi et al., in
preparation). The removal of either site resulted in an increase in incubation period
after TSE challenge. However, the relative importance of each site differed between
strains; the first site appears particularly important for the transmission of murine
scrapie strain ME7 and the second site for murine BSE (Neuendorf et al., 2004; Tuzi
et al., in preparation). The data in this thesis uniquely show that the two N-glycan
attachment sites also have radically different effects on the cross-species
transmission of the TSE agent (Chapter 5).
Absence of glycosylation at PrP's first site retards the cross-species transmission of
the hamster TSE strain 263K, as illustrated by a decrease in disease incidence and
increase in time to disease onset (Chapter 5). Thus glycosylation of asparagine 180
appears to facilitate TSE transmission across a species barrier. The alteration in
transmission of TSE may be attributable to a direct effect on the innate ability of PrP
to misfold (Chapter 7). In contrast, glycosylation of PrP's second site protects the
host from TSE challenge with 263K or sporadic CJD, since mice lacking
glycosylation at this site exhibit a higher disease incidence and shorter time to
disease onset than controls (Chapters 5 and 6). The protective effect of
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glycosylation of the second site is only observed after challenge across the species
barrier, since numerous within-species transmissions to transgenic mice lacking the
second site have never exhibited accelerated disease (DeArmond et al., 1997;
Neuendorf et al., 2004; Tuzi et al., in preparation) (appendix ii).
Thus could the function of glycosylation of asparagine 196 be to protect the host
from infection with TSE strains from other species? Perhaps the role may even be to
counter the facilitatory effect of glycosylation of the first site on TSE transmission?
However, N-glycosylation at 196 does not protect the host against cross-species
challenge with all TSE strains. Indeed glycosylation of the second site appears to
facilitate transmission of vCJD to mice (Chapter 6). Thus the effect of the
glycosylation of the second site on cross-species transmission does not simply occur
because of a global destabilisation of PrP. Moreover, the effect of second site
glycosylation on the cross-species transmission of 263K to mice does not appear to
be mediated by an alteration in PrP's conversion efficiency (Chapter 7). This
suggests that glycosylation of PrP can influence TSE pathogenesis independently of
a direct effect on misfolding.
Glycan attachment to PrP was disrupted in these experiments by threonine for
asparagine substitutions in the N-glycan attachment sequence. These amino acid
changes reduce homology between murine PrPc and donor PrPSc. The degree of
sequence homology between PrPc and PrPSc has been previously reported to be a key
determinate of the species barrier (Scott et al., 1989). Thus the amino acid changes
used in the models may influence the TSE species barrier independently of their role
in preventing glycosylation of PrP . However, the only way to selectively disrupt
the glycosylation of one protein in vivo is by an amino acid substitution within its
glycan attachment site. The amino acid changes in PrP used in the experiments
described in this thesis are not associated with any known pathogenic mutation.
However, these experiments carry the caveat that the effects observed may occur
either because of a change of glycosylation or the amino acids.
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In conclusion, the data in this thesis uniquely suggest that N-glycan attachment to
PrP contributes to the barrier to cross-species TSE transmission in a site of
attachment and TSE strain dependent manner. These effects appear to be mediated
by multiple mechanisms including an alteration in the localisation of PrPc and a
change in the innate ability of the protein to convert to the disease associated form.
8.2 Possible mechanisms for the observed alteration in cross-species
transmission to G3 transgenic mice
G3 transgenic mice lack both PrP N-glycan attachment sites. These mice exhibit
enhanced resistance to or significantly increased incubation times after cross-species
challenge with all TSE agents investigated (Chapters 5 and 6). This alteration in
transmission occurred independently of a change in the level of PrPc or its
membrane attachment (Chapter 3), factors that are known to influence TSE disease
(Chesebro et ah, 2005; Manson et al., 1994b). The G3 transgenic mice studied here,
and a comparable conventional murine PrP glycosylation deficient transgenic model
[UCSF], also have greatly extended incubation times after and/or increased
resistance to within-species TSE challenge (DeArmond et al., 1997; Tuzi et al., in
preparation) (appendix ii). This suggests that the resistance of the G3 transgenic
mice to cross-species TSE challenge is not caused by a specific affect on the TSE
species barrier, but by an affect on all types of TSE transmission. Additionally, G3
transgenic mice do not accumulate significant PrPSc within the CNS after cross-
species TSE challenge; this may cause the observed resistance of these mice to
disease (Chapters 5 and 6).
The reduced level of PrP detectable in the neuropil of G3 transgenic mice may have
resulted in the increased resistance of these mice to TSE challenge and the absence
of significant PrPSc (Chapter 6). A similar explanation was proposed for the
observed TSE resistance of conventional un-glycosylated PrP murine transgenics
[UCSF] (DeArmond et al., 1997). TSE transmissions to independent conventional
un-glycosylated PrP murine transgenics [Riems] have yet to be reported (Neuendorf
et al., 2004). The cellular localisation of PrP in the Riems model is anticipated to
277
resemble that of the normally glycosylated protein (Neuendorf et al., 2004).
Comparison of the results of TSE transmissions to these mice with those to the G3
transgenic model [NPU] will be very useful to further test the hypothesis that the
elevated resistance of the G3 transgenic mice to TSE challenge is a result of altered
PrP localisation.
The localisation of PrPc has been previously reported to be important for the
accumulation of PrPSc and the development of TSE clinical signs in other PrP model
systems (Chesebro et ah, 2005; Taraboulos et ah, 1995; Vetrugno et ah, 2005).
Although intracellular misfolding of PrP can occur (Ma and Lindquist, 2002), post-
Golgi localisation of PrPc may be required for the biologically relevant interaction of
PrPc with the TSE agent/PrPSc. Indeed some authors have suggested that conversion
may occur after the endocytosis of PrP, in an endosomal or lysosomal compartment
(Laszlo et al., 1992). The observed significant reduction in PrP detectable in the
neuropil, but apparently unchanged ER or Golgi localisation in the G3 transgenic
mice, and absence of accumulated PrPSc in this model, is consistent with conversion
principally occurring in a post-Golgi compartment, as has been previously suggested
(Taraboulos et al., 1995). The local availability of cofactors or environmental
conditions such as pH may change the ability of PrP to misfold in the G3 transgenic
mice. Previous work has shown that the subcellular localisation of Huntingtin is
known to dramatically influence its aggregation (Rousseau et al., 2004). However, it
is clear that conversion can occur in the G3 transgenic mice after TSE challenge
(Chapter 5; Tuzi et al., in preparation; appendix ii). This suggests that the site of
conversion may be TSE strain dependent and/or localisation of PrP only affects the
probability of conversion rather than being an absolute determinant of it.
However, in addition to the effect on localisation, in vitro PrP conversion
experiments also suggest that the innate convertibility of PrP is reduced in the G3
transgenic mice (Chapter 7). Conversion of G3 PrPc, seeded by both heterologous
(263K) and homologous (79A or ME7) PrPSo, occurred less readily than that of
normally glycosylated control-PrPc. Thus the glycosylation state of PrPc may also
directly contribute to the reduction in cross-species transmission of TSE to the G3
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transgenic mice via this effect on the innate convertibility of the protein. This may
occur via a direct effect on the ability of G3/PrP to interact with cellular components
which mediate conversion. However, the observed alteration in localisation of PrPc
and its changed innate convertibility in the G3 transgenic mice may be linked. The
localisation of PrPc and PrPSc in a contiguous lipid membrane (Baron et al., 2002)
and the local lipid environment (Pinheiro, 2006) are known to influence the ability of
C • C •
PrP to convert. The observed alteration in localisation of G3 PrP may thus directly
alter the ability of the protein to convert to the disease associated form.
Alternatively, the observed change in TSE transmission to the G3 transgenic mice
may occur independently of the observed alteration in G3/PrP's convertibility. The
N-glycans may directly mediate the interaction of PrP with the TSE agent, and hence
may be essential for disease development. A number of specific host glycans are
similarly known to be key to facilitate the interaction of toxins, bacterial and viral
pathogens with the host (Chu and Whittaker, 2004; Falk et al., 1995; Griffitts et al.,
2003; Kunz et al., 2005). Equally, the absence of PrPSc in the TSE challenged G3
transgenic mice may result from a failure of the misfolded form of PrP to accumulate
rather than an absence of its formation. Previous work examining the glycosylation
state of Alzheimer's Disease associated tau suggested that paired helical filaments,
characteristic of the diseased state, dissociated when tau was not glycosylated (Wang
et al., 1996). Similarly the nature of PrPSc may be changed in the G3 transgenic
mice and thus it may not be recognised as misfolded by conventional methods.
Alternatively, the clearance rate of G3/PrPSc may be enhanced.
8.3 Possible mechanisms for the altered transmission of 263K to G1 transgenic
mice
Transgenic mice which lack PrP's first glycosylation site only (G1 NPU) also exhibit
enhanced resistance to or significantly increased incubation periods after cross-
species TSE challenge with hamster scrapie 263K (Chapter 5). The results of further
cross-species transmission studies are required to determine if the resistance to 263K
occurs because of a generic resistance of these transgenic mice to cross-species TSE
279
transmission. In contrast to G3 transgenic mice, limited amounts of misfolded PrP
were observed to accumulate in a number of G1 mice after cross-species challenge
(Chapter 5). Thus although both G1 and G3 transgenic mice lack the first
glycosylation site, the mechanism(s) responsible for the observed effects on
transmission may differ between the two models.
In particular the cellular localisation of PrPc does not appear to be changed by the
absence of glycosylation at the first site (G1 NPU) (Chapter 4). This contrasts with
r
results of one comparable conventional murine transgenics in which PrP was
reported to be localised predominately in the nerve cell body (DeArmond et ah,
1997). However the point mutation used in this conventional model is known to
change the biology of PrP , including its localisation, independent of its effect on
glycosylation (Capellari et ah, 2000b). Other conventional murine transgenic
models [Riems] that also lack PrP's first N-glycan attachment site are anticipated to
exhibit plasma membrane localisation of PrP in vivo (Neuendorf et ah, 2004),
consistent with the results observed in the G1 transgenic mice presented here. Thus
the effect of the absence of an N-glycan at the first attachment site on cross-species
TSE transmission is not the result of altered localisation of PrP . Moreover the
p p
amount of PrP within the CNS and the membrane anchorage of PrP in the G1
transgenic mice also do not differ from normally glycosylated controls (Chapter 3;
Cancellotti et ah, 2005).
In vitro heterologous PrP conversion reactions seeded with 263K/PrPSe suggested
that Gl/PrP was unable to convert to a PK resistant form in vitro (Chapter 7). This
may underlie the observed enhanced resistance of G1 murine transgenic mice to
challenge with hamster scrapie, since the misfolding of host PrP may be required for
the propagation of infectivity. Gl/PrPc is also not converted by ME7/PrPSc and only
weakly and not significantly by 79A/PrPSc. However, 79A can be successfully
transmitted to G1 transgenic mice, albeit with an increased incubation time,
questioning how closely in vitro conversion efficiency reflects that which occurs in
vivo. Further optimisation of PMCA reaction conditions may permit the significant
79A/PrPSc seeded amplification of Gl/PrPc. Alternatively, an in vivo specific effect
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may mediate the transmission of 79A murine scrapie to the G1 transgenic mice.
Although the in vitro conversion (PMCA) reactions contain total CNS components,
these factors are homogenised so that normal in vivo concentrations and interactions
may be disrupted. Thus in vitro conversion may not precisely mimic that in vivo
because of an absence of factors that would normally be found at the site of
conversion, or equally because of the presence of factors that are normally excluded.
Despite these caveats, both the in vivo and in vitro data suggest that the Gl/PrP is
less able to convert to the disease associated form than that which is normally
glycosylated. However G3/PrP which also lacks the first N-glycan attachment site is
able to convert to a PK resistant conformation, albeit with reduced efficiency. Thus
although glycosylation of PrP's first site appears to facilitate misfolding of PrP, the
failure of G1 PrP to convert can not be solely attributable to lack of the first site.
Indeed current data would suggest that the N-glycans attached to the second site in
Gl/PrP may mediate the failure of this glycoform to convert.
8.4 The role of glycosylation of the second site in the TSE species barrier
In contrast to the effect of the first or both glycosylation sites on cross-species TSE
transmission, the absence of an N-glycan attached to PrP's second site (G2 NPU)
specifically promotes the cross-species transmission of some TSE strains (Chapters 5
and 6). The facilitation of cross-species TSE transmission to the G2 transgenic mice
is associated with enhanced PrPSc accumulation in the CNS (Chapter 5 and 6),
suggesting that PrPSc or its capacity to misfold may have altered in these mice.
However, the effect of the second site on cross-species transmission and PrPSc
accumulation is dependent upon TSE strain. Nevertheless, the importance of the
glycosylation of PrPc is not determined by the PrPSc glycoform of the challenging
agent alone since the data presented here demonstrate the PrPc glycosylation
requirement of vCJD and 263K significantly differ, despite sharing an almost
identical PrPSc glycoform. Thus the importance of PrPc glycosylation to the TSE
species barrier is not to simply provide the required PrPSc glycotype. Equally,
species differences in the glycosylation of PrPSc (Xanthopoulos et ah, 2006) also
may not solely dictate the importance of PrP 's glycosylation state to TSE
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transmission, as illustrated by differences in the transmission of vCJD and sporadic
CJD to the glycosylation deficient transgenic mice.
The site-specific glycosylation of other host proteins is suggested to prevent the
cross-species transmission of viruses (Marin et ah, 2003; Wentworth and Holmes,
2001). In these cases glycosylation of the resistant receptor directly acted to prevent
interaction with the pathogen perhaps by shielding the host protein from the virus. A
• p
similar mechanism may determine how second site glycosylation of PrP prevents
transmission of 263K and sporadic CJD to murine hosts. However, in these
examples the N-glycan attachment site is unique to the resistant host species. This
contrasts with PrP's second site of glycan attachment which is found in all species.
In contrast to the accelerated accumulation of misfolded PrP in the G2 transgenic
mice challenged with 263K, the in vitro misfolding efficiency of G2/PrP , seeded by
263K/PrPSc, was not significantly different from that of normally glycosylated PrPc
(Chapters 5 and 7). This difference suggests factors other than misfolding efficiency
must mediate the accelerated accumulation of PrPSc observed in vivo. This may be,
mediated by a difference in the rate of clearance of G2/PrPSc compared to normally
glycosylated PrPSc. This may occur if G2/PrPSc is recognised differently by the
cellular clearance machinery. Indeed clearance proteins like the N-glycan specific
E3-ligase Fbx2, that recognises and targets proteins for proteasome degradation via
their attached N-glycans, may interact differently with G2/PrPSc (Yoshida et al.,
2002). Equally, the different glycosylation state of G2/PrP may directly change the
stability of the protein, perhaps by an alteration in its ability to resist proteinase
digestion. Alternatively, the absence of glycosylation of the second site may alter
the conformation or aggregation of misfolded PrP which may indirectly alter
turnover in vivo. Indeed the altered pattern of PrPd deposition observed in G2
transgenic mice challenged with vCJD suggests that glycosylation at the second site
may be important to the conformation or aggregation of misfolded PrP. However,
no such changes in the pattern or type of PrPd deposition were observed in the G2
transgenic mice after challenge with 263K, which also exhibited a dramatically
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different transmission phenotype, highlighting that the glycosylation state of PrP
may mediate its species barrier role by multiple mechanisms.
8.5 Glycosylation of PrP( and the TSE species barrier
The barrier to cross-species TSE transmission has been recognised since the 1960's
(Pattison, 1965) and it came under renewed interested during the BSE epidemic.
The unusually wide host range of BSE and the emergence of new strains, such as
CWD, make it increasingly important to accurately predict the extent of the TSE
r ...
species barrier. PrP is a key TSE host susceptibility factor (Bueler et al., 1993;
Manson et al., 1994b) and clear evidence links this protein to the extent of the
species barrier (Manson et al., 1999; Scott et al., 1989). However, it is still not
possible to make accurate predictions of the host range of a new TSE strain. The
data presented here demonstrate that glycosylation of host PrP , particularly of the
second site, is a key determinant of the TSE species barrier.
A number of host factors have been reported to influence the extent of the TSE
species barrier, including the degree of amino acid sequence homology between host
PrPc and incoming PrPSc, and PrP interaction with species specific conversion
factors (Scott et al., 1989; Telling et al., 1995). Glycan attachment to PrPc may
specifically modify the effects of PrP amino acid differences between TSE host
species and hence their role in cross-species transmission of TSE. However,
although two amino acids differ between the hamster and mouse sequence proximal
to the second glycan attachment site, these residues are conserved between human
and mouse (Locht et al., 1986; Oesch et al., 1985). Thus the effect of second site
glycosylation on cross-species transmission would not appear to be the result of the
influence of the N-linked glycans on the local amino acid differences between host
PrPc and donor PrPSc. Interestingly the removal of PrP's second site N-glycan has a
greater effect on the cross-species transmission of sporadic CJD MM-cortical (type
2) than the expression of human PRNP-(MM) in a gene-targeted murine transgenic
model (Personal communication Mr. Matthew Bishop). This supports the idea of
additional species specific factors that interact with PrP having a significant role in
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TSE disease pathogenesis and highlight that the species barrier is not purely the
result of PrP amino acid homology. Moreover, perhaps PrP's N-glycans influence
the interaction of the protein with these factors in vivo.
The increased incidence of alteration in TSE strain characteristics after cross-species
transmission led to the hypothesis that an adaptation or zero-replication phase may
underlie the species barrier (Kimberlin and Walker, 1979). Recent experimental
evidence has linked this idea to the alteration in PrPSc conformation that correlates
with TSE transmission across a species barrier (Peretz et al., 2002). Others have
suggested that strain differences in cross-species transmission may be the result of
the extent of PrP conformational compatibility between host PrPc and TSE PrPSc
(Hill and Collinge, 2003; Kellershohn and Laurent, 1998). Absence of the N-glycan
attached to PrP at the second site may increase the range of conformations that the
host protein can adopt (Rudd et al., 2001; Zuegg and Gready, 2000), and hence the
range of TSE strains that can induce it to misfold. However, absence of
glycosylation at the second site does not result in an increase in 263K-seeded in vitro
conversion of PrP, nor to enhanced transmission of all strains across the TSE species
barrier. Thus the observed increase in transmission to the G2 transgenic mice does
not appear to be attributable to a direct effect on conformational compatibility of
p ...
PrP . Equally, the species barrier is observed in the absence of significant
adaptation of the strain to the new host, suggesting that a change in conformation of
PrPSc has not occurred (Bruce et al., 1997; Kimberlin et al., 1989). Thus it would
appear that the TSE species barrier is not solely the result of conformational
compatibility of host and donor PrP.
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Although the data presented here demonstrate that glycosylation of murine PrP 's
second site leads to an increase in disease incidence and decrease in time to disease
onset after challenge with two TSE sources, no cases of acquired/sporadic human
TSE disease have been reported associated with an alteration in glycosylation at the
second site. The normal development and survival of G2 transgenic mice indicates
that loss of the second glycosylation site is not detrimental, thus one would predict
occurrence of mutations ablating the second glycosylation site within the human
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population. However, the frequency of such individuals may be very low. This,
coupled with the low exposure to TSE agents in the environment, may account for
the current absence of any reported cases of TSE infected individuals with disruptive
mutations in the second N-glycan attachment site. Moreover, transmission of vCJD
is hindered by absence of the second glycosylation site. Absence of the second
glycosylation site would thus be predicted to be protective against BSE exposure.
This may also account for the absence of cases of acquired disease associated with
mutations in the second site, since in recent years most environment TSE exposure
will have been to BSE in the United Kingdom. Alternatively, the glycosylation state
of PrPc may also effect peripheral replication and transportation of infectivity. Thus
absence of glycosylation of the second site may influence cross-species TSE
transmission by natural routes of infection differently to those observed in the
experimental system examined here.
Three cases of familial CJD have been reported to be associated with loss of the first
glycosylation site (Chasseigneaux et al., 2006; Grasbon-Frodl et al., 2004; Nitrini et
al., 1997). The transmission studies presented here suggest that this change would
protect against acquired TSE disease. However, this effect may display TSE strain
dependence. Moreover the point mutation reported to disrupt the glycosylation of
PrP differed from those used here and was linked to the development of familial TSE
disease, not as a risk factor for acquired infection. Indeed the mutation in two of
these kindreds (Grasbon-Frodl et al., 2004; Nitrini et al., 1997), has been reported to
have pathogenic effects on PrP's cellular localisation and solubility, independent of
its effects on the protein's glycosylation state (Capellari et al., 2000b).
The data presented here demonstrate that the species barrier role of glycosylation of
asparagine 196 is TSE strain dependent (Chapters 5 and 6). Specifically, the results
demonstrate that the cross transmission of vCJD is hindered by the absence of
glycosylation of PrP's second site, whereas N-glycans attached to this site appears to
protect the host against the cross-species transmission of other strains of TSE. This
suggests that the vCJD TSE agent is adapted to exploit di-glycosylated PrP which is
the most abundant glycotype, in vivo, in all species so far examined. This may
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contribute to the unusually wide host range of the strain since the results presented
here suggest that glycosylation of PrPc's second site usually protect the host from
infection with TSE from other species. Why an agent that apparently originated in
domestic cattle exhibits a preference for PrP glycosylated at its second site is
unclear. Further studies are required to ascertain if the effect observed in the murine
model system used here is also important in other hosts and whether glycosylation of
host PrPc affects the transmission of other biologically relevant TSE strains such as
CWD and atypical BSE.
8.6 Future Work and Ongoing Studies
The work presented here raises many new questions.
Is the cross-species transmission of variant CJD and sporadic CJD influenced by
glycosylation of PrP 's first site?
Does glycosylation of PrP alter peripheral TSE pathogenesis and transmission by
natural routes?
Is the conformation of PrPSc altered by the absence of N-glycans at either the first or
second site and does this relate to TSE strain and neurotoxicity?
Why is the cross-species transmission of 263K and sporadic CJD promoted by the
absence of an N-glycan attached to PrP 's second site and why is that of vCJD
hindered?
Is clearance of PrPSc affected by its glycosylation state?
Does glycosylation of PrP affect the variant CJD and sporadic CJD in vitro
conversion efficiency?
What prevents the misfolding of Gl-PrP?
• • C
Why is cellular localisation of PrP altered in the G3 transgenic mice?
Does the change in location of PrPc really underlie the resistance of G3 transgenic
mice to cross-species TSE challenge?
Further studies of the effect of glycosylation on cross-species TSE transmission are
currently ongoing. G1 transgenic mice have been challenged by ic inoculation with
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variant and sporadic CJD. These studies will be analysed by similar methods to
those outlined in Chapters 5 and 6 and will permit a fuller understanding of the role
of first site glycosylation in cross-species transmission. Additionally, further cross-
species transmission studies to the PrP glycosylation deficient transgenic mice could
be undertaken, to increase the range of strains investigated. In particular it would be
interesting to examine if the transmission of atypical BSE (Biacabe et al., 2004;
Casalone et al., 2004) and CWD were also subject to the effects of PrPc
glycosylation state, since the ability of these agents to cross the species barrier to
humans is of growing concern.
To investigate if the peripheral pathogenesis of TSE disease after cross-species
challenge is affected by the glycosylation state of PrPc, peripheral transmission
experiments to the glycosylation deficient mice could be undertaken. The PrP
glycosylation deficient transgenic mice could be challenged either by intraperitoneal
injection or by a more natural transmission route, such as the feeding of TSE
infected material. Peripheral routes of challenge are often less efficient and may
result in longer incubation periods than the direct ic inoculations used here, thus
larger experimental groups will be required. Furthermore any such experimental
design must take account of the significantly enhanced resistance of G1 and G3
transgenic mice to cross-species transmissions observed in this thesis.
The species barrier is classically defined by the difference in incubation period
between first and subsequent passages (Pattison, 1965). Thus CNS material from
TSE infected G2 transgenic and normally glycosylated control mice has been used to
challenge groups of G2 transgenic and normally glycosylated control animals to
assess the extent of the species barrier at primary passage. Moreover, comparison of
the pattern of vacuolar pathology at second passage will provide further information
regarding the strain of agent that infected the murine models at primary transmission.
This is being further investigated by transmission of CNS material infected with
vCJD, sporadic CJD and 263K to two strains of wild type mice and their F1 cross
(Bruce, 2003). This system has been previously used to show that BSE and vCJD
were caused by the same TSE strain (Bruce et al., 1997). Strain typing data will thus
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demonstrate if the differences in incubation period observed in the G2 transgenic
mice were the result of colonisation by different strains of agent or by an alteration
in the rate of disease progression. In addition to these experiments, the effect of
glycosylation on the conformation of PrPSc could also be assessed, so as to further
explore the link between strain, the species barrier and PrPSc as proposed by the
experimental work of Peretz (Peretz et al., 2002). In parallel the relative
neurotoxicity and stability of the different PrPSc glycoforms derived from the PrP
glycosylation deficient murine transgenics could be investigated by their application
to cultured cells.
To further investigate the importance of TSE strain to the ability of different PrP
glycotypes to be converted by heterologous PrPSc, PMCA reactions seeded with
variant or sporadic CJD could be undertaken. These data could be used to further
interpret the cross-species transmission studies presented in this thesis. Similarly the
relative ability of other TSE sources to seed conversion of different PrPc glycotypes
could be explored including the more recently emergent agents of CWD, atypical
BSE and scrapie. Equally, PMCA generated glycosylation deficient PrPRes or in vivo
derived PrPSc from the G2 transgenic mice could be used to seed further reactions to
examine the importance of PrPSc glycosylation state to its ability to induce PrPc
conversion.
The nature of the N-glycans attached to Gl-PrPc and G2-PrPc are unknown,
although current data suggest the combination of glycans attached differs (Chapter
3). Absence of one of PrP's glycosylation sites may alter the combination of glycans
• P P
attached to the other site, such that glycans attached to Gl-PrP and G2-PrP may
not resemble those of wild type PrPc. To investigate this and in particular to further
understand why Gl- PrP is relatively unable to adopt a PK resistant conformation,
the glycans attached to the cellular forms of the proteins could be investigated by
mass spectrometry. However, it may be technically challenging to isolate sufficient
P •
murine PrP for this analysis. Alternative, less technically challenging, but less
definitive, approaches to this question could also be employed. Differences in lectin
binding between the forms of PrP could be examined to estimate differences in
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glycan composition (Xanthopoulos et al., 2006). Additionally, 2-D electrophoresis
could be used to further determine if the N-glycans moieties differ in size or charge.
• c • •
An examination of the interaction of glycan deficient PrP with candidate PrP
binding partners, such as laminin receptor precursor or cellular chaperones (Capellari
et al., 1999; Rieger et al., 1997), may provide information regarding the role of PrP's
glycosylation state in TSE transmission. Equally, the influence PrP 's N-glycan on
the protein's interaction with other cellular components such as lipids could also be
explored; this may be particularly relevant to the observed altered localisation of
G3/PrP . Cultured cells could additionally be used to further examine the trafficking
and turnover of un- and partially glycosylated PrP . Primary neurons derived from
the PrP glycosylation deficient transgenic mice [NPU] and/or neuronal cell lines
transfected with the appropriate Prnp constructs could be used. These ex vivo
systems will allow the influence of N-glycans on the half-life and trafficking of PrPc
to be examined, since such measurements are extremely difficult to make in vivo.
However it should be remembered that the data acquired in culture are only an
estimate of these phenomena in vivo. For example the half-life of PrPc observed in
neuronal cells and within the CNS in vivo significantly differ (Caughey et al., 1989;
Safar et al., 2005). These differences may be the result of culture cells being an
unrepresentative subset of those in vivo or because of the very different physical
environment that cells are exposed to in culture.
To further investigate the role of un-glycosylated and partially glycosylated PrPc in
TSE disease, a murine bacterial artificial chromosomes (BACs) transgenic murine
model could be generated. BACs are able to carry several hundred Kb of transgenic
DNA (Yang et al., 1997), in contrast to the far smaller constructs which can be used
by conventional methods. Thus both a gene's open reading frame and all its
surroundings regulatory sequences can be incorporated in the construct. In contrast
to gene-targeted transgenic mice, BAC technology permits multiple copies of the
construct to be carried (Yang et al., 1999). Thus a BAC PrP transgenic model could
express transgenic PrP in the correct spatial and temporal context but at higher levels
than in the gene-targeted transgenic mice. Thus they could be used to magnify the
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influence of PrP's N-glycans on TSE disease. In particular, BAC transgenic mice
could be used to address if absence of disease after TSE challenge, as observed in
G3 transgenic mice, is attributable to absolute resistance or increase in the incubation
period.
The work presented here suggests that the glycosylation of PrP influences the cross-
species transmission both by a direct effect on formation of PrPSc and via another
undefined mechanism. This highlights that processes other than rate of PrPSc
• cformation have dramatic effects on TSE pathogenesis and are influenced by PrP .
The TSE disease pathways altered in the G2 glycosylation deficient transgenic mice
may also be important to the transmission of TSE to normally glycosylated hosts
both within and between species. Thus further study of the G2 murine transgenic
model to identify and understand the aspects of TSE pathogenesis, which are altered
in the model, may have wide relevance. Equally, study of the G1 and G3 transgenics
could be used to further understanding of the link between PrP cellular localisation,
formation of PrPSc and TSE disease.
Indeed, given the dramatic effect glycosylation of PrP has on TSE disease, the
glycosylation of other proteins that misfold during neurodegenerative disorders may
also be important to the pathogenesis of these diseases. Previous work has suggested
that the glycosylation state of tau may be important to its role in Alzheimer's
Disease (Wang et al., 1996). Equally, misfolded neuroserpin, which forms Collins
body's, in a form of familial encephalopathy, is N-linked glycosylated, although the
importance of this to disease is currently unknown (Davis et al., 1999).
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Summary of published work on the importance of glycosylation state to the
cellular localisation of PrP


































tgMo(3F4) in CHO cells Tunicamycin Surface staining Lehmann and
Harris 1997
tgSHa PrP in murine PrP0/0
(2-4 X)
T183A Cell bodies in vivo DeArmond et
al., 1997
tgSHa PrP in murine PrP0/0
(2-4 X)





tgSHa PrP in murine PrP0/0
(2-4 X)
T183A, T199A Cell bodies in vivo DeArmond et
al., 1997
tgMHM2 PrP in ScN2a N180Q,N196Q Surface staining Korth et al.,
2000





















tgMo(3F4) in murine PrP0/0
(1-4X)




tgMo(3F4) in murine PrP0/0
(1-4X)




tgMo(3F4) in murine PrP0/0
(1-4X)





Appendix ii Summary of TSE transmissions to PrP glycosylation deficient
transgenics
Model TSE agent Incubation Period
dpi
Reference
Mouse TgSHaPrP (T183A) or
(T183A, T199A)





Mouse TgSHaPrP (T199A) 139H 555
Mouse TgSHaPrP (T199A) 139H 548
Mouse SHaPrP Sc237 55
Mouse SHaPrP 139H 64
Mouse TgMoPrP (T182N) #1 Chandler 163 (Neuendorf
Mouse TgMoPrP (T182N) #2 Chandler 240 et ah, 2004)
Mouse TgMoPrP (T182N) #1 ME7 308
Mouse TgMoPrP (T182N) #2 ME7 323
Mouse TgMoPrP (T182N) #1 Murine BSE 169
Mouse TgMoPrP (T182N) #2 Murine BSE 224
Mouse TgMoPrP (T198A)#1 Chandler 305
Mouse TgMoPrP (T198A)#2 Chandler 390
Mouse TgMoPrP (T198A)#1 ME7 408
Mouse TgMoPrP (T198A) #2 ME7 405
Mouse TgMoPrP (T198A) #1 Murine BSE 390
Mouse TgMoPrP (T198A) #2 Murine BSE 392
Mouse (C57/B6) Chandler 164
Mouse (C57/B6) ME7 172
Mouse (C57/B6) Murine BSE 197
Mouse gtMoPrP (N180T) 79A 194 Tuzi et ah, in
Mouse gtMoPrP (N180T) ME7 >600 preparation
Mouse gtMoPrP (N196T) 79A 167
Mouse gtMoPrP (N196T) ME7 160
Mouse gtMoPrP (N196T) 301C 354
Mouse gtMoPrP (N180T, N196T) 79A 435 *
Mouse gtMoPrP (N180T, N196T) ME7 >700
Mouse (129/Ola) 79A 148
Mouse (129/Ola) ME7 163
Mouse (129/Ola) 301C 166
*Disease incidence 4/21
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Appendix iii Titration of anti-tubulin antibody (rat monoclonal)
Concentration 1/1000
of anti-tubulin
1/2000 1/4000 1/6000 1/8000
50 KDa
Western blot of total brain proteins was used to determine required
concentration of anti-tubulin rat monoclonal required for clear signal.
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Appendix iv Titration of anti-PrP antibody 6H4 in 263K challenged mice
IHC performed on sections from a G2 transgenic challenged with 263K that
were subjected to antigen retrival. Anti-PrP antibody (6H4) used at (A, B)
1/20,000, (C & D) 1/40,000, (E & F) 1/80,000. Normal mouse serum
(1/20,000) used as negative control (G & H). Scale bar 500 pm (A, C, E, G)
and 50 pm (B, D, F, H).
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Appendix v Titration of anti-PrP antibody 8H4 in 263K challenged mice
IHC performed on sections from a G2 transgenic challenged with 263K that
were subjected to antigen retrival. Anti-PrP antibody (8H4) used at (A, B)
1/5000, (C & D) 1/10,000, (E & F) 1/20,000. Normal mouse serum
(1/10,000) used as negative control (G & H). Scale bar 500 pm (A, C, E, G)
50 pm (B, D, F, H).
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Appendix vi
Localisation of the 6H4 and 8H4 epitopes on PrP (Based on the
structure of murine PrP amino acid 121-231 published by Riek et
al 2006). The epitope of anti-PrP antibody 6H4 is located in the
first a-helix (amino acids 143-151 red )and the epitope of anti-PrP
antibody 8H4 is located in the third a-helix (amino acids 175-185
blue) and includes the first N-glycan attachment site (N-glycan
linked asaparagine180 in pink), neither epitope is located near the
second N-glycan attachment site (N-glycan linked asaparagine196
cyan).
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Appendix vii Titration of 6H4 in sporadic CJD MM type 2 challenged mice
'■.■.V.
-
IHC performed on sections from a G2 transgenic challenged with sporadic
CJD that were subjected to antigen retrival. Anti-PrP antibody (6H4) was used
at (A) 1/10,000, (B) 1/20,000, (0)1/40,000, (D) 1/80,000. Normal mouse






of anti-PrP antibody (8H4) in sporadic CJD challenged
IHC performed on sections from a G2 transgenic challenged with sporadic
CJD that were subjected to antigen retrival. Anti-PrP antibody (8H4) was
used at (A & B) 1/5,000, (C & D) 1/10,000, (E & F)1/20,000. Normal mouse
serum (1/20,000) was used as a negative control (G & H) and anti-PrP
antibody (6H4 1/20,000) (I & J). Scale-bar 500 pm (A, C, E, G) and 50 pm
(B, D, F, H).
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Appendix ix Tritration of anti-PrP antibody 6H4 in variant CJD challenged
mice
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Appendix xTitration of anti-PrP anti-body in variant CJD challenged mice
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Appendix ix Titration 6H4 on variant CJD challenged mice
IHC was performed on sections from a clinical endpoint control mouse challenged
with variant CJD that were subjected to antigen retrieval. Anti-PrP antibody (6H4)
was used at (A & B) 1/10,000, (C & D) 1/20,000, (E & F) 1/40,000 and (G & H)
1/80,000. Normal mouse serum (I & J) 1/20,000 was used as a negative control.
Scale bar 500 pm (A, C, E, G) and 50 pm (B, D, F, H).
Appendix x Titration 8H4 on variant CJD challenged mice
IHC was performed on sections from a clinical endpoint control mouse challenged
with variant CJD that were subjected to antigen retrieval. Anti-PrP antibody (8H4)
was used at (C & D) 1/2,500, (E & F) 1/5,000 and (G & H) 1/10,000. Anti-PrP
antibody 6H4 1/20,000 was used as a positive control (A & B). Normal mouse
serum 1/20,000 (I & K) and 8H4 (1/5,000) staining of section from a PrP null mouse
(J & L) were used as a negative controls; non-specific binding to PrP null section
was observed at 8H4 (1/2,500) data not shown. Scale bar 500 pm (A, C, E, G) and
50 pm (B, D, F, H).
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Appendix xi Western bot of false positive ME7 seeded G1 PrPc
substrate PMCA
129/OIa G1 Null
F I SI S2 F I SI S2 F I SI S2 129/OIa
+ ++ + + + + + + + + +
Western blot of ME7 seeded PMCA reactions in duplicate (S1 &
S2), non-sonicated controls incubated at 37 °C (I) or frozen (F).
Using normal brain homogenate as source of PrPc from a PrP
null, G1 transgenic and a normally glycosylated 129/OIa mouse,
as indicated. A ratio of 1:100 ME7 to normal brain homogenate (5
mM EDTA) was used. Samples were digested with PK (50
pg/ml, 37 °C, 1 hour). Although by densitometric criteria the G1
PMCA reactions scored as positive amplifications, this appears
to be an experimental artefact, incomplete PK digestion may
have occured in these samples, additionally the frozen control in
particular has not resolved during electrophoresis perhaps
because of an excess of loaded protien in this sample.
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